<SEC-DOCUMENT>0001638833-23-000070.txt : 20230502
<SEC-HEADER>0001638833-23-000070.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502080245
ACCESSION NUMBER:		0001638833-23-000070
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surgery Partners, Inc.
		CENTRAL INDEX KEY:			0001638833
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		IRS NUMBER:				473620923
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37576
		FILM NUMBER:		23876677

	BUSINESS ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		615-234-5900

	MAIL ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgry-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:8139a9e6-f0c0-4663-a359-16b44ae9e913,g:a1e20cbb-0632-4ba5-9f9a-c20d61b98cc5,d:4d12193c1ac449cbaaec870c0a7c1b7d--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:sgry="http://www.surgerypartners.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgry-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV80LTEtMS0xLTgyMDA0_d402282c-9490-48f3-8578-45644d412be1">0001638833</ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV81LTEtMS0xLTgyMDA0_d89f2bea-8c17-4822-a155-a6bfca2746b7">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV85LTEtMS0xLTgyMDA0_1e0a7011-c59b-428c-b200-de71c24d27cc">2023</ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV8xMC0xLTEtMS04MjAwNA_172cb7cb-2aae-4691-9ab0-09063478a680">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV8xMS0xLTEtMS04MjAwNA_735ff264-dfd3-4cdc-889b-e80e46bae865">false</ix:nonNumeric><ix:nonNumeric contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0xLTEtMS04MjAwNA_eaac48d6-4a38-4801-99ed-58a72d155519">http://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNet</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgry-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d41fd45700a4164beb54fee998d920a_I20230425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic87dcd9813304e79b4016a38d95a6b26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa47a92aabfb4f198bd892ae1c73b47e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5a939bdb244adf9d443c23ec72a6eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ee09ce3e1544a3a10503ec164f9559_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i419bf181460249fe83b08bb14c6fc0dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1bfc86bd81947fd8321bee696e14ba8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77b33bfc579485d9d202b8fa5835ebb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73c97f747ea40c89ca7360664151a1d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9656398a8cdc4c2684fa3528cd1fd737_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i394eeacceb884d9dac0bffe547fcfd9b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c7ebcc457244ff879740e6b5842dc7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace256156ecb46e7a7879df0ee315f58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559d3e62ec804801a7d58ea449905c65_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8748cab7c3f340cebd27f76f35614534_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d01a25902b4073a79e1ac8105bab03_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e64b243cb74e08990bb73929ab0a6c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f16ef7c61754a9f9f05d6a9e5783680_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0eb096987544bb6a2a82e082c5b28e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4215fc76964f4337aa436bd3e933e2e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1faa6a90751245b287153e4d2de4bf31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba00892a7dbf473f9ebd08d01e3af4c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4ad6ada487b44178e469d7d80790c65_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05afb4f94a984b2c822ccdd467908600_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f5ba699a656478ba51b4056199d52d2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8759e8dfad94c5fa466de092b896d4f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68f4679b2c94c25b3f7f0f693b6ec14_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b423adca5e4dd9968d29cc90df2d4e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3357462c707d4acfb10096d245e66a3a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb9d22b38ff4ca790e312d6a32e41d2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d30c499f0834cf2882c4d2c725d4e29_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="facility"><xbrli:measure>sgry:facility</xbrli:measure></xbrli:unit><xbrli:context id="i7b158a1a0b39401183f6b663f67d5119_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesAmbulatorySurgeryCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e67a4ba4b7b45ec9fb013fdd2a9a8c7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesSurgicalHospitalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>sgry:state</xbrli:measure></xbrli:unit><xbrli:context id="i93fbb84ab8e54bf68ae45319f7ceed8e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i330b18e5ad5743db8b6302ffdf866646_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i194a9154acd5484889805e9286e14672_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5333aa040ad4421ea9ff5171113791b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347c2e534f60472f9aa78f23e2b7662d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a958c4d33242709d5e6b4c8a16d451_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174f2ef7f43b4017be096fd6960d0dd8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13bc8547fc6249f391018e3c36ac7ae5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cec9a12adb2490880d03b5e2db3fb51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e91e1eeba04f3cb636ac9f9e9c742e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc7653a276442c2895ba6dc6f426066_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0554ebc49d4fcb999fb93084ca8790_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b023be21c94ca6b3fda57d05624b2b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic894bd77f5d24d9f8d642bd4486553b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3a0d5b4af849048366464b85a609df_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1d727596c449d1aa589faede2c444c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb44bf1e649f4f9797567c55c11d2a57_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fdfeafd2b2b44c581d7ae62c305a05b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c8b6e80870471584d0662cd5e62ce1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3533ff5f75840c8b83b791c1edd4b8b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c5f1fcb27242be90a9519d3a5daa49_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb60ee5f491a4d759f3f80d61bc39428_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c5bb7aafa14f84b6d67420515600b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaad3032980a44f9b79dd84b65b8a8f3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie11e527c61994fc4b8612c9529f84738_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4059e6a11b044239991a9cd274ca93af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ccbab58e225409b8f397b22aaa0921a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690afa60488b471bad71d09dde1be1f5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb842e8e10b4aa2b02cfaeca3e9e29e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567b65cfc1644f8ca0a4e2059d874857_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39473dc95e60480a8548a0f5e95a4826_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c371e19dfa4eec95e299e3a708563a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if395609fbdf14ab7bd54498a1f593d2b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a12e5fa6f448c88de9a7f5391b609d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d8f30c03d949d484d4aa733ea4240d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b4ddef7045437ba1eaade0bc4fe400_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae41732101204d4c86f049ad4216697b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b22c450786b4f0091dc4d4eae7d1675_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9bc921c9b0344e5bb467bc42eaf8791_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3330b0a2e34c18a19a93f183c72e49_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323cf8e399eb45778ab71e463913d7f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6455bc1ca084f939e75bb4558e43b7d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idacc70d8240e4b39bd9280d74b6d9b33_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08eb459530bf461880a8962c3bbf26b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195064f2c74144fa80d098a0e694c828_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c30227944194e40b8bf2475f00b0c1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="physician_practice"><xbrli:measure>sgry:physician_practice</xbrli:measure></xbrli:unit><xbrli:context id="i7fa03c70c0ed47c68e5d1597b922d233_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20dd80291ba42deb6354c4af9a710ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife322ebfae344c06aadeb5444f977b01_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesAndPhysicianPracticesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia038e278a48340bda3280d3d858e408e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesAndPhysicianPracticesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9dc705bdaf4307a20eb8262bdc4a27_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0289c146748495ea969e604a4ecc4a0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602c53397d114d5783de58eea6a301e1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:ExistingSurgicalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79df32098d2a43b6b68b90171d47d5e8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:ExistingSurgicalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe2f8852d0e443be810017d409db5c10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3637827bd8fa46638845369ff6cefb32_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec7a6a99212642aab1d11f46ef8b71e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:OneSurgicalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia62b48e259754cf8b5b649d1146431d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="business_entity"><xbrli:measure>sgry:business_entity</xbrli:measure></xbrli:unit><xbrli:context id="i9d5a67a56b014b7b8024c968af016c48_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5360c902c0454970be9a1279e60a08c7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31e09c8a7f742a7be738ff2b92bbe76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8a68d29d5ed4fd982d2f908018f3c10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife734a9e9b7c478480dcde8c8c378846_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8254371571844ad8161e4d28a3392c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d1e8e2eb6f4636a25ae23bd08dab22_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23e712005c5d48dc978669d2c705456c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4be4e474695442ff8609d04af8b53bf2_D20230113-20230113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-13</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615ae79f54e248ed8c11df419a474567_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d03e45ac72242afb2e27ac00a7fede9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ba191127c0e418d98b7c137b8b3b012_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd37df4ed4f4e928da39c9e8a3b97d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b122a7729f846aa83ebcbf74914d1ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fdfc90ff3a14df4942da87910339b7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe42526145740de8a9b4f2c4ab6be7b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc4d54f90673412ab5865efd54bf31bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3ddfc6326b430ba42803e01d9ea155_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7aaa64d2b9647c0880375718f91f9aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0ee0c2d30114fa7a498e11d518d5e86_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc717c4e3294018b3a17b8db7550574_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3958dd7b5c43feb0b399d644cfcd76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef97110d9b04fc3800be00674d398a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6363d1608b80467fabaff6452dee18c1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f20c8303b34ed89344ee532d50feb5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ac93228961451d928a5d157461cb0c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad3beb2f31c412db347647224886c3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d43b1d96bd4419da9eece9e1cdddd7c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2552dc67907f4497afcc3243f335c0da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53660b17d444b948667db475ff5f35b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32f04ce941249ddbd22432651106a15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic698993ebca540e6a16d6647445084ef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i372b7962442b41a2ad5aae90be62bfd9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id13b3e0bc44448129d260b0bf3a9c405_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83325c5100f64cd79cec11f2d4874566_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46fd0fed21334b48980d887244b2c6db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>sgry:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="i8302a05487cc46e38e8ff3204b1ef2ad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e445dd464d44ade88f9c43c91d57652_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033d3f1806b744ce9eadad25192e34c5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:SixUndersignedInterestRateSwapsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3af8b13e57f44b27bb771a94d96d89aa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1065326829d4decbc61f91f23875e3b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4cece3ff2e407f9fb299708f2e854b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bca9cce39a74eb380fb5d884f2da248_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a74f9aadc8a47c890d7ae741d0d1e9e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i517ad963d7114f93893b2d189dc801a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8812d79ba0e7406a8a6f1c6d561cc07a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29099c90b3434f62bb442dd9874e5c47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5cac67689284faabfc9916d5cb46d63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic979a115883d4f5592bb7c07055ffbf5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3a9b4bf3a2433f898c5e81d44b1b91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9adfa3e753a42ca88143d956ce95e86_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a6a63c9b104ac2a07649af064d610e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbafff4d10d840b2955f9a765fcf5409_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c827cd5ece5427082bea6ecb15df8c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886a6e64b9a743b0aca7c22e739b1e1d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica8d344040734175a530bc09317337aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4a8d2749ec405c9d0f00d16b8d1584_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i363d451cc1cb4d0c96744998ea60df5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759de978c1164030aaf39f8ac3180d79_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eab5cbc43744770be5708852cdd239c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife80b1a65af94f9b863703998b3c1df8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab134fcb68746328d5adb54f4ab2b41_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e51254b066146b68172b2d7e45eabf9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i570ad1cc62c24af1a4a594dacdc9450a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879bc0eafd88419c89015946c25ea837_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sgry:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9989159902245b3958bc162627b001a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2157333f54a64133b4ed6c8fe0d8ed07_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6579947ad8ee4c769d03065a92a8c1d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f25d93459534f5c84a4cb1633eb1ef7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac3c71c2dd4b44f78bf883755b6def96_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic762e7cc857a43c1a2f037d3352477ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33fb3f237a04410498509c0ce5185504_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16570392805a4746b263e0633c73a07a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b3621d88dc14df6923e768f491fc566_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc84e42df6a4279be1365d3ba61b0e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f9f79b8aa34e08805a3d3c55374c19_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:TwoSurgicalFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0801f484705247ca9f81ed5e46fa3718_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">sgry:InDevelopmentDeNovoSurgicalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtMi0xLTEtODIwMDQ_2aee640c-d5ee-4c65-9d06-3183f99eb627 id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtMi0xLTEtODIwMDQ_1da8f9b1-483f-4542-85c2-5ef648da6eb7 id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtNC0xLTEtODIwMDQ_a86f7bca-360e-408d-a5c7-69577988ff87 id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtNC0xLTEtODIwMDQ_b606e16c-d033-4319-9dd0-f2ca51061163" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzM4_8c7f44ae-4bd9-429d-8ad8-ce4f130e9864">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzUz_022cb0f8-de3c-4df6-8343-6ecd622cd26e">&#9746;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yOTg_893bc05a-7fd9-40b7-8e7e-4fe949019158">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzU0_d5cb52fb-9982-43ec-9f0f-e831394e67aa">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:&#160; <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQx_db350650-8fae-4609-94b4-c9d501703a1d">001-37576</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ3_afbf416c-c57c-4cb5-8ed7-e247b7e5f45d">Surgery Partners, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.583%"><tr><td style="width:1.0%"></td><td style="width:47.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6MDVlMjE5NWVhZGI3NGIzZTk0NjJmZThhOGQ1YTEwNDcvdGFibGVyYW5nZTowNWUyMTk1ZWFkYjc0YjNlOTQ2MmZlOGE4ZDVhMTA0N18wLTAtMS0xLTgyMDA0_75e510b8-3eca-4fb1-a058-9cace73f903c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6MDVlMjE5NWVhZGI3NGIzZTk0NjJmZThhOGQ1YTEwNDcvdGFibGVyYW5nZTowNWUyMTk1ZWFkYjc0YjNlOTQ2MmZlOGE4ZDVhMTA0N18wLTItMS0xLTgyMDA0_6d458f7f-96de-41c4-b03d-466380b24e02">47-3620923</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ4_05221ff5-abb1-44ac-8e3f-2f703c5221b2">340 Seven Springs Way, Suite&#160;600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ2_12f70043-fd10-4728-8608-8ab9ef5a4a70">Brentwood</ix:nonNumeric>, <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ5_5c046435-3d86-4657-9b4b-0e6f5f61e7f5">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQw_8ee1a829-679f-4e84-87ca-4fc88a438b3f">37027</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzUw_debaad5b-9ff9-4614-839a-8d0178d79f4e">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQz_a1f1d446-2935-4ce6-b88b-7110090dab90">234-5900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:33.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6Y2I4MGFlZTA1M2QzNDQ1ZWIwNjdhN2E4NDI4MmQ2OWEvdGFibGVyYW5nZTpjYjgwYWVlMDUzZDM0NDVlYjA2N2E3YTg0MjgyZDY5YV8xLTAtMS0xLTgyMDA0_0a29adef-fba1-4c93-8b22-5febbe6e7f3e">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6Y2I4MGFlZTA1M2QzNDQ1ZWIwNjdhN2E4NDI4MmQ2OWEvdGFibGVyYW5nZTpjYjgwYWVlMDUzZDM0NDVlYjA2N2E3YTg0MjgyZDY5YV8xLTItMS0xLTgyMDA0_d2f73b05-7822-4247-92c6-e7b5ea73baa2">SGRY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6Y2I4MGFlZTA1M2QzNDQ1ZWIwNjdhN2E4NDI4MmQ2OWEvdGFibGVyYW5nZTpjYjgwYWVlMDUzZDM0NDVlYjA2N2E3YTg0MjgyZDY5YV8xLTQtMS0xLTgyMDA0_d1e72c3d-4086-4981-b45b-e2ac4e01fda0">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQy_a3a9f0f5-0352-4867-af89-4217ad8dfdfd">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzUx_00cdf9d6-6ea7-4fe7-be44-9e252003a1e6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.&#160;</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"></td><td style="width:46.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6ZGVlYmZjZDEyOGFlNGFmMzljYmFhYzYwNGFkZjZjNWEvdGFibGVyYW5nZTpkZWViZmNkMTI4YWU0YWYzOWNiYWFjNjA0YWRmNmM1YV8wLTAtMS0xLTgyMDA0L3RleHRyZWdpb246NzU2ZjVhYjEzMzA0NDRlMmI0YTNkYzliOWUxODg3NDdfNA_016c1e97-5f61-45e4-9f00-effcb5ad1fbb">Large accelerated filer</ix:nonNumeric>&#160;&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer&#160;&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6ZGVlYmZjZDEyOGFlNGFmMzljYmFhYzYwNGFkZjZjNWEvdGFibGVyYW5nZTpkZWViZmNkMTI4YWU0YWYzOWNiYWFjNjA0YWRmNmM1YV8xLTItMS0xLTgyMDA0L3RleHRyZWdpb246NTRiMGVmYmIyYWFjNGFkZmE2Njk2MDUzZjhmZDgwY2FfMzA_7b233eb3-cb4c-4557-bce2-67e38729d50e">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company&#160;<ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6ZGVlYmZjZDEyOGFlNGFmMzljYmFhYzYwNGFkZjZjNWEvdGFibGVyYW5nZTpkZWViZmNkMTI4YWU0YWYzOWNiYWFjNjA0YWRmNmM1YV8yLTItMS0xLTgyMDA0L3RleHRyZWdpb246ZDYxNjE4ZjVlNzE5NDBlZTk2ZjExMGI3Zjg5ODFiMGZfMjg_ea8ed59f-3e82-4d33-a7a0-e7e905a264b9">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF80OTQ3ODAyMzI3MzU3_dcd222b5-7459-4563-bac1-ccf0a7bd2dba">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of April&#160;25, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i4d41fd45700a4164beb54fee998d920a_I20230425" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMjgx_60e75b9a-c1a3-4f1b-a1d7-12e5f26baa8f">126,476,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_10">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_10">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_13">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_16">Condensed Consolidated Statements of Operations (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_19">Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_22">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_25">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_28">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_28">6</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_61">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_61">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_61">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_88">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_88">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_91">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_91">25</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_94">PART II - OTHER INFORMATION</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_97">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_97">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_100">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_100">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_103">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_103">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_103">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_106">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_106">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_106">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_109">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_109">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_109">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_112">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_112">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_112">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_115">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_115">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_115">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_118">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_118">29</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="margin-bottom:4pt;text-align:center"><span><br/></span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_13"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Dollars in millions, except per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNC0yLTEtMS04MjAwNA_4f0a4c84-2de7-45d1-8bc9-9cc958ffd423">245.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNC00LTEtMS04MjAwNA_bd8a1fa8-a05c-4f96-b8e3-a05efe4d8bd9">282.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNS0yLTEtMS04MjAwNA_ad6e04fa-a57e-448e-b36d-74bb09d7d804">452.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNS00LTEtMS04MjAwNA_2057dfa4-0cf6-4960-945d-f4a4534e7852">456.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNi0yLTEtMS04MjAwNA_48e4945b-901a-4eb5-96be-e4ecffb61935">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNi00LTEtMS04MjAwNA_45c729e2-d2b4-41b4-869d-2037d0595236">71.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNy0yLTEtMS04MjAwNA_34e7c9ad-47cd-4231-8e0a-8d352bcd8a6d">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNy00LTEtMS04MjAwNA_c969968e-94d5-4206-9b98-4d7010bdc721">31.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOC0yLTEtMS04MjAwNA_b07f19cb-0a17-46d3-a104-c82d7d354638">69.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOC00LTEtMS04MjAwNA_c4d33ed3-10f8-46ba-8163-4be67c15f889">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOS0yLTEtMS04MjAwNA_9b8cfc24-779c-42c2-8d55-4942cb9e8d96">868.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOS00LTEtMS04MjAwNA_bdc824c7-1630-45cb-983a-04d371eab84a">921.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo0YjdmODFhOGRiNTE0ZDI4YWE0MWM5MGRkMThjZjc2N182Mw_019c9bca-df7a-4f84-8f22-a44fb9a99681">382.7</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo0YjdmODFhOGRiNTE0ZDI4YWE0MWM5MGRkMThjZjc2N183MA_a8e20036-e75f-4e18-b7af-59c0da7ac9a6">374.3</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtMi0xLTEtODIwMDQ_e1c90e44-2d16-4729-a1f0-0fbea6eb2c0f">844.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtNC0xLTEtODIwMDQ_8920889a-457b-4480-9ac7-776cac8d38a0">876.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill and other intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTEtMi0xLTEtODIwMDQ_f2a784b9-a088-48f6-af7b-93a1e5f87113">4,252.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTEtNC0xLTEtODIwMDQ_95b0089b-bd87-4dd2-8e7d-05dba93f89f1">4,179.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in and advances to affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTItMi0xLTEtODIwMDQ_2ac0e09b-59c4-43d5-a204-27d2fb12c857">191.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTItNC0xLTEtODIwMDQ_f5904ebd-69e6-4b75-a6f2-fb2f88ad3f9a">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTMtMi0xLTEtODIwMDQ_c76178b4-871f-41a8-8a36-5e45798e3acf">274.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTMtNC0xLTEtODIwMDQ_40bf8205-bf48-4774-908b-6d7bb23bcdad">279.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTQtMi0xLTEtODIwMDQ_a4ee74d6-be90-4f45-b533-139ba401f1ce">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTQtNC0xLTEtODIwMDQ_795dc63d-3092-4ed0-8955-fd29acc5b3b0">91.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTUtMi0xLTEtODIwMDQ_657b055f-be24-46f6-a677-9843a7364f89">118.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTUtNC0xLTEtODIwMDQ_60d66d41-00f3-46bc-9a58-6f63418d8eb7">144.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTYtMi0xLTEtODIwMDQ_ade213a8-5e53-4c31-b197-cf7f883a30c3">6,643.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTYtNC0xLTEtODIwMDQ_13a48bb2-990f-4415-9a62-bda951c9ae70">6,682.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjAtMi0xLTEtODIwMDQ_249f62b5-3ebb-43bb-bb82-64b0a00c2074">144.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjAtNC0xLTEtODIwMDQ_a241d29c-8a1a-448a-887d-59ed9fd732c3">151.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjEtMi0xLTEtODIwMDQ_c0c817b5-8430-4851-8047-edcf6369ab38">67.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjEtNC0xLTEtODIwMDQ_9aa0f7b9-062a-4b2a-b3f0-c3e1e58e5596">68.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjMtMi0xLTEtODIwMDQ_7c0920bb-45cd-4428-b5a2-bbaf709abac0">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjMtNC0xLTEtODIwMDQ_9fe5aab8-3163-4c37-8583-5399d90b63b4">210.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjQtMi0xLTEtODIwMDQ_9dc435ee-ea8f-4650-9df7-636dee304ec4">62.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjQtNC0xLTEtODIwMDQ_3e84c354-e90f-41aa-909e-d9827afdf8bb">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjUtMi0xLTEtODIwMDQ_451d0172-e687-4e4b-8a53-b2c9b0d3a36a">475.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjUtNC0xLTEtODIwMDQ_9f7e128b-354b-4bac-8123-23df62726978">493.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, less current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjYtMi0xLTEtODIwMDQ_97de9482-1021-410f-b0a9-24d3f739101f">2,530.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjYtNC0xLTEtODIwMDQ_00a87cdc-c20f-4aac-986e-bdbf96219964">2,559.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjctMi0xLTEtODIwMDQ_4ddcb943-ebf2-42a6-b1b5-73ad99598a55">268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjctNC0xLTEtODIwMDQ_4b9270b2-2329-48f4-918f-cb805542eeb9">271.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjgtMi0xLTEtODIwMDQ_849b3675-490b-422e-bbef-76e5fe8fe0da">80.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjgtNC0xLTEtODIwMDQ_b4d5318d-bd8d-4f77-a03e-9581f4d2cf8a">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzAtMi0xLTEtODIwMDQ_1d9a3b04-483e-42d2-88ed-8764f8a1d973">345.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzAtNC0xLTEtODIwMDQ_0b288e89-d2d4-457f-8947-ec229b3172bc">342.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV8yMQ_a1dcd0ca-9e93-4698-9dfc-d9f742110e00"><ix:nonFraction unitRef="usdPerShare" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV8yMQ_dc0f6bb5-ab8c-4b58-880e-4731d45e0504">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV81NQ_9bfded86-1031-45b5-b566-9c1bf833f30c"><ix:nonFraction unitRef="shares" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV81NQ_eee24c0d-e4fa-4bb3-83cd-6236dc5aea6d">20,310,000</ix:nonFraction></ix:nonFraction>; shares issued or outstanding - <ix:nonFraction unitRef="shares" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_bcf2bfb8-a977-466c-8b2e-715004685f36"><ix:nonFraction unitRef="shares" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_cbc59b6c-ec76-4a55-b641-348cc4819251"><ix:nonFraction unitRef="shares" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_d85c780a-bf20-4496-9ca1-015ce824e506"><ix:nonFraction unitRef="shares" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_f4f17f26-2276-4e6d-aec3-a378d9c65038">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMi0xLTEtODIwMDQ_a56293fc-9400-45b4-9b1b-ef276aecde41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtNC0xLTEtODIwMDQ_6413a105-51a0-447b-9064-33a8e68f416e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF8xOA_9e3881e4-f15b-4b41-b1f4-14b791ce0737"><ix:nonFraction unitRef="usdPerShare" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF8xOA_dd988d44-1bee-4397-b18b-3965a2d0a883">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF81Mg_2aaa6386-0a1d-4c24-a8e5-3bd16693c442"><ix:nonFraction unitRef="shares" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF81Mg_6c7ffdb8-f40d-471e-8235-6457c14b3b8f">300,000,000</ix:nonFraction></ix:nonFraction>; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF84OA_776d7313-7fe3-4d59-9bcf-7313eb3ec5e8"><ix:nonFraction unitRef="shares" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF84OA_d1fb450b-b1be-4c2e-886a-d610cf7103ea">126,480,483</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF85NQ_12daadbd-88af-4967-a8c2-a1998ab5e72b"><ix:nonFraction unitRef="shares" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF85NQ_b24a6a7d-ded2-4693-a614-0c6b637ef659">125,960,834</ix:nonFraction></ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMi0xLTEtODIwMDQ_7b17fc34-5179-4be5-a7ac-3d4276c853eb">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtNC0xLTEtODIwMDQ_0efbeb1d-4ccf-42a6-b882-287ed1be751e">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzUtMi0xLTEtODIwMDQ_76f3f860-9ef1-4808-8501-0e8b87d27228">2,478.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzUtNC0xLTEtODIwMDQ_bde3eb1b-03fb-4885-81ae-aa5c6005a73f">2,478.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzYtMi0xLTEtODIwMDQ_e2b85ccb-c6ae-4b05-98d6-b241115eb79f">64.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzYtNC0xLTEtODIwMDQ_9228dd3b-1249-4a2b-8401-f835993152e1">76.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzctMi0xLTEtODIwMDQ_cdbd449c-e64d-4dd8-96c7-859b02ba2e48">582.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzctNC0xLTEtODIwMDQ_2ff73547-b9ac-4da6-8cca-3e1a11e03df4">557.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Surgery Partners, Inc. stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzgtMi0xLTEtODIwMDQ_b17f9597-51d8-4af0-9486-fa88266906a5">1,962.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzgtNC0xLTEtODIwMDQ_6bee3928-8b37-487f-82e7-499f1a16a9a2">1,998.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interests&#8212;non-redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzktMi0xLTEtODIwMDQ_32c1ab14-60fe-4d5c-a9ec-eb3b568b1551">980.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzktNC0xLTEtODIwMDQ_399117bb-3131-4144-b784-35cdba6f66ef">942.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDAtMi0xLTEtODIwMDQ_1d999397-9e1b-49b0-a503-c68f039a8358">2,942.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDAtNC0xLTEtODIwMDQ_1e965199-f927-466f-beb5-ce48d1c2ddca">2,940.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDEtMi0xLTEtODIwMDQ_0434635b-13e6-4ffd-a19b-563aefa44dcd">6,643.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDEtNC0xLTEtODIwMDQ_31337741-e7c6-407e-b51a-1cc4802e3ab7">6,682.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_16"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions, except per share amounts, shares in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:73.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMy0yLTEtMS04MjAwNA_4738197f-dad8-4490-8726-1131211b7677">666.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMy00LTEtMS04MjAwNA_ee79cdaf-1674-4fa9-8b96-95a0d6b6447b">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNS0yLTEtMS04MjAwNA_8f563ca3-0265-4102-aa42-987915ccf8e3">202.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNS00LTEtMS04MjAwNA_ed2361fb-d102-4108-bc05-24ae3634eaba">178.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNi0yLTEtMS04MjAwNA_b54a059e-54c6-4fcb-9621-75be8f408705">188.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNi00LTEtMS04MjAwNA_57d990f7-bf00-4eee-9300-9a68ab2e4089">171.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional and medical fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNy0yLTEtMS04MjAwNA_fc0719c1-e754-4c27-8896-c6da16d4b259">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNy00LTEtMS04MjAwNA_fcef044a-6134-4cf2-8e0f-c93d170c9f45">63.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:OperatingAndFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOC0yLTEtMS04MjAwNA_4547c386-cfb2-4af8-bc84-bae689728c40">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:OperatingAndFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOC00LTEtMS04MjAwNA_f156fdd7-5648-4cf3-a015-16729365b88f">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOS0yLTEtMS04MjAwNA_d19b53ec-b32b-4137-a3de-89ddfb254f1e">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOS00LTEtMS04MjAwNA_f543dea9-3107-4341-a599-0fcc32f178a8">37.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTAtMi0xLTEtODIwMDQ_71a45c13-53e4-4ff9-8c4f-f5b8a8e13f3b">532.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTAtNC0xLTEtODIwMDQ_9a20176a-b353-4395-9e66-9a83f105be20">471.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTEtMi0xLTEtODIwMDQ_42d5109a-f4de-44e6-adc6-905cf342e5f4">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTEtNC0xLTEtODIwMDQ_26153c51-fe44-4997-a05e-577463ee89dd">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTItMi0xLTEtODIwMDQ_9a63f5c7-5c43-42cc-9389-ed8754e16167">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTItNC0xLTEtODIwMDQ_9c855cd7-5557-40c3-b4b2-617c4ad00d07">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTMtMi0xLTEtODIwMDQ_45864894-f936-47d5-99ca-3c91f036dea9">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTMtNC0xLTEtODIwMDQ_a62dee08-d3e4-44b1-8710-7204090bf380">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTQtMi0xLTEtODIwMDQ_acddd4bd-dbc9-4a96-9d0b-82b3a130022f">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTQtNC0xLTEtODIwMDQ_31eb8449-12c9-4e8f-a4c8-540d7a872ba0">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) on disposals, consolidations and deconsolidations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTUtMi0xLTEtODIwMDQ_9d88d424-a9d4-467b-b521-4f40a9d9141f">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTUtNC0xLTEtODIwMDQ_70a7d233-ff9c-453e-8bfb-dc289bb9b295">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTYtMi0xLTEtODIwMDQ_2c579ada-eb66-4b91-8877-706a64dc3b8d">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTYtNC0xLTEtODIwMDQ_31b7f1f4-056d-4601-b860-9fdca5ebe133">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTctMi0xLTEtODIwMDQ_ddd88054-f5fe-409e-83b3-08521663e45d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTctNC0xLTEtODIwMDQ_31972981-bb6d-4b69-9285-f10c5b7e7ce2">32.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTktMi0xLTEtODIwMDQ_f63e320a-496a-4203-aa2b-3e91815b61ab">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTktNC0xLTEtODIwMDQ_4f9b5655-2b8e-46d9-8990-02b4a3c00296">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjAtMi0xLTEtODIwMDQ_696b7967-f98f-4498-81bd-9fc2130ab51b">619.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjAtNC0xLTEtODIwMDQ_15256e53-3e77-41bd-a350-81292764dd4c">495.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjEtMi0xLTEtODIwMDQ_cc6b14cc-6187-4733-9d56-7cb41c9b159a">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjEtNC0xLTEtODIwMDQ_e318cf64-8fc9-44a5-a51a-8a5bf10c1beb">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjItMi0xLTEtODIwMDQ_5d41b906-63f7-4d6d-855b-c36a91672cd3">46.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjItNC0xLTEtODIwMDQ_7d857e88-0d79-4dd1-82ea-4435fb877cf6">56.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjMtMi0xLTEtODIwMDQ_05864361-8ce6-45c5-9ce9-605bc51c5372">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjMtNC0xLTEtODIwMDQ_39664994-cdc5-4cc0-bce4-6c971bbcf53f">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit (expense) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjQtMi0xLTEtODIwMDQ_89734329-97b0-4641-9c4c-dadef759a59b">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjQtNC0xLTEtODIwMDQ_d4d972c9-a53e-466e-8e64-c73bc7ab94a6">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjUtMi0xLTEtODIwMDQ_0879b225-9535-4b9a-9377-bc5f5f6844ea">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjUtNC0xLTEtODIwMDQ_dbe2456e-2b4a-4aa3-abd0-19b919b073ac">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjYtMi0xLTEtODIwMDQ_d348ac7c-7d11-45b9-883b-4c812424dce4">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjYtNC0xLTEtODIwMDQ_b2623d75-e28e-48ee-abe1-2f697b0650e1">30.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjctMi0xLTEtODIwMDQ_f3f12ac0-aa7a-4995-ab94-68160200a587">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjctNC0xLTEtODIwMDQ_cd56bb52-eaf3-48ce-88c8-97a9cfe1aae3">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzItMi0xLTEtODIwMDQ_bdd099a3-4793-4050-ae57-cffc527e32e0">0.20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzItNC0xLTEtODIwMDQ_22b60dff-6dd4-4d40-b1e4-e1ef0c5af217">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtMi0xLTEtODIwMDQ_2aee640c-d5ee-4c65-9d06-3183f99eb627">0.20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtNC0xLTEtODIwMDQ_a86f7bca-360e-408d-a5c7-69577988ff87">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzUtMi0xLTEtODIwMDQ_a300e41b-47ea-4740-983a-8b6e0048f8fd">125,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzUtNC0xLTEtODIwMDQ_386bfd3b-4425-46f2-8043-691f12df08e4">87,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtMi0xLTEtODIwMDQ_1da8f9b1-483f-4542-85c2-5ef648da6eb7">125,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtNC0xLTEtODIwMDQ_b606e16c-d033-4319-9dd0-f2ca51061163">90,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219" footnoteRole="http://www.xbrl.org/2003/role/footnote">The impact of potentially dilutive securities for the three months ended March 31, 2023 was not considered because the effect would be anti-dilutive.</ix:footnote></span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfMy0yLTEtMS04MjAwNA_0879b225-9535-4b9a-9377-bc5f5f6844ea">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfMy00LTEtMS04MjAwNA_dbe2456e-2b4a-4aa3-abd0-19b919b073ac">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative activity, net of tax of $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjBiNmFlYjk0MTFmZjRmMTViNGRjZTRkNmVlMjFlYWQyXzEwNDQ1MzYwNDYzOTE0_4e3956f4-3115-42d0-91b5-ea3a04d88abb"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjBiNmFlYjk0MTFmZjRmMTViNGRjZTRkNmVlMjFlYWQyXzEwNDQ1MzYwNDYzOTE0_705b3542-1ebf-402e-9973-6bf41f1393d3">0</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS0yLTEtMS04MjAwNA_161cd937-cdb7-4837-9a86-3dc53e7eefdb">11.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS00LTEtMS04MjAwNA_4ac75ab6-79a6-4ddc-810f-4af6b45a6d65">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNi0yLTEtMS04MjAwNA_1b014676-6e53-4998-929c-f7783b4e2588">10.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNi00LTEtMS04MjAwNA_2fcd02e7-758e-41aa-b40c-3fc619ddf784">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Comprehensive income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNy0yLTEtMS04MjAwNA_b56f99e5-8a71-46bc-b006-63dddf16be4c">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNy00LTEtMS04MjAwNA_d7e450dd-1763-4ef3-835a-2d9880a205d1">30.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive (loss) income attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfOC0yLTEtMS04MjAwNA_c8d4b64b-2c47-4030-965f-29a895088fda">36.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfOC00LTEtMS04MjAwNA_8d3b1839-df7f-4cfc-a800-456512c5170a">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions, shares in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.797%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional <br/>Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests&#8212;  <br/>Non-Redeemable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa47a92aabfb4f198bd892ae1c73b47e_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0xLTEtMS04MjYxMw_5575a845-c9e1-4885-8c06-9e9e972cf59f">89,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa47a92aabfb4f198bd892ae1c73b47e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0zLTEtMS04MjYxMw_431f816a-fe21-4840-b090-9e0494b10512">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5a939bdb244adf9d443c23ec72a6eb_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy01LTEtMS04MjYxMw_390c7ac3-52d1-45f0-af2d-ebf9bc7f072b">1,622.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65ee09ce3e1544a3a10503ec164f9559_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy03LTEtMS04MjYxMw_f8dab29e-3377-4b5e-aa7c-0065dfb4131e">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i419bf181460249fe83b08bb14c6fc0dc_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy05LTEtMS04MjYxMw_93850cd6-5274-4a74-b292-4302b128f9a1">502.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bfc86bd81947fd8321bee696e14ba8_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0xMS0xLTEtODI2MTM_50d61b9c-2eb0-4f94-8762-2e33c1af489c">880.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0xMy0xLTEtODU1MTY_53c931c7-4c1b-4b29-9261-64d793d08a9e">1,969.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77b33bfc579485d9d202b8fa5835ebb_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNC05LTEtMS04MjYxMw_c50fceb1-a84a-4bb0-adba-b8a0f54deb6c">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNC0xMS0xLTEtODI2MTM_19264287-d74c-4014-9e55-451b40386d2d">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNC0xMy0xLTEtODU1MTY_af4cf467-7bdd-4120-b91c-aea2cf2eadfc">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id73c97f747ea40c89ca7360664151a1d_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNS0xLTEtMS04MjYxMw_01d14915-0b5c-4f54-a749-1b6716ef4b3c">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9656398a8cdc4c2684fa3528cd1fd737_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNS01LTEtMS04MjYxMw_3de9c624-0a81-4cba-871e-0c10207fcaed">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNS0xMy0xLTEtODU1MTY_a5bdd112-79b5-4fdd-b87d-d44a4b4c632a">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394eeacceb884d9dac0bffe547fcfd9b_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNi03LTEtMS04MjYxMw_8684ad31-7e11-4629-9d57-171144875b43">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNi0xMy0xLTEtODU1MTY_809ae90b-cafb-4b3b-88cc-c9d46fad5f7e">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9656398a8cdc4c2684fa3528cd1fd737_D20220101-20220331" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNy01LTEtMS04MjYxMw_0c9f29c3-bfac-4d3b-a8f9-936a86420ec5">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNy0xMS0xLTEtODI2MTM_1876c379-730e-4945-ba86-027062792724">24.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNy0xMy0xLTEtODU1MTY_2d06f44f-2009-4aba-8386-e55a1af2d8bc">29.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interests&#8212;non-redeemable holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOC0xMS0xLTEtODI2MTM_f1d56bc7-ed9f-4380-b24c-f959e417c6e4">24.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOC0xMy0xLTEtODU1MTY_213195ec-96bc-4a76-9b34-334219597514">24.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74c7ebcc457244ff879740e6b5842dc7_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0xLTEtMS04NTUxNg_a82b1866-740b-4f32-85f6-aa25874b1abc">89,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c7ebcc457244ff879740e6b5842dc7_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0zLTEtMS04NTUxNg_b73c0467-cb34-41df-a04b-1e870e3e467d">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace256156ecb46e7a7879df0ee315f58_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS01LTEtMS04NTUxNg_9a8c0326-5beb-4026-a3b4-fcecbc273f96">1,625.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559d3e62ec804801a7d58ea449905c65_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS03LTEtMS04NTUxNg_33c4c6aa-d0db-4048-ac16-1010541bec14">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8748cab7c3f340cebd27f76f35614534_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS05LTEtMS04NTUxNg_1b5a532b-8ff0-4c7b-b53a-f3740a594392">490.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d01a25902b4073a79e1ac8105bab03_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0xMS0xLTEtODU1MTY_c442001e-d6dd-4a95-9eee-4581b7124c4e">851.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e64b243cb74e08990bb73929ab0a6c_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0xMy0xLTEtODU1MTY_b4170dfa-cc1d-40e6-a5ca-59b030d3ae56">2,012.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f16ef7c61754a9f9f05d6a9e5783680_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0xLTEtMS04MjAwNA_5ee46090-100f-4689-937c-1fc8bb1ac96b">125,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f16ef7c61754a9f9f05d6a9e5783680_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0zLTEtMS04MjAwNA_3a5820b4-358c-4980-b20f-92c44758b726">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0eb096987544bb6a2a82e082c5b28e5_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy01LTEtMS04MjAwNA_eecc463d-80a6-4606-aed5-85a350a6c2b2">2,478.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4215fc76964f4337aa436bd3e933e2e2_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy03LTEtMS04MjAwNA_7a4da19b-c0b3-426c-a2a6-ce06e4c16089">76.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1faa6a90751245b287153e4d2de4bf31_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy05LTEtMS04MjAwNA_9230be2e-1e18-4237-a289-80a82876f243">557.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba00892a7dbf473f9ebd08d01e3af4c7_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0xMS0xLTEtODIwMDQ_8d9c8a3c-58fd-48d6-8baf-54afd706f2c5">942.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0xMy0xLTEtODIwMDQ_39b2e8e3-01f0-4b00-82b0-1de98121e419">2,940.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4ad6ada487b44178e469d7d80790c65_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNC05LTEtMS04MjAwNA_c296c1ed-3ba5-4382-9eaf-63347727c1bb">25.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNC0xMS0xLTEtODIwMDQ_5fc37412-ae3e-452d-8b57-48ff3cef7b19">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNC0xMy0xLTEtODIwMDQ_b3648142-d5f8-40d4-8cf7-a6d2312b5575">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05afb4f94a984b2c822ccdd467908600_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNS0xLTEtMS04MjAwNA_3a1de5fc-0533-4989-be0a-43b1bf168fec">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5ba699a656478ba51b4056199d52d2_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNS01LTEtMS04MjAwNA_6a906330-55f9-4ea9-b41a-cbdffcb2a85b">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNS0xMy0xLTEtODIwMDQ_c343c10e-78dc-4752-b286-df74cb034aa5">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8759e8dfad94c5fa466de092b896d4f_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNi03LTEtMS04MjAwNA_c9b82adb-69f8-4202-9abd-1d5b089ae760">11.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNi0xMy0xLTEtODIwMDQ_95b30cb7-5a04-44e5-8a28-c88647b12541">11.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f5ba699a656478ba51b4056199d52d2_D20230101-20230331" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNy01LTEtMS04MjAwNA_b197e6f6-44e3-46a2-9107-c17222a3bed6">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNy0xMS0xLTEtODIwMDQ_2877d8eb-824c-4000-8362-25649dfb79ed">49.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNy0xMy0xLTEtODIwMDQ_0ac24c48-c402-48be-a180-28d14ea3a07d">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interests&#8212;non-redeemable holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOC0xMS0xLTEtODIwMDQ_549de89c-70b7-47e5-b987-58c323e270d4">30.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOC0xMy0xLTEtODIwMDQ_8d809269-7c37-4d8c-a11b-f7f0361c6b11">30.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib68f4679b2c94c25b3f7f0f693b6ec14_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0xLTEtMS04MjAwNA_ad73764d-10f5-496b-8734-e0c8af0884dd">126,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68f4679b2c94c25b3f7f0f693b6ec14_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0zLTEtMS04MjAwNA_784927ae-83c9-4092-8ee0-a99356fdd700">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b423adca5e4dd9968d29cc90df2d4e_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS01LTEtMS04MjAwNA_f68a4ff3-4844-4467-97a2-a53b88aec8a8">2,478.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3357462c707d4acfb10096d245e66a3a_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS03LTEtMS04MjAwNA_e48dbbe3-460b-43e0-ba28-839a5ba29826">64.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cb9d22b38ff4ca790e312d6a32e41d2_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS05LTEtMS04MjAwNA_1e64f2da-27dd-4105-a942-dba50f0427da">582.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d30c499f0834cf2882c4d2c725d4e29_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0xMS0xLTEtODIwMDQ_6f889558-375c-47ff-87ca-5526f59d1abc">980.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0xMy0xLTEtODIwMDQ_12868292-028c-4a5e-9bce-084fe3b234be">2,942.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMy0yLTEtMS04MjAwNA_01d76b5d-b809-413a-85b1-ca73934be022">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMy00LTEtMS04MjAwNA_31932d9d-0e7b-4945-b4bb-9844592a2565">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNS0yLTEtMS04MjAwNA_34c63081-88f3-4fde-afbb-bad19b4a093e">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNS00LTEtMS04MjAwNA_dc2e3664-b8ca-45df-afea-9742efcceef2">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi0yLTEtMS04NjY0Nw_7157d91e-7f6d-474e-be12-9ce6011b7ccf">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi00LTEtMS04NjY0Nw_d8fd45a9-9f76-4869-a41c-e7209b577553">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="sgry:NoncashInterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi0yLTEtMS04MjAwNA_1e72732c-b8cc-413a-905f-b4e6f24f809d">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="sgry:NoncashInterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi00LTEtMS04MjAwNA_a1db8d53-7282-4e2d-ad4b-8d2a8a9d9ad3">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNy0yLTEtMS04MjAwNA_4e8b0839-551d-47aa-9c68-7c2315a26599">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNy00LTEtMS04MjAwNA_666a1e96-538e-4b35-8098-9ba343a6e9d0">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) on disposals, consolidations and deconsolidations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfOC0yLTEtMS04MjAwNA_970f46aa-b215-486b-a379-765117d40dbe">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfOC00LTEtMS04MjAwNA_b939b01b-302b-4d1d-bd75-1c0a93e42e72">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTAtMi0xLTEtODIwMDQ_1f5f996c-4ae3-4f32-8f76-6c1d932d2294">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTAtNC0xLTEtODIwMDQ_8455649c-f3ea-44ff-92d2-b0fbd7250acb">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates, net of distributions received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTEtMi0xLTEtODIwMDQ_6bcc6bfd-eb12-4457-9a2b-784dca81d3e6">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTEtNC0xLTEtODIwMDQ_eb3d3a4d-320d-489f-ad63-3e1583510ff4">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTQtMi0xLTEtODIwMDQ_1ad7b57e-b958-4039-b14f-9fc586b3b9d5">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTQtNC0xLTEtODIwMDQ_39e4a51f-f0e8-46b5-aa15-45e867b1a6a0">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare accelerated payments and deferred governmental grants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTUtMi0xLTEtODIwMDQ_3362fc6d-e8bf-4504-9eab-fd8700943473">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTUtNC0xLTEtODIwMDQ_907c9b8f-0b98-49b4-a71e-b9d0c37f796a">18.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTctMi0xLTEtODIwMDQ_0e3b654e-f85e-499f-a911-8a8653cf1b3c">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTctNC0xLTEtODIwMDQ_876db0fd-c639-4700-a35c-cf99dc96813a">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTgtMi0xLTEtODIwMDQ_ab63219e-9d3d-447e-928d-c22c92abfbce">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTgtNC0xLTEtODIwMDQ_5ff705c0-afd0-498b-bba9-025b374f12f9">79.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjEtMi0xLTEtODIwMDQ_4101df1a-341e-46b9-adc8-5d3ec7416203">24.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjEtNC0xLTEtODIwMDQ_1ab6d682-115e-4885-a90b-597c3a1aa908">18.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for acquisitions, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjItMi0xLTEtODIwMDQ_82bb5021-746d-4082-9a38-3301b655c189">40.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjItNC0xLTEtODIwMDQ_1a6e8271-5198-44c0-95be-15848c046809">31.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from disposals of facilities and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjMtMi0xLTEtODIwMDQ_3f4cdb28-a505-4045-be6b-9e84d5de6c62">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjMtNC0xLTEtODIwMDQ_c87b6781-4225-432c-a009-df989a1e6edb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjQtMi0xLTEtODIwMDQ_19d6a3ef-a0e3-4e68-9988-ef8bff0323f2">9.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjQtNC0xLTEtODIwMDQ_cedccd85-6bcc-4585-9540-10bed5fe6315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjUtMi0xLTEtODIwMDQ_da0264a5-316c-47ba-8d82-67e7968ace0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjUtNC0xLTEtODIwMDQ_fb487279-8e39-4793-ac7e-15bff7c10749">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjYtMi0xLTEtODIwMDQ_09610741-f072-4285-ac1a-b7dae7a2bdec">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjYtNC0xLTEtODIwMDQ_7798fa21-4dce-4485-a51a-636881e8fced">9.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjctMi0xLTEtODIwMDQ_3cb873d8-047c-4e97-94cc-c7caf5ba6863">70.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjctNC0xLTEtODIwMDQ_bbacabc7-b9a5-4066-bc42-16d1d4bdf3d5">47.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtMi0xLTEtODIwMDQ_519687bc-8465-4d23-84c8-f54800c1adc4">15.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtNC0xLTEtODIwMDQ_1066e445-7372-4777-b2a5-f136bad54b89">17.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzEtMi0xLTEtODIwMDQ_ef317b0c-b362-4035-b132-f74e83a52410">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzEtNC0xLTEtODIwMDQ_b41f7c8d-fb81-42d9-8284-1e21d32bf429">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtMi0xLTEtODk2MTU_08ef02a6-7c3c-4ae5-b027-eea4dc02ea43">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtNC0xLTEtODk2MTU_157488dc-f3ed-4b30-90f1-c8fe4b40f163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzYtMi0xLTEtODIwMDQ_f53bda1c-ffb3-4a0c-9931-a583c5f27d75">41.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzYtNC0xLTEtODIwMDQ_1756f5dc-90e1-4562-89e6-3477cee70fdf">36.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipts (payments) related to ownership transactions with non-controlling interest holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzctMi0xLTEtODIwMDQ_22df0328-5b9c-4f76-9d0b-2c3b2d1e6fc5">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzctNC0xLTEtODIwMDQ_2261140c-7e60-4c78-8d5e-6acb251f8035">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzgtMi0xLTEtODIwMDQ_9f14670e-86b5-4847-9d87-39ad927e8444">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzgtNC0xLTEtODIwMDQ_ecc9d7d5-e299-4864-86d1-97f7279967ef">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzktMi0xLTEtODIwMDQ_d8faab32-342b-497b-8de8-a9d2da6515ee">41.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzktNC0xLTEtODIwMDQ_ad757b7e-eb3e-4d6f-962b-4963bba87097">43.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDAtMi0xLTEtODIwMDQ_3de84d02-8c0f-4f21-a444-131b10fa2ab7">37.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDAtNC0xLTEtODIwMDQ_595c2260-e12c-47eb-963c-f4a8d2402047">11.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDEtMi0xLTEtODIwMDQ_38bf2454-72b9-4e09-a81d-915091cc69bf">282.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDEtNC0xLTEtODIwMDQ_1ce527c7-6826-44a5-8efb-5726571dec2c">389.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDItMi0xLTEtODIwMDQ_a2d8ca10-91cb-4755-b3f6-c4a780e5b7bb">245.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e64b243cb74e08990bb73929ab0a6c_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDItNC0xLTEtODIwMDQ_40c3a74b-76d6-404f-a616-dc4c899131b3">378.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_31"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNTQ_fc84f001-d107-49dc-b4ee-e6f840994e53" continuedAt="i5710a184ed8e449b87de907a14c19945" escape="true">Organization and Summary of Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i5710a184ed8e449b87de907a14c19945" continuedAt="ice211e88e7744b3db2ef26fc4c7aa32f"><div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company owned or operated a portfolio of <ix:nonFraction unitRef="facility" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTAyMQ_f442c3a9-75d2-47ad-984c-80d48a658bac">145</ix:nonFraction> surgical facilities, comprised of <ix:nonFraction unitRef="facility" contextRef="i7b158a1a0b39401183f6b663f67d5119_I20230331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA1OA_174e6408-c95a-48d1-b22f-bf322d30fcaa">127</ix:nonFraction> ASCs and <ix:nonFraction unitRef="facility" contextRef="i4e67a4ba4b7b45ec9fb013fdd2a9a8c7_I20230331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA3MA_12b5619d-b2db-405e-acdf-f80c7ab5b90a">18</ix:nonFraction> surgical hospitals in <ix:nonFraction unitRef="state" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5NQ_e621ebda-89a3-45e1-a5df-d6ac20b746ae">31</ix:nonFraction> states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in <ix:nonFraction unitRef="facility" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTI5NA_5d1ef008-be49-4b9a-a342-9da6d2fa3988">92</ix:nonFraction> of these surgical facilities and consolidated <ix:nonFraction unitRef="facility" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwnedConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTM0MQ_15801e32-c7e4-498e-b0de-cc0ac9d5ebec">118</ix:nonFraction> of these facilities for financial reporting purposes.</span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMjQ_ce38c3f8-80ba-4975-aaea-121fe0b6310d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#8217;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the "2022 Annual Report on Form 10-K").</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMTQ_b2f2e687-5fef-4c51-afb3-5276c271a213" escape="true">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwOTI_e69d479b-c6b3-4717-b98c-ecf3e86b67d2" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNzQ_8f02eb63-ab64-4670-8a21-cb0c34f9e66f" continuedAt="i9b857b55db0a44c2a3496709453bc707" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ice211e88e7744b3db2ef26fc4c7aa32f" continuedAt="i0c83458460a14ca7830de02f28025ca5"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwODQ_c172ef3a-bc7d-44ed-818b-7e1ac937eec9" continuedAt="icb3e38b7759849deac634c66de00a83d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93fbb84ab8e54bf68ae45319f7ceed8e_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfMy0yLTEtMS04MjAwNA_eb711367-a812-4938-a6d2-125e1b4e8018">96.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i330b18e5ad5743db8b6302ffdf866646_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfMy00LTEtMS04MjAwNA_17334063-a04b-4554-acad-5326f5ff3b48">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i194a9154acd5484889805e9286e14672_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNC0yLTEtMS04MjAwNA_eb5a6d1c-63c1-493b-820c-89c982f240f4">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5333aa040ad4421ea9ff5171113791b9_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNC00LTEtMS04MjAwNA_6b93e7a6-268d-40b0-a62d-0c2abc937882">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i347c2e534f60472f9aa78f23e2b7662d_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNS0yLTEtMS04MjAwNA_cd5d7ea9-5094-4969-92b5-2de207097e34">98.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24a958c4d33242709d5e6b4c8a16d451_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNS00LTEtMS04MjAwNA_08195f5b-6286-4a6f-851d-525095d8643c">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174f2ef7f43b4017be096fd6960d0dd8_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNi0yLTEtMS04MjAwNA_5ded17d8-31cf-42f7-bb31-d7dd8b90f735">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13bc8547fc6249f391018e3c36ac7ae5_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNi00LTEtMS04MjAwNA_0972e317-4fa1-4f2e-8a87-ab20bca57487">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cec9a12adb2490880d03b5e2db3fb51_D20230101-20230331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNy0yLTEtMS04MjAwNA_59b412ad-c0a1-43ba-9172-7d8c93f77cfd">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1e91e1eeba04f3cb636ac9f9e9c742e_D20220101-20220331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNy00LTEtMS04MjAwNA_a349f79b-934d-49ba-bdd7-09233bf80b85">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:continuation id="i9b857b55db0a44c2a3496709453bc707"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div></ix:continuation><ix:continuation id="icb3e38b7759849deac634c66de00a83d" continuedAt="i62e1a6308c564bfab95aa5c088547a14"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc7653a276442c2895ba6dc6f426066_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC0yLTEtMS04MjAwNA_72bd2336-c7b1-4a5d-aab9-d36359856c47">335.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf0554ebc49d4fcb999fb93084ca8790_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC00LTEtMS04MjAwNA_e6b3b569-b386-48de-b001-57b24e4fd7fa">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b023be21c94ca6b3fda57d05624b2b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC02LTEtMS04MjAwNA_4933af6b-b3d3-4fb8-9c57-44e3616f4c78">300.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic894bd77f5d24d9f8d642bd4486553b9_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC04LTEtMS04MjAwNA_f4cbb0e6-82e3-4640-9eab-f1a051b00b8e">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3a0d5b4af849048366464b85a609df_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS0yLTEtMS04MjAwNA_773c798e-03b6-48ee-b4ca-b0c256d002b3">287.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a1d727596c449d1aa589faede2c444c_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS00LTEtMS04MjAwNA_da9f0fc9-823c-4997-8b56-8dedac881d8f">43.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb44bf1e649f4f9797567c55c11d2a57_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS02LTEtMS04MjAwNA_742dd573-8fbc-466c-a4c4-673980781c00">249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fdfeafd2b2b44c581d7ae62c305a05b_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS04LTEtMS04MjAwNA_7185f815-19b4-4fa0-83ec-6fc68f3d2796">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c8b6e80870471584d0662cd5e62ce1_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi0yLTEtMS04MjAwNA_7f4d20ff-d489-40c9-a722-ed64cd6e3b7c">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3533ff5f75840c8b83b791c1edd4b8b_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi00LTEtMS04MjAwNA_15c849b2-8aae-4c1a-9c26-b0f34a15f64a">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c5f1fcb27242be90a9519d3a5daa49_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi02LTEtMS04MjAwNA_c5128157-7403-497f-8bb8-400434278bc9">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb60ee5f491a4d759f3f80d61bc39428_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi04LTEtMS04MjAwNA_9f0983fa-c75f-4c6e-adeb-b31f606b23d9">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c5bb7aafa14f84b6d67420515600b5_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy0yLTEtMS04MjAwNA_c1582bb5-1403-4682-b25c-ed94360f6ab1">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibaad3032980a44f9b79dd84b65b8a8f3_D20230101-20230331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy00LTEtMS04MjAwNA_c34bf31e-8a19-447f-8ccc-794942940244">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11e527c61994fc4b8612c9529f84738_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy02LTEtMS04MjAwNA_b95adbe6-4fcd-4401-8a8f-73ca90165e3d">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4059e6a11b044239991a9cd274ca93af_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy04LTEtMS04MjAwNA_87ac1b0d-9519-4952-bd28-458696a5a475">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccbab58e225409b8f397b22aaa0921a_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC0yLTEtMS04MjAwNA_e3c7708d-6da7-43ab-a04a-b7364a5e2067">656.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i690afa60488b471bad71d09dde1be1f5_D20230101-20230331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC00LTEtMS04MjAwNA_60399ebc-02f5-4e41-b12f-83adee3c2930">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb842e8e10b4aa2b02cfaeca3e9e29e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC02LTEtMS04MjAwNA_f10026a7-9989-4322-a69d-85d4bf10a767">587.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i567b65cfc1644f8ca0a4e2059d874857_D20220101-20220331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC04LTEtMS04MjAwNA_d2e44993-9896-4087-a133-3cba4c2b8b1b">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39473dc95e60480a8548a0f5e95a4826_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOS0yLTEtMS04MjAwNA_f10eff37-f60c-458c-9b0d-1da097bff7be">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86c371e19dfa4eec95e299e3a708563a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOS02LTEtMS04MjAwNA_637e0146-61af-41b3-9ecf-e39afbda9a54">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfMTAtMi0xLTEtODIwMDQ_349972d2-bbee-484d-9132-90895de9a99d">666.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfMTAtNi0xLTEtODIwMDQ_3561db90-b31e-4558-b33c-ef072a15b248">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:continuation id="i62e1a6308c564bfab95aa5c088547a14" continuedAt="ibc58859ae0eb4c21a03d44d0c5067342">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"><ix:continuation id="ibc58859ae0eb4c21a03d44d0c5067342">Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types.</ix:continuation> </span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMDY_6faaa47b-77e7-469b-b000-e5f184a16c34" continuedAt="i3fc2b83f6b8f4615add51a883a0c17b8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i0c83458460a14ca7830de02f28025ca5" continuedAt="if9850db38c114ed6919306d76a716306"><ix:continuation id="i3fc2b83f6b8f4615add51a883a0c17b8" continuedAt="i0520f89715a549209602e8db3752da6d"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i0520f89715a549209602e8db3752da6d">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</ix:continuation> </span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMDI_104f7220-a146-4a76-b1f2-268643374e56" escape="true"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's effective tax rate was <ix:nonFraction unitRef="number" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTIyNDk_20123c50-fbdb-4bd7-9e76-cfe9a4b44608">400.0</ix:nonFraction>% for the three months ended March&#160;31, 2023 compared to <ix:nonFraction unitRef="number" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTIyOTE_ac7cd998-8cde-4cc9-9184-b0663f9776b5">2.9</ix:nonFraction>% for the three months ended March&#160;31, 2022. For the three months ended March&#160;31, 2023, the effective tax rate differed from the federal corporate tax rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1ODA4Ng_6a2f3297-e3ce-465c-a56e-4da167dbe489">1.8</ix:nonFraction>&#160;million related to the vesting of restricted stock awards. For the three months ended March 31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMzg0ODI5MDcyMTAzNQ_348e7826-c51e-46c2-a72a-a9044d677a76">4.6</ix:nonFraction>&#160;million related to the vesting of restricted stock awards, (b) $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMzg0ODI5MDcyMTA0OQ_acedf43f-62b0-42ec-b705-c6a5bee95c85">1.8</ix:nonFraction>&#160;million attributable to non-recurring earnings&#8217; impact on the Company&#8217;s valuation allowance, and (c) $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMzg0ODI5MDcyMTA2Mw_bcdfe9d6-cdb6-4b91-b7ea-c048cc677552">1.0</ix:nonFraction>&#160;million related to entity divestitures. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwODA_42b10398-ec5b-4361-aa67-0a73d0d49ba4" continuedAt="id1c8147cac014fa98872c95a233a3432" escape="true">Goodwill</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="id1c8147cac014fa98872c95a233a3432">Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.</ix:continuation> A summary of the Company's acquisitions and disposals for the three months ended March&#160;31, 2023 is included in Note 2. "Acquisitions and Disposals."</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="if9850db38c114ed6919306d76a716306" continuedAt="i55f0e07e6dc747b69b889500a9c8eb44"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNjI_c4c10082-67c7-482e-be0d-252ae1db2364" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to goodwill for the three months ended March&#160;31, 2023 is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMC0yLTEtMS04MjAwNA_6ba4f746-9925-40fc-88d5-06db2fa9e02e">4,137.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMS0yLTEtMS04MjAwNA_a0158620-6c56-4576-bb26-98cf76415a5c">91.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMi0yLTEtMS04NjQyNA_7421ac16-4ac6-48e2-9672-1a07011ec48f">11.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMy0yLTEtMS04MjAwNA_25918f6b-e964-4d97-a6ee-323fd234aac7">4,217.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A detailed evaluation of potential impairment indicators was performed as of March&#160;31, 2023, which specifically considered recent increases in interest rates, inflation risk and market volatility. On the basis of available evidence as of March&#160;31, 2023, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company&#8217;s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.</span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNDc_0f0ad54f-2fd7-43cf-94d5-07abb5f480bd" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="sgry:RedeemableNoncontrollingInterestPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxNDU_01035b22-8bbd-4174-a427-5d0bf4c86433" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests&#8212;Redeemable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNjM_469deaf9-66bf-4118-81f1-8889de7e8948" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to non-controlling interests&#8212;redeemable is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfMy0yLTEtMS04MjAwNA_f10447ab-08f2-4f90-9736-f4af784341b9">342.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfMy00LTEtMS04MjAwNA_e9b10a21-0b22-49b5-a9f1-0998d7bcf9d7">330.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNC0yLTEtMS04MjAwNA_ca0a6d07-1345-43d0-8794-654fc7901a94">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNC00LTEtMS04MjAwNA_0262e533-91c6-4d18-b010-622ff28c3021">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNS0yLTEtMS04MjAwNA_b08f2177-ffb7-4b2f-b816-afa05da5d253">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNS00LTEtMS04MjAwNA_926d8e22-6f28-4977-8bf4-7afde915e0e3">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest&#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNi0yLTEtMS04MjAwNA_47e1a2db-f776-42a7-8cb1-1e8a66d4171c">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNi00LTEtMS04MjAwNA_be34f6fd-7db6-4785-8227-13ca2397cee9">11.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNy0yLTEtMS04MjAwNA_b14254d8-8cd8-47fe-9b61-7cc7b15ce6ab">345.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e64b243cb74e08990bb73929ab0a6c_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNy00LTEtMS04MjAwNA_02a789ee-c560-4687-953a-71b103b49db3">341.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Medicare Accelerated Payments and Deferred Governmental Grants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received grant funds distributed under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) and other governmental assistance programs. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues. The Company estimates $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:GrantRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTc5MjM_095c1312-9043-49a9-aee9-4c250fdfe2e7">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:GrantRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1MTAyMw_75c70224-1d4b-4b7c-b2f8-52f61e28d320">1.2</ix:nonFraction> million of grant funds received qualified for recognition as a reduction in operating expenses for the three months ended March&#160;31, 2023 and 2022, respectively. There were no remaining unrecognized grant funds as of March 31, 2023. As of December&#160;31, 2022 approximately $<ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-6" name="sgry:UnrecognizedGrantFundsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1MTIxNw_83fdfdf5-72c5-4bc1-95f2-cda99fa4acbd">3</ix:nonFraction>&#160;million of unrecognized grant funds received was reflected as a component of other current liabilities within the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received accelerated payments under the Medicare Accelerated and Advance Payment Program. The payments received were deferred and included in the condensed consolidated balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the remaining deferred accelerated payments was minimal. During the three months ended March 31, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-6" name="sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1MTM2MA_27c0dd20-7f05-43db-bbb1-bd23e6950a6a">18</ix:nonFraction>&#160;million was repaid in </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i55f0e07e6dc747b69b889500a9c8eb44"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">accordance with the terms of the program. These repayments are included as a component of the change in Medicare accelerated payments and deferred government grants in the condensed consolidated statements of cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policies for relief received under the CARES Act and other governmental assistance programs, including the recognition of grant funds, is unchanged from the policies described in Note 1 to the Company&#8217;s consolidated financial statements included in the 2022 Annual Report on Form 10-K.</span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMzM_a5d25924-ddec-4943-8bcd-4201ac1405a9" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNDQ_7876eff1-5df7-4242-8c23-757ac2c442f7" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if395609fbdf14ab7bd54498a1f593d2b_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy0yLTEtMS04MjAwNA_fdb7ea72-bb6d-4873-bf74-b20ff024b5af">1,370.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a12e5fa6f448c88de9a7f5391b609d_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy00LTEtMS04MjAwNA_16423808-e476-4bae-9874-9757f1f9631f">1,370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d8f30c03d949d484d4aa733ea4240d_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy02LTEtMS04MjAwNA_ce9127b0-f435-47cb-a372-6e04d15c5f54">1,353.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b4ddef7045437ba1eaade0bc4fe400_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy04LTEtMS04MjAwNA_267c5074-7490-4222-9048-883d60761ed1">1,359.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae41732101204d4c86f049ad4216697b_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOmNhZGZiNDBmNmE2NzQ4ZGI5Njg5MTg1NjljMjUwOTY4XzQ_fdc4efbc-40b7-49de-86f5-8683a4794e74">6.750</ix:nonFraction>% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b22c450786b4f0091dc4d4eae7d1675_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC0yLTEtMS04MjAwNA_66afc026-c3fc-4b61-8613-2fdbe1e59ee4">185.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bc921c9b0344e5bb467bc42eaf8791_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC00LTEtMS04MjAwNA_1a57df2c-1391-4c6b-9de9-0c52f216c471">185.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e3330b0a2e34c18a19a93f183c72e49_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC02LTEtMS04MjAwNA_75df6f42-6708-43ce-869f-f2d4d2fcaf45">181.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323cf8e399eb45778ab71e463913d7f4_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC04LTEtMS04MjAwNA_3db257d3-663f-4493-a877-4abd8c1bdd3a">183.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6455bc1ca084f939e75bb4558e43b7d_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjU5OGNiNjE4NDVlMzRiNmNiN2UzZWUwNTczMTg3YTU2XzQ_09d685b2-3421-402e-9045-828dd189add1">10.000</ix:nonFraction>% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idacc70d8240e4b39bd9280d74b6d9b33_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS0yLTEtMS04MjAwNA_9e1a89aa-d6f6-409e-a1a7-620ccdb10422">320.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08eb459530bf461880a8962c3bbf26b8_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS00LTEtMS04MjAwNA_2fe91aca-f1f4-4cb5-8b17-f858d1a68f93">320.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195064f2c74144fa80d098a0e694c828_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS02LTEtMS04MjAwNA_4673c2f4-f62e-4814-965a-8f93e2dd1789">326.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c30227944194e40b8bf2475f00b0c1d_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS04LTEtMS04MjAwNA_ed974a3b-bca5-418e-89db-ec945146494d">326.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMTI_c2a1b25d-7450-47ec-a934-6e36a9fe5fcb" continuedAt="i159727612d3442fe9ebf92689990376a" escape="true">Variable Interest Entities</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><ix:continuation id="i159727612d3442fe9ebf92689990376a" continuedAt="i752b712df4b8440a856f882fb2f259c2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i752b712df4b8440a856f882fb2f259c2">". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.</ix:continuation> As of March&#160;31, 2023, the Company's consolidated VIEs include <ix:nonFraction unitRef="facility" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="sgry:VariableInterestEntityNumberOfFacilities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE3MDQ_e8f06487-64c9-4bd2-9998-44f67e08b36c">seven</ix:nonFraction> surgical facilities and <ix:nonFraction unitRef="physician_practice" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="INF" name="sgry:VariableInterestEntityNumberOfFacilities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE3MzE_f720aad8-3cac-4d9e-b8c1-f518b13da682">five</ix:nonFraction> physician practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of March&#160;31, 2023 and December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="i7fa03c70c0ed47c68e5d1597b922d233_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE5MzM_642b6869-78cc-4c37-a1c0-04c555964b4d">69.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic20dd80291ba42deb6354c4af9a710ba_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE5NDA_09b8d207-e48e-431f-8b34-7b3cde8c5263">64.9</ix:nonFraction> million, respectively, and the total liabilities of the consolidated VIEs were $<ix:nonFraction unitRef="usd" contextRef="i7fa03c70c0ed47c68e5d1597b922d233_I20230331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwMTQ_2ac497d7-e408-4419-8c85-ebc65f27ca56">44.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic20dd80291ba42deb6354c4af9a710ba_I20221231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwMjE_37974085-7b25-4ff2-bc33-42b27ce61420">40.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_34"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNDM0Mw_30f19a4c-9523-49ea-ac7c-648351c32e27" continuedAt="i0612e35d2b1b4cb5ab79b4e5f10e81ce" escape="true">Acquisitions and Disposals </ix:nonNumeric></span></div><ix:continuation id="i0612e35d2b1b4cb5ab79b4e5f10e81ce" continuedAt="idd066de070b344508e063b1ac1b09209"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company acquired a controlling interest in a surgical facility and a physician practice for aggregate cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ife322ebfae344c06aadeb5444f977b01_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNzE0NjgyNTU5NDgxMQ_5840c088-e9c0-47ee-ae7c-fd92d5d36f0e">16.2</ix:nonFraction>&#160;million, net of cash acquired, and non-cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ife322ebfae344c06aadeb5444f977b01_D20230101-20230331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfOTQ3_a03e324b-5316-4ae0-8bd2-1993cfb9dace">1.3</ix:nonFraction>&#160;million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $<ix:nonFraction unitRef="usd" contextRef="ia038e278a48340bda3280d3d858e408e_I20230331" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTE1Mw_34001e42-79c9-42a3-ad6a-6ebef75eb69c">12.0</ix:nonFraction>&#160;million and goodwill of $<ix:nonFraction unitRef="usd" contextRef="ia038e278a48340bda3280d3d858e408e_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTE3Mg_16e2272a-1aeb-40b5-8d6f-9f1cabc24e18">25.7</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="idd066de070b344508e063b1ac1b09209"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company acquired a controlling interest in <ix:nonFraction unitRef="facility" contextRef="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzI5ODUzNDkwNTU5Mw_a3fc57f9-337f-4532-bed3-2b8cefa2cfe6">two</ix:nonFraction> surgical facilities which were previously accounted for as equity method investments for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNzE0NjgyNTU5NTAxNQ_021d0263-39bc-4095-bd9d-a8f09345c538">24.5</ix:nonFraction>&#160;million, net of cash acquired. As a result of these transactions, the Company obtained control of the previously non-controlled surgical facilities, resulting in the consolidation of the previously non-consolidated entities. The previously held non-controlling were remeasured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data. The acquisition date fair value of the previously held non-controlling interests was $<ix:nonFraction unitRef="usd" contextRef="i9b9dc705bdaf4307a20eb8262bdc4a27_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3MTg3MA_6f1e5548-fbb9-4b7f-b9a0-02555afb32ff">8.3</ix:nonFraction>&#160;million. As a result of stepping up its ownership interest, the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk2OTA3MA_adc8189b-1be8-424a-823b-bcca8e6b5720">2.9</ix:nonFraction>&#160;million included in net loss (gain) on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023. The net loss was determined based on the difference between the fair value of the Company's previously held non-controlling interests in the entities and the carrying values immediately prior to the transactions. In connection with the acquisitions, the Company preliminarily recognized non-controlling interests of $<ix:nonFraction unitRef="usd" contextRef="ia0289c146748495ea969e604a4ecc4a0_I20230331" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3MjQ2NA_4c236e8a-9bca-45af-a35b-70deaf8b70ff">34.2</ix:nonFraction>&#160;million and goodwill of $<ix:nonFraction unitRef="usd" contextRef="ia0289c146748495ea969e604a4ecc4a0_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3MjQ4NA_5bcce062-41a9-4d97-a094-60c909ddc649">65.6</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company acquired non-controlling interests in an existing surgical facility and an in-development de novo surgical facility for an aggregate cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="i602c53397d114d5783de58eea6a301e1_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3NDY0Mw_ec3ab212-d53f-471c-95a4-83944373018a">12.4</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i79df32098d2a43b6b68b90171d47d5e8_I20230331" decimals="-5" name="sgry:DeferredPaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3NDY1Nw_1360d78b-c635-4883-91f7-1074860b6f9c">2.8</ix:nonFraction>&#160;million was deferred and will be paid in April 2023. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. In April 2023, the Company obtained control of an existing non-controlled surgical facility due to an amendment to the facility operating agreement, resulting in the consolidation of the previously non-consolidated entity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company acquired a controlling interest in <ix:nonFraction unitRef="facility" contextRef="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTA5OTUxMTYzMjgxMw_98432af4-0681-4d7d-92a8-d21e65ba2e78">two</ix:nonFraction> surgical facilities, <ix:nonFraction unitRef="facility" contextRef="ibe2f8852d0e443be810017d409db5c10_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTA5OTUxMTYzMjgxOQ_65435f74-5f76-4744-9ac9-6955cb6f6ff1">one</ix:nonFraction> of which was merged into an existing surgical facility, for aggregate cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNzE0NjgyNTU5NTMzMg_ee529020-0c51-4971-802a-b8376f98bfa8">31.1</ix:nonFraction>&#160;million, net of cash acquired, and non-cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTA5OTUxMTYzMzA4NA_63002c4c-4926-47ce-a31d-48f270d045d5">2.6</ix:nonFraction>&#160;million. In connection with the acquisitions, the Company preliminarily recognized non-controlling interests of $<ix:nonFraction unitRef="usd" contextRef="i3637827bd8fa46638845369ff6cefb32_I20220331" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTU0NQ_f4d18fb8-c463-46dd-a4c2-e8f84366c700">10.6</ix:nonFraction>&#160;million and goodwill of $<ix:nonFraction unitRef="usd" contextRef="i3637827bd8fa46638845369ff6cefb32_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTU2NA_6d6288f7-2fa1-420a-9e22-0d4999910cd2">42.7</ix:nonFraction>&#160;million. During the three months ended March&#160;31, 2023, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Disposals</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company sold its interests in a surgical facility for a cash sales price of $<ix:nonFraction unitRef="usd" contextRef="iec7a6a99212642aab1d11f46ef8b71e8_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk2OTkwMA_d059aa02-907b-4e07-baf0-b09a4d2ee10c">8.8</ix:nonFraction>&#160;million, a portion of which was held in escrow pursuant to the purchase agreement. In connection with the sale, the Company recognized a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="iec7a6a99212642aab1d11f46ef8b71e8_D20230101-20230331" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk2OTk4OA_15e2def0-2610-46e5-a362-4d9c4b88f4e5">0.2</ix:nonFraction>&#160;million included in net loss (gain) on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company sold its interests in a surgical facility, which was previously accounted for as an equity method investment, for net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjU3Ng_f7c94af2-2d91-4d0e-926e-af1d7d7352f0">11.5</ix:nonFraction>&#160;million, and recognized a pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjU5MQ_e85aa547-a8c9-48b0-a07f-6f203f1fff91">0.4</ix:nonFraction>&#160;million included in loss (gain) on disposals and consolidations, net in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company contributed its interests in <ix:nonFraction unitRef="facility" contextRef="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331" decimals="INF" name="sgry:DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYwNA_bd6f9b45-dde9-450e-afda-d3bad12f1b70">two</ix:nonFraction> surgical facilities as non-cash consideration for non-controlling interests in <ix:nonFraction unitRef="business_entity" contextRef="ia62b48e259754cf8b5b649d1146431d7_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYzMw_7292dcca-4f86-40a6-b08c-f9c668be57fb">two</ix:nonFraction> new separate entities. As a result of these transactions, the Company lost control of the previously controlled surgical facilities but retains a non-controlling interest in each, resulting in the deconsolidation of the previously consolidated entities. The remaining non-controlling interests were accounted for as equity method investments, and initially measured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data, to measure the fair value of the retained non-controlling interests. The fair value determination was based on a combination of multiple valuation methods, which included discounted cash flow and market value approach, which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. The fair value of the investments of $<ix:nonFraction unitRef="usd" contextRef="i9d5a67a56b014b7b8024c968af016c48_I20220331" decimals="-5" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYwNg_4ee072e5-d6cc-44fa-a29a-2f6a1502f89b">9.8</ix:nonFraction>&#160;million was recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. Further, based on the valuation, the transactions resulted in a pretax net loss on deconsolidations of $<ix:nonFraction unitRef="usd" contextRef="i5360c902c0454970be9a1279e60a08c7_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYyMA_a04f39d2-44a8-4377-8206-cd4552ce768f">5.6</ix:nonFraction>&#160;million, which is included in net loss (gain) on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2022. The gains were determined based on the difference between the fair value of the Company's retained interests in the entities and the carrying values of both the tangible and intangible assets of the entities immediately prior to the transactions.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTE5Nw_58562afd-506e-4944-88f0-daca508b50a7" continuedAt="icb2b45aa1a73412ea215283a5740dc33" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="icb2b45aa1a73412ea215283a5740dc33"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTE4Mg_065c5b2f-8503-472b-88d6-4a046cb227f7" continuedAt="if2748cc562ee4a5fad44aeb3f0700e97" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31e09c8a7f742a7be738ff2b92bbe76_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMi0yLTEtMS04MjAwNA_565e24e7-6ce8-478f-971d-b313869ab404">1,370.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a68d29d5ed4fd982d2f908018f3c10_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMi00LTEtMS04MjAwNA_3ba4c971-4fb0-478a-a050-b1b06fe7c15b">1,370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae41732101204d4c86f049ad4216697b_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMy0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjM0MWFkMjNjY2U0OTRlMGRhOTNmZjg1ZDQ0MWY1Zjc3XzQ_fdc4efbc-40b7-49de-86f5-8683a4794e74">6.750</ix:nonFraction>% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae41732101204d4c86f049ad4216697b_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMy0yLTEtMS04MjAwNA_66bcab8c-36b3-4557-9825-89b4d5e8ccd2">185.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife734a9e9b7c478480dcde8c8c378846_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMy00LTEtMS04MjAwNA_47f6ac14-babd-4b78-98eb-63c9bb169a4f">185.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6455bc1ca084f939e75bb4558e43b7d_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNC0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjYyNThhOWVhNjMyNDRlNDg5Y2I5MTAxZjA3N2U0MWI2XzQ_09d685b2-3421-402e-9045-828dd189add1">10.000</ix:nonFraction>% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6455bc1ca084f939e75bb4558e43b7d_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNC0yLTEtMS04MjAwNA_a906a913-6e66-42fd-8020-2096951af0f6">320.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8254371571844ad8161e4d28a3392c2_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNC00LTEtMS04MjAwNA_e186b43f-530c-4f6f-a3bd-53521cf8abc3">320.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d1e8e2eb6f4636a25ae23bd08dab22_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNS0yLTEtMS04MjAwNA_b3909872-fe7f-4809-9aca-90d55c69b3ac">174.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23e712005c5d48dc978669d2c705456c_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNS00LTEtMS04MjAwNA_e0cd38d2-f8ec-4bba-8626-23170572c938">171.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNi0yLTEtMS04MjAwNA_43c4fec7-ca68-4053-9416-33e151a743c9">553.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNi00LTEtMS04MjAwNA_af591794-7552-4cb0-b431-c5cd49f6f395">585.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNy0yLTEtMS04MjAwNA_f9dae3fd-d396-4dd9-b48e-e0872e3fa67d">9.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNy00LTEtMS04MjAwNA_af998bea-bba0-4d98-b71e-5afb80bb6852">10.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOC0yLTEtMS04MjAwNA_2b773edb-753e-4539-9ebc-64286ecf033a">2,593.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOC00LTEtMS04MjAwNA_dfefae5c-b53c-4b0e-ade7-48759274f942">2,621.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOS0yLTEtMS04MjAwNA_9dc435ee-ea8f-4650-9df7-636dee304ec4">62.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOS00LTEtMS04MjAwNA_3e84c354-e90f-41aa-909e-d9827afdf8bb">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMTAtMi0xLTEtODIwMDQ_ab1e2d18-c30f-41bd-8746-c61a532c9536">2,530.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMTAtNC0xLTEtODIwMDQ_28151d88-a0e7-4fe5-970f-e06cc8084c95">2,559.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><ix:continuation id="if2748cc562ee4a5fad44aeb3f0700e97" continuedAt="i9b7503ae6ca444c18d75ff92e4efef41"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $<ix:nonFraction unitRef="usd" contextRef="ie31e09c8a7f742a7be738ff2b92bbe76_I20230331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTIy_c89c8327-9c26-4aa6-9565-ad2431a32560">2.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="ie8a68d29d5ed4fd982d2f908018f3c10_I20221231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTA5OTUxMTYyOTAwMA_c534175b-fa79-4cc4-8b74-b4fa84360929">2.1</ix:nonFraction>&#160;million as of March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:continuation id="i9b7503ae6ca444c18d75ff92e4efef41">December&#160;31, 2022, respectively.</ix:continuation> </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 13, 2023, the Company entered into an amendment to the credit agreement governing its revolving credit facility (the "Revolver"), which amended and supplemented the credit agreement, dated as of August 31, 2017 (the "Credit Agreement"), to provide a $<ix:nonFraction unitRef="usd" contextRef="i4be4e474695442ff8609d04af8b53bf2_D20230113-20230113" decimals="-5" name="sgry:LineOfCreditFacilityIncreaseInBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTA5OTUxMTYyOTU0NA_2062535e-a2f6-4ba7-a3f1-75ebe869065d">203.8</ix:nonFraction>&#160;million increase in the outstanding commitments under the Revolver. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company's availability on its Revolver was $<ix:nonFraction unitRef="usd" contextRef="i615ae79f54e248ed8c11df419a474567_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTA1Mw_e304282a-8dd7-4377-8385-beeb8cb5e019">545.9</ix:nonFraction> million (including outstanding letters of credit of $<ix:nonFraction unitRef="usd" contextRef="i4d03e45ac72242afb2e27ac00a7fede9_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTEwMA_90bfeb5e-2e21-46b3-9268-1434a38cd876">7.9</ix:nonFraction> million). There were <ix:nonFraction unitRef="usd" contextRef="i4ba191127c0e418d98b7c137b8b3b012_I20221231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTExNg_9156d910-5a1a-42c3-83f8-12803c246298"><ix:nonFraction unitRef="usd" contextRef="iffd37df4ed4f4e928da39c9e8a3b97d1_I20230331" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTExNg_d4480cde-1e74-4417-b738-495009ea51cd">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under the Revolver as of both March&#160;31, 2023 and December&#160;31, 2022.</span></div></ix:continuation><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_40"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTEzNQ_0cc7951f-f9f0-4294-85e9-0ea9b03eab4c" continuedAt="icd0de391d5a64177b4770c069418beac" escape="true"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTEzNQ_c9cc57c5-4bcc-44fc-8ef0-2b4e88b8e8aa" continuedAt="i1488c9fed9bf407fbed5011bd264ca42" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="icd0de391d5a64177b4770c069418beac" continuedAt="i91a980fa002e42d7b054c792d84b7687"><ix:continuation id="i1488c9fed9bf407fbed5011bd264ca42" continuedAt="i5c1f5435e27043f4a469d7103f578103"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. </span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="sgry:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTE0MQ_b423d0a9-fce8-4740-a678-779c1ef8411a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMy00LTEtMS04MjAwNA_c0d017ec-74ac-4647-8696-6862a54a8921">274.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMy02LTEtMS04MjAwNA_55845dd7-4869-4ecc-ba15-bbc25c49b1fd">279.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC00LTEtMS04MjAwNA_4f21b3d6-2dd4-41e6-9ef7-e899bf908b14">490.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC02LTEtMS04MjAwNA_03e7f332-7ea2-43ba-a9e8-a3a5ee4d237c">529.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="sgry:LeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNS00LTEtMS04MjAwNA_786d7b02-9fbb-4823-9a7a-aa8e2e195035">764.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="sgry:LeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNS02LTEtMS04MjAwNA_d3a4627b-5571-4897-bba5-2eebd38ed373">808.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS00LTEtMS04MjAwNA_501a2948-edfb-4c9b-a696-a6bf16245d23">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS02LTEtMS04MjAwNA_85c57cbb-499f-474a-9946-e6f87d96c285">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTAtNC0xLTEtODIwMDQ_1e8131ac-9a4d-4c8b-8967-0ba0f8f3db15">268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTAtNi0xLTEtODIwMDQ_2af6597e-e1e8-4a8f-975a-c1c72ada6cfa">271.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTEtNC0xLTEtODIwMDQ_8b5db528-074d-4852-b092-4a395b1e452a">306.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTEtNi0xLTEtODIwMDQ_3f8b3606-25f9-4c5b-8efc-ca2fff6be998">307.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtNC0xLTEtODIwMDQ_73d4ad1c-d08d-41bc-8189-2ab4806ba059">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtNi0xLTEtODIwMDQ_4e2ec62c-cf09-4059-b198-784dbc868a7c">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtNC0xLTEtODIwMDQ_a47af8a3-ca57-4b63-a131-4fe599b151b6">532.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtNi0xLTEtODIwMDQ_4185b66d-35f4-4128-bfa9-496392e77d2a">564.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTUtNC0xLTEtODIwMDQ_a3d7121f-e60f-409c-97b3-917060fc6fb2">553.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTUtNi0xLTEtODIwMDQ_29c181eb-2483-4e0c-9186-e1cc97714826">585.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="sgry:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTYtNC0xLTEtODIwMDQ_e3b2fc06-ece9-46c6-877f-c00e13d117b3">860.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="sgry:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTYtNi0xLTEtODIwMDQ_309c0d04-4185-46b9-aa78-fa2566ed742b">893.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i91a980fa002e42d7b054c792d84b7687"><ix:continuation id="i5c1f5435e27043f4a469d7103f578103"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTE0Mg_5ad0917c-b8f5-4cd3-b521-4e10e9d9e797" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense included in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfMi0yLTEtMS04MjAwNA_c337e375-a67e-491a-a47c-8370e33a831d">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfMi00LTEtMS04MjAwNA_cd43ce0b-1720-4eaf-afb7-cadaff89f16f">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNC0yLTEtMS04MjAwNA_52eadc15-69c6-41f3-9281-42f7f3bfdf11">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNC00LTEtMS04MjAwNA_26e465f5-2e5f-4eaf-8af8-c53e1b8c2bac">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNS0yLTEtMS04MjAwNA_4843d182-d235-4322-ac61-5c230929964d">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNS00LTEtMS04MjAwNA_29da0316-c3a6-497e-81d0-6bb746ea1dbf">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNi0yLTEtMS04MjAwNA_eba8d3f5-176f-4c16-a197-6e8d809e8ed2">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNi00LTEtMS04MjAwNA_e7b37fa8-e0aa-4511-9432-73525a4b2270">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:VariableAndShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNy0yLTEtMS04MjAwNA_22681007-3936-48b2-97ec-688a0a2ac37b">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:VariableAndShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNy00LTEtMS04MjAwNA_5c11a7c2-378c-4b43-a12f-2dfb1b82d9ef">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfOC0yLTEtMS04MjAwNA_0fa42936-c7a3-4392-a803-12768179bedd">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfOC00LTEtMS04MjAwNA_679b3519-40d1-4cf7-b820-7615ed8da13e">39.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfMy0xLTEtMS04MjAwNA_08fab6f6-2803-4418-87eb-ed2610bf05bd">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfMy0zLTEtMS04MjAwNA_1e0a5d70-0352-4e17-aa44-9f4062241f47">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNC0xLTEtMS04MjAwNA_baa47103-c54e-445c-aacc-0f61d2c7f1fa">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNC0zLTEtMS04MjAwNA_ac83e286-c1f0-4922-8ff3-600ef12b9959">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNS0xLTEtMS04MjAwNA_b7f28632-15f9-4175-b223-1c08799d804f">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNS0zLTEtMS04MjAwNA_a1c48df9-af69-42aa-a82b-cd75f9dca65f">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOC0xLTEtMS04MjAwNA_7278d136-4a93-4b27-8250-c08facd97c03">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOC0zLTEtMS04MjAwNA_4d560588-df76-4d36-a382-fdbfcb5e3138">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOS0xLTEtMS04MjAwNA_48ec38e9-d900-4f2a-9450-34ceb9e997ae">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOS0zLTEtMS04MjAwNA_8e38924e-272d-4321-b0e1-e28deb082b15">89.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_43"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNTAxMw_c031c677-a520-4bfc-9a90-b14db32eb740" continuedAt="iccb433b075c24c1bb5c93e562fcfbedb" escape="true">Derivatives and Hedging Activities</ix:nonNumeric></span></div><ix:continuation id="iccb433b075c24c1bb5c93e562fcfbedb" continuedAt="i32a446ac703045a588faf9841e50b52e"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMzI5ODUzNDg5MzA0MA_6ace8335-0914-44ed-bd5d-8cafd130d946" continuedAt="id3ee793457fa4a5fb42f916929e3d8ac" escape="true">During 2023 and 2022, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.</ix:nonNumeric></span></div><ix:continuation id="id3ee793457fa4a5fb42f916929e3d8ac"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The key terms of interest rate swaps and interest rate caps outstanding are presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b122a7729f846aa83ebcbf74914d1ea_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMi00LTEtMS04OTIyNg_5e776f9e-16d2-473e-bd41-c50bf8d0d59f">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fdfc90ff3a14df4942da87910339b7d_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMi04LTEtMS04OTIyNg_2927ed26-f4ce-42ea-951e-ac8b0f7d4113">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe42526145740de8a9b4f2c4ab6be7b_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMy00LTEtMS04OTIyNg_29bab942-f899-4adc-ac51-b84bbe935b47">330.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4d54f90673412ab5865efd54bf31bd_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMy04LTEtMS04OTIyNg_221faae4-e46d-4024-bb28-e02e3bd71ad5">330.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3ddfc6326b430ba42803e01d9ea155_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNC00LTEtMS04OTIyNg_8dfa1d68-74b4-44a1-87c6-ee77eb6f0dfe">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7aaa64d2b9647c0880375718f91f9aa_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNC04LTEtMS04OTIyNg_374c0c9a-9ba4-4279-9f85-c13ff9bf596b">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ee0c2d30114fa7a498e11d518d5e86_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNS00LTEtMS04OTIyNg_5a7591e6-f1e9-4d48-9eed-c732e8ba4c8e">157.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cc717c4e3294018b3a17b8db7550574_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNS04LTEtMS04OTIyNg_127bbb23-1af2-4d77-8d26-3d2299c1ad65">159.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3958dd7b5c43feb0b399d644cfcd76_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNi00LTEtMS04OTIyNg_696b72a0-8620-42c3-887b-37b6052d8b2e">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef97110d9b04fc3800be00674d398a8_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNi04LTEtMS04OTIyNg_feb05990-1f0c-4834-b6bb-265668ffe783">159.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6363d1608b80467fabaff6452dee18c1_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNy00LTEtMS04OTIyNg_30ff7335-435a-4999-94b4-79ee74f7cde3">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f20c8303b34ed89344ee532d50feb5_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNy04LTEtMS04OTIyNg_574c2fd1-50ae-4e1c-82a3-f6db2c7873c8">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ac93228961451d928a5d157461cb0c_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOC00LTEtMS04OTIyNg_1fda5d12-7898-4736-937e-f6d9e52aac06">120.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad3beb2f31c412db347647224886c3c_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOC04LTEtMS04OTIyNg_2d698c08-10c9-43b1-8dd7-cc7b8609a94e">120.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d43b1d96bd4419da9eece9e1cdddd7c_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOS00LTEtMS04OTIyNg_d2a750a6-f303-4513-b2d6-b55aa5c73f8b">150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2552dc67907f4497afcc3243f335c0da_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOS04LTEtMS04OTIyNg_77c3f8b5-c72d-4fb5-b7d8-ea3354f5de44">150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie53660b17d444b948667db475ff5f35b_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTAtNC0xLTEtODkyMjY_82c5f8d4-9cf5-4f86-a0fd-d4dbcdaac84d">165.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if32f04ce941249ddbd22432651106a15_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTAtOC0xLTEtODkyMjY_0ce97118-e6ff-4ba8-a7a4-b2a5ca4c49f7">165.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic698993ebca540e6a16d6647445084ef_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTEtNC0xLTEtODkyMjY_c6867962-5666-436c-ab9d-a8001fe79f23">120.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i372b7962442b41a2ad5aae90be62bfd9_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTEtOC0xLTEtODkyMjY_e96a317b-d595-45df-8ffe-7e80c628393f">120.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13b3e0bc44448129d260b0bf3a9c405_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTItNC0xLTEtODkyMjY_c131c76f-a742-4b06-a769-ae37f109ad32">150.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83325c5100f64cd79cec11f2d4874566_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTItOC0xLTEtODkyMjY_313dfb89-b97f-4e70-aee0-dbec528e4bc6">150.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTMtNC0xLTEtOTA0MzY_ce68380f-8f09-4cd0-846a-c3a3da8af36b">1,366.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTMtOC0xLTEtOTA0Mzg_6c3d9098-4207-44d4-847a-5e1eec6d75e1">1,518.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had <ix:nonFraction unitRef="interest_rate_swap" contextRef="i46fd0fed21334b48980d887244b2c6db_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTIxMQ_da76f8e6-e799-4821-8ac7-d596ce4f639e">nine</ix:nonFraction> interest rate swaps with a total net notional amount of $<ix:nonFraction unitRef="usd" contextRef="i46fd0fed21334b48980d887244b2c6db_I20230331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTI3Nw_aebe842d-af26-4d3f-be84-76c2c849323d">1.2</ix:nonFraction>&#160;billion. Of the <ix:nonFraction unitRef="interest_rate_swap" contextRef="i46fd0fed21334b48980d887244b2c6db_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTM1Ng_1441a3e3-2910-4266-9f60-132f285a3561">nine</ix:nonFraction> interest rate swaps, <ix:nonFraction unitRef="interest_rate_swap" contextRef="i8302a05487cc46e38e8ff3204b1ef2ad_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTM4MA_3e0f428d-8213-4b46-8847-45c1afd97ae6">three</ix:nonFraction> are pay-fixed, receive 1-Month LIBOR (subject to a minimum of <ix:nonFraction unitRef="number" contextRef="i8e445dd464d44ade88f9c43c91d57652_I20230331" decimals="INF" name="us-gaap:DerivativeVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTQ0NQ_3ffc5e97-8dcd-43da-b70a-6ef682d0ef65">0.75</ix:nonFraction>%) interest rate swaps designated in cash flow hedging relationships with a total notional amount of $<ix:nonFraction unitRef="usd" contextRef="i8302a05487cc46e38e8ff3204b1ef2ad_I20230331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTU0Nw_1383eea2-f2c5-4ae8-97d3-591dac428fad">1.2</ix:nonFraction>&#160;billion and a termination date of March 31, 2025. The remaining <ix:nonFraction unitRef="interest_rate_swap" contextRef="i033d3f1806b744ce9eadad25192e34c5_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTU5NA_9848966a-3537-4235-9795-8e4fcb5463f3">six</ix:nonFraction> interest rate </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i32a446ac703045a588faf9841e50b52e" continuedAt="i7babc2f31dcc4aaba667ef2e641f5086"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">swaps are undesignated and consist of <ix:nonFraction unitRef="interest_rate_swap" contextRef="i3af8b13e57f44b27bb771a94d96d89aa_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTY0OQ_fd6807b3-f303-46a6-92f3-c3277100458d">three</ix:nonFraction> pay-fixed, receive 1-Month LIBOR (subject to a minimum of <ix:nonFraction unitRef="number" contextRef="ic1065326829d4decbc61f91f23875e3b_I20230331" decimals="INF" name="us-gaap:DerivativeVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTcxMA_12387927-d8ac-46f5-a0d5-745a82987687">1.00</ix:nonFraction>%) interest rate swaps and <ix:nonFraction unitRef="interest_rate_swap" contextRef="idb4cece3ff2e407f9fb299708f2e854b_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTczOA_27b975c2-f403-4a11-8bc9-dd17b8441899">three</ix:nonFraction> pay 1-Month LIBOR (subject to a minimum of <ix:nonFraction unitRef="number" contextRef="i6bca9cce39a74eb380fb5d884f2da248_I20230331" decimals="INF" name="us-gaap:DerivativeVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTc4NA_63bb71fc-70e0-4584-967a-aea2812a187d">1.00</ix:nonFraction>%), receive-fixed interest rate swaps with a termination date of November 30, 2023. The pay-floating, receive-fixed swaps are designed to economically offset the undesignated pay-fixed, receive-floating swaps. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had <ix:nonFraction unitRef="interest_rate_swap" contextRef="i0a74f9aadc8a47c890d7ae741d0d1e9e_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTA5OTUxMTYzNDExMw_73dd42c0-480a-4f1f-8595-55e7a3ae8d90">two</ix:nonFraction> interest rate caps designated in cash flow hedging relationships with a total notional amount of $<ix:nonFraction unitRef="usd" contextRef="i0a74f9aadc8a47c890d7ae741d0d1e9e_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTA5OTUxMTYzNDE0OQ_945d3e57-2b05-42aa-9836-9268f66df76d">166.1</ix:nonFraction>&#160;million. The interest rate caps each have a termination date of March 31, 2025. During the three months ended March 31, 2023, the Company partially terminated a previously undesignated portion of one of its interest rate caps. In connection with the termination, the Company received $<ix:nonFraction unitRef="usd" contextRef="i517ad963d7114f93893b2d189dc801a1_D20230101-20230331" decimals="-5" name="sgry:ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNjA0NzMxMzk2MjMzMw_0b2f60b7-4087-44e8-963c-7612ced3622d">8.6</ix:nonFraction>&#160;million, which is included as a component of operating activities in the condensed consolidated statements of cash flows for the three months ended March 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Within the Company&#8217;s condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives and the undesignated swaps are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Cash settlements related to the undesignated swaps will offset and are classified as operating activities in the condensed consolidated cash flows. Within the Company&#8217;s condensed consolidated balance sheets, the interest rate caps, including the undesignated portion, are recorded at fair value. The cash flows related to the interest rate caps, including the undesignated portion, are classified as operating activities in the condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps are determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt. Over the next 12 months, the Company estimates that an additional $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNjA0NzMxMzk2MTY5NA_4ef60cb2-9725-4015-88b1-8c0e218dc58c">33.6</ix:nonFraction> million will be reclassified as a decrease to interest expense.</span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNTAxMQ_7d550073-4d6d-46c0-a625-d6c906ef0edc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8812d79ba0e7406a8a6f1c6d561cc07a_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMy04LTEtMS04MzMyNQ_83dce34d-57e2-4f93-937c-668bea794861">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29099c90b3434f62bb442dd9874e5c47_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMy00LTEtMS04MjAwNA_6e2531f9-54b1-4731-aba0-4014a61f0110">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5cac67689284faabfc9916d5cb46d63_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMy04LTEtMS04MjAwNA_e9c35a3b-66f6-4b27-a136-550e97b86d3d">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic979a115883d4f5592bb7c07055ffbf5_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNC02LTEtMS04MjAwNA_d2551b0b-f94a-4116-967e-481920f713ee">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3a9b4bf3a2433f898c5e81d44b1b91_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNC0xMC0xLTEtODIwMDQ_2b3096d6-4b15-4472-94bc-5ec0a2eee384">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9adfa3e753a42ca88143d956ce95e86_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNy00LTEtMS04MjAwNA_8212fd13-aa24-498b-a65a-fd3b6c0ea926">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a6a63c9b104ac2a07649af064d610e_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNy04LTEtMS04MjAwNA_3b8b563f-6f25-4af2-8fed-1507d46aefd6">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbafff4d10d840b2955f9a765fcf5409_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOC00LTEtMS04MjAwNA_6979c285-a67d-4cd6-b524-f43642d8ba40">70.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c827cd5ece5427082bea6ecb15df8c7_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOC04LTEtMS04MjAwNA_eb06ab72-c83d-41a0-94fb-0c4858661ce3">85.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886a6e64b9a743b0aca7c22e739b1e1d_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOS02LTEtMS04MjAwNA_d4567ad6-cca2-455b-b8c4-f7058c99d440">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica8d344040734175a530bc09317337aa_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOS0xMC0xLTEtODIwMDQ_908aac8c-f569-47c6-ae9f-4ca506848052">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtNC0xLTEtODIwMDQ_81dfc5b7-2f55-47c8-92ca-a639fb078fd7">85.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtNi0xLTEtODIwMDQ_caa13c3f-3deb-4534-ad7c-d458aba2c1e9">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtOC0xLTEtODIwMDQ_0ca74934-0121-400b-9150-fdfbc608f4ff">113.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtMTAtMS0xLTgyMDA0_7a278b85-5a47-4324-a2f3-a84d7e462fd3">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The balance  is related to the financing component of the pay-fixed, receive floating interest rate swaps.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7babc2f31dcc4aaba667ef2e641f5086" continuedAt="if126513d69a84aaeafedbe67cb20854b"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNTAxMg_36c00bf6-2cc5-4d23-969a-0a9bfa67c633" continuedAt="ibfcae17fca054941b338a79b0024c7fe" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:54.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.230%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss recognized in income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4a8d2749ec405c9d0f00d16b8d1584_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfMy0zLTEtMS04MjAwNA_47e0ec70-c1ff-4634-937c-1cae675bd04c">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363d451cc1cb4d0c96744998ea60df5c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfMy01LTEtMS04MjAwNA_cbf527a9-3b4f-4dd2-ad5f-15780aceff48">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i759de978c1164030aaf39f8ac3180d79_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNi0zLTEtMS04MjAwNA_990037cc-c727-4451-acc2-07f0a0360146">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eab5cbc43744770be5708852cdd239c_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNi01LTEtMS04MjAwNA_cec73fc5-6735-40ae-bf17-46f3e7ce9a7f">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss reclassified from accumulated OCI into income (effective portion) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0xLTEtMS04MjAwNA_eaac48d6-4a38-4801-99ed-58a72d155519">Interest expense, net</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i759de978c1164030aaf39f8ac3180d79_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0zLTEtMS04MjAwNA_2f1ad4e8-0572-4672-be79-03cc68647856">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eab5cbc43744770be5708852cdd239c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy01LTEtMS04MjAwNA_77d8a0d8-46cd-49aa-992a-fb1675c3bf93">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:continuation id="if126513d69a84aaeafedbe67cb20854b" continuedAt="id8dca4675e9b4f2ea1c4311d044553d5"><ix:continuation id="ibfcae17fca054941b338a79b0024c7fe" continuedAt="i02a9c627a99c490489a2a2ee8e970f66">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"><ix:continuation id="id8dca4675e9b4f2ea1c4311d044553d5"><ix:continuation id="i02a9c627a99c490489a2a2ee8e970f66">Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNDgwNQ_21c74d0b-188f-41a4-9d71-fba1933c5bb1">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTA5OTUxMTYzNTEyNQ_a9c1823d-5cde-468a-807b-7714e930a9da">5.3</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively.</ix:continuation></ix:continuation> </span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_46"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RleHRyZWdpb246OGM5MDYzODY2OTA3NDllMjgzYmY4YWMyY2ExYzcyNTBfMTMzNg_841342bb-a7f2-4be0-99ab-4889b15b871f" continuedAt="ice2d54fa046b4f27b1514e0e81e74893" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="ice2d54fa046b4f27b1514e0e81e74893"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RleHRyZWdpb246OGM5MDYzODY2OTA3NDllMjgzYmY4YWMyY2ExYzcyNTBfMTMzOQ_f3af74c0-7f51-451e-ad48-c6cf514abd84" continuedAt="i48a43e485658417d9b6ee160bfbc18d1" escape="true">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </ix:nonNumeric></span></div><ix:continuation id="i48a43e485658417d9b6ee160bfbc18d1"><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to Surgery Partners, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMy0xLTEtMS04MjAwNA_f3f12ac0-aa7a-4995-ab94-68160200a587">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMy0zLTEtMS04MjAwNA_cd56bb52-eaf3-48ce-88c8-97a9cfe1aae3">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOC0xLTEtMS04MjAwNA_40a07f52-7e6d-4451-8462-736c1a2b8959">125,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOC0zLTEtMS04MjAwNA_de54a245-36a5-430a-982b-8bb192fdf610">87,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOS0xLTEtMS04MjAwNA_252996ba-afcd-481f-9d6e-f3beac8aae3c">125,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOS0zLTEtMS04MjAwNA_d3fb2777-b30a-4f9b-adda-073d47062ee4">90,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Loss) income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTItMS0xLTEtODIwMDQ_cd830a76-d0e3-48be-8e60-b7460bdaa3ea">0.20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTItMy0xLTEtODIwMDQ_ee0b33e6-e28b-43d3-8f87-c5604d26d8eb">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTMtMS0xLTEtODIwMDQ_5ea318ff-8ffd-4885-8cf1-d95005ffc0e5">0.20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTMtMy0xLTEtODIwMDQ_299b70d3-be0a-49aa-a617-2b0d1b4c3260">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife80b1a65af94f9b863703998b3c1df8_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTYtMS0xLTEtODIwMDQ_60f29c26-9267-4a8c-a725-077b94093ffe">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifab134fcb68746328d5adb54f4ab2b41_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTYtMy0xLTEtODIwMDQ_f33d01ca-32ce-4cad-ad1d-41cf98812f21">1,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e51254b066146b68172b2d7e45eabf9_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTctMS0xLTEtODIwMDQ_f836c76d-a8ec-4317-a621-97d121976edd">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i570ad1cc62c24af1a4a594dacdc9450a_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTctMy0xLTEtODIwMDQ_3e74e5a2-4b9e-4714-becb-0f3c06584870">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for the three months ended March 31, 2023, was not considered because the effect would be anti-dilutive.</span></div></ix:continuation></ix:continuation><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_49"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RleHRyZWdpb246OGFiNzFlZjJjMDg3NDVmYjkyYzI3NzIzYjE3MTY0MWZfMTA4_ddc3f76e-f002-421b-aa7a-692c5080ea7c" continuedAt="iabbf8dc667ea46efa94b26184dc0b79f" escape="true">Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="iabbf8dc667ea46efa94b26184dc0b79f"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RleHRyZWdpb246OGFiNzFlZjJjMDg3NDVmYjkyYzI3NzIzYjE3MTY0MWZfMTEx_abd5e144-0211-4884-842e-7ff1d14c605c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy0yLTEtMS04MjAwNA_cfbe713a-c4de-493e-92c1-e369c63793fa">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy00LTEtMS04MjAwNA_22bccde8-93e4-4cbb-9e78-72cc01f33952">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="srt:PayablesToCustomers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy0yLTEtMS04MzU2NQ_295d6d18-bd01-4699-8a13-e76c0713d631">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="srt:PayablesToCustomers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy00LTEtMS04MzU2NQ_8d766d9c-d5e2-4911-9ae2-dfd98cd0b85d">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="sgry:CostReportLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC0yLTEtMS04ODQ1NA_4cf1d48f-14bf-401c-a7fb-3802af55ec5d">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="sgry:CostReportLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC00LTEtMS04ODQ1NA_316958c8-3832-4f23-b304-90edd51ce4c6">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNS0yLTEtMS04MzU5NQ_a0798bdc-b2da-4473-a0da-6e448ea1f385">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNS00LTEtMS04MzU5NQ_e3f1f414-0928-45d7-a0a4-d5cf8e2eb767">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="sgry:AcquisitionEscrowLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC0yLTEtMS04MjAwNA_311d1da9-e139-4e54-91a3-7c5779a04a64">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="sgry:AcquisitionEscrowLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC00LTEtMS04MjAwNA_13030c05-660f-4eff-b75f-2bc0e08ce27b">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOC0yLTEtMS04MjAwNA_f7723037-737c-4c82-a523-cc083a34b016">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOC00LTEtMS04MjAwNA_2b23ba10-f9bc-459a-8e14-1c0ed28f631f">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOS0yLTEtMS04MjAwNA_a400735c-1f83-4e3c-bc6f-69500dd3ad46">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOS00LTEtMS04MjAwNA_c6ed5620-44b6-4f83-97fc-bcff93af4103">210.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfODc3NQ_4cd614eb-3952-42ec-84f4-0f63d145a739" continuedAt="i8d86cabc053041e0823ce2fe0c536e0b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i8d86cabc053041e0823ce2fe0c536e0b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Professional, General and Workers' Compensation Liability Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTAwNg_c23c7bc8-17c6-4eff-a9f9-98ecfff8344d">22.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTAxMw_97276daa-3d5f-4312-b4b3-895c024fc02b">20.8</ix:nonFraction> million, respectively. Expected insurance recoveries of $<ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTA2NA_71d65bbc-14f9-42f3-aa8f-f7a979ac2493"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTA2NA_ab97f010-c96f-4251-8d41-4ecd03276456">12.7</ix:nonFraction></ix:nonFraction> million as of both March&#160;31, 2023 and December&#160;31, 2022 are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 4, 2017, a purported Company stockholder filed an action in the Delaware Court of Chancery (the "Delaware Action"). That action is captioned Witmer v. H.I.G. Capital, L.L.C., et al., C.A. No. 2017-0862. The plaintiff in the Delaware Action asserted claims against (i) certain current and former members of the Company&#8217;s Board of Directors (together, the "Directors"); (ii) H.I.G. Capital, LLC and certain of its affiliates (collectively, "H.I.G."); and (iii) Bain Capital Private Equity, L.P. and certain of its affiliates (collectively, "Bain Capital" and, together with the Directors and H.I.G., the "Defendants"). The parties to the Delaware Action negotiated a final stipulation of settlement (the &#8220;Settlement Stipulation&#8221;), which governs the terms of the settlement of the Delaware Action, and which they filed with the Court of Chancery on November 22, 2021. On February 11, 2022, the Court of Chancery approved the settlement of the Delaware Action as memorialized in the Settlement Stipulation. That decision became final and non-appealable on March 14, 2022. The case is now closed. Pursuant to the settlement, the Company received $<ix:nonFraction unitRef="usd" contextRef="i879bc0eafd88419c89015946c25ea837_D20220301-20220331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMzQ1Ng_16bea11f-ed57-4f4f-ad69-37c636e7035a">32.8</ix:nonFraction>&#160;million in March 2022, which was included in litigation settlement in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Acquired Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the federal physician self-referral law, or Stark Law, the statute commonly known as the federal Anti-Kickback statute, the federal False Claims Act, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Potential Physician Investor Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTY0MA_475c2179-99c8-435d-9956-177ec1c3d54f" continuedAt="idab65cf8c59a40dbb936b9a2f52e8a3d" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="idab65cf8c59a40dbb936b9a2f52e8a3d" continuedAt="i5876f73df6f8454498d8cd868f4bfd0e"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in&#160;<ix:nonFraction unitRef="segment" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjE_f3647f98-d9a4-4e0f-b96f-107ee02e8cdd">two</ix:nonFraction>&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment includes the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of the Company's corporate general and administrative functions.</span></div><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTY0OA_784603d1-c2b9-4d43-a49d-da1712053e05" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMy0yLTEtMS04MjAwNA_3f34dc88-5622-461d-ae9f-c1a960a4b4dd">649.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9989159902245b3958bc162627b001a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMy00LTEtMS04MjAwNA_1f7f2a12-98ae-4c55-9cec-c2e94d6519c4">578.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNC0yLTEtMS04MjAwNA_0a019978-d1d9-45d7-a414-6b4f92fb612b">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNC00LTEtMS04MjAwNA_251256de-c502-490a-be65-aa3724071f83">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNS0yLTEtMS04MjAwNA_15b850f8-2f64-42f3-b1b1-c9f8d76b44e1">666.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNS00LTEtMS04MjAwNA_c52e81d3-3d53-4d9d-97fa-e19eea120076">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOC0yLTEtMS04MjAwNA_5d5e2e25-a9c8-44a0-9868-7306e00e037d">118.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9989159902245b3958bc162627b001a_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOC00LTEtMS04MjAwNA_6f5404ea-6418-44ed-ae55-35c49f907332">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOS0yLTEtMS04MjAwNA_1e0722cc-2e6f-410e-8c88-85771901b36d">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOS00LTEtMS04MjAwNA_4648cae8-246c-4ab6-a695-42dc409e74a7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2157333f54a64133b4ed6c8fe0d8ed07_D20230101-20230331" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTAtMi0xLTEtODIwMDQ_9f58a3b6-98a9-43cf-9670-4b03a3323afc">27.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6579947ad8ee4c769d03065a92a8c1d8_D20220101-20220331" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTAtNC0xLTEtODIwMDQ_d53eda87-eab8-4e18-ae48-ad68ccac85e0">24.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTEtMi0xLTEtODIwMDQ_674558df-c91e-4726-a80e-ba21ef3b7075">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTEtNC0xLTEtODIwMDQ_62106f90-f305-4f7f-90f2-d97082be5e7c">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTQtMi0xLTEtODIwMDQ_09eac37d-1cd9-49eb-b4d8-2f7fb5edee61">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTQtNC0xLTEtODIwMDQ_3f7c981f-8756-460d-abe3-7e025f8f7a00">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTYtMi0xLTEtODIwMDQ_80c33c8c-f513-4f80-a2f6-42b7260645ce">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTYtNC0xLTEtODIwMDQ_d83d57f9-53e0-4446-89ad-2ff02e6fd991">30.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctMi0xLTEtODg0OTM_097e29b1-04db-4d74-a44e-d78bf8bcc775">46.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctNC0xLTEtODg0OTM_338bce20-8335-4175-89de-4910aff78309">56.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctMi0xLTEtODIwMDQ_e6672bb9-b43a-44d1-bb3e-513049d704cc">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctNC0xLTEtODIwMDQ_eb59bec4-d9c8-48e3-854d-ca03ba042498">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTktMi0xLTEtODIwMDQ_c00e379b-5c21-4fee-a8f9-e4d069f37f34">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTktNC0xLTEtODIwMDQ_2235edaa-24b6-4c80-a1b8-cd085e08c05d">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjAtMi0xLTEtODIwMDQ_7406f638-c1d6-4789-a791-fb1dd9a5c21b">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjAtNC0xLTEtODIwMDQ_c996d8cf-1555-467f-86bb-496e59b0c7d8">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) on disposals, consolidations and deconsolidations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjEtMi0xLTEtODIwMDQ_ac135a43-3098-4d3c-8f9c-ba3293fd01f6">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjEtNC0xLTEtODIwMDQ_2cacd61a-ebb5-49b8-b108-190fe3f2bfdc">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlements and regulatory change impact </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="sgry:GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjItMi0xLTEtODg1MDQ_eb88042d-f81f-4efc-9885-fa57115d578d">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjItNC0xLTEtODg1MDQ_0a821ae1-18ce-4a9d-9f33-0bcbed0cc22a">30.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Undesignated derivative activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="sgry:UndesignatedDerivativeActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjMtMi0xLTEtODg1MjU_ba08c98c-a06a-4d0b-b73e-899f09059467">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:UndesignatedDerivativeActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjMtNC0xLTEtODg1MzI_0e0f964e-4c74-41d9-a259-186fe58d5e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjUtMi0xLTEtODIwMDQ_e37add40-dfe3-42f3-aa5a-8538816a807b">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjUtNC0xLTEtODIwMDQ_4c47b780-e3b6-4152-95b4-7f34e0a82c29">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjg5_e50d03c5-4fcc-42df-86ed-cab1d784d1a8">12.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjk2_f6079df2-c4da-4376-b646-1b27b8ccc384">7.1</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfODM0_ce10e24f-afc0-450f-aec8-666f46dc9433">0.3</ix:nonFraction> million for the three months ended March&#160;31, 2023, with no comparable costs for the three months ended March 31, 2022.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes an $<ix:nonFraction unitRef="usd" contextRef="i2f25d93459534f5c84a4cb1633eb1ef7_D20230101-20230331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NjY1MQ_980a17e4-8783-4a66-96e4-acf591afdb01">8.5</ix:nonFraction>&#160;million loss for the three months ended March 31, 2023 related to a surgical facility with a book value of the asset group in excess of the fair value based on a letter of intent.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes a litigation settlement loss of $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU0Nw_da99a8bf-2d65-40d9-b9f3-51e1c548a722">3.0</ix:nonFraction> million and a gain of $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU2Ng_85ac19a2-d744-496e-8c30-93675af774ab">32.8</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount also includes other litigation costs of $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU4Ng_878f572e-a47b-4b00-8c24-f1e50535713d">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU5NA_500aebd0-8903-4619-b9b0-702f08ca2e08">2.0</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. Additionally, the three months ended March 31, 2023, includes $<ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="sgry:InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTY4NQ_50440205-ba59-42dd-8307-e8e43a062b2e">4.4</ix:nonFraction> million related to the impact of recent changes in Florida law regarding the use of letters of protection.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTYyNg_e945fde9-d8d8-4bd4-a9be-2b97c9997569" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac3c71c2dd4b44f78bf883755b6def96_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMi0yLTEtMS04MjAwNA_3dfdc8ab-2398-4c99-80e6-327087c689ef">6,049.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic762e7cc857a43c1a2f037d3352477ab_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMi00LTEtMS04MjAwNA_564b7791-7199-4f39-8899-7bb59a06106b">6,001.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33fb3f237a04410498509c0ce5185504_I20230331" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMy0yLTEtMS04MjAwNA_83a48a08-0421-4196-900c-d03ebf98f131">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16570392805a4746b263e0633c73a07a_I20221231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMy00LTEtMS04MjAwNA_432d027e-e802-464c-8082-e28c41227769">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b3621d88dc14df6923e768f491fc566_I20230331" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNC0yLTEtMS04MjAwNA_9b7195cf-0d3b-4348-90e1-53653df76924">552.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc84e42df6a4279be1365d3ba61b0e9_I20221231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNC00LTEtMS04MjAwNA_4e639bb3-dadf-47d8-8ecf-6e87b5517877">639.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNS0yLTEtMS04MjAwNA_dd1d3c89-8c10-466e-829e-496bca4673d0">6,643.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNS00LTEtMS04MjAwNA_1d7dbbd2-4766-4660-bd7e-a45100e83c5e">6,682.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><ix:continuation id="i5876f73df6f8454498d8cd868f4bfd0e"><ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTYzMw_f0e3d31d-2b1e-453f-97c6-3a5b4def0f6c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfMy0yLTEtMS04MjAwNA_0b25870c-2d58-4dd0-9c29-359efcc6fd58">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9989159902245b3958bc162627b001a_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfMy00LTEtMS04MjAwNA_0fa373fa-6554-4379-881e-a6e8fee32836">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNC0yLTEtMS04MjAwNA_94fb0fa4-c7b1-4efa-a539-369762d25483">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNC00LTEtMS04MjAwNA_54d0f9ae-68fb-4d46-9572-90c87eabf263">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2157333f54a64133b4ed6c8fe0d8ed07_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNS0yLTEtMS04MjAwNA_0540bb0c-25c3-4f20-856e-8b03f5490aaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6579947ad8ee4c769d03065a92a8c1d8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNS00LTEtMS04MjAwNA_84445d23-9c0b-41bd-8c91-ae3e0af32720">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNi0yLTEtMS04MjAwNA_1137b372-6576-4baf-851c-444455c3a88f">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNi00LTEtMS04MjAwNA_3fca4b7b-2551-4256-a020-d0f040a83ab6">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_58"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfNDQ_b61b4390-de48-4c3d-ab9e-0c512a506a64" continuedAt="ifd3b71f78a07411896f0d2ce023f6b5f" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="ifd3b71f78a07411896f0d2ce023f6b5f"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, the Company completed the sale of <ix:nonFraction unitRef="facility" contextRef="i78f9f79b8aa34e08805a3d3c55374c19_D20230401-20230430" decimals="INF" name="sgry:DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfMzI5ODUzNDg4NDIyNA_f0c620de-d121-4441-b343-65c14b18d4cd">two</ix:nonFraction> surgical facilities for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i78f9f79b8aa34e08805a3d3c55374c19_D20230401-20230430" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfNjA0NzMxMzk1MzQwNQ_8d823184-786d-4b2f-bb39-1b9e2a594661">23.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, the Company acquired non-controlling interests in an in-development de novo surgical facility for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i0801f484705247ca9f81ed5e46fa3718_D20230401-20230430" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfNjA0NzMxMzk1MzYxNQ_459dff6b-71a8-442a-a996-b7416d65cd3a">6.1</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this report and our 2022 Annual Report on Form 10-K. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries. Unless the context implies otherwise, the term &#8220;affiliates&#8221; means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms &#8220;facilities&#8221; or &#8220;hospitals&#8221; refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term &#8220;employees&#8221; refers to employees of affiliates of Surgery Partners, Inc.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_64"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This report contains forward-looking statements, which are based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report are forward-looking statements. These statements include, but are not limited to, statements regarding our future financial position, business strategy, budgets, effective tax rate, projected costs and plans and objectives of management for future operations. The words "projections," "believe," "continue," "drive," "estimate," "expect," "intend," "may," "plan," "will," "could," "would" and similar expressions are generally intended to identify forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results to differ from the expectations expressed in the statements. Many of these factors are beyond our ability to control or predict. These factors include, without limitation, reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring surgical facilities; the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease, such as COVID-19, on our business; and the risks and uncertainties set forth under the heading "Risk Factors" in our 2022 Annual Report on Form 10-K and discussed from time to time in our reports filed with the SEC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These forward-looking statements speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_67"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we owned or operated, primarily in partnership with physicians, a portfolio of 145 surgical facilities comprised of 127 ASCs and 18 surgical hospitals across 31 states. We owned a majority interest in 92 of these surgical facilities and consolidated 118 of these facilities for financial reporting purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenues for the first quarter of 2023 increased 11.7% to&#160;$666.2 million&#160;from&#160;$596.2 million&#160;for the first quarter of 2022. Days adjusted same-facility revenues for the first quarter of 2023 increased 10.3% from the same period last year, with a 4.8% increase in revenue per case and a 5.3% increase in same-facility cases. Additionally, for the first quarter of 2023, Adjusted EBITDA increased 16.9% to&#160;$90.1 million compared to $77.1 million for the same period last year.&#160;For the first quarter of 2023, the Company&#8217;s net loss attributable to Surgery Partners, Inc. was $24.9 million compared to net income of&#160;$12.2 million for the first quarter of 2022. A reconciliation of non-GAAP financial measures appears below under "Certain Non-GAAP Measures." </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and other portfolio management initiatives. During the first quarter of 2023 we completed the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We acquired controlling interests in three surgical facilities, two of which were previously accounted for as equity method investments, and a physician practice for aggregate cash consideration of $40.7 million, net of cash acquired and non-cash consideration of $1.3 million.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We acquired non-controlling interests in an existing surgical facility and an in-development de novo surgical facility for an aggregate cash purchase price of $12.4&#160;million, of which $2.8&#160;million was deferred and was paid in April 2023.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We sold our interests in a surgical facility for net cash proceeds of $8.8&#160;million, a portion of which will be held in escrow pursuant to the purchase agreement.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We&#160;had cash and cash equivalents of&#160;$245.5 million&#160;and $545.9 million of borrowing capacity under our revolving credit facility at March&#160;31, 2023. Operating cash inflows were $74.5 million in the first quarter of 2023, compared to $79.8 million in the prior year period. Net operating cash inflows, including operating cash flows less distributions to non-controlling interests, were $32.6 million for the first quarter of 2023, compared to $43.6 million for the first quarter of 2022. </span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_73"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our surgical facility services and ancillary services segments. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest and management services we provide to physician practices for which we are not required to provide capital or additional assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our revenues by service type as a percentage of total revenues for the periods indicated: </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical facilities revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Payor Mix</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities which we consolidate for financial reporting purposes in the periods indicated: </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Surgical Case Mix</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the percentage of cases in each specialty performed at the surgical facilities which we consolidate for financial reporting purposes for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthopedic and pain management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ophthalmology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gastrointestinal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General surgery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_76"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of significant accounting policies is disclosed in our 2022 Annual Report on Form 10-K under the caption &#8220;Critical Accounting Policies&#8221; in the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section. There have been no material changes in the nature of our critical accounting policies or the application of those policies since December 31, 2022.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_79"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2023 Compared to Three Months Ended March&#160;31, 2022 </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes certain results from the statements of operations for the three months ended March&#160;31, 2023 and 2022 (dollars in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) on disposals, consolidations and deconsolidations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:  Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022 were as follows (dollars in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">656.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues increased 11.7% to $656.4 million for the first quarter of 2023 compared to $587.7 million for the first quarter of 2022. The increase was driven by an 10.3% increase in days adjusted same-facility revenues and acquisitions completed in 2023 and 2022. The increase in days adjusted same-facility revenues was attributable to a 4.8% increase in same-facility revenue per case and a 5.3% increase in same-facility case volumes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenues was $532.2 million for the first quarter of 2023 compared to $471.4 million for the first quarter of 2022. The increase was primarily driven by acquisitions completed since the prior year period. As a percentage of revenues, cost of revenues were 79.9% for the 2023 period and 79.1% for the 2022 period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  General and administrative expenses were $32.0 million for the first quarter of 2023 compared to $29.5 million for the first quarter of 2022. As a percentage of revenues, general and administrative expenses were 4.8% for the 2023 period and 4.9% for the 2022 period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization expenses were $33.7 million for the first quarter of 2023 compared to $27.4 million for the first quarter of 2022. As a percentage of revenues, depreciation and amortization expenses were 5.1% for the 2023 period compared to 4.6% for the 2022 period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Transaction and Integration Costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  We incurred $12.5 million of transaction and integration costs for the first quarter of 2023 compared to $7.1 million for the first quarter of 2022. The costs for both periods primarily relate to ongoing development initiatives and the integration of acquisitions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Loss (Gain) on Disposals, Consolidations and Deconsolidations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   The net loss on disposals, consolidations and deconsolidations in the first quarter of 2023 was partially attributable to activity discussed in Note. 2. "Acquisitions and Disposals" to our condensed consolidated financial statements included elsewhere in this report. The remaining net loss was attributable to disposals of other long-lived assets.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Litigation Settlements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Litigation settlements in first quarter of 2022 was primarily attributable to the resolution of the stockholder litigation matter, as discussed in Note 8. "Commitments and Contingencies" to our condensed consolidated financial statements included elsewhere in this report. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  As a percentage of revenues, interest expense, net decreased to 7.0% for the 2023 period compared to 9.4% for the 2022 period. The decrease is attributable to the pay down of certain long-term debt in the fourth quarter of 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit (Expense).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  The income tax benefit was $1.6 million for the three months ended March&#160;31, 2023 compared to income tax expense of $1.3 million for the three months ended March&#160;31, 2022. The effective tax rate was 400.0% for the three months ended March&#160;31, 2023 compared to 2.9% for the three months ended March&#160;31, 2022. For the three months ended March&#160;31, 2023, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and a discrete tax benefit of $1.8&#160;million related to the vesting of restricted stock awards. For the three months ended March&#160;31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $4.6&#160;million related to the vesting of restricted stock awards, (b) $1.8&#160;million attributable to non-recurring earnings&#8217; impact on the Company&#8217;s valuation allowance, and (c) $1.0&#160;million related to entity divestitures. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Income Attributable to Non-Controlling Interests. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As a percentage of revenues, net income attributable to non-controlling interests was 3.9% for the 2023 period and 5.1% for the 2022 period.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents were $245.5 million at March 31, 2023 compared to $282.9 million at December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary source of our operating cash flows is the collection of accounts receivable from federal and state agencies (under the Medicare and Medicaid programs), private insurance companies and individuals. Our cash flows provided by operating activities was $74.5 million for the first quarter of 2023 compared to $79.8 million in the first quarter of 2022. The $5.3 million decrease was primarily driven by operating cash flows in the first quarter of 2022 that did not repeat in the current year, including the receipt of stockholder litigation proceeds of $32.8 million partially offset by repayments of $18.0 million of Medicare advanced payments provided through the CARES Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities during the first quarter of 2023 was $70.7 million compared to $47.1 million for the first quarter of 2022. Key factors contributing to the change include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">An aggregate increase in payments for acquisitions (net of cash acquired) and purchases of equity method investments of $19.2 million;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">An aggregate decrease of $3.5 million in proceeds from sales of facilities and equity method investments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">An increase in purchases of property and equipment of $6.1 million;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">A decrease in cash used of $5.2&#160;million related to other investing activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in financing activities during the first quarter of 2023 was $41.2 million compared to cash used in financing activities of $43.7 million for the first quarter of 2022. Key factors contributing to the change include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"> An increase of $4.0 million in borrowings of long-term debt;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">An increase in proceeds related to ownership transactions with non-controlling interest holders of $8.2 million, partially offset by an increase in distributions to non-controlling interest holders of an $5.7 million; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">An increase in cash used of $3.8 million related to other financing activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net working capital was approximately $393.8&#160;million at March&#160;31, 2023 compared to $427.6&#160;million at December 31, 2022. The decrease is primarily due to a decrease in cash, as discussed above, partially offset by a decrease in accounts payable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to cash flows from operations and available cash, other sources of capital include amounts available on our Revolver as well as anticipated continued access to the capital markets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes outside of the ordinary course of business to our upcoming cash obligations during the three months ended March&#160;31, 2023 from those disclosed under &#8220;Material Cash Requirements&#8221; in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our 2022 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Broad economic factors, including recent increases in interest rates, inflation and supply chain risks and market volatility, could negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If general economic conditions continue to deteriorate or remain uncertain for an extended period of time, our ability to access capital could be harmed, which could negatively affect our liquidity and ability to repay our outstanding debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on our current level of operations, we believe cash flows from operations, available cash, available capacity on our Revolver and continued anticipated access to capital markets, will be adequate to meet our short-term (i.e., 12 months) and long-term (beyond 12 months) liquidity needs.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_85"></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certain Non-GAAP Measures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted EBITDA and Adjusted EBITDA excluding grant funds are not measurements of financial performance under GAAP and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from these non-GAAP metrics are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA and Adjusted EBITDA excluding grant funds may not be comparable to similarly titled measures reported by other companies. We use Adjusted EBITDA and Adjusted EBITDA excluding grant funds as measures of financial performance. Adjusted EBITDA and Adjusted EBITDA excluding grant funds are key measures used by our management to assess operating performance, make business decisions and allocate resources.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles Adjusted EBITDA and Adjusted EBITDA excluding grant funds to (loss) income before income taxes, the most directly comparable GAAP financial measure (in millions and unaudited):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Plus (minus):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) on disposals, consolidations and deconsolidations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlements and regulatory change impact </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Undesignated derivative activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Impact of grant funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA excluding grant funds</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $12.5 million and $7.1 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $0.3 million for the three months ended March&#160;31, 2023, with no comparable costs for the three months ended March 31, 2022.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes a litigation settlement loss of $3.0 million and a gain of $32.8 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount also includes other litigation costs of $0.6 million and $2.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. Additionally, the three months ended March 31, 2023, includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Represents the impact of grant funds recognized, net of amounts attributable to non-controlling interests.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We use Credit Agreement EBITDA as a measure of liquidity and to determine our compliance under certain covenants pursuant to our credit facilities. Credit Agreement EBITDA is determined on a trailing twelve-month basis. We have included it because we believe that it provides investors with additional information about our ability to incur and service debt and make capital expenditures. Credit Agreement EBITDA is not a measurement of liquidity under GAAP and should not be considered in isolation or as a substitute for any other measure calculated in accordance with GAAP. The items excluded from Credit Agreement EBITDA are significant components in understanding and evaluating our liquidity. Our calculation of Credit Agreement EBITDA may not be comparable to similarly titled measures reported by other companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When we use the term &#8220;Credit Agreement EBITDA,&#8221; we are referring to Adjusted EBITDA, as defined above, further adjusted for acquisitions and synergies. These adjustments do not relate to our historical financial performance and instead relate to estimates compiled by our management and calculated in conformance with the definition of &#8220;Consolidated EBITDA&#8221; used in the credit agreements governing our credit facilities. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles Credit Agreement EBITDA to cash flows from operating activities, the most directly comparable GAAP financial measure (in millions and unaudited):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2023</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Plus (minus):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates, net of distributions received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlements and regulatory change impact</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hurricane-related impacts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Undesignated derivative activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and synergies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Credit Agreement EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Represents impact of acquisitions as if each acquisition had occurred on April 1, 2022. Further this includes revenue and cost synergies from other business initiatives and de novo facilities and an adjustment for the effects of adopting the new lease accounting standard, as defined in the credit agreement governing the Senior Secured Credit Facilities.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_88"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.&#160;We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates.&#160;Additionally, we periodically enter into interest rate swap and cap agreements to manage our exposure to interest rate fluctuations. Our interest rate swap and cap agreements involve the exchange of fixed and variable rate interest payments between two parties, based on common notional principal amounts and maturity dates. The notional amounts of the interest rate swap and cap agreements represent balances used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the interest rate swap and cap agreements are with creditworthy financial institutions. The interest payments under these agreements are settled on a net basis. These derivatives have been recognized in the financial statements at their respective fair values. Changes in the fair value of these derivatives, which are designated as cash flow hedges, are included in other comprehensive income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our variable rate debt instruments are primarily indexed to the prime rate or LIBOR.&#160;Without derivatives, interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements. Based on our indebtedness and the effectiveness of our interest rate swap and cap agreements at March&#160;31, 2023, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2023.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_91"></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An evaluation was performed under the supervision and with the participation of our management, including the chief executive officer and the chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended) as of March&#160;31, 2023. Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_97"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are, from time to time, subject to claims and suits, or threats of claims or suits, relating to our business, including claims for damages for personal injuries, breach of management contracts and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages, which may not be covered by insurance or may otherwise have a material adverse effect on our business or results of operations. In the opinion of management, we are not currently a party to any proceedings that would have a material adverse effect on our business, financial condition or results of operations.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_100"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes with respect to the risk factors discussed in our 2022 Annual Report on Form 10-K.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_103"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company did not repurchase any shares of common stock during the three months ended March&#160;31, 2023. At March&#160;31, 2023, the Company continued to have authority to repurchase up to $46.0&#160;million of shares of common stock under its Board-authorized share repurchase program.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_106"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_109"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_112"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1638833/000163883323000021/ye2022exhibit1015.htm">Ninth Amendment to the Credit Agreement, dated as of January 13, 2023, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., the other Guarantors party thereto, Jefferies Finance LLC and the other lenders party thereto (incorporated herein by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed March 1, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q1exhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q1exhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q1exhibit321.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, formatted in Inline XBRL (included in Exhibit 101).</span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i4d12193c1ac449cbaaec870c0a7c1b7d_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4d12193c1ac449cbaaec870c0a7c1b7d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:5pt;padding-left:180pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SURGERY PARTNERS,&#160;INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">/s/  David T. Doherty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David T. Doherty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: May&#160;2, 2023 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2023q1exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7589d6407cfb4f2f847fbbfdec7da61b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, J. Eric Evans, certify that&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Surgery Partners, Inc.&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;2, 2023 </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2023q1exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8c2b173331294e0ab73c345be6ff1fa3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, David T. Doherty, certify that&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Surgery Partners, Inc.&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;2, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2023q1exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if3ab68dd2e9545fca6b72f52da1d961e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the quarterly report of Surgery Partners, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;2, 2023 </font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;2, 2023 </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sgry-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8139a9e6-f0c0-4663-a359-16b44ae9e913,g:a1e20cbb-0632-4ba5-9f9a-c20d61b98cc5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgry="http://www.surgerypartners.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.surgerypartners.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.surgerypartners.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPolicies" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies">
        <link:definition>0000009 - Disclosure - Organization and Summary of Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposals" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals">
        <link:definition>0000010 - Disclosure - Acquisitions and Disposals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.surgerypartners.com/role/LongTermDebt">
        <link:definition>0000011 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.surgerypartners.com/role/Leases">
        <link:definition>0000012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivities" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities">
        <link:definition>0000013 - Disclosure - Derivatives and Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.surgerypartners.com/role/EarningsPerShare">
        <link:definition>0000014 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilities" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities">
        <link:definition>0000015 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies">
        <link:definition>0000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.surgerypartners.com/role/SegmentReporting">
        <link:definition>0000017 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.surgerypartners.com/role/SubsequentEvents">
        <link:definition>0000018 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesPolicies" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies">
        <link:definition>0000019 - Disclosure - Organization and Summary of Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesTables" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables">
        <link:definition>0000020 - Disclosure - Organization and Summary of Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.surgerypartners.com/role/LongTermDebtTables">
        <link:definition>0000021 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.surgerypartners.com/role/LeasesTables">
        <link:definition>0000022 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesTables" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables">
        <link:definition>0000023 - Disclosure - Derivatives and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables">
        <link:definition>0000024 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesTables" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables">
        <link:definition>0000025 - Disclosure - Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.surgerypartners.com/role/SegmentReportingTables">
        <link:definition>0000026 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesOrganizationDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails">
        <link:definition>0000027 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails">
        <link:definition>0000028 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails">
        <link:definition>0000029 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails">
        <link:definition>0000030 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails">
        <link:definition>0000031 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails">
        <link:definition>0000032 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails">
        <link:definition>0000033 - Disclosure - Organization and Summary of Accounting Policies - Medicare Accelerated Payments and Deferred Governmental Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails">
        <link:definition>0000034 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails">
        <link:definition>0000035 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsAcquisitionsDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails">
        <link:definition>0000036 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails">
        <link:definition>0000037 - Disclosure - Acquisitions and Disposals - Disposals and Deconsolidations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofLongtermDebtDetails" roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails">
        <link:definition>0000038 - Disclosure - Long-Term Debt - Summary of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofLongtermDebtDetails_1" roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1">
        <link:definition>0000038 - Disclosure - Long-Term Debt - Summary of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails">
        <link:definition>0000039 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" roleURI="http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails">
        <link:definition>0000040 - Disclosure - Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseandCashFlowInformationDetails" roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails">
        <link:definition>0000041 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails">
        <link:definition>0000042 - Disclosure - Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesNarrativeDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails">
        <link:definition>0000043 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails">
        <link:definition>0000044 - Disclosure - Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails">
        <link:definition>0000045 - Disclosure - Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSummaryDetails" roleURI="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails">
        <link:definition>0000046 - Disclosure - Earnings Per Share - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesSummaryDetails" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails">
        <link:definition>0000047 - Disclosure - Other Current Liabilities - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000048 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" roleURI="http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails">
        <link:definition>0000049 - Disclosure - Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails">
        <link:definition>0000050 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails">
        <link:definition>0000051 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgry_GrantRevenue" abstract="false" name="GrantRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_PayFixedSwapThreeMember" abstract="true" name="PayFixedSwapThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_InterestRateCapTwoMember" abstract="true" name="InterestRateCapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" abstract="false" name="GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_OtherPatientServiceRevenueSourcesMember" abstract="true" name="OtherPatientServiceRevenueSourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SurgicalFacilitiesMember" abstract="true" name="SurgicalFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_DeferredPaymentsToAcquireEquityMethodInvestments" abstract="false" name="DeferredPaymentsToAcquireEquityMethodInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" abstract="false" name="DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestPolicyTextBlock" abstract="false" name="RedeemableNoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgry_SurgicalFacilitiesExistingMarketsMember" abstract="true" name="SurgicalFacilitiesExistingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SeniorUnsecuredNotesDue2025Member" abstract="true" name="SeniorUnsecuredNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_ReceiveFixedSwapOneMember" abstract="true" name="ReceiveFixedSwapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" abstract="true" name="ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" abstract="false" name="NumberOfSurgicalFacilitiesOwnedConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_SixUndersignedInterestRateSwapsMember" abstract="true" name="SixUndersignedInterestRateSwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity" abstract="false" name="LineOfCreditFacilityIncreaseInBorrowingCapacity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" abstract="false" name="NumberOfSurgicalFacilitiesOwnedMajorityInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_ExistingSurgicalFacilityMember" abstract="true" name="ExistingSurgicalFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_OperatingAndFinanceLeaseExpense" abstract="false" name="OperatingAndFinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestRollForward" abstract="true" name="RedeemableNoncontrollingInterestRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" abstract="false" name="InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_FinanceLeaseCost1Abstract" abstract="true" name="FinanceLeaseCost1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgry_NotesPayableAndSecuredLoansMember" abstract="true" name="NotesPayableAndSecuredLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SeniorUnsecuredNotesDue2027Member" abstract="true" name="SeniorUnsecuredNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_InterestRateCapOneMember" abstract="true" name="InterestRateCapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_ReceiveFixedSwapThreeMember" abstract="true" name="ReceiveFixedSwapThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_PayFixedSwapOneMember" abstract="true" name="PayFixedSwapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_OneSurgicalFacilityMember" abstract="true" name="OneSurgicalFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_PrivateInsuranceMember" abstract="true" name="PrivateInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" abstract="true" name="ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SurgicalFacilityServicesMember" abstract="true" name="SurgicalFacilityServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_UnrecognizedGrantFundsReceived" abstract="false" name="UnrecognizedGrantFundsReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" abstract="false" name="NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" abstract="false" name="RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_TwoSurgicalFacilitiesMember" abstract="true" name="TwoSurgicalFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_AcquisitionEscrowLiabilityCurrent" abstract="false" name="AcquisitionEscrowLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_A2017SeniorSecuredCreditFacilityMember" abstract="true" name="A2017SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_UndesignatedDerivativeActivity" abstract="false" name="UndesignatedDerivativeActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NoncashInterestIncomeExpenseNet" abstract="false" name="NoncashInterestIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" abstract="false" name="ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ReceiveFixedSwapTwoMember" abstract="true" name="ReceiveFixedSwapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SelfPayRevenueMember" abstract="true" name="SelfPayRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_PayFixedSwapTwoMember" abstract="true" name="PayFixedSwapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" abstract="false" name="IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" abstract="true" name="ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_FacilitiesAmbulatorySurgeryCentersMember" abstract="true" name="FacilitiesAmbulatorySurgeryCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_VariableInterestEntityNumberOfFacilities" abstract="false" name="VariableInterestEntityNumberOfFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" abstract="false" name="BusinessCombinationIntegrationRelatedCostsAndMergerCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_SurgicalFacilitiesAndPhysicianPracticesMember" abstract="true" name="SurgicalFacilitiesAndPhysicianPracticesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="EarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_HealthcareOrganizationPatientServiceMember" abstract="true" name="HealthcareOrganizationPatientServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_InDevelopmentDeNovoSurgicalFacilityMember" abstract="true" name="InDevelopmentDeNovoSurgicalFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_OtherServicesMember" abstract="true" name="OtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwned" abstract="false" name="NumberOfSurgicalFacilitiesOwned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" abstract="false" name="RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_VariableAndShortTermLeaseCost" abstract="false" name="VariableAndShortTermLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CostReportLiabilitiesCurrent" abstract="false" name="CostReportLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_AncillaryServicesMember" abstract="true" name="AncillaryServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" abstract="false" name="GainLossOnDispositionOfAssetsAndDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_FacilitiesSurgicalHospitalsMember" abstract="true" name="FacilitiesSurgicalHospitalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_A2017TermLoanMaturing2024Member" abstract="true" name="A2017TermLoanMaturing2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" abstract="false" name="DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_PayFixedSwapFourMember" abstract="true" name="PayFixedSwapFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_PayFixedSwapFiveMember" abstract="true" name="PayFixedSwapFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_PayFixedSwapSixMember" abstract="true" name="PayFixedSwapSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_A2022DisposalsMember" abstract="true" name="A2022DisposalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sgry-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8139a9e6-f0c0-4663-a359-16b44ae9e913,g:a1e20cbb-0632-4ba5-9f9a-c20d61b98cc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_66a7853e-fbc5-4a26-92d2-b9949c392eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:to="loc_us-gaap_AssetsCurrent_66a7853e-fbc5-4a26-92d2-b9949c392eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e35897de-0bc8-4a61-8a76-23e455c85be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e35897de-0bc8-4a61-8a76-23e455c85be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_53789ac9-c5a2-4a1a-a251-ac4903549f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_53789ac9-c5a2-4a1a-a251-ac4903549f23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_bae46ad7-4311-491b-957b-0fdd33585392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_bae46ad7-4311-491b-957b-0fdd33585392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca328d69-84cb-4f04-8d53-a48beed9dcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ca328d69-84cb-4f04-8d53-a48beed9dcc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae96e12a-0867-48b1-bb7d-decba58e28b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae96e12a-0867-48b1-bb7d-decba58e28b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f0e1c86f-62a5-4af5-a140-db9b7e851cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34b7ede-85f8-4a2a-9e24-aa6f8811f7ab" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f0e1c86f-62a5-4af5-a140-db9b7e851cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_570e58fc-2e58-4f3c-a785-05fb6ba93857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_117a3cc0-4022-474c-af5b-c1aaf9a816dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_570e58fc-2e58-4f3c-a785-05fb6ba93857" xlink:to="loc_us-gaap_AccountsPayableCurrent_117a3cc0-4022-474c-af5b-c1aaf9a816dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1734275f-97ef-4ed8-9f71-e27335bf202f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_570e58fc-2e58-4f3c-a785-05fb6ba93857" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1734275f-97ef-4ed8-9f71-e27335bf202f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_aef3c292-2c5c-4cfe-966f-7c5a7a5f9bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_570e58fc-2e58-4f3c-a785-05fb6ba93857" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_aef3c292-2c5c-4cfe-966f-7c5a7a5f9bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ac238051-b90e-4922-bf19-3068600b013b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_570e58fc-2e58-4f3c-a785-05fb6ba93857" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ac238051-b90e-4922-bf19-3068600b013b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0bbd4a59-3df5-49ec-a59c-2f5c862c0312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_91cb777b-4acd-4da9-b826-63dcbdeb895b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0bbd4a59-3df5-49ec-a59c-2f5c862c0312" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_91cb777b-4acd-4da9-b826-63dcbdeb895b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fa7fed99-5d31-42cf-92a0-a4e03d8a5b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0bbd4a59-3df5-49ec-a59c-2f5c862c0312" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fa7fed99-5d31-42cf-92a0-a4e03d8a5b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bb6a73a0-7806-40d5-89b0-7ccf31e17b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0bbd4a59-3df5-49ec-a59c-2f5c862c0312" xlink:to="loc_us-gaap_InventoryNet_bb6a73a0-7806-40d5-89b0-7ccf31e17b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_657c2344-3976-485f-b2af-69f361d7399a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0bbd4a59-3df5-49ec-a59c-2f5c862c0312" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_657c2344-3976-485f-b2af-69f361d7399a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7730c09c-4d06-4091-917e-be31e69316a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0bbd4a59-3df5-49ec-a59c-2f5c862c0312" xlink:to="loc_us-gaap_OtherAssetsCurrent_7730c09c-4d06-4091-917e-be31e69316a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e4aad22-b5e6-4511-ae65-247747db61a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_931dc0d5-e582-494c-ab3a-4cb2c8b047e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e4aad22-b5e6-4511-ae65-247747db61a4" xlink:to="loc_us-gaap_StockholdersEquity_931dc0d5-e582-494c-ab3a-4cb2c8b047e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8c0c09c3-f3c3-4fb0-95dd-48838a1b26a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e4aad22-b5e6-4511-ae65-247747db61a4" xlink:to="loc_us-gaap_MinorityInterest_8c0c09c3-f3c3-4fb0-95dd-48838a1b26a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef9e87f8-7216-452f-ba1c-0d7bf422df5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ff4ed756-9c38-4efa-b5d7-70acd9988e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ef9e87f8-7216-452f-ba1c-0d7bf422df5a" xlink:to="loc_us-gaap_PreferredStockValue_ff4ed756-9c38-4efa-b5d7-70acd9988e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_181e9b53-b414-4b7f-87fe-06dabc877e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ef9e87f8-7216-452f-ba1c-0d7bf422df5a" xlink:to="loc_us-gaap_CommonStockValueOutstanding_181e9b53-b414-4b7f-87fe-06dabc877e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3898f451-9fb1-41fa-93aa-b5770c792085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ef9e87f8-7216-452f-ba1c-0d7bf422df5a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3898f451-9fb1-41fa-93aa-b5770c792085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ada78523-45b4-424f-96db-9551d6ea8e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ef9e87f8-7216-452f-ba1c-0d7bf422df5a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ada78523-45b4-424f-96db-9551d6ea8e96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83278a71-130e-4c79-b699-44354bb88fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ef9e87f8-7216-452f-ba1c-0d7bf422df5a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83278a71-130e-4c79-b699-44354bb88fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e5ef9e6-d69b-4ba0-a5dd-f5e9196829f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6b41ff35-ce71-4055-942c-82f65c100f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e5ef9e6-d69b-4ba0-a5dd-f5e9196829f0" xlink:to="loc_us-gaap_LiabilitiesCurrent_6b41ff35-ce71-4055-942c-82f65c100f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_71af9572-bf3f-418a-8fc1-6896c4ba5ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e5ef9e6-d69b-4ba0-a5dd-f5e9196829f0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_71af9572-bf3f-418a-8fc1-6896c4ba5ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ae6c84d-fe7e-44f3-b1f6-aeb2d13f88e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e5ef9e6-d69b-4ba0-a5dd-f5e9196829f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ae6c84d-fe7e-44f3-b1f6-aeb2d13f88e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c00a82df-4df9-46be-82d2-be37df8fad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e5ef9e6-d69b-4ba0-a5dd-f5e9196829f0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c00a82df-4df9-46be-82d2-be37df8fad6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3122ef8e-3574-497b-9ac2-955c5f5b8ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e5ef9e6-d69b-4ba0-a5dd-f5e9196829f0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3122ef8e-3574-497b-9ac2-955c5f5b8ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa3ced86-2c38-475a-8c50-8310a48c521c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e5ef9e6-d69b-4ba0-a5dd-f5e9196829f0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa3ced86-2c38-475a-8c50-8310a48c521c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_0cafdb41-2544-4cdf-b0d7-e5df8609a7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_23ea4c40-fc05-4bd2-a3b9-fed2932a7668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0cafdb41-2544-4cdf-b0d7-e5df8609a7ab" xlink:to="loc_us-gaap_LaborAndRelatedExpense_23ea4c40-fc05-4bd2-a3b9-fed2932a7668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_8715d799-1178-4824-a609-701357b9b176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0cafdb41-2544-4cdf-b0d7-e5df8609a7ab" xlink:to="loc_us-gaap_SuppliesExpense_8715d799-1178-4824-a609-701357b9b176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_a15d9cfa-b26b-4ec3-acfc-c377d593dfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0cafdb41-2544-4cdf-b0d7-e5df8609a7ab" xlink:to="loc_us-gaap_ProfessionalFees_a15d9cfa-b26b-4ec3-acfc-c377d593dfc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense_e32566fc-bad3-4fb2-99ad-eac4a0f17b69" xlink:href="sgry-20230331.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0cafdb41-2544-4cdf-b0d7-e5df8609a7ab" xlink:to="loc_sgry_OperatingAndFinanceLeaseExpense_e32566fc-bad3-4fb2-99ad-eac4a0f17b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_ee20c682-0c7c-4a8c-83a2-86ca872f1c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_0cafdb41-2544-4cdf-b0d7-e5df8609a7ab" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_ee20c682-0c7c-4a8c-83a2-86ca872f1c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_6381399f-a140-4c64-b4a9-e9484f6ac097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_6381399f-a140-4c64-b4a9-e9484f6ac097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fa24c3ee-9185-4016-b79a-e271e1d26011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fa24c3ee-9185-4016-b79a-e271e1d26011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_280418cc-ef53-40f9-a878-6c224950c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_280418cc-ef53-40f9-a878-6c224950c78a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_747bb367-98db-4bf9-8c4f-9f591aa389f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_747bb367-98db-4bf9-8c4f-9f591aa389f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_97b93c2d-b6ab-4ead-aab0-67f304c819f4" xlink:href="sgry-20230331.xsd#sgry_GrantRevenue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_sgry_GrantRevenue_97b93c2d-b6ab-4ead-aab0-67f304c819f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_5e86c979-053b-4e7e-863a-79b8f7ab4cf0" xlink:href="sgry-20230331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_5e86c979-053b-4e7e-863a-79b8f7ab4cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0e1f26f6-bdf5-47f3-9b03-cf345466b777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0e1f26f6-bdf5-47f3-9b03-cf345466b777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ba42ffb8-a2c7-466e-a596-0ab1ad79b4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ba42ffb8-a2c7-466e-a596-0ab1ad79b4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_c99be8c6-aa3a-4d9b-8b6b-d606347ce4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_91700d5e-4e8e-4c90-9d06-a1ebc61ee1a6" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_c99be8c6-aa3a-4d9b-8b6b-d606347ce4de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6e6a1eb3-53a5-47a6-a5d2-0218389c22bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_23d22da2-a26c-43fa-80de-87e3c0e44ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6e6a1eb3-53a5-47a6-a5d2-0218389c22bf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_23d22da2-a26c-43fa-80de-87e3c0e44ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f0b2a66f-1602-46ce-8251-1de9e38e6f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6e6a1eb3-53a5-47a6-a5d2-0218389c22bf" xlink:to="loc_us-gaap_OperatingExpenses_f0b2a66f-1602-46ce-8251-1de9e38e6f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e6f3770-8c59-42c6-893c-8062343ef72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dd1cc042-575b-41b1-b6ab-9a22142db1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3e6f3770-8c59-42c6-893c-8062343ef72e" xlink:to="loc_us-gaap_ProfitLoss_dd1cc042-575b-41b1-b6ab-9a22142db1c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e6065ee-e043-43bc-b215-c3812c317938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3e6f3770-8c59-42c6-893c-8062343ef72e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e6065ee-e043-43bc-b215-c3812c317938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7b57eafc-468d-426f-b236-b5bc4057d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2330d165-5040-4f3a-b421-d2c818347592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7b57eafc-468d-426f-b236-b5bc4057d013" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2330d165-5040-4f3a-b421-d2c818347592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d96c0ddf-bd5a-4278-88f1-4b086ba3ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7b57eafc-468d-426f-b236-b5bc4057d013" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d96c0ddf-bd5a-4278-88f1-4b086ba3ce09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7cf24df0-5e1c-4bc4-9ed5-e9506398aa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_146f6a52-e9f2-4901-b728-6bbbb8a59e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7cf24df0-5e1c-4bc4-9ed5-e9506398aa5a" xlink:to="loc_us-gaap_OperatingIncomeLoss_146f6a52-e9f2-4901-b728-6bbbb8a59e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b025409e-7b55-415b-af35-88b034c758ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7cf24df0-5e1c-4bc4-9ed5-e9506398aa5a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b025409e-7b55-415b-af35-88b034c758ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f44042d6-75c6-45de-95e5-637ed1d32e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7e62e054-98dc-441b-8c63-1dddc1490337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f44042d6-75c6-45de-95e5-637ed1d32e16" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7e62e054-98dc-441b-8c63-1dddc1490337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_773b5f45-6b7e-48c7-a64e-fea07db425f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f44042d6-75c6-45de-95e5-637ed1d32e16" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_773b5f45-6b7e-48c7-a64e-fea07db425f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d7909d19-746e-452f-b9a4-7c6d5afb195b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_99888195-d396-4069-bf1a-2a59583f0583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d7909d19-746e-452f-b9a4-7c6d5afb195b" xlink:to="loc_us-gaap_ProfitLoss_99888195-d396-4069-bf1a-2a59583f0583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_99672b00-bda5-43ba-b5de-75608e3a70b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d7909d19-746e-452f-b9a4-7c6d5afb195b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_99672b00-bda5-43ba-b5de-75608e3a70b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ee8f1e8-6a4a-4fcf-ae86-5b493b822611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0958ff9-7530-4ca6-b716-a1eaebda501f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ee8f1e8-6a4a-4fcf-ae86-5b493b822611" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0958ff9-7530-4ca6-b716-a1eaebda501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_daabcad1-385f-49b4-927b-96aa5b314306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ee8f1e8-6a4a-4fcf-ae86-5b493b822611" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_daabcad1-385f-49b4-927b-96aa5b314306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_40f11769-6c93-49c3-837f-e797a6323576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ee8f1e8-6a4a-4fcf-ae86-5b493b822611" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_40f11769-6c93-49c3-837f-e797a6323576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e66e144-6182-4a7f-b2ff-16a537bccde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bccc4e63-20d0-48a6-9ce6-296b9083ba91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e66e144-6182-4a7f-b2ff-16a537bccde8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bccc4e63-20d0-48a6-9ce6-296b9083ba91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0af55780-9217-4e97-a00a-a0d45477bb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e66e144-6182-4a7f-b2ff-16a537bccde8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0af55780-9217-4e97-a00a-a0d45477bb13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_1cb2324d-b184-4991-8613-e4e6fb8da8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e66e144-6182-4a7f-b2ff-16a537bccde8" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_1cb2324d-b184-4991-8613-e4e6fb8da8a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_df912f8d-3d23-4557-8c34-3e74539b7211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e66e144-6182-4a7f-b2ff-16a537bccde8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_df912f8d-3d23-4557-8c34-3e74539b7211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_d4dd4a86-2074-4b26-b6b9-1b5b0057a514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e66e144-6182-4a7f-b2ff-16a537bccde8" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_d4dd4a86-2074-4b26-b6b9-1b5b0057a514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b94f064b-2d06-411e-af57-c10494d20ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e66e144-6182-4a7f-b2ff-16a537bccde8" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b94f064b-2d06-411e-af57-c10494d20ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cddada1e-2eb4-4e0b-a560-d708cf529c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_ProfitLoss_cddada1e-2eb4-4e0b-a560-d708cf529c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_68bb8ecf-e59a-4aba-ab0a-4cfdf5a17220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_68bb8ecf-e59a-4aba-ab0a-4cfdf5a17220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet_042d1412-4744-43a0-a3e6-142dc28b47eb" xlink:href="sgry-20230331.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_sgry_NoncashInterestIncomeExpenseNet_042d1412-4744-43a0-a3e6-142dc28b47eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ce437a39-a3c0-4c01-a787-1bb2e886f106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_ShareBasedCompensation_ce437a39-a3c0-4c01-a787-1bb2e886f106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_5b3404cc-4807-4d8d-9e48-17102d9a909f" xlink:href="sgry-20230331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_5b3404cc-4807-4d8d-9e48-17102d9a909f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd958f17-3845-4e84-973d-cab529850ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd958f17-3845-4e84-973d-cab529850ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_800aa5c6-3774-4102-9264-059adfaf1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_800aa5c6-3774-4102-9264-059adfaf1b33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_40baf1d0-dcc2-4ae8-a08b-b3a65387f040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_OperatingLeaseExpense_40baf1d0-dcc2-4ae8-a08b-b3a65387f040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_30fd3627-86da-4d7d-a0cc-997cd7c20c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_30fd3627-86da-4d7d-a0cc-997cd7c20c6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_ef7ea8de-1a50-4370-854b-64b225994529" xlink:href="sgry-20230331.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_ef7ea8de-1a50-4370-854b-64b225994529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b93983e0-866a-4d6a-bece-0d44581c9f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fb6a82f-59d8-40ad-b213-80a0cf3f9e0d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b93983e0-866a-4d6a-bece-0d44581c9f2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f8787f4-ecd2-4f94-8aca-e582528624bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_36ee9890-8e7d-489c-b351-8a1c0f4e41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f8787f4-ecd2-4f94-8aca-e582528624bf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_36ee9890-8e7d-489c-b351-8a1c0f4e41f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_f4d69832-7f58-499f-8b9d-9fd0653311fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f8787f4-ecd2-4f94-8aca-e582528624bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_f4d69832-7f58-499f-8b9d-9fd0653311fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_16233772-97c9-416f-b2da-21a112fb6fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f8787f4-ecd2-4f94-8aca-e582528624bf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_16233772-97c9-416f-b2da-21a112fb6fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_bf6f5e91-5b55-437a-9371-1707f2415c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f8787f4-ecd2-4f94-8aca-e582528624bf" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_bf6f5e91-5b55-437a-9371-1707f2415c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0d7afbc4-78e2-47b1-8fb1-d216ce71d34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f8787f4-ecd2-4f94-8aca-e582528624bf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0d7afbc4-78e2-47b1-8fb1-d216ce71d34e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_37731092-90e1-42fd-aa6c-73c741093e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f8787f4-ecd2-4f94-8aca-e582528624bf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_37731092-90e1-42fd-aa6c-73c741093e7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtSummaryofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_02583d57-bd46-459b-9199-a2749b4a501e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c2f8c58e-c48c-4842-8d9f-bebd9112147a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_02583d57-bd46-459b-9199-a2749b4a501e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c2f8c58e-c48c-4842-8d9f-bebd9112147a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0c5e698d-f3a5-464b-a5fc-5049d51ef06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_02583d57-bd46-459b-9199-a2749b4a501e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0c5e698d-f3a5-464b-a5fc-5049d51ef06f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtSummaryofLongtermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_99edb550-6453-4e4e-b0d2-91c8e2ac566d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9d909a43-fb8d-40dd-8881-fc2e97fac328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_99edb550-6453-4e4e-b0d2-91c8e2ac566d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9d909a43-fb8d-40dd-8881-fc2e97fac328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_faa1afa5-7b57-44ed-afa9-8fc9063b37d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_99edb550-6453-4e4e-b0d2-91c8e2ac566d" xlink:to="loc_us-gaap_FinanceLeaseLiability_faa1afa5-7b57-44ed-afa9-8fc9063b37d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_96c4aefc-c031-44c5-a728-44db865a1a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_99edb550-6453-4e4e-b0d2-91c8e2ac566d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_96c4aefc-c031-44c5-a728-44db865a1a46" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b55d699e-6595-4571-8204-7f8008c139f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_aba97e6a-a2e8-43e3-84f6-321652213437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b55d699e-6595-4571-8204-7f8008c139f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_aba97e6a-a2e8-43e3-84f6-321652213437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8da822e-1041-4a43-8ec3-8ffa8dbff2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b55d699e-6595-4571-8204-7f8008c139f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8da822e-1041-4a43-8ec3-8ffa8dbff2ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability_f4b44241-a867-4752-a40b-8ca654d45353" xlink:href="sgry-20230331.xsd#sgry_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_745ba1fe-e898-49d4-8f98-5260227c0e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseLiability_f4b44241-a867-4752-a40b-8ca654d45353" xlink:to="loc_us-gaap_FinanceLeaseLiability_745ba1fe-e898-49d4-8f98-5260227c0e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_13723144-e645-4e1c-8e5d-4a2d9a3e1b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseLiability_f4b44241-a867-4752-a40b-8ca654d45353" xlink:to="loc_us-gaap_OperatingLeaseLiability_13723144-e645-4e1c-8e5d-4a2d9a3e1b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a77fc95a-6cfa-428a-aba6-743679faaab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_54c8d338-220b-4819-a4ae-a72faa1d928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_a77fc95a-6cfa-428a-aba6-743679faaab4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_54c8d338-220b-4819-a4ae-a72faa1d928d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_eb6e36a9-bd56-47f1-aca8-33794920f4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_a77fc95a-6cfa-428a-aba6-743679faaab4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_eb6e36a9-bd56-47f1-aca8-33794920f4b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset_b9c7875b-e7d9-4edf-99dd-c9e1e0db66b3" xlink:href="sgry-20230331.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_abeb436e-b386-41be-80a2-d0dcc675f48a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseRightOfUseAsset_b9c7875b-e7d9-4edf-99dd-c9e1e0db66b3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_abeb436e-b386-41be-80a2-d0dcc675f48a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1dadcce8-8345-466b-af6b-b2eca73d36fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseRightOfUseAsset_b9c7875b-e7d9-4edf-99dd-c9e1e0db66b3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1dadcce8-8345-466b-af6b-b2eca73d36fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LeasesLeaseExpenseandCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_26b6d13e-a554-49d6-a000-869e9e38ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_faf06a38-46e4-480f-81b2-9cd2ff37dc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_26b6d13e-a554-49d6-a000-869e9e38ac5c" xlink:to="loc_us-gaap_OperatingLeaseCost_faf06a38-46e4-480f-81b2-9cd2ff37dc6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_bc2cf5ae-cedb-44ef-a8c2-c19803fcec16" xlink:href="sgry-20230331.xsd#sgry_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_26b6d13e-a554-49d6-a000-869e9e38ac5c" xlink:to="loc_sgry_FinanceLeaseCost_bc2cf5ae-cedb-44ef-a8c2-c19803fcec16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost_1992147b-da5e-4e32-9895-93897e691f8c" xlink:href="sgry-20230331.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_26b6d13e-a554-49d6-a000-869e9e38ac5c" xlink:to="loc_sgry_VariableAndShortTermLeaseCost_1992147b-da5e-4e32-9895-93897e691f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_2e2119b8-dc00-4b29-a415-5a9d87c75843" xlink:href="sgry-20230331.xsd#sgry_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_95885120-5113-44b7-8e07-6d6aa552a21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_FinanceLeaseCost_2e2119b8-dc00-4b29-a415-5a9d87c75843" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_95885120-5113-44b7-8e07-6d6aa552a21f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_9e77609b-d164-4be8-88a1-ea34c786a4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_FinanceLeaseCost_2e2119b8-dc00-4b29-a415-5a9d87c75843" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_9e77609b-d164-4be8-88a1-ea34c786a4e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_fc2af120-5c1f-4fef-8844-67fea7d6e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_ce5977b5-823a-4b84-8abc-6e1916e9cbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeNotionalAmount_fc2af120-5c1f-4fef-8844-67fea7d6e6af" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_ce5977b5-823a-4b84-8abc-6e1916e9cbba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_c69f219a-8447-4e6d-bf60-f0fe0e2446f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeNotionalAmount_fc2af120-5c1f-4fef-8844-67fea7d6e6af" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_c69f219a-8447-4e6d-bf60-f0fe0e2446f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OtherCurrentLiabilitiesSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4b493941-2a86-40c5-b346-4acde9c0dcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_17bf93fd-498b-410d-be8d-f55a11e0341b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4b493941-2a86-40c5-b346-4acde9c0dcfc" xlink:to="loc_us-gaap_InterestPayableCurrent_17bf93fd-498b-410d-be8d-f55a11e0341b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers_07c4910a-91dd-4910-b8af-0643923ee324" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PayablesToCustomers"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4b493941-2a86-40c5-b346-4acde9c0dcfc" xlink:to="loc_srt_PayablesToCustomers_07c4910a-91dd-4910-b8af-0643923ee324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent_cf3c3a83-a66f-4494-9fa2-e1c275f2eba7" xlink:href="sgry-20230331.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4b493941-2a86-40c5-b346-4acde9c0dcfc" xlink:to="loc_sgry_CostReportLiabilitiesCurrent_cf3c3a83-a66f-4494-9fa2-e1c275f2eba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f2eaf9d0-4fd9-4cac-9c09-d34c678db2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4b493941-2a86-40c5-b346-4acde9c0dcfc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f2eaf9d0-4fd9-4cac-9c09-d34c678db2cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_82d48b4b-0423-4fed-bff9-a770244a78a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4b493941-2a86-40c5-b346-4acde9c0dcfc" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_82d48b4b-0423-4fed-bff9-a770244a78a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AcquisitionEscrowLiabilityCurrent_865127bc-6b8a-4f48-a665-cee33acc986b" xlink:href="sgry-20230331.xsd#sgry_AcquisitionEscrowLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4b493941-2a86-40c5-b346-4acde9c0dcfc" xlink:to="loc_sgry_AcquisitionEscrowLiabilityCurrent_865127bc-6b8a-4f48-a665-cee33acc986b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sgry-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8139a9e6-f0c0-4663-a359-16b44ae9e913,g:a1e20cbb-0632-4ba5-9f9a-c20d61b98cc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i02ed681edc5c40299d2cfb7dfc422ee7_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cc8e198-cf5f-43aa-867e-e5448f1a0466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cc8e198-cf5f-43aa-867e-e5448f1a0466" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9b74ac36-0f5f-4b8c-a7c9-65d04bcca58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9b74ac36-0f5f-4b8c-a7c9-65d04bcca58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d10f79f9-7d7b-4a72-b3d6-e1bb2ed2c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d10f79f9-7d7b-4a72-b3d6-e1bb2ed2c4f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab5220f2-ec18-4502-bc31-942801545de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab5220f2-ec18-4502-bc31-942801545de1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70870964-b6ad-4fa4-b22b-f2b22ac3850d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70870964-b6ad-4fa4-b22b-f2b22ac3850d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_67814559-2ed6-41f7-b32b-ec0c12858827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_67814559-2ed6-41f7-b32b-ec0c12858827" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34ad0832-e9e3-4f97-98bd-2327577a24d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34ad0832-e9e3-4f97-98bd-2327577a24d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_56a1fafc-f41e-45e3-ae9c-bb7ec965eff3" xlink:href="sgry-20230331.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_56a1fafc-f41e-45e3-ae9c-bb7ec965eff3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_daa7838c-6efa-49f3-a1d7-450c3059e517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_daa7838c-6efa-49f3-a1d7-450c3059e517" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a97582b7-8545-4b56-a94d-b58b0e4e6a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99e0b259-9938-4da7-a0f2-72461b584fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_28c64a20-365b-4d0c-8851-842ae2cfbaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1cc8e198-cf5f-43aa-867e-e5448f1a0466" xlink:to="loc_us-gaap_StatementTable_28c64a20-365b-4d0c-8851-842ae2cfbaff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b410648-257b-4573-98c9-a6b0ede48e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_28c64a20-365b-4d0c-8851-842ae2cfbaff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b410648-257b-4573-98c9-a6b0ede48e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b410648-257b-4573-98c9-a6b0ede48e8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b410648-257b-4573-98c9-a6b0ede48e8c" xlink:to="loc_us-gaap_EquityComponentDomain_6b410648-257b-4573-98c9-a6b0ede48e8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b410648-257b-4573-98c9-a6b0ede48e8c" xlink:to="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2a5561b2-47fb-46da-b60a-e8dc8c582f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_CommonStockMember_2a5561b2-47fb-46da-b60a-e8dc8c582f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a59e9435-8b8f-4743-bb9a-44e21d987311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a59e9435-8b8f-4743-bb9a-44e21d987311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ed1961c-970f-41c1-87d6-3b3d9a2201c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ed1961c-970f-41c1-87d6-3b3d9a2201c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a86a058-823d-42ca-b231-437582c7fb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_RetainedEarningsMember_4a86a058-823d-42ca-b231-437582c7fb7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e8b8cb37-5df9-4c81-9fd5-bb4a678c1717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e8b8cb37-5df9-4c81-9fd5-bb4a678c1717" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="extended" id="i5449376fb08f4a258c0d1acf92053b6b_OrganizationandSummaryofAccountingPoliciesOrganizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned_6daebe27-e3ae-4e54-8a2c-bf76b92d0c23" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwned_6daebe27-e3ae-4e54-8a2c-bf76b92d0c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_c2cb4004-53f4-4ceb-a972-0bcc41485b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_c2cb4004-53f4-4ceb-a972-0bcc41485b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_11a15d1e-1839-44f0-8d2b-abcf1d6a7edc" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_11a15d1e-1839-44f0-8d2b-abcf1d6a7edc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_df58452d-c0da-44db-93b0-adb8c398b662" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_df58452d-c0da-44db-93b0-adb8c398b662" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_6aa7486e-d610-4e43-8546-bdda9caf79bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_6aa7486e-d610-4e43-8546-bdda9caf79bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af9972a8-e12c-44b4-be20-69cc4800f570" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_6aa7486e-d610-4e43-8546-bdda9caf79bc" xlink:to="loc_srt_ProductOrServiceAxis_af9972a8-e12c-44b4-be20-69cc4800f570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af9972a8-e12c-44b4-be20-69cc4800f570_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_af9972a8-e12c-44b4-be20-69cc4800f570" xlink:to="loc_srt_ProductsAndServicesDomain_af9972a8-e12c-44b4-be20-69cc4800f570_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_af9972a8-e12c-44b4-be20-69cc4800f570" xlink:to="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_095803b5-5ca7-49ed-898d-5a397ba4195f" xlink:href="sgry-20230331.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:to="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_095803b5-5ca7-49ed-898d-5a397ba4195f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember_07301b6a-9fdd-4b56-8b61-0354ce8f72e6" xlink:href="sgry-20230331.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:to="loc_sgry_FacilitiesSurgicalHospitalsMember_07301b6a-9fdd-4b56-8b61-0354ce8f72e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="extended" id="if91cdf5a3df44151808eeb4358811b1a_OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_fdc03780-e742-4f3b-8533-c94afa7031b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3926b795-c6e3-4fda-a9a5-3732c729d1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_fdc03780-e742-4f3b-8533-c94afa7031b1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3926b795-c6e3-4fda-a9a5-3732c729d1ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_fdc03780-e742-4f3b-8533-c94afa7031b1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fe6c0ca0-5173-455d-bba1-e32a52906554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fe6c0ca0-5173-455d-bba1-e32a52906554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe6c0ca0-5173-455d-bba1-e32a52906554_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe6c0ca0-5173-455d-bba1-e32a52906554" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe6c0ca0-5173-455d-bba1-e32a52906554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_78ec0b90-372a-45a2-a54f-d7ad9932b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe6c0ca0-5173-455d-bba1-e32a52906554" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_78ec0b90-372a-45a2-a54f-d7ad9932b42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d49781f6-7601-467a-827f-c5022bd08879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78ec0b90-372a-45a2-a54f-d7ad9932b42b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d49781f6-7601-467a-827f-c5022bd08879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d077cb0-6b7b-46d9-9515-5dd402a8aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d077cb0-6b7b-46d9-9515-5dd402a8aae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d077cb0-6b7b-46d9-9515-5dd402a8aae3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d077cb0-6b7b-46d9-9515-5dd402a8aae3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d077cb0-6b7b-46d9-9515-5dd402a8aae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05abb968-e342-4fb2-969e-be4caa73fc69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d077cb0-6b7b-46d9-9515-5dd402a8aae3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05abb968-e342-4fb2-969e-be4caa73fc69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_22831304-8a12-4c38-9498-9a814cab983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05abb968-e342-4fb2-969e-be4caa73fc69" xlink:to="loc_us-gaap_SalesRevenueNetMember_22831304-8a12-4c38-9498-9a814cab983c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5127d5ee-32e7-40ed-920a-67a3cd10fe58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:to="loc_srt_ProductOrServiceAxis_5127d5ee-32e7-40ed-920a-67a3cd10fe58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5127d5ee-32e7-40ed-920a-67a3cd10fe58_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5127d5ee-32e7-40ed-920a-67a3cd10fe58" xlink:to="loc_srt_ProductsAndServicesDomain_5127d5ee-32e7-40ed-920a-67a3cd10fe58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5127d5ee-32e7-40ed-920a-67a3cd10fe58" xlink:to="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:href="sgry-20230331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_029fbbd8-5934-4bdb-988e-130121cc756e" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:to="loc_sgry_SurgicalFacilityServicesMember_029fbbd8-5934-4bdb-988e-130121cc756e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_d08b8ae8-2b28-4ade-94e7-5816d9e5933c" xlink:href="sgry-20230331.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:to="loc_sgry_AncillaryServicesMember_d08b8ae8-2b28-4ade-94e7-5816d9e5933c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_e18104e6-07d5-4f8d-9641-18eccc6838a2" xlink:href="sgry-20230331.xsd#sgry_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:to="loc_sgry_OtherServicesMember_e18104e6-07d5-4f8d-9641-18eccc6838a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="extended" id="i0931eeaeb7ba4d028f09421bf75da8d4_OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d29440d2-5323-47b1-afdf-42e747aa8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d29440d2-5323-47b1-afdf-42e747aa8f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_49c9b5ed-2bc4-453c-b413-7778e65fd481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_49c9b5ed-2bc4-453c-b413-7778e65fd481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a98be025-683c-4b5c-ba5b-fff3eab2d8f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:to="loc_srt_ProductOrServiceAxis_a98be025-683c-4b5c-ba5b-fff3eab2d8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a98be025-683c-4b5c-ba5b-fff3eab2d8f7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a98be025-683c-4b5c-ba5b-fff3eab2d8f7" xlink:to="loc_srt_ProductsAndServicesDomain_a98be025-683c-4b5c-ba5b-fff3eab2d8f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a98be025-683c-4b5c-ba5b-fff3eab2d8f7" xlink:to="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:href="sgry-20230331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember_21a70881-1d29-46e8-b093-91dced9912c1" xlink:href="sgry-20230331.xsd#sgry_PrivateInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_sgry_PrivateInsuranceMember_21a70881-1d29-46e8-b093-91dced9912c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_418f3a1d-73a8-4717-92cf-c922500c56b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_us-gaap_GovernmentContractMember_418f3a1d-73a8-4717-92cf-c922500c56b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember_07ccd032-bfbb-4752-8047-b91bdcb2e656" xlink:href="sgry-20230331.xsd#sgry_SelfPayRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_sgry_SelfPayRevenueMember_07ccd032-bfbb-4752-8047-b91bdcb2e656" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember_879e62ce-d234-427a-b03d-465f9f815cd1" xlink:href="sgry-20230331.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_sgry_OtherPatientServiceRevenueSourcesMember_879e62ce-d234-427a-b03d-465f9f815cd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_d8b568ab-3a44-40c3-bebb-d3442dacb114" xlink:href="sgry-20230331.xsd#sgry_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:to="loc_sgry_OtherServicesMember_d8b568ab-3a44-40c3-bebb-d3442dacb114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e911665a-5649-4572-bdf9-ed3e3ae47613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e911665a-5649-4572-bdf9-ed3e3ae47613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_57daf5d5-bd02-4731-8ba4-d8e0ba68ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e911665a-5649-4572-bdf9-ed3e3ae47613" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_57daf5d5-bd02-4731-8ba4-d8e0ba68ad54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aadb9873-531a-4314-bfe2-108649f7c635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aadb9873-531a-4314-bfe2-108649f7c635" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aadb9873-531a-4314-bfe2-108649f7c635_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aadb9873-531a-4314-bfe2-108649f7c635" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aadb9873-531a-4314-bfe2-108649f7c635_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c756e9d1-a7d7-44a6-8c00-bed6d7dfebc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aadb9873-531a-4314-bfe2-108649f7c635" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c756e9d1-a7d7-44a6-8c00-bed6d7dfebc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c77f78d5-f194-4490-b0f7-6d04aac57d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c756e9d1-a7d7-44a6-8c00-bed6d7dfebc7" xlink:to="loc_us-gaap_SalesRevenueNetMember_c77f78d5-f194-4490-b0f7-6d04aac57d2c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="extended" id="ic351685bd5bd465db49f4e4030606a9c_OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f662e5fe-b66f-4529-ad4a-8d7f75f3890e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:to="loc_us-gaap_LongTermDebt_f662e5fe-b66f-4529-ad4a-8d7f75f3890e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8125c68b-1d73-403a-8fab-4ad176cdd6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8125c68b-1d73-403a-8fab-4ad176cdd6b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1507a76-5c69-4b08-8e3b-7e33a43ad63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1507a76-5c69-4b08-8e3b-7e33a43ad63b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f1507a76-5c69-4b08-8e3b-7e33a43ad63b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1507a76-5c69-4b08-8e3b-7e33a43ad63b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f1507a76-5c69-4b08-8e3b-7e33a43ad63b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1507a76-5c69-4b08-8e3b-7e33a43ad63b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d1b4a576-ebd6-46e4-a832-6c411d6bd1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:to="loc_us-gaap_SecuredDebtMember_d1b4a576-ebd6-46e4-a832-6c411d6bd1be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8ed8e068-a407-48ec-8554-ff85feec2e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:to="loc_us-gaap_SeniorNotesMember_8ed8e068-a407-48ec-8554-ff85feec2e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a26515e8-0e80-47cd-be3f-37d159445c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_a26515e8-0e80-47cd-be3f-37d159445c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a26515e8-0e80-47cd-be3f-37d159445c50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a26515e8-0e80-47cd-be3f-37d159445c50" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a26515e8-0e80-47cd-be3f-37d159445c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a26515e8-0e80-47cd-be3f-37d159445c50" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_b1ba8641-9227-4f29-b7b0-ebfd8ad98fc1" xlink:href="sgry-20230331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_b1ba8641-9227-4f29-b7b0-ebfd8ad98fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_580bd716-f2a3-44fa-aec4-45feec9caebe" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_580bd716-f2a3-44fa-aec4-45feec9caebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_d1f12ef3-25fc-4a1e-b15d-9b97d6ab84ef" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_d1f12ef3-25fc-4a1e-b15d-9b97d6ab84ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_867a2cb7-e697-4b86-9dd8-f062847e945b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_867a2cb7-e697-4b86-9dd8-f062847e945b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_867a2cb7-e697-4b86-9dd8-f062847e945b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_867a2cb7-e697-4b86-9dd8-f062847e945b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_867a2cb7-e697-4b86-9dd8-f062847e945b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9541a7f3-0b82-43ac-b261-95fe6e5cc876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_867a2cb7-e697-4b86-9dd8-f062847e945b" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9541a7f3-0b82-43ac-b261-95fe6e5cc876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9541a7f3-0b82-43ac-b261-95fe6e5cc876" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ae2e0964-2d62-444a-aff3-faf7ec476f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ae2e0964-2d62-444a-aff3-faf7ec476f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0ff56f19-73ce-483a-b03e-2e92d7a31db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0ff56f19-73ce-483a-b03e-2e92d7a31db7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32aa9461-328f-4b30-a12f-372051c3ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32aa9461-328f-4b30-a12f-372051c3ef9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32aa9461-328f-4b30-a12f-372051c3ef9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32aa9461-328f-4b30-a12f-372051c3ef9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32aa9461-328f-4b30-a12f-372051c3ef9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0359eb8-3a82-46d6-8193-a81c672cae82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32aa9461-328f-4b30-a12f-372051c3ef9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0359eb8-3a82-46d6-8193-a81c672cae82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bf659222-5b2f-4395-a1e4-3978ddf38703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0359eb8-3a82-46d6-8193-a81c672cae82" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bf659222-5b2f-4395-a1e4-3978ddf38703" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended" id="icc3d40bb3f9b4f6d97a536bb0fae3bd5_OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities_24f38388-5bcd-429d-afe6-fa560939d2c6" xlink:href="sgry-20230331.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:to="loc_sgry_VariableInterestEntityNumberOfFacilities_24f38388-5bcd-429d-afe6-fa560939d2c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ae7c5f48-0201-4a96-97e4-ba660b415b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:to="loc_us-gaap_Assets_ae7c5f48-0201-4a96-97e4-ba660b415b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c362a969-6ca6-49fa-9dd6-297af4e59479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:to="loc_us-gaap_Liabilities_c362a969-6ca6-49fa-9dd6-297af4e59479" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e875a082-827e-4556-8e17-3f51af7d1337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e875a082-827e-4556-8e17-3f51af7d1337" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e875a082-827e-4556-8e17-3f51af7d1337" xlink:to="loc_srt_ConsolidatedEntitiesAxis_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_43c159bd-ce2b-4370-be94-0d80128ef37a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_43c159bd-ce2b-4370-be94-0d80128ef37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c97d07e7-21d9-4ae8-9f44-d77955085ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_43c159bd-ce2b-4370-be94-0d80128ef37a" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c97d07e7-21d9-4ae8-9f44-d77955085ab2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#AcquisitionsandDisposalsAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="extended" id="i89b424aa42a24e6f850990f55e2e40ac_AcquisitionsandDisposalsAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_aa1e687a-9df8-4185-9df2-3d0ac418cd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_aa1e687a-9df8-4185-9df2-3d0ac418cd8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7a03595b-fb8b-49c0-9196-78b8081f8985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7a03595b-fb8b-49c0-9196-78b8081f8985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4c302bdc-a36a-42cb-b693-723c2756207c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4c302bdc-a36a-42cb-b693-723c2756207c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6c4aea49-abbe-4d0f-a3e2-50f2d482721a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_Goodwill_6c4aea49-abbe-4d0f-a3e2-50f2d482721a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_358f2d08-f4da-4620-bafc-ac7a346dd2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_358f2d08-f4da-4620-bafc-ac7a346dd2b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a76749eb-9220-4a39-b824-c3fcd0c1bf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a76749eb-9220-4a39-b824-c3fcd0c1bf5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_5cde1c1d-2279-4e6f-9602-7284c1302ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_5cde1c1d-2279-4e6f-9602-7284c1302ce6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_939ab02d-6fed-4e0f-af13-9e0e8f11fc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_939ab02d-6fed-4e0f-af13-9e0e8f11fc30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredPaymentsToAcquireEquityMethodInvestments_426d991e-f317-47ac-96d4-d400726f684f" xlink:href="sgry-20230331.xsd#sgry_DeferredPaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_sgry_DeferredPaymentsToAcquireEquityMethodInvestments_426d991e-f317-47ac-96d4-d400726f684f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ba011441-e2f7-411a-9905-110b0772b84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ba011441-e2f7-411a-9905-110b0772b84c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_963d1af3-8a1b-42f1-9c92-397ee214d98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ba011441-e2f7-411a-9905-110b0772b84c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_963d1af3-8a1b-42f1-9c92-397ee214d98d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_963d1af3-8a1b-42f1-9c92-397ee214d98d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_963d1af3-8a1b-42f1-9c92-397ee214d98d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_963d1af3-8a1b-42f1-9c92-397ee214d98d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_963d1af3-8a1b-42f1-9c92-397ee214d98d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesAndPhysicianPracticesMember_f1668242-43bf-4b79-825b-fb45a2fa97fc" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesAndPhysicianPracticesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_SurgicalFacilitiesAndPhysicianPracticesMember_f1668242-43bf-4b79-825b-fb45a2fa97fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember_35419f01-82ce-442d-9df9-af0d4bdb4ed3" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_SurgicalFacilitiesMember_35419f01-82ce-442d-9df9-af0d4bdb4ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ExistingSurgicalFacilityMember_a440e2ce-fb63-4e77-92e9-0e51e7ce5957" xlink:href="sgry-20230331.xsd#sgry_ExistingSurgicalFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_ExistingSurgicalFacilityMember_a440e2ce-fb63-4e77-92e9-0e51e7ce5957" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember_4666330e-db36-4382-8551-38d1013a8cdb" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_SurgicalFacilitiesExistingMarketsMember_4666330e-db36-4382-8551-38d1013a8cdb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="extended" id="i0e36ef4eef034480a974ef2a0650d33c_AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_e3e6f53d-946b-438b-84b6-b8a3bc8d3432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_e3e6f53d-946b-438b-84b6-b8a3bc8d3432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ef2135da-6a52-47a3-a260-8ee9ac0e708d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ef2135da-6a52-47a3-a260-8ee9ac0e708d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_9d0e0edf-2f8b-4be6-bbfc-4e2aeeec6f62" xlink:href="sgry-20230331.xsd#sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_9d0e0edf-2f8b-4be6-bbfc-4e2aeeec6f62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_63e1d233-0c80-424f-af53-2d3fae78a517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_63e1d233-0c80-424f-af53-2d3fae78a517" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_00ebb97d-00b6-45f9-bda6-f0ad4f880bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_00ebb97d-00b6-45f9-bda6-f0ad4f880bba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6122a931-77f0-4bb5-a5cf-26233178298f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6122a931-77f0-4bb5-a5cf-26233178298f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6122a931-77f0-4bb5-a5cf-26233178298f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6122a931-77f0-4bb5-a5cf-26233178298f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6122a931-77f0-4bb5-a5cf-26233178298f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6122a931-77f0-4bb5-a5cf-26233178298f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OneSurgicalFacilityMember_230b3f81-5d7a-4883-acf3-7ff092f5638e" xlink:href="sgry-20230331.xsd#sgry_OneSurgicalFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:to="loc_sgry_OneSurgicalFacilityMember_230b3f81-5d7a-4883-acf3-7ff092f5638e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2022DisposalsMember_347eb324-70d6-4c4a-a8de-f922b6cc4fef" xlink:href="sgry-20230331.xsd#sgry_A2022DisposalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:to="loc_sgry_A2022DisposalsMember_347eb324-70d6-4c4a-a8de-f922b6cc4fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6defb441-238e-4b4d-b66f-16017ea2c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6defb441-238e-4b4d-b66f-16017ea2c62c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6defb441-238e-4b4d-b66f-16017ea2c62c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6defb441-238e-4b4d-b66f-16017ea2c62c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6defb441-238e-4b4d-b66f-16017ea2c62c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_017a738e-b98e-4ff2-8104-61bb81d16eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6defb441-238e-4b4d-b66f-16017ea2c62c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_017a738e-b98e-4ff2-8104-61bb81d16eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9d4b4c37-d267-4282-97ad-2095518e6ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_017a738e-b98e-4ff2-8104-61bb81d16eee" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9d4b4c37-d267-4282-97ad-2095518e6ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bc179d24-967d-4dfd-ab31-eaf129cac350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bc179d24-967d-4dfd-ab31-eaf129cac350" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc179d24-967d-4dfd-ab31-eaf129cac350_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bc179d24-967d-4dfd-ab31-eaf129cac350" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc179d24-967d-4dfd-ab31-eaf129cac350_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f595abe-f2ed-424d-80e9-5df5f4fc0a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bc179d24-967d-4dfd-ab31-eaf129cac350" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f595abe-f2ed-424d-80e9-5df5f4fc0a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_68eb4a42-8337-45a7-b71d-93df16e0e110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f595abe-f2ed-424d-80e9-5df5f4fc0a15" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_68eb4a42-8337-45a7-b71d-93df16e0e110" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtSummaryofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails" xlink:type="extended" id="i9e557228026f4a7193e42cdea5132979_LongTermDebtSummaryofLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0224a161-17be-40c6-a82c-e5036f897c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0224a161-17be-40c6-a82c-e5036f897c6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_56caf7a3-5216-43d2-acc1-62cf046e13c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_FinanceLeaseLiability_56caf7a3-5216-43d2-acc1-62cf046e13c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_487bb180-8558-4812-bbcb-7cf19e55bf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_487bb180-8558-4812-bbcb-7cf19e55bf1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_494b1627-6086-4eba-8170-a5df66e2fe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_494b1627-6086-4eba-8170-a5df66e2fe0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_53d851df-bf6f-4bb3-be5d-61ee4c1e99cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_53d851df-bf6f-4bb3-be5d-61ee4c1e99cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_aad4ab00-cea4-4b29-8cc1-e85925ce456e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_aad4ab00-cea4-4b29-8cc1-e85925ce456e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_874b0155-1bd5-4ded-a29f-0ad5d84c1198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_874b0155-1bd5-4ded-a29f-0ad5d84c1198" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_66020496-ebd8-4bdd-9164-7b1eeaff4696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_66020496-ebd8-4bdd-9164-7b1eeaff4696" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5662e215-6ac3-425f-8b43-fdb7547b62c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5662e215-6ac3-425f-8b43-fdb7547b62c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5662e215-6ac3-425f-8b43-fdb7547b62c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5662e215-6ac3-425f-8b43-fdb7547b62c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5662e215-6ac3-425f-8b43-fdb7547b62c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5662e215-6ac3-425f-8b43-fdb7547b62c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_715d9662-1c7c-4fab-af8a-175c8d795ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:to="loc_us-gaap_SecuredDebtMember_715d9662-1c7c-4fab-af8a-175c8d795ccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ad18f86d-59af-4820-aa29-efb72c95d14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:to="loc_us-gaap_SeniorNotesMember_ad18f86d-59af-4820-aa29-efb72c95d14e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember_07dd9f5f-7431-43b0-a90e-4983e31d2885" xlink:href="sgry-20230331.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:to="loc_sgry_NotesPayableAndSecuredLoansMember_07dd9f5f-7431-43b0-a90e-4983e31d2885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6ebd19e7-3f83-472b-8f00-438eeac2f7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:to="loc_us-gaap_DebtInstrumentAxis_6ebd19e7-3f83-472b-8f00-438eeac2f7b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6ebd19e7-3f83-472b-8f00-438eeac2f7b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ebd19e7-3f83-472b-8f00-438eeac2f7b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6ebd19e7-3f83-472b-8f00-438eeac2f7b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ebd19e7-3f83-472b-8f00-438eeac2f7b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_13ff0851-a471-48d7-802f-62baf0505e7d" xlink:href="sgry-20230331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_13ff0851-a471-48d7-802f-62baf0505e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_dd37b8d0-6a36-41db-b867-9aa91fdaf37c" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_dd37b8d0-6a36-41db-b867-9aa91fdaf37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_03ee4d98-3e36-4e76-8014-32882842ef7c" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_03ee4d98-3e36-4e76-8014-32882842ef7c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" id="i0d2808f2a59740878eb1a2b1c014fcf7_LongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity_a6aaa9e7-8174-4143-8dff-dcf745504a08" xlink:href="sgry-20230331.xsd#sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:to="loc_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity_a6aaa9e7-8174-4143-8dff-dcf745504a08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_161dd7a2-954c-4c03-8800-a10ae80f4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_161dd7a2-954c-4c03-8800-a10ae80f4fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1ac75f24-b73c-4130-9706-17acdb57791b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:to="loc_us-gaap_LineOfCredit_1ac75f24-b73c-4130-9706-17acdb57791b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:to="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_11674495-84cb-48e1-b5f4-1664a4fc2156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:to="loc_us-gaap_CreditFacilityAxis_11674495-84cb-48e1-b5f4-1664a4fc2156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_11674495-84cb-48e1-b5f4-1664a4fc2156_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_11674495-84cb-48e1-b5f4-1664a4fc2156" xlink:to="loc_us-gaap_CreditFacilityDomain_11674495-84cb-48e1-b5f4-1664a4fc2156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_11674495-84cb-48e1-b5f4-1664a4fc2156" xlink:to="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d9bc6020-b123-4eca-be6a-16bdbd705b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d9bc6020-b123-4eca-be6a-16bdbd705b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_2aed804a-aab8-4e88-9e58-f0841f60e041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:to="loc_us-gaap_LetterOfCreditMember_2aed804a-aab8-4e88-9e58-f0841f60e041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_feb98690-c303-4291-91df-06b59b78a09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_feb98690-c303-4291-91df-06b59b78a09d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_feb98690-c303-4291-91df-06b59b78a09d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_feb98690-c303-4291-91df-06b59b78a09d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_feb98690-c303-4291-91df-06b59b78a09d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_da126b85-bcc0-47dc-b6b3-3d8a6dc50b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_feb98690-c303-4291-91df-06b59b78a09d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_da126b85-bcc0-47dc-b6b3-3d8a6dc50b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b61b4a9c-0974-4838-b984-008549e31d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_da126b85-bcc0-47dc-b6b3-3d8a6dc50b8a" xlink:to="loc_us-gaap_SecuredDebtMember_b61b4a9c-0974-4838-b984-008549e31d55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ae9f3cc-362a-45d9-be0f-1948c06d1f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ae9f3cc-362a-45d9-be0f-1948c06d1f69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ae9f3cc-362a-45d9-be0f-1948c06d1f69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ae9f3cc-362a-45d9-be0f-1948c06d1f69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ae9f3cc-362a-45d9-be0f-1948c06d1f69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4a12c9a-f388-4c50-8567-216993131ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ae9f3cc-362a-45d9-be0f-1948c06d1f69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4a12c9a-f388-4c50-8567-216993131ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c915125d-d1a6-4a08-aba0-3bc0b9cf4caf" xlink:href="sgry-20230331.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4a12c9a-f388-4c50-8567-216993131ec8" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c915125d-d1a6-4a08-aba0-3bc0b9cf4caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e503bab1-ba69-49fe-8e01-e43890268ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e503bab1-ba69-49fe-8e01-e43890268ef3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3b70123a-816b-4503-a39a-06ab592fb9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dbd685cd-e09a-4b26-b927-5598c18a71c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="extended" id="ice534dacba754f99ba8d456b1ef66677_DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_4c71ed16-f53b-4d28-8bcd-c25b45b9803f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_4c71ed16-f53b-4d28-8bcd-c25b45b9803f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0ed21341-9b6f-410d-81b5-6088c73f899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0ed21341-9b6f-410d-81b5-6088c73f899b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c9ab3d32-5f96-47b0-8421-be1fb1d48bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c9ab3d32-5f96-47b0-8421-be1fb1d48bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a4777e90-ca70-46f6-a486-3d8103495abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a4777e90-ca70-46f6-a486-3d8103495abf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_01c99bf4-ed4a-4d69-b243-fe538a19312d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a4777e90-ca70-46f6-a486-3d8103495abf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_01c99bf4-ed4a-4d69-b243-fe538a19312d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_01c99bf4-ed4a-4d69-b243-fe538a19312d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_01c99bf4-ed4a-4d69-b243-fe538a19312d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_01c99bf4-ed4a-4d69-b243-fe538a19312d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_01c99bf4-ed4a-4d69-b243-fe538a19312d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapOneMember_1b276c21-d8c6-487b-a82e-11e89c970e80" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapOneMember_1b276c21-d8c6-487b-a82e-11e89c970e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapTwoMember_c80b0981-0ab7-461d-b48e-9de558259f2e" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapTwoMember_c80b0981-0ab7-461d-b48e-9de558259f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapThreeMember_ca64e20c-f317-40fd-b7ef-422ea0cd41e5" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapThreeMember_ca64e20c-f317-40fd-b7ef-422ea0cd41e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapOneMember_7f18a9c7-5bd7-4986-aa53-00a0edbba92f" xlink:href="sgry-20230331.xsd#sgry_InterestRateCapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_InterestRateCapOneMember_7f18a9c7-5bd7-4986-aa53-00a0edbba92f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapTwoMember_6ae0f7b7-a6a7-4e4f-97ea-a8e6428935f5" xlink:href="sgry-20230331.xsd#sgry_InterestRateCapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_InterestRateCapTwoMember_6ae0f7b7-a6a7-4e4f-97ea-a8e6428935f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFourMember_df914778-7bca-4b6d-8b34-9109990c4ed2" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapFourMember_df914778-7bca-4b6d-8b34-9109990c4ed2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFiveMember_90971004-f52f-4fa2-92bf-e9bb231951e4" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapFiveMember_90971004-f52f-4fa2-92bf-e9bb231951e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapSixMember_efdaa1a7-cc55-4100-b1c3-bebb0a067055" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapSixMember_efdaa1a7-cc55-4100-b1c3-bebb0a067055" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapOneMember_8efd3e66-e9e0-411e-8e3d-690aaecf13ed" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_ReceiveFixedSwapOneMember_8efd3e66-e9e0-411e-8e3d-690aaecf13ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapTwoMember_60e7faa2-7c42-4557-a13c-af3672841305" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_ReceiveFixedSwapTwoMember_60e7faa2-7c42-4557-a13c-af3672841305" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapThreeMember_44d3802b-ec3f-41a2-ad7a-cbed82599401" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_ReceiveFixedSwapThreeMember_44d3802b-ec3f-41a2-ad7a-cbed82599401" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="extended" id="i397698fc311e4e41944399365c70c328_DerivativesandHedgingActivitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_70a20a46-70c8-4b07-89dd-acb51f838fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_70a20a46-70c8-4b07-89dd-acb51f838fc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_6a7ca0d2-dde7-4bec-aabe-d6da7b222b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_6a7ca0d2-dde7-4bec-aabe-d6da7b222b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeVariableInterestRate_2dff0907-ed1b-43d2-92ee-61f0d8878dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_DerivativeVariableInterestRate_2dff0907-ed1b-43d2-92ee-61f0d8878dfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities_2fe8823e-3095-4a73-8d82-53b654a89bef" xlink:href="sgry-20230331.xsd#sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities_2fe8823e-3095-4a73-8d82-53b654a89bef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_4f10a209-79b0-4cf4-ba46-f4dcef2dc806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_4f10a209-79b0-4cf4-ba46-f4dcef2dc806" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cf96f4c6-e05f-413c-ab40-3467036bf199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cf96f4c6-e05f-413c-ab40-3467036bf199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cf96f4c6-e05f-413c-ab40-3467036bf199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cf96f4c6-e05f-413c-ab40-3467036bf199" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cf96f4c6-e05f-413c-ab40-3467036bf199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cf96f4c6-e05f-413c-ab40-3467036bf199" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:to="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member_8e9fbb29-9d61-47f9-a0f5-90393e494c37" xlink:href="sgry-20230331.xsd#sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:to="loc_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member_8e9fbb29-9d61-47f9-a0f5-90393e494c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:href="sgry-20230331.xsd#sgry_SixUndersignedInterestRateSwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:to="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member_076910f5-d222-4bb5-b7e0-84b6714a8cc4" xlink:href="sgry-20230331.xsd#sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:to="loc_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member_076910f5-d222-4bb5-b7e0-84b6714a8cc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member_6591464d-8d9b-4655-af2a-55d3c5d88a20" xlink:href="sgry-20230331.xsd#sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:to="loc_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member_6591464d-8d9b-4655-af2a-55d3c5d88a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_5c70c862-5f33-4d48-bd7e-eaeb00eb335c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:to="loc_us-gaap_InterestRateCapMember_5c70c862-5f33-4d48-bd7e-eaeb00eb335c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_68bcebc6-9734-4b07-ae8c-c166ba9db580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_us-gaap_HedgingDesignationAxis_68bcebc6-9734-4b07-ae8c-c166ba9db580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_68bcebc6-9734-4b07-ae8c-c166ba9db580_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_68bcebc6-9734-4b07-ae8c-c166ba9db580" xlink:to="loc_us-gaap_HedgingDesignationDomain_68bcebc6-9734-4b07-ae8c-c166ba9db580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_68bcebc6-9734-4b07-ae8c-c166ba9db580" xlink:to="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3779b30e-8974-4287-860c-a4c2344974bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3779b30e-8974-4287-860c-a4c2344974bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e3af3045-c084-4d0d-a86b-a6383635f140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:to="loc_us-gaap_NondesignatedMember_e3af3045-c084-4d0d-a86b-a6383635f140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c5103e2b-50ae-4413-a095-ee31562a97a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_us-gaap_VariableRateAxis_c5103e2b-50ae-4413-a095-ee31562a97a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c5103e2b-50ae-4413-a095-ee31562a97a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c5103e2b-50ae-4413-a095-ee31562a97a2" xlink:to="loc_us-gaap_VariableRateDomain_c5103e2b-50ae-4413-a095-ee31562a97a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_27762218-fc79-4bbf-b048-be4669b7d5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c5103e2b-50ae-4413-a095-ee31562a97a2" xlink:to="loc_us-gaap_VariableRateDomain_27762218-fc79-4bbf-b048-be4669b7d5c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fca356cb-9148-4d3f-b920-e818ac90e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_27762218-fc79-4bbf-b048-be4669b7d5c5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fca356cb-9148-4d3f-b920-e818ac90e13c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e34a164-3eef-44e5-b898-d578909935f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_srt_RangeAxis_0e34a164-3eef-44e5-b898-d578909935f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e34a164-3eef-44e5-b898-d578909935f8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0e34a164-3eef-44e5-b898-d578909935f8" xlink:to="loc_srt_RangeMember_0e34a164-3eef-44e5-b898-d578909935f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7403b963-904d-430b-8ce8-7f85a897e9e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0e34a164-3eef-44e5-b898-d578909935f8" xlink:to="loc_srt_RangeMember_7403b963-904d-430b-8ce8-7f85a897e9e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fc159f7b-a0ec-4128-8ebf-264b38f4c31a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7403b963-904d-430b-8ce8-7f85a897e9e1" xlink:to="loc_srt_MinimumMember_fc159f7b-a0ec-4128-8ebf-264b38f4c31a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="extended" id="i2ee634e3070e4145a9c410535ffea505_DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_8cb59deb-5566-4801-a571-95374289904e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_8cb59deb-5566-4801-a571-95374289904e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_3413f0a3-0b62-489f-9bb3-f0410b7040ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_3413f0a3-0b62-489f-9bb3-f0410b7040ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:to="loc_us-gaap_HedgingDesignationAxis_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c" xlink:to="loc_us-gaap_HedgingDesignationDomain_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c" xlink:to="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a3d951a8-b558-4d7c-adba-86b480e64ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:to="loc_us-gaap_NondesignatedMember_a3d951a8-b558-4d7c-adba-86b480e64ea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2a644ae8-999e-4c0b-8156-1882817dea89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2a644ae8-999e-4c0b-8156-1882817dea89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_98e04f4f-fe47-4c52-8bf3-4abc9cabc005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_98e04f4f-fe47-4c52-8bf3-4abc9cabc005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_98e04f4f-fe47-4c52-8bf3-4abc9cabc005_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_98e04f4f-fe47-4c52-8bf3-4abc9cabc005" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_98e04f4f-fe47-4c52-8bf3-4abc9cabc005_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_98e04f4f-fe47-4c52-8bf3-4abc9cabc005" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_fac48907-53a1-47fd-b59b-e130145ecbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_fac48907-53a1-47fd-b59b-e130145ecbb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2a0ac266-b8ae-4625-88f7-7903cfc5b318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2a0ac266-b8ae-4625-88f7-7903cfc5b318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_ceb51eca-e3e5-470e-80f8-036e33470f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:to="loc_us-gaap_InterestRateCapMember_ceb51eca-e3e5-470e-80f8-036e33470f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_86cf8270-fccb-42dc-bd2b-662ff8b5b39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:to="loc_us-gaap_InterestRateSwapMember_86cf8270-fccb-42dc-bd2b-662ff8b5b39c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="extended" id="i19a0136048824ac88f24c433811db5e3_DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0cc6ef26-5e4b-40ad-8e75-f8705399e278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0cc6ef26-5e4b-40ad-8e75-f8705399e278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_73867e35-7138-43f0-9415-b68545897131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_73867e35-7138-43f0-9415-b68545897131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_dbac5d6e-0577-45ec-b661-e21ff5714ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_dbac5d6e-0577-45ec-b661-e21ff5714ca4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_601f02bf-fdf1-4750-b321-b45c776280f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_601f02bf-fdf1-4750-b321-b45c776280f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a69faab0-cbbe-494a-91a6-b92296513843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a69faab0-cbbe-494a-91a6-b92296513843" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_303cd526-5a10-4a89-81c9-3a9b757cb137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_303cd526-5a10-4a89-81c9-3a9b757cb137" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_02fa385f-c992-4fee-b1ec-26efb442393b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_303cd526-5a10-4a89-81c9-3a9b757cb137" xlink:to="loc_us-gaap_HedgingDesignationAxis_02fa385f-c992-4fee-b1ec-26efb442393b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_02fa385f-c992-4fee-b1ec-26efb442393b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_02fa385f-c992-4fee-b1ec-26efb442393b" xlink:to="loc_us-gaap_HedgingDesignationDomain_02fa385f-c992-4fee-b1ec-26efb442393b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_02fa385f-c992-4fee-b1ec-26efb442393b" xlink:to="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8cf1d6b8-3e77-47dd-acfa-77178f5455e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:to="loc_us-gaap_NondesignatedMember_8cf1d6b8-3e77-47dd-acfa-77178f5455e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26738b95-ee97-4a1f-b403-f14e549e54ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26738b95-ee97-4a1f-b403-f14e549e54ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#EarningsPerShareSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="extended" id="i99493b30b3ca4143af529064c6cddc26_EarningsPerShareSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_9ac2944a-1017-4648-90b6-7d38f15efe58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_NetIncomeLossAbstract_9ac2944a-1017-4648-90b6-7d38f15efe58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_773b8590-f3e4-4a5b-82ac-9ccca142c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9ac2944a-1017-4648-90b6-7d38f15efe58" xlink:to="loc_us-gaap_NetIncomeLoss_773b8590-f3e4-4a5b-82ac-9ccca142c6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0719e94e-7d48-4e7c-b792-c6cf69f9bcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0719e94e-7d48-4e7c-b792-c6cf69f9bcd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86c38862-b4c2-45b4-8cbe-eb89f297a316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86c38862-b4c2-45b4-8cbe-eb89f297a316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6dfd5718-61ce-4552-83e2-8e5ec6657582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:to="loc_us-gaap_EarningsPerShareBasic_6dfd5718-61ce-4552-83e2-8e5ec6657582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e17fd6d6-89d5-4c9d-bfe0-01c0ee9d3401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e17fd6d6-89d5-4c9d-bfe0-01c0ee9d3401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_246af275-bfdb-4e9c-9805-7e668e52cc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_246af275-bfdb-4e9c-9805-7e668e52cc99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0b187cf0-4797-4b6e-aa18-d3fc63f8141e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0b187cf0-4797-4b6e-aa18-d3fc63f8141e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75aa5e0e-79fc-46f2-b6c6-fd3676b57287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0b187cf0-4797-4b6e-aa18-d3fc63f8141e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75aa5e0e-79fc-46f2-b6c6-fd3676b57287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75aa5e0e-79fc-46f2-b6c6-fd3676b57287_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75aa5e0e-79fc-46f2-b6c6-fd3676b57287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75aa5e0e-79fc-46f2-b6c6-fd3676b57287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75aa5e0e-79fc-46f2-b6c6-fd3676b57287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c0f968c1-d6d8-4a9d-85bf-b0c653038625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c0f968c1-d6d8-4a9d-85bf-b0c653038625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b930b5a8-5ca6-4835-9cc9-999186085cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:to="loc_us-gaap_RestrictedStockMember_b930b5a8-5ca6-4835-9cc9-999186085cb6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" xlink:type="extended" id="i730700cc76904d3c9ffc86b72b58b210_SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6d5e82b-da1d-41f7-b00f-9d1c74188f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6d5e82b-da1d-41f7-b00f-9d1c74188f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_b85c2a23-2b36-43cf-aaca-652a83f0a845" xlink:href="sgry-20230331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_b85c2a23-2b36-43cf-aaca-652a83f0a845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7ce8cd35-2e07-416a-a3a9-1554b719f68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7ce8cd35-2e07-416a-a3a9-1554b719f68e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_34688ff3-430c-4cb5-8796-5e5394f57a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_34688ff3-430c-4cb5-8796-5e5394f57a55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_28cef182-04cb-4437-a753-14de9b433241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_28cef182-04cb-4437-a753-14de9b433241" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_34ca3e02-a8b1-4677-a2fc-a506f4fa1e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_34ca3e02-a8b1-4677-a2fc-a506f4fa1e38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f17bc369-36c4-46e7-925f-cbd2cdd60bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_ShareBasedCompensation_f17bc369-36c4-46e7-925f-cbd2cdd60bea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_0818b4ae-3947-4f8d-bb43-d52095237a00" xlink:href="sgry-20230331.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_0818b4ae-3947-4f8d-bb43-d52095237a00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_c64bc5ce-7195-425d-be3b-ab217dbf40d3" xlink:href="sgry-20230331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_c64bc5ce-7195-425d-be3b-ab217dbf40d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact_c12ac269-fc14-41fe-931d-1ceaf9da149a" xlink:href="sgry-20230331.xsd#sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact_c12ac269-fc14-41fe-931d-1ceaf9da149a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UndesignatedDerivativeActivity_ca2a818a-8b9a-4307-81d7-144518027450" xlink:href="sgry-20230331.xsd#sgry_UndesignatedDerivativeActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_UndesignatedDerivativeActivity_ca2a818a-8b9a-4307-81d7-144518027450" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_68ac03dd-c05e-4b65-ae95-0856bea9f88b" xlink:href="sgry-20230331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_d0e7f431-2148-492a-8868-ff40bd5e6d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_d0e7f431-2148-492a-8868-ff40bd5e6d64" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5a1f05ab-9257-40a3-9652-36d15e019b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5a1f05ab-9257-40a3-9652-36d15e019b39" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_caf8ee05-a3f4-4ee1-b83f-7f3e682216ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_caf8ee05-a3f4-4ee1-b83f-7f3e682216ea" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_58d137e1-160e-4722-9f39-98706d8df111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_LitigationSettlementExpense_58d137e1-160e-4722-9f39-98706d8df111" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation_17c9690f-91db-4ef3-80ab-40ddd5644cf8" xlink:href="sgry-20230331.xsd#sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation_17c9690f-91db-4ef3-80ab-40ddd5644cf8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3d9b4be0-33c2-49fb-9d85-256e74157b2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:to="loc_srt_ConsolidationItemsAxis_3d9b4be0-33c2-49fb-9d85-256e74157b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3d9b4be0-33c2-49fb-9d85-256e74157b2f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_3d9b4be0-33c2-49fb-9d85-256e74157b2f" xlink:to="loc_srt_ConsolidationItemsDomain_3d9b4be0-33c2-49fb-9d85-256e74157b2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_3d9b4be0-33c2-49fb-9d85-256e74157b2f" xlink:to="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_afa434c2-5b53-4508-9bcf-4c24ef7e7860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:to="loc_us-gaap_OperatingSegmentsMember_afa434c2-5b53-4508-9bcf-4c24ef7e7860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2003512d-2ea9-477e-b139-f39907e0e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2003512d-2ea9-477e-b139-f39907e0e46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_49579199-b7de-4561-b302-b48dde996da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_49579199-b7de-4561-b302-b48dde996da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_49579199-b7de-4561-b302-b48dde996da8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_49579199-b7de-4561-b302-b48dde996da8" xlink:to="loc_us-gaap_SegmentDomain_49579199-b7de-4561-b302-b48dde996da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_49579199-b7de-4561-b302-b48dde996da8" xlink:to="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_23094003-5852-4d35-a9da-15973fa876ed" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:to="loc_sgry_SurgicalFacilityServicesMember_23094003-5852-4d35-a9da-15973fa876ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_769d5d9d-a61d-41de-b345-15c16c188526" xlink:href="sgry-20230331.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:to="loc_sgry_AncillaryServicesMember_769d5d9d-a61d-41de-b345-15c16c188526" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="extended" id="i4577601067e14b08b5168e8d9b62e2d9_SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_adbdee25-07a3-40ee-9cfd-fb6dfb7e4a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:to="loc_us-gaap_Assets_adbdee25-07a3-40ee-9cfd-fb6dfb7e4a6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b0fc2c8-779e-4704-b216-e6c3a3072a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b0fc2c8-779e-4704-b216-e6c3a3072a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f9508529-dd0c-4cb1-b48e-7815fe50ffa8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:to="loc_srt_ConsolidationItemsAxis_f9508529-dd0c-4cb1-b48e-7815fe50ffa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f9508529-dd0c-4cb1-b48e-7815fe50ffa8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f9508529-dd0c-4cb1-b48e-7815fe50ffa8" xlink:to="loc_srt_ConsolidationItemsDomain_f9508529-dd0c-4cb1-b48e-7815fe50ffa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f9508529-dd0c-4cb1-b48e-7815fe50ffa8" xlink:to="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_619f4f6d-e990-4b72-bbe6-cb13796efaac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:to="loc_us-gaap_OperatingSegmentsMember_619f4f6d-e990-4b72-bbe6-cb13796efaac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0e258f39-d6f9-4b76-a117-d80ae47befb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0e258f39-d6f9-4b76-a117-d80ae47befb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1549626f-063c-4c70-93fa-0a0140e78534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1549626f-063c-4c70-93fa-0a0140e78534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1549626f-063c-4c70-93fa-0a0140e78534_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1549626f-063c-4c70-93fa-0a0140e78534" xlink:to="loc_us-gaap_SegmentDomain_1549626f-063c-4c70-93fa-0a0140e78534_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1549626f-063c-4c70-93fa-0a0140e78534" xlink:to="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_e8eff3da-f908-4bf2-a5d8-c84ff438ac03" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:to="loc_sgry_SurgicalFacilityServicesMember_e8eff3da-f908-4bf2-a5d8-c84ff438ac03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_78334f00-61d3-4820-b16c-09e0b63285e7" xlink:href="sgry-20230331.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:to="loc_sgry_AncillaryServicesMember_78334f00-61d3-4820-b16c-09e0b63285e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="extended" id="ibd44d35e7b1941dd874e89713385089b_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed_70047b31-692a-4a7d-ae17-d42513d2aa99" xlink:href="sgry-20230331.xsd#sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:to="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed_70047b31-692a-4a7d-ae17-d42513d2aa99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02e57e1a-e6e7-492a-8e90-bfec335abf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02e57e1a-e6e7-492a-8e90-bfec335abf1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ae482e78-d8b1-471b-9972-b4352f5a9c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ae482e78-d8b1-471b-9972-b4352f5a9c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:to="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_62a383eb-0b4c-412e-af4c-1354823f57bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_62a383eb-0b4c-412e-af4c-1354823f57bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_62a383eb-0b4c-412e-af4c-1354823f57bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_62a383eb-0b4c-412e-af4c-1354823f57bc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_62a383eb-0b4c-412e-af4c-1354823f57bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0068949a-e977-4532-acd0-bbff640e58ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_62a383eb-0b4c-412e-af4c-1354823f57bc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0068949a-e977-4532-acd0-bbff640e58ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8e175232-4906-461b-8467-35ee4b835724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0068949a-e977-4532-acd0-bbff640e58ed" xlink:to="loc_us-gaap_SubsequentEventMember_8e175232-4906-461b-8467-35ee4b835724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f99e896e-15ff-4f03-be0f-3d158dc75729" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f99e896e-15ff-4f03-be0f-3d158dc75729" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f99e896e-15ff-4f03-be0f-3d158dc75729_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f99e896e-15ff-4f03-be0f-3d158dc75729" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f99e896e-15ff-4f03-be0f-3d158dc75729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3c3c2ef8-a912-4094-bc99-3126abbd4063" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f99e896e-15ff-4f03-be0f-3d158dc75729" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3c3c2ef8-a912-4094-bc99-3126abbd4063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InDevelopmentDeNovoSurgicalFacilityMember_3ad32f00-f514-44d1-ae64-800767250164" xlink:href="sgry-20230331.xsd#sgry_InDevelopmentDeNovoSurgicalFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3c3c2ef8-a912-4094-bc99-3126abbd4063" xlink:to="loc_sgry_InDevelopmentDeNovoSurgicalFacilityMember_3ad32f00-f514-44d1-ae64-800767250164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d002825b-b459-4821-9704-8de4959b6efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d002825b-b459-4821-9704-8de4959b6efe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d002825b-b459-4821-9704-8de4959b6efe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d002825b-b459-4821-9704-8de4959b6efe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d002825b-b459-4821-9704-8de4959b6efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6c09004e-53ad-4387-aa7f-cd2cad8d5c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d002825b-b459-4821-9704-8de4959b6efe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6c09004e-53ad-4387-aa7f-cd2cad8d5c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e927b283-12bc-4118-ba3a-0f9eb6cb19cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6c09004e-53ad-4387-aa7f-cd2cad8d5c71" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e927b283-12bc-4118-ba3a-0f9eb6cb19cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_464d7a3c-95ce-4e5f-89ef-6c1d97258951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_464d7a3c-95ce-4e5f-89ef-6c1d97258951" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_464d7a3c-95ce-4e5f-89ef-6c1d97258951_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_464d7a3c-95ce-4e5f-89ef-6c1d97258951" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_464d7a3c-95ce-4e5f-89ef-6c1d97258951_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc090900-531e-425d-b0c6-e6f6476f6976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_464d7a3c-95ce-4e5f-89ef-6c1d97258951" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc090900-531e-425d-b0c6-e6f6476f6976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TwoSurgicalFacilitiesMember_194f8054-78bc-4c59-9647-dd3892b97213" xlink:href="sgry-20230331.xsd#sgry_TwoSurgicalFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc090900-531e-425d-b0c6-e6f6476f6976" xlink:to="loc_sgry_TwoSurgicalFacilitiesMember_194f8054-78bc-4c59-9647-dd3892b97213" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sgry-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8139a9e6-f0c0-4663-a359-16b44ae9e913,g:a1e20cbb-0632-4ba5-9f9a-c20d61b98cc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b851af34-3def-47b2-87ae-67c2d706f00b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8a3c9e0a-6b15-414a-b5f1-320f26108c3d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_3b5d4a11-20fc-4528-b18c-e4a279b294dd_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_802e1afc-bf4e-4f95-b718-de0a9cc17155_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ba368335-c5af-4358-8dec-f594f5cfc9c3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_3cfb945f-f423-4337-a7b4-ed458ba4290e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_d22a66ec-100c-416b-b3fc-5784790f0359_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f168816b-ba97-40cb-8149-d06c83470b56_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_743c059d-4ab2-4d4c-9e1a-e70edb621eeb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TwoSurgicalFacilitiesMember_2ca788a9-7d86-4c0b-a41d-97b93bf6f2be_terseLabel_en-US" xlink:label="lab_sgry_TwoSurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Surgical Facilities</link:label>
    <link:label id="lab_sgry_TwoSurgicalFacilitiesMember_label_en-US" xlink:label="lab_sgry_TwoSurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Surgical Facilities [Member]</link:label>
    <link:label id="lab_sgry_TwoSurgicalFacilitiesMember_documentation_en-US" xlink:label="lab_sgry_TwoSurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Surgical Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TwoSurgicalFacilitiesMember" xlink:href="sgry-20230331.xsd#sgry_TwoSurgicalFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TwoSurgicalFacilitiesMember" xlink:to="lab_sgry_TwoSurgicalFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ed141429-c145-4865-95e9-d115a9daff57_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_fbccaac8-2120-46f1-996a-ec4a9ae991c0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_4b537034-0b24-4919-a3b9-a7a1918429e7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_51ab825a-7577-44ec-acf4-f580fe8e6281_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f07cb0ec-b2d1-4ba2-aca6-ec207ade2c61_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ec192fb7-1fc1-49b3-83fb-7fb0adf77f50_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7ce67737-825e-4cef-afcc-907c409dad26_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member_6c458bd3-3531-46a5-8356-d72301cea32e_terseLabel_en-US" xlink:label="lab_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 1.00%</link:label>
    <link:label id="lab_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member_label_en-US" xlink:label="lab_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed, Receive 1-Month LIBOR, Subject To Minimum Of 1.00% [Member]</link:label>
    <link:label id="lab_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member_documentation_en-US" xlink:label="lab_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed, Receive 1-Month LIBOR, Subject To Minimum Of 1.00%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" xlink:href="sgry-20230331.xsd#sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" xlink:to="lab_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_e16bd305-a4e3-4703-9f28-b853617eff8e_terseLabel_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest Taxes Depreciation And Amortization</link:label>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest Taxes Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="sgry-20230331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_71d611e9-d842-411a-b914-ff117dd1ea88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_dc9608be-58b9-4cc9-bd7d-174cc0ec133a_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a684c350-cde9-40a3-9a6e-a086fb671800_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_0d9a02a9-e6ea-49b2-a333-09ede87a3042_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact_3e7f33aa-48a5-4be2-a41e-d3440d3b9a92_negatedLabel_en-US" xlink:label="lab_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlements and regulatory change impact</link:label>
    <link:label id="lab_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact_label_en-US" xlink:label="lab_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact</link:label>
    <link:label id="lab_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact_documentation_en-US" xlink:label="lab_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" xlink:href="sgry-20230331.xsd#sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" xlink:to="lab_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_867b9e25-583f-4297-bd1f-da093ae2ecc6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3eafa836-4f66-43c7-b03f-4f947901e3b3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_94e92992-3059-469c-a144-ea8cb7477bfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_03a4acca-bc6e-4537-acc8-e0299576f3d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts (payments) related to ownership transactions with non-controlling interest holders</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LeaseLiability_200dd985-ea88-4bc2-aaa3-652c02339a80_totalLabel_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_sgry_LeaseLiability_label_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_sgry_LeaseLiability_documentation_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability" xlink:href="sgry-20230331.xsd#sgry_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LeaseLiability" xlink:to="lab_sgry_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4ad09a97-93dd-4bf2-851d-6787aff6dd37_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $382.7 and $374.3, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0a1d1e43-b2c4-4e24-88ea-3375fd613fdf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_778b5cc6-e50c-4cb4-a6fa-f8db53e0ae55_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_4f3dda08-fcdf-45a2-9315-10e6103a9545_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of shares of non-controlling interests, net&#8212;redeemable</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:to="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_980543e9-2f0f-4ba7-8048-d2cd44dcb407_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_506a9c8e-e6d7-4691-a60b-876dca2e4314_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_dd27bec7-ead2-47f2-98dc-e74439f1b34d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapSixMember_c014f639-405c-4cfd-83bf-a39977a98449_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapSixMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Six [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapSixMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Six Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapSixMember" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapSixMember" xlink:to="lab_sgry_PayFixedSwapSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_d1c310b9-eb3d-4e7c-b0e3-4319fc51f702_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fca1ea35-32c5-4a4c-b9d6-6dc403b68a37_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a0731c1e-5f75-48ce-9f3f-da67e881ffba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_473d15d8-c664-4bbd-9d4d-8abff6d5b579_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_a72eb2ce-2537-47c0-a04c-520714c11c86_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_32982c69-8aa4-49f5-a7d4-e2dfff270fa5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_53cdea91-1889-4e54-937f-eee4aca069af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits attributable to non-recurring earnings' impact on the valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PrivateInsuranceMember_ec494c3c-9d8d-4dbc-a013-c9fe620f469f_terseLabel_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private insurance</link:label>
    <link:label id="lab_sgry_PrivateInsuranceMember_label_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Insurance [Member]</link:label>
    <link:label id="lab_sgry_PrivateInsuranceMember_documentation_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember" xlink:href="sgry-20230331.xsd#sgry_PrivateInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PrivateInsuranceMember" xlink:to="lab_sgry_PrivateInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_65f9777f-99cd-4d00-89d7-d873aec70023_terseLabel_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable and other secured loans</link:label>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_label_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Secured Loans [Member]</link:label>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_documentation_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Secured Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember" xlink:href="sgry-20230331.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NotesPayableAndSecuredLoansMember" xlink:to="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f2d7a852-8695-4dd8-8f69-d6cecd49bd7e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_0f93c531-4254-4bb5-8468-bfa3bb47024e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4ca4de39-69b6-4790-bb62-5f2c504cab51_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_60dd46fd-5bb0-47c7-9b5d-8639c9267073_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_f822742c-568b-4fbd-9f42-62be03b82c7a_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f2910e07-a012-42f0-b716-87160d45b369_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_fca49c46-1922-4809-aa0c-87c5a34286a9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity_fbae09c7-e911-4e7a-9a96-3a91cd5fbce3_terseLabel_en-US" xlink:label="lab_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, increase in borrowing capacity</link:label>
    <link:label id="lab_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity_label_en-US" xlink:label="lab_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Increase In Borrowing Capacity</link:label>
    <link:label id="lab_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity_documentation_en-US" xlink:label="lab_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Increase In Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity" xlink:href="sgry-20230331.xsd#sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity" xlink:to="lab_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a36b4fb3-a01f-47e4-a192-a97ba093c5e5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_86b4c6d0-cc50-4e59-8d91-2127283ccc12_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_e6fd323a-3685-4f3e-8b86-0f1a37e7eef3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of line of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_0bf96988-caa8-47d6-a01d-c8fa32160929_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 126,480,483 and 125,960,834, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a4068a92-2660-4178-9d02-3fa17c6fbc83_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_3eeeb17c-c23d-41ea-bd6b-75767bf429f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_912e0ab8-33d7-456d-9fd7-b126b66bcff4_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned, majority interest</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Facilities Owned, Majority Interest</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned, Majority Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_363cefa9-f073-4931-82df-7d9bbf8da1c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_bbc5275d-cc08-4899-aee0-4bb27b7c511f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OneSurgicalFacilityMember_d511d8e2-2f3a-4d42-b929-e7da845e7f9f_terseLabel_en-US" xlink:label="lab_sgry_OneSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Surgical Facility</link:label>
    <link:label id="lab_sgry_OneSurgicalFacilityMember_label_en-US" xlink:label="lab_sgry_OneSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Surgical Facility [Member]</link:label>
    <link:label id="lab_sgry_OneSurgicalFacilityMember_documentation_en-US" xlink:label="lab_sgry_OneSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Surgical Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OneSurgicalFacilityMember" xlink:href="sgry-20230331.xsd#sgry_OneSurgicalFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OneSurgicalFacilityMember" xlink:to="lab_sgry_OneSurgicalFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ee3b00b3-f52e-4c62-91f6-6013d0dabaa5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_15353254-949b-41dc-b1aa-0ec991fe9b6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ce0ff94b-27f3-4032-a60b-08d41af359d4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2d6d8ca8-18ad-45ff-acfb-ac553f57c5bd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_61cd0ec0-7bd7-4b4d-91dd-281d85f7f460_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits related to the sale of partnership interests</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GrantRevenue_f59a7b47-bbc1-42f9-b1f7-28c277c18f90_negatedTerseLabel_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funds</link:label>
    <link:label id="lab_sgry_GrantRevenue_label_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_sgry_GrantRevenue_documentation_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue" xlink:href="sgry-20230331.xsd#sgry_GrantRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GrantRevenue" xlink:to="lab_sgry_GrantRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8ecb1302-d801-4ea5-b032-f18b46865cb0_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_f237f343-6cbe-40ea-a441-5867f4a442c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposals of facilities and other assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b5ab3416-2ff7-4096-981a-8e9662264aae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) reclassified from accumulated OCI into income (effective portion)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a9975d7-7ac5-4e3b-b517-cb8be3e5a20a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_769e8c9c-61bb-4418-83ce-d61fbf07db1d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0b1fdbd-74b8-4e7b-8246-3382ae788bcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_31f1a521-0767-4f88-9e30-9aa70f7a5d06_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ReceiveFixedSwapThreeMember_03aacb55-e914-479b-8ecc-32df36c1566b_terseLabel_en-US" xlink:label="lab_sgry_ReceiveFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed swap</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapThreeMember_label_en-US" xlink:label="lab_sgry_ReceiveFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Three [Member]</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapThreeMember_documentation_en-US" xlink:label="lab_sgry_ReceiveFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Three Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapThreeMember" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ReceiveFixedSwapThreeMember" xlink:to="lab_sgry_ReceiveFixedSwapThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ebb9fc9-f961-4334-8792-c2596b0075e4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_01b07fc1-f103-4b78-9ef0-bba806505337_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3ade6524-33b7-414e-8a60-430a8102ae3b_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_69858256-3706-43fe-88e1-3aec04351af9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ebf706ca-9770-465e-b29d-abf9afb4d494_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_141285eb-852f-438e-9ec7-a8e06b04b6be_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c23a049a-c692-4b21-94e1-c905a7baae28_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a9a38fd3-e09b-4ace-b8a0-bd7a6fabec73_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d3ab9624-5f00-4005-ac2c-f6ebd9e50cb6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4f46586c-4d53-4066-b635-9a498ae0eed0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_1fe45f85-7f02-428d-b852-9e0b04c10bb7_terseLabel_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Revolver</link:label>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Senior Secured Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:href="sgry-20230331.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:to="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member_d0ecb0b9-4a42-4053-bcb8-8b848cf70e4a_terseLabel_en-US" xlink:label="lab_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 0.75%</link:label>
    <link:label id="lab_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member_label_en-US" xlink:label="lab_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 0.75% [Member]</link:label>
    <link:label id="lab_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member_documentation_en-US" xlink:label="lab_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed Interest Rate Swaps Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" xlink:href="sgry-20230331.xsd#sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" xlink:to="lab_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_9b2c95fb-07e5-4801-b6e6-e5eabfc3a5a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_525ca413-f8b4-4c8b-961a-2a19ebc2627b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain recognized in OCI (effective portion)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fe1c8b9f-f6c1-4bf6-9a0e-45c16ef4d7c2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_e14c693c-25e2-401d-a052-73390c6b08c8_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_a5ff1633-afa2-43fa-bfca-8b228bac2522_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_b99afa57-dbeb-4749-93b1-14a83cd0233f_terseLabel_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals</link:label>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_label_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals [Member]</link:label>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_documentation_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember" xlink:href="sgry-20230331.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FacilitiesSurgicalHospitalsMember" xlink:to="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e3b41a62-5b02-4ded-a0d0-43b2df2cd6d3_verboseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_e053645e-5f77-4462-b198-674f68a2184c_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction, integration and acquisition costs</link:label>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_label_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs, And Merger Costs</link:label>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs, And Merger Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:href="sgry-20230331.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:to="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bca805ca-2f27-4b21-a8ea-688f73006505_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_fffe49d0-b318-4b6c-a6e3-7ca7915e5bcd_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_3268eec9-0071-4076-933d-e3e0a2b63f30_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d46d0410-6779-4a40-8624-79833372bcfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1688ba72-d9dc-4094-999f-ca983ef6361e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_2e21596b-802e-4757-ac4d-a7658c303dc6_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5520d58e-39d5-452d-9b0c-2cc6f411cd26_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b513bb4c-937f-478e-9e4c-6e20ab1f83fe_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapFiveMember_4a5d795a-bd75-4173-9b87-264baa72137f_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapFiveMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Five [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapFiveMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Five Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFiveMember" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapFiveMember" xlink:to="lab_sgry_PayFixedSwapFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c3baffb-536b-4155-a538-cf6295da99e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_3c562217-cf4c-4c2a-8a31-db2703b5192d_terseLabel_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10.000% senior unsecured notes due 2027</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_label_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes, Due 2027 [Member]</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_documentation_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes, Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SeniorUnsecuredNotesDue2027Member" xlink:to="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e44847c2-3f07-4849-bfd1-6f8117a82daf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_f7194bd1-dc66-469f-8b6a-5ed4f18ca717_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_72b89369-049c-44e2-b674-43b1d4f83e8c_terseLabel_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs:</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_label_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost1 [Abstract]</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_documentation_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost1 [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost1Abstract" xlink:href="sgry-20230331.xsd#sgry_FinanceLeaseCost1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FinanceLeaseCost1Abstract" xlink:to="lab_sgry_FinanceLeaseCost1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7a89613c-293e-4017-891a-c40561bf3500_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2f313ccf-8f87-4db9-922b-ee378515f947_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_380065d5-bda3-4452-8c5f-8355bb3ff22d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AcquisitionEscrowLiabilityCurrent_8d7380c4-e038-479a-a2e6-92d414415857_terseLabel_en-US" xlink:label="lab_sgry_AcquisitionEscrowLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition escrow</link:label>
    <link:label id="lab_sgry_AcquisitionEscrowLiabilityCurrent_label_en-US" xlink:label="lab_sgry_AcquisitionEscrowLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Escrow Liability Current</link:label>
    <link:label id="lab_sgry_AcquisitionEscrowLiabilityCurrent_documentation_en-US" xlink:label="lab_sgry_AcquisitionEscrowLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Escrow Liability Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AcquisitionEscrowLiabilityCurrent" xlink:href="sgry-20230331.xsd#sgry_AcquisitionEscrowLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AcquisitionEscrowLiabilityCurrent" xlink:to="lab_sgry_AcquisitionEscrowLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCapMember_e085acd6-9ad3-4e75-a833-31a41627fbf3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Caps</link:label>
    <link:label id="lab_us-gaap_InterestRateCapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCapMember" xlink:to="lab_us-gaap_InterestRateCapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PayablesToCustomers_66c8c53e-e0e0-4b8e-beb8-667fd540fbae_terseLabel_en-US" xlink:label="lab_srt_PayablesToCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to patients and payors</link:label>
    <link:label id="lab_srt_PayablesToCustomers_label_en-US" xlink:label="lab_srt_PayablesToCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker-Dealer, Payable to Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PayablesToCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PayablesToCustomers" xlink:to="lab_srt_PayablesToCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_6f6f80be-6427-405d-a6c0-04b3b7948b35_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_539fdd66-a08c-429a-a4eb-82ad4b151171_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_4bffccc6-82d6-4b70-b0c6-1b032d425cb4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of accumulated OCI related</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_75dcb380-be31-44bc-924d-6411b98cb184_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_c4053791-470f-45fe-8369-ab5e8d9ecd22_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_0be0427f-0d06-4164-b18b-105dcb8195dc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6204dc48-2919-4504-bbc0-cfe1e7161e07_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_58ac6c83-7eb0-43fe-b629-fa989dbfb5eb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_94f5bd88-b957-4d74-8e63-764f56dd6e86_verboseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ac3b03ae-2d2a-4e50-bb4f-24ad6211fb18_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3b7e3ecf-5776-484f-80e1-33df551b9e6d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilitiesAndPhysicianPracticesMember_51c901f7-5505-42f0-b53e-c624a56204d1_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilitiesAndPhysicianPracticesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility and Physician Practice</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesAndPhysicianPracticesMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilitiesAndPhysicianPracticesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities And Physician Practices [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesAndPhysicianPracticesMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilitiesAndPhysicianPracticesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities And Physician Practices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesAndPhysicianPracticesMember" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesAndPhysicianPracticesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilitiesAndPhysicianPracticesMember" xlink:to="lab_sgry_SurgicalFacilitiesAndPhysicianPracticesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_5509e873-fac8-4ae0-a0f2-9dad961923ed_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fab57948-4508-4e81-a7a9-a1721eb2ba2a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_23075d10-9bac-4abe-8fd4-68fa8f13b82e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonrecurring (Income) Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:to="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_7d295f00-4ff7-4e29-9fba-5e198bbbe458_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e4dcb192-25f6-4e00-995a-344c8e9cc906_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b7dcc6e-67aa-4cf9-b814-4ef26f9f78b6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_611daf3e-c000-48e4-8921-0e61d969f77e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9ca1b889-39fa-4de3-aeb1-ec88d5e29ed7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c4df5441-56ee-4776-ba9d-fbaf65cdbb70_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_d472ee21-d29b-4433-8756-0be26343c184_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ac2482fd-adca-4b01-96a7-aaeb62302639_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_7760a5a7-029e-4167-80d4-200b1161aa8d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests&#8212;non-redeemable</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c7dd34e0-84c7-48bf-8d9b-5347c7b9a296_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a63b42aa-4616-45f1-97cd-86f28a6c0e78_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation_000cf56a-7732-48a3-85bc-e1d51bef1a95_terseLabel_en-US" xlink:label="lab_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest expense for Florida LOP regulation change</link:label>
    <link:label id="lab_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation_label_en-US" xlink:label="lab_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Impact Of Change In Letter Of Protection Regulation</link:label>
    <link:label id="lab_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation_documentation_en-US" xlink:label="lab_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Impact Of Change In Letter Of Protection Regulation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" xlink:href="sgry-20230331.xsd#sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" xlink:to="lab_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d678e717-949a-4582-b9b4-5d53c505c14d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilitiesMember_06b7b391-4cd5-4b6e-808a-e095c8b539c2_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilitiesMember" xlink:to="lab_sgry_SurgicalFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cafb829d-9352-471c-a628-0d598e3ab66d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4aa95972-0fb6-42ed-b1ae-7641a550adb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_07880a94-9695-4848-82b2-6b2e12dbfb0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest holders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_aec73661-fa56-4fcf-b62a-3328ddc8da37_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_952e61c2-5421-4891-9f17-a0c2d7e27f66_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_60aaf9cd-4e07-43bd-9391-52902dbf59ad_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_068460ea-3721-4e68-bce4-a70cab5ec935_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_18d43f3c-44c6-4bcc-99e2-436b62f79741_terseLabel_en-US" xlink:label="lab_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_c77ef381-933b-4d3f-b15c-40009293ff7c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_0c968cc7-ae4f-49fe-9042-c5b3e772d45e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_959de9d7-62b4-4077-918a-f318c3c5f600_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_09021956-632b-4eaf-b06e-a45d73a549c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d2f1bbeb-a701-42d0-9b84-cf8c1473a38e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_871c2f06-3668-4517-83e3-8daf54bffdb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_38e5d3fe-60f3-41bc-a10d-90a9a66b2ee4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_d611d53f-1042-42c2-8471-d65ae4a75748_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_6f71f8fd-c49b-4614-b7f6-f2486b5b6470_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e190bee4-13d2-4c7a-9071-d06c3a15526f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by service type as a proportion of total revenues (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_08f8755b-8d36-4b41-8729-b03778583876_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a8860eda-4bce-418a-8be9-44fa3c6d2494_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative activity, net of tax of $0</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ReceiveFixedSwapTwoMember_ab74908a-a711-427b-9274-2b49f0cafe60_terseLabel_en-US" xlink:label="lab_sgry_ReceiveFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed swap</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapTwoMember_label_en-US" xlink:label="lab_sgry_ReceiveFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Two [Member]</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapTwoMember_documentation_en-US" xlink:label="lab_sgry_ReceiveFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Two Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapTwoMember" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ReceiveFixedSwapTwoMember" xlink:to="lab_sgry_ReceiveFixedSwapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ee7f7f37-9066-4978-a3e4-a81e8f472947_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_UnrecognizedGrantFundsReceived_925d9363-3a75-46ab-aa70-9a12ec920d84_terseLabel_en-US" xlink:label="lab_sgry_UnrecognizedGrantFundsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized grant funds received</link:label>
    <link:label id="lab_sgry_UnrecognizedGrantFundsReceived_label_en-US" xlink:label="lab_sgry_UnrecognizedGrantFundsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Grant Funds Received</link:label>
    <link:label id="lab_sgry_UnrecognizedGrantFundsReceived_documentation_en-US" xlink:label="lab_sgry_UnrecognizedGrantFundsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Grant Funds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UnrecognizedGrantFundsReceived" xlink:href="sgry-20230331.xsd#sgry_UnrecognizedGrantFundsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_UnrecognizedGrantFundsReceived" xlink:to="lab_sgry_UnrecognizedGrantFundsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_e7822138-eaee-45b9-9401-4e46737ab0dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rollforward of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_ff67cb5a-eb35-4f24-8818-33246796906f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_27fddff9-7659-4774-b614-3e8fb5856ca5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_41e420ab-118e-447b-9aed-30f2693e19b8_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_InDevelopmentDeNovoSurgicalFacilityMember_25a1d95b-82f3-4747-9703-314b9ead8173_terseLabel_en-US" xlink:label="lab_sgry_InDevelopmentDeNovoSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Development De Novo Surgical Facility</link:label>
    <link:label id="lab_sgry_InDevelopmentDeNovoSurgicalFacilityMember_label_en-US" xlink:label="lab_sgry_InDevelopmentDeNovoSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Development De Novo Surgical Facility [Member]</link:label>
    <link:label id="lab_sgry_InDevelopmentDeNovoSurgicalFacilityMember_documentation_en-US" xlink:label="lab_sgry_InDevelopmentDeNovoSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Development De Novo Surgical Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InDevelopmentDeNovoSurgicalFacilityMember" xlink:href="sgry-20230331.xsd#sgry_InDevelopmentDeNovoSurgicalFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_InDevelopmentDeNovoSurgicalFacilityMember" xlink:to="lab_sgry_InDevelopmentDeNovoSurgicalFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5355d99d-3d5f-41fb-b690-ad8f71f5398c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5316fe00-ee2b-4f80-bc1f-a816bfc9b150_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Surgery Partners, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_6cebf997-dc84-4ae1-abf0-a7696d096e34_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_a4544036-410e-4ca6-8a58-68a2e245ba8f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_f9f1d019-6530-44c1-bfc4-e934334cc2f0_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_29914da5-6a07-46c5-aa59-ecedf0492ea5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_681bc869-e7fb-4064-9051-e0b2e314019c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5dd87dfa-e508-49b1-9fa5-08b6c3242089_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_6d8cbd13-85b5-40a2-a55b-bfadccc42831_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_aead2495-2e08-4a2b-b7c4-c465fc588ab3_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7b921969-1c70-4ae2-87c1-cbe69d8a1a56_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_a6ad2578-83cb-4863-b595-77104fb2f643_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_967d3b30-38a2-4e75-919d-8813984e66a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlements</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_8d81f903-6c81-4246-bf51-b5d3b4630ca1_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_74f3c5b2-5ae4-4bdf-ba78-7e1facd5e2e5_netLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_c8234911-606f-44cc-a7ad-32744c9733de_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_43f08571-d1e7-4b3c-af81-f4c92fdab475_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_edccb115-f2ce-4160-9035-b1f06e9e7113_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_60fc4cee-5a64-40f1-8166-9dbbd364d203_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Expense and Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_80866ee0-578e-493f-bec2-13ae50687247_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1eb1302a-7e07-497d-ac08-dd46defd4e5c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2f526c25-f4b7-456d-a229-cc1c8d8a512a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_d72424e5-83cd-4074-a1e9-b4adcaec94c0_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0116c8c3-c3db-495b-bd74-8e4ecdc881e7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_b0cc864c-7f07-4650-98a8-6c4f8bbfcdc9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4727176b-cb35-4b94-a880-e9d2577e7d49_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_711e009b-b828-4409-bb6b-02b426d6d282_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_8aac05ea-08aa-4fb7-933d-696a1ceb055a_terseLabel_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_label_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Expense</link:label>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_documentation_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense" xlink:href="sgry-20230331.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OperatingAndFinanceLeaseExpense" xlink:to="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_cdc2f5d0-e255-45ef-96db-528c53198117_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_49a68b63-dd04-48b5-953f-df75ddc563f7_negatedTerseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest&#8212;redeemable holders</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_babcbf0b-ab70-492f-826e-074ebc1eecb3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b9b7e38e-7dea-48e5-8030-27c1c8198a3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f9143be5-9366-4197-9627-aa6e527074af_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8a34efce-e01d-4724-bf42-5288e2aefa6d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_b3d5d770-fe02-4495-b3aa-bcfb79ff7adf_negatedLabel_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) on disposals, consolidations and deconsolidations</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_7b3802b8-83c9-4deb-94af-fa388bb1c2f4_negatedTerseLabel_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) on disposals, consolidations and deconsolidations</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_label_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets And Deconsolidation</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_documentation_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets And Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:href="sgry-20230331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:to="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_ca3d9357-03c3-4b65-9726-ced9c745a8d5_terseLabel_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities included in VIE</link:label>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_label_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number Of Facilities</link:label>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_documentation_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities" xlink:href="sgry-20230331.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_VariableInterestEntityNumberOfFacilities" xlink:to="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_909ee172-9c7b-4b08-85be-655c47e74612_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_c23d89d5-7a24-4777-a27d-b46cc02b8191_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e76a9c4a-43e9-4e54-a14a-f3c5d9b6662f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c33a95fb-435a-4024-8cef-05c08b7cfcb6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OtherServicesMember_6d4dc98c-78b6-456f-b047-45e4843fc178_verboseLabel_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other service revenues</link:label>
    <link:label id="lab_sgry_OtherServicesMember_label_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:label id="lab_sgry_OtherServicesMember_documentation_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember" xlink:href="sgry-20230331.xsd#sgry_OtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OtherServicesMember" xlink:to="lab_sgry_OtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f1157bc2-2294-4ab3-a489-1df761c7a2ed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_514af0e0-6df6-4eb9-addf-41d5bb1d5dff_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractMember_ac790b37-c0cb-43ee-bfdb-de82b8f67252_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_us-gaap_GovernmentContractMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractMember" xlink:to="lab_us-gaap_GovernmentContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_cb351b43-e843-4fd7-b91b-3b11a637e9e6_terseLabel_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Right-of-use Assets and Liabilities Related to Leases</link:label>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="sgry-20230331.xsd#sgry_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c6fefc88-cca3-42ed-bfcb-5ec3d380ffd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of unconsolidated affiliates, net of distributions received</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_54a772f5-152d-4898-a9bf-d5bbddd962a1_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests - Redeemable [Roll Forward]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestRollForward" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward" xlink:to="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_4e494c2c-22ce-42f6-a54b-cd9ff93c949f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:to="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ReceiveFixedSwapOneMember_4aa1e5c3-ca7f-4b31-b3dc-4f68a6a32bc1_terseLabel_en-US" xlink:label="lab_sgry_ReceiveFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed swap</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapOneMember_label_en-US" xlink:label="lab_sgry_ReceiveFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap One [Member]</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapOneMember_documentation_en-US" xlink:label="lab_sgry_ReceiveFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap One Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapOneMember" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ReceiveFixedSwapOneMember" xlink:to="lab_sgry_ReceiveFixedSwapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_366af06a-1733-435b-ab29-7d0ba1bfa223_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_848c6f67-2ca8-45a4-8b1d-778c7672ab84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_87faf500-9f9e-47bd-ab0b-b45e60ca175d_terseLabel_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of grants received</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_label_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_documentation_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:href="sgry-20230331.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:to="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d7e98b12-2e5f-4457-bc53-8ef7820f3e8c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0b117b66-0de9-46c4-8181-4304d29e1fc3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a44347c2-af05-433f-883d-99d7f955671f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_76c8816b-39ff-4bd8-aa56-d778a672f771_terseLabel_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare accelerated payments and deferred governmental grants</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_label_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_documentation_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:href="sgry-20230331.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:to="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_848619ee-2c5a-4cb9-9bc8-4bc0cacc7fa1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_0a06a950-874f-44b8-baf5-de6781f6a13f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c5cf6e87-a66b-4560-84c6-1088bf128fe5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_95680766-7126-4fcf-be7c-6ed7d0cc85f8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c988cc0d-1490-45fb-9db6-32cedb269536_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_786be542-e5cf-480a-be1d-030eaaa56fd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_badca535-cdb4-4508-9407-5d788b112662_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized fair value discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2022DisposalsMember_8c18cb82-ec98-4b71-82ea-590578c01341_terseLabel_en-US" xlink:label="lab_sgry_A2022DisposalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Disposals</link:label>
    <link:label id="lab_sgry_A2022DisposalsMember_label_en-US" xlink:label="lab_sgry_A2022DisposalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Disposals [Member]</link:label>
    <link:label id="lab_sgry_A2022DisposalsMember_documentation_en-US" xlink:label="lab_sgry_A2022DisposalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2022DisposalsMember" xlink:href="sgry-20230331.xsd#sgry_A2022DisposalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2022DisposalsMember" xlink:to="lab_sgry_A2022DisposalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_987706ba-e6fb-4a48-b43d-2761a31e89c1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d426e6b9-3cd0-4d51-b269-a57a545d9d26_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c4ec56cc-8ed0-46d9-83a7-0004f2c822b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d8ce3a62-a0ca-454b-8e66-575801d8516b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_79ea4e91-dc1c-427e-bcae-904d773d4bab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and advances to affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b779629e-00e5-443d-a1ba-dd85015164e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_644c77fb-4daa-42fc-a4be-9705ffbeef8f_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_b6d16f76-b30d-4a61-9f64-89c72e2f22a6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_a8061628-9706-4e3d-bb6b-f4d305f420d8_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_c892259f-2f2e-491a-9fb8-bbe27671a1b1_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned, consolidated</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Facilities Owned, Consolidated</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned, Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fe0d942d-f292-457a-abf6-570e2ae00fc3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a71a9fdd-00f2-49ea-9089-ae9479ec2914_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d6618eec-5fb3-4484-8561-076849a8ee3c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_aa39f958-c55c-4434-bff8-e248488142fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e7020187-189e-49ee-9340-8865bc2b0f3b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8c1ffa53-3f3c-4449-885c-42e92808d633_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_bf06071f-7ce5-478e-98ae-673d4300be77_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_659293ea-02d4-4f53-b49f-5a6b902ee43b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd7d8c5b-270f-4cd8-acc8-5ee3c5e39436_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_055c4761-6f11-4c2c-a5d8-5edac77e2ba0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding- diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c7c67052-bb89-4774-bb51-d58a69029cd4_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7af46890-8210-4781-a71a-bca339c25d14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_c975a87c-5ee5-4017-a4eb-df39a79b0e7f_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests&#8212;Redeemable</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Policy Text Block]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_adc33cd5-21ce-4b17-8fbe-14a9e0c7414f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_f3434d4e-342a-45e2-935e-47be232892bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction and integration costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_81974c34-06e2-4f9f-831d-6ecd244ae09c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_140e11bb-2878-4f26-9a6b-0bdaa3e60bb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_693d111d-5c58-4e5d-b1a6-3d8d55762da1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount estimated to be reclassified as a reduction to interest expense over next 12 months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed_c36e5f0b-1c03-442a-8681-87b9adab1ee4_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interests sold</link:label>
    <link:label id="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed_label_en-US" xlink:label="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed</link:label>
    <link:label id="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed_documentation_en-US" xlink:label="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" xlink:href="sgry-20230331.xsd#sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" xlink:to="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_020e6362-a1b4-4648-80fb-7406afeb1a08_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_9997d8aa-b799-46fd-af5b-773aa97e48bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_4bf66563-cf56-45ea-9029-7c4bdc9c4a9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Source</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_ef58a1e9-cb93-4b42-8621-4d20ddb6da74_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8308d6ec-db09-49ef-936a-68ef3edef087_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40b95557-1c18-4fdf-8158-974e0ddbca03_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities_01fb4fa8-ea2e-469f-9d64-f46f6bfa2160_terseLabel_en-US" xlink:label="lab_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on termination</link:label>
    <link:label id="lab_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities_label_en-US" xlink:label="lab_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Terminated Derivative Instrument, Operating Activities</link:label>
    <link:label id="lab_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities_documentation_en-US" xlink:label="lab_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Terminated Derivative Instrument, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" xlink:href="sgry-20230331.xsd#sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" xlink:to="lab_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bfd1986c-d080-4bb8-b0f4-4af2dd2d400a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_79c61f9c-bf6f-42ce-a82d-c533ea3d0727_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_97c01ef4-0594-4d65-8dc7-c1108eeabf7f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a95b1161-f2b2-460f-aabb-b92438f05269_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5fce68b4-bbf8-46d8-806e-5376bc9cc936_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8fbf2c54-4f5c-4076-8d89-89b105330dd7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_f0b70e83-ce29-4980-a325-a1dc1a81e595_totalLabel_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leased assets</link:label>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset" xlink:href="sgry-20230331.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LeaseRightOfUseAsset" xlink:to="lab_sgry_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_982c1532-d3d5-4683-b092-cea462440e82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative activity, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_5f5885f9-366c-4271-be54-1ae766b7aa7f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_752fae81-b2b8-4906-bebc-2606d8965824_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-up costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_06303eee-4046-4791-98c9-11b9cfbc7a65_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SelfPayRevenueMember_63e922d1-9c25-42e2-8e7d-6494ea2fe001_terseLabel_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-pay</link:label>
    <link:label id="lab_sgry_SelfPayRevenueMember_label_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Revenue [Member]</link:label>
    <link:label id="lab_sgry_SelfPayRevenueMember_documentation_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember" xlink:href="sgry-20230331.xsd#sgry_SelfPayRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SelfPayRevenueMember" xlink:to="lab_sgry_SelfPayRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_ff6f4ce2-1c4c-4187-ae1e-665159b8ebcb_terseLabel_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_label_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patient Service Revenue Sources [Member]</link:label>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_documentation_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patient Service Revenue Sources [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember" xlink:href="sgry-20230331.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OtherPatientServiceRevenueSourcesMember" xlink:to="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_739fc609-d929-41e1-98d1-4b1b165e4b74_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_77cf9d35-d4c2-4fb6-a06d-408d74f41c19_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c4010b55-593f-40e0-8de5-7a307f3104a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_e0316a58-7b99-4e5a-9398-0ff511286497_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and medical fees</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_1ff58224-f788-496f-a5c9-d53b0d1ef29a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities:</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_59b04983-ed96-4f38-9fa8-b6b0219c689a_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwned" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_22dcdc17-9acf-48f1-93c1-a4bf80607d04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_5696e09c-59b6-4dfb-aff8-71f742cd6ca8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest, fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f7251bbf-df3e-4e1d-a4a1-fee0a024d893_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_6a7512c8-8682-4960-9ced-b5b475df1f5a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including post acquisition adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5ea345e6-0e9e-41ad-b4de-a2ca73c2fd29_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Disposals</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_38a2cf26-cab9-4eab-8d24-bc2e4f57c78f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Information by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_d6c2da68-f8a9-431b-b3c6-51774fe1c26e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Adjusted EBITDA:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ebd708bf-528f-4ac6-8c73-52cf73062054_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_01960649-ba2d-49fe-8fcb-d2487b2264ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_a5d3d160-355d-4973-9034-332cbf397c0c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_39fa7142-04eb-4771-84d5-5bd71c415c64_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e7b9860e-74b4-49bf-a37e-f20bfd9428eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_0c482360-964f-4105-b291-6ba2e8f42b4e_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services</link:label>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilityServicesMember" xlink:to="lab_sgry_SurgicalFacilityServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8915717a-8a73-4f3f-887a-265fa0f46e52_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_332e27ef-d81a-48e1-87e6-86c02136c264_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_eab7d91d-5601-4cb1-acdb-c05128f94cd9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_InterestRateCapTwoMember_61d70645-c162-473c-af3d-091b0f9c3c38_terseLabel_en-US" xlink:label="lab_sgry_InterestRateCapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap</link:label>
    <link:label id="lab_sgry_InterestRateCapTwoMember_label_en-US" xlink:label="lab_sgry_InterestRateCapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap Two [Member]</link:label>
    <link:label id="lab_sgry_InterestRateCapTwoMember_documentation_en-US" xlink:label="lab_sgry_InterestRateCapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapTwoMember" xlink:href="sgry-20230331.xsd#sgry_InterestRateCapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_InterestRateCapTwoMember" xlink:to="lab_sgry_InterestRateCapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_b91b410e-5c83-4124-88d7-78fb0280c16d_verboseLabel_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.750% senior unsecured notes due 2025</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_label_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2025 [Member]</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_documentation_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SeniorUnsecuredNotesDue2025Member" xlink:to="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bda1c1eb-538e-44e8-b48e-003a0fc9b52b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs and discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_08982a71-69f1-4400-88d1-38fdd56acbe2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AncillaryServicesMember_e11902f7-2e19-4599-bd52-6f6d81547de0_terseLabel_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services</link:label>
    <link:label id="lab_sgry_AncillaryServicesMember_label_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services [Member]</link:label>
    <link:label id="lab_sgry_AncillaryServicesMember_documentation_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember" xlink:href="sgry-20230331.xsd#sgry_AncillaryServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AncillaryServicesMember" xlink:to="lab_sgry_AncillaryServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_e1a05f09-c938-4027-b7b2-bcc9d7baa287_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d8e122aa-fc0d-4c56-90d5-517b118840fb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_356c1785-26e7-4a78-85d8-ad9e86244b90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Interest Rate Swaps</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_3f2b0cdc-54f4-4316-a188-e9461c10ed94_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_813d5ec1-7683-4e94-adfa-ab4b783a379c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f47bebee-ed80-4f62-b5f7-06a0493b4e84_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_b67e2241-732e-4867-b264-2ca6c80902a9_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_946941ee-5577-46c7-ae8d-19857c81bfac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_eb6976d1-f1cd-4fa1-aa3c-820b272c5f2d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_b0eaa35e-39b4-4555-b6fa-9cab3328d808_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gain (loss) on disposals and deconsolidations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_efddac10-f097-4322-aa68-51638733b901_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9ee73752-d786-445f-9a2c-0fb0531ec24a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_e4d65d12-1bd7-45cf-9fff-f3e5acaf5fd7_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional, general and workers' compensation insurance reserve</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserve" xlink:to="lab_us-gaap_SelfInsuranceReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_eb488ba3-b40c-4545-a18d-3af12fa5e136_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6dddbe44-5b5e-46ee-b07f-89bfcc08dbfa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_3f25884f-ef28-4161-b259-61430e5542b2_negatedTerseLabel_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense, net</link:label>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_label_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Income (Expense), Net</link:label>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_documentation_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet" xlink:href="sgry-20230331.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NoncashInterestIncomeExpenseNet" xlink:to="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_611fb0a4-9211-4957-a436-eb78f9a63866_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_681ffc28-70fb-45db-927b-86673ec79c48_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_3534ffd5-0e1c-45c5-878b-7df19d080e6d_terseLabel_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers</link:label>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_label_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers [Member]</link:label>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_documentation_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:href="sgry-20230331.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:to="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5995a422-f598-47d3-a441-a5787cd0ee04_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_edd1d013-e8ec-4228-8b59-6ed36b8d32bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2c9f1af-41e6-4230-8307-11e396bdfe06_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a7167a28-e4d0-44ff-a506-f506df44b549_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_a28665ca-d674-47c3-bff9-b8de0653a0d8_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in cash flow hedging relationships</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b3adbd0b-2930-4689-a3d7-7471fa61261e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d1fd24d7-5bcd-4db0-9a3e-2887e1cecb5a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_fed927ba-1b56-4d9b-bf27-e8d9d19515a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_5242899b-a2f1-4f38-91d3-604e32901297_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Assets from Segment to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_f6e22272-3b7c-43b8-862a-27b8b242db0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interests&#8212;non-redeemable holders</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_34ceb211-6166-41d6-8c43-e009f14d81e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_12afb035-277d-49da-a4a0-4b3dacb69917_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5b99d8b8-19ba-4b0e-a252-29568d875aab_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_ae0b387e-4df7-4242-a42a-2fd46260944b_terseLabel_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost report liabilities</link:label>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_label_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Report Liabilities, Current</link:label>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Report Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent" xlink:href="sgry-20230331.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CostReportLiabilitiesCurrent" xlink:to="lab_sgry_CostReportLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_b3fa3525-0a9b-46cd-83c8-d8c8ae8d6877_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_8b5477dc-95ec-4af2-9980-5ea2642cb630_verboseLabel_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secure term loan</link:label>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_label_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loan, Maturing 2024 [Member]</link:label>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_documentation_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loan, Maturing 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member" xlink:href="sgry-20230331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2017TermLoanMaturing2024Member" xlink:to="lab_sgry_A2017TermLoanMaturing2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_31b7482d-14a9-45f0-ba6c-f6d7a7381e2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6c771c54-3fa0-4daf-8a45-9255dee4f0af_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredPaymentsToAcquireEquityMethodInvestments_5347c955-b342-44d1-a967-4c58643fbf22_terseLabel_en-US" xlink:label="lab_sgry_DeferredPaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions, deferred</link:label>
    <link:label id="lab_sgry_DeferredPaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_sgry_DeferredPaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Payments To Acquire Equity Method Investments</link:label>
    <link:label id="lab_sgry_DeferredPaymentsToAcquireEquityMethodInvestments_documentation_en-US" xlink:label="lab_sgry_DeferredPaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Payments To Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredPaymentsToAcquireEquityMethodInvestments" xlink:href="sgry-20230331.xsd#sgry_DeferredPaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredPaymentsToAcquireEquityMethodInvestments" xlink:to="lab_sgry_DeferredPaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_f28f4c30-9da1-4e5b-80a2-10b482e45d9e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) gain on fair value of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_efceb4c7-7978-4d29-a4b4-8ad7bb396050_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2a9b8421-90ab-4f95-ac6b-baec79f3873a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9bdeb198-1922-49e7-a42c-ba6617a74b3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SixUndersignedInterestRateSwapsMember_b4fbac50-7f6d-4831-a7c9-43bbd22ebe41_terseLabel_en-US" xlink:label="lab_sgry_SixUndersignedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Undersigned Interest Rate Swaps</link:label>
    <link:label id="lab_sgry_SixUndersignedInterestRateSwapsMember_label_en-US" xlink:label="lab_sgry_SixUndersignedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Undersigned Interest Rate Swaps [Member]</link:label>
    <link:label id="lab_sgry_SixUndersignedInterestRateSwapsMember_documentation_en-US" xlink:label="lab_sgry_SixUndersignedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Undersigned Interest Rate Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SixUndersignedInterestRateSwapsMember" xlink:href="sgry-20230331.xsd#sgry_SixUndersignedInterestRateSwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SixUndersignedInterestRateSwapsMember" xlink:to="lab_sgry_SixUndersignedInterestRateSwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_84ef47d2-18de-4648-a9f5-71f69ca7b234_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_16e31692-cb64-4bea-a7c7-ce9d6615c4e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_dd9b6c9c-6637-403b-a3a6-9c0f1ed24b8d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2ad2047e-bd5c-4ae9-86df-da6f870b0586_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2f31b5b0-d3b2-46d0-a459-ae32fa008eef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits related to vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_bcf0b97e-17f1-4c13-b17b-51bad70d5cc3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recognized in income</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_UndesignatedDerivativeActivity_fe67467a-be97-4323-be35-5b4c51c471bd_negatedTerseLabel_en-US" xlink:label="lab_sgry_UndesignatedDerivativeActivity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated derivative activity</link:label>
    <link:label id="lab_sgry_UndesignatedDerivativeActivity_label_en-US" xlink:label="lab_sgry_UndesignatedDerivativeActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Derivative Activity</link:label>
    <link:label id="lab_sgry_UndesignatedDerivativeActivity_documentation_en-US" xlink:label="lab_sgry_UndesignatedDerivativeActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Derivative Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UndesignatedDerivativeActivity" xlink:href="sgry-20230331.xsd#sgry_UndesignatedDerivativeActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_UndesignatedDerivativeActivity" xlink:to="lab_sgry_UndesignatedDerivativeActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdac764d-128c-4cdb-b4fd-8294585e7a2f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_50c536c7-b3a5-4d5a-a716-f221e57d5f2f_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d013f831-dbed-4d01-8352-c5f6abe8508e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_3f140c44-decd-4835-8b84-e83ab3881cd4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_bbf24f8c-f294-43db-82fa-09400dfffeed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_ccfd3f5c-f72b-4a37-a0ca-dc02c5ab1cca_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_ca187d3b-da37-48fd-902b-7972097b3d6e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation on property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_59380176-3d74-4975-91e9-52dde6122082_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_9e89d27b-637b-4ce4-aea1-c4a0246e7782_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:to="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f1ff76d3-e8d9-4f64-a6c8-1a9c2bca1a13_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_e5d4e7da-6620-4e1c-95d2-ac42d944325a_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rollforward of Noncontrolling Interest - Redeemable</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9c49aea-ee4d-474d-b8aa-2c039f834077_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6338ce5d-8772-468b-a80d-bf52649a09b6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding- basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9b019bb0-581d-4562-a695-f18ee6cd0147_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e45e11e-08f4-4f77-8543-22d84ec46ed2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CashFlowLesseeAbstract_af78f43f-29f8-4a04-8f8d-e0a955d1b67c_terseLabel_en-US" xlink:label="lab_sgry_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_sgry_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_sgry_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_sgry_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_sgry_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CashFlowLesseeAbstract" xlink:href="sgry-20230331.xsd#sgry_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CashFlowLesseeAbstract" xlink:to="lab_sgry_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapOneMember_f56c4511-bb2e-4a5d-85e6-42230e0aef54_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapOneMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap One [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapOneMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap One Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapOneMember" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapOneMember" xlink:to="lab_sgry_PayFixedSwapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_58f765b0-4630-41d3-85b4-a3e0fa67d584_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_f541fc6a-8778-4a4a-b99e-73478fb8b91f_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_0f6dd45a-b582-4758-9afe-c2c4b252345b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_981e3382-1175-4fa3-9dac-bf769a9d064b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4097dd30-f06b-4b0e-a456-5b0ba6f7bdc0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_1022f36a-2329-4e7a-8c21-2c4da1999c01_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests&#8212;redeemable</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_008e24c4-67d2-4aed-bcb2-1e3db68acd24_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_22e2c72c-3fc2-4a7f-8f79-96c72c4f39ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_22ffcb2b-75df-421b-ad7f-f5e8e049f25c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_e99f37f4-d6d1-48c1-93b2-0bd2f3aa7a69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member_dfb6160d-28b4-4052-b87a-74bef0201648_terseLabel_en-US" xlink:label="lab_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00%</link:label>
    <link:label id="lab_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member_label_en-US" xlink:label="lab_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00% [Member]</link:label>
    <link:label id="lab_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member_documentation_en-US" xlink:label="lab_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" xlink:href="sgry-20230331.xsd#sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" xlink:to="lab_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f342ad13-9cc7-4405-ba59-1261a994bcfb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6bc56338-3c2e-4d32-8cab-2276fa941e5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_a29e39dc-8688-4f18-a3cc-7aa2d25a4d87_terseLabel_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and disposal of shares of non-controlling interests, net</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_label_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_documentation_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:href="sgry-20230331.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:to="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_5698add0-94fe-4644-b580-eb8e136b95d0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapTwoMember_463cd9a2-ac66-4491-b12c-e04d30f0d495_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapTwoMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Two [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapTwoMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Two Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapTwoMember" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapTwoMember" xlink:to="lab_sgry_PayFixedSwapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2b2ea5d0-2405-423c-8009-3959f01d7512_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_a9c8c8fe-2f81-4639-b6e1-da4c51762609_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests&#8212; Non-Redeemable</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_636f5e11-de7b-437e-b45d-8accc3ab2704_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_97aba3d5-9ca3-431e-bf6b-26bd02ece579_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_3af3b278-b9ca-4030-8702-27645ac14e73_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d21b38b7-cf2b-46cf-b45f-214af867e7af_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_9eb05e25-9cd1-4888-8d82-7d412e6aa82f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_18f7e51e-dbdd-403f-a66b-6122fc464573_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests&#8212;redeemable</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49bf50a0-5bfe-4016-8e0c-9f82064dbf21_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_db3a0acd-ae68-4222-9669-bc9b5a8ba88f_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_03ab6635-e737-49b3-9605-95c0df8359f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_41a4e42a-fc4e-49f1-8fdc-afcb9dbc9712_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fbb60a30-7f3b-4ae2-9d8f-e15c4fb19756_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_040e4283-10d7-4f84-92af-6829a334de58_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized non-controlling interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_88009c2a-a656-4f0a-ad70-232a22eda535_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_726d40e6-fc7c-4489-9d0c-2eab020eef71_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Revenue and Operating Income</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1ef30f45-3323-45ef-911e-4d16507aad0a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4ebcc141-ea20-4847-9c11-1447d7ea680f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_13e5c9b6-a1ba-4252-b00d-db2684695bc8_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_75f421a3-d3c5-48be-9b5a-c7f6bb2d2789_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_97d423f3-be21-4576-b6d3-e93f7c9b573b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_3819f62f-53e1-4a05-bff6-eb9eed574bd9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_2119a453-70db-4272-8741-5e7029349573_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_ddfe20ac-326a-47fb-a66a-336d4269b343_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_cb363ddd-cef8-4ff1-80bf-b9baa5f39d24_verboseLabel_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent service revenues</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_0f810449-a477-4a2e-8426-552d32c0319f_terseLabel_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient service revenues</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_label_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Patient Service [Member]</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_documentation_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember" xlink:href="sgry-20230331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember" xlink:to="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2eefd573-89c2-427a-addb-7be73a03c40b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a5c68bf9-33e1-499b-b5df-910f1b86cc44_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_72bb1270-2c31-436c-a5b1-8a5fbeccd5fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2f9033dd-0850-4a70-8a75-0ecd9b204464_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4e9c6350-2b49-4bcc-826e-ae6fd540f66f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapThreeMember_ce2985f6-6824-45c9-b344-2cfba5a3fc80_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapThreeMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Three [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapThreeMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Three Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapThreeMember" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapThreeMember" xlink:to="lab_sgry_PayFixedSwapThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ExistingSurgicalFacilityMember_a8715058-ebcb-49d5-8321-563d77666673_terseLabel_en-US" xlink:label="lab_sgry_ExistingSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Surgical Facility</link:label>
    <link:label id="lab_sgry_ExistingSurgicalFacilityMember_label_en-US" xlink:label="lab_sgry_ExistingSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Surgical Facility [Member]</link:label>
    <link:label id="lab_sgry_ExistingSurgicalFacilityMember_documentation_en-US" xlink:label="lab_sgry_ExistingSurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Surgical Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ExistingSurgicalFacilityMember" xlink:href="sgry-20230331.xsd#sgry_ExistingSurgicalFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ExistingSurgicalFacilityMember" xlink:to="lab_sgry_ExistingSurgicalFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FinanceLeaseCost_0cb32fd1-6ddf-4852-8ae2-600cebe9915d_totalLabel_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease costs</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost_label_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost_documentation_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost" xlink:href="sgry-20230331.xsd#sgry_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FinanceLeaseCost" xlink:to="lab_sgry_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_baa14c12-9862-4f67-9fe4-0a0411a29439_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_bc34c3c7-76bf-438e-9874-bc7ce092e21b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Availability on line of credit instrument</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5beaa634-6e3b-45d5-b1af-0e700c9cb0ad_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeVariableInterestRate_ae0ff75d-c04a-4bd0-88dd-24588a5348e1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rate of derivative instrument (percent)</link:label>
    <link:label id="lab_us-gaap_DerivativeVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Variable Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeVariableInterestRate" xlink:to="lab_us-gaap_DerivativeVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_edc3b451-d4f0-4cf1-a1b6-02a886230621_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_b5ae67b3-a335-4168-9943-cc8b3882d47f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_de7fee41-31a0-4305-8e4e-b491b5837da3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_3c2cdf14-a5c0-4d0a-8895-bec5b99b5d9d_terseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected insurance recoveries</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_82c96ba2-b1cc-4f7c-a6ea-a4e823e254c8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5cd37aab-8ae2-49f3-acbf-4191880763a1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_dd98552f-6be0-4134-89b9-78cd928727ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapFourMember_b68898c3-8319-4cb5-81dd-52c25c969ba7_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapFourMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Four [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapFourMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Four Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFourMember" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapFourMember" xlink:to="lab_sgry_PayFixedSwapFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_4a34f928-adcf-4498-9211-61610dda2c23_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_b849dd4e-9e44-4ddf-85b7-2257fcce8f0e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_e73465fc-0187-412c-88d4-492315df5b4c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other litigation costs</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b67a2b9-f1af-4f49-a362-03339cae20df_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_10d86dad-37fa-44b2-9eb6-a1cabb2b5680_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_105e4c93-51b4-435b-97a8-d7cfeb7315f9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1b1a700c-467d-47c2-b191-8c28fb899722_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b7929282-12c5-48dd-946e-2c507f7af96f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2803ce9f-0122-4011-9814-8e374a675793_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7f6fb371-f52e-442c-bea3-95c2fb1128ae_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_726dc649-737b-4b89-8abc-a13014c7d39b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_b3cecb61-b6d9-426f-90cb-4e867e629428_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a5a8e58f-567d-489e-a519-0870e9e7b5a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5621f578-5a4a-4453-bc78-2f1d19a7fccb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f5ddca73-a12d-4b53-95c5-6fb828a19dd6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3f208caf-1dd9-4878-98a8-29969c614684_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash consideration</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0affe92f-cb3f-41c8-8b81-cb64f23e2e66_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_9ce78085-8a2c-415f-ad35-95cd23b10e18_terseLabel_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable and short-term lease costs</link:label>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_label_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-Term Lease, Cost</link:label>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_documentation_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost" xlink:href="sgry-20230331.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_VariableAndShortTermLeaseCost" xlink:to="lab_sgry_VariableAndShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_299cb3c5-ce86-4d22-8cb6-8e0fe079b076_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_87c2bdea-5f95-4579-9711-ff29cb017ed2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_94130ebe-3f5e-45d2-ab58-ce7504024b2a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_f06493ba-bcbd-4e04-bc6f-d40e974b2feb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_InterestRateCapOneMember_b6edfc86-a17d-451f-b508-b99a2d36b7c6_terseLabel_en-US" xlink:label="lab_sgry_InterestRateCapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap</link:label>
    <link:label id="lab_sgry_InterestRateCapOneMember_label_en-US" xlink:label="lab_sgry_InterestRateCapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap One [Member]</link:label>
    <link:label id="lab_sgry_InterestRateCapOneMember_documentation_en-US" xlink:label="lab_sgry_InterestRateCapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapOneMember" xlink:href="sgry-20230331.xsd#sgry_InterestRateCapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_InterestRateCapOneMember" xlink:to="lab_sgry_InterestRateCapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_91f22968-752c-4f9e-b804-6dd2b661d73d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b589e912-06c0-4fba-b32e-bb1666c91a47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_eba96526-6b70-4fc6-958f-576a69edfbd9_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities contributed as non-cash consideration</link:label>
    <link:label id="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_label_en-US" xlink:label="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration</link:label>
    <link:label id="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_documentation_en-US" xlink:label="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:href="sgry-20230331.xsd#sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:to="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_40ac294a-aba4-43b6-b179-342ae67053a9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b0de679-05ed-467d-8144-1d6339a496d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7ff73b7-7042-4593-b2c1-00c5a59a4ba2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_f12cd66f-3572-4b65-8cd8-a4f715238279_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ddc98571-2e80-4d3c-aba8-62e332280182_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4e9fe5b4-2636-4341-96c6-4727a172d2ea_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sgry-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8139a9e6-f0c0-4663-a359-16b44ae9e913,g:a1e20cbb-0632-4ba5-9f9a-c20d61b98cc5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Cover" xlink:type="simple" xlink:href="sgry-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aaf6f5c6-2808-483d-908d-0127429a2224" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_DocumentType_aaf6f5c6-2808-483d-908d-0127429a2224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b3c504ca-919b-4242-abe4-ca65390513fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_DocumentQuarterlyReport_b3c504ca-919b-4242-abe4-ca65390513fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d1987d95-d5d2-4d3b-96a1-28e6f3c4efdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_DocumentPeriodEndDate_d1987d95-d5d2-4d3b-96a1-28e6f3c4efdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f63d6ac9-604f-4506-be83-a945e2606d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_DocumentTransitionReport_f63d6ac9-604f-4506-be83-a945e2606d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_46043868-66f1-46d3-8150-e38cf70a20a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityFileNumber_46043868-66f1-46d3-8150-e38cf70a20a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3f6853de-a1b4-4615-94c2-40b8741df41f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityRegistrantName_3f6853de-a1b4-4615-94c2-40b8741df41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_202e4a9f-ee4e-47a2-8287-af0715c3a720" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityIncorporationStateCountryCode_202e4a9f-ee4e-47a2-8287-af0715c3a720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6ee9996a-d307-4d97-8dda-ba7ad56fa435" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityTaxIdentificationNumber_6ee9996a-d307-4d97-8dda-ba7ad56fa435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_60a8ee43-2338-4a8a-9943-7551dcb95d1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityAddressAddressLine1_60a8ee43-2338-4a8a-9943-7551dcb95d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_de316e31-c8fa-44f4-ae17-9c2a56241866" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityAddressCityOrTown_de316e31-c8fa-44f4-ae17-9c2a56241866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_80435feb-3ef3-498b-bc15-8bc7dec7add9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityAddressStateOrProvince_80435feb-3ef3-498b-bc15-8bc7dec7add9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_51271fb7-4c27-49c1-8017-47bb96ade9d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityAddressPostalZipCode_51271fb7-4c27-49c1-8017-47bb96ade9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1a984446-7952-4eb3-b7b7-bfdded38b193" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_CityAreaCode_1a984446-7952-4eb3-b7b7-bfdded38b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f9042b9d-cc77-41b4-bee4-c703fa0e16e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_LocalPhoneNumber_f9042b9d-cc77-41b4-bee4-c703fa0e16e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9bd20dce-201e-49d6-bef6-4e7e12439c7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_Security12bTitle_9bd20dce-201e-49d6-bef6-4e7e12439c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_aec4d1bb-7162-4392-a6b9-7f6643137bf5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_TradingSymbol_aec4d1bb-7162-4392-a6b9-7f6643137bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5aafd278-810c-48c1-bb29-2af91e7fa872" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_SecurityExchangeName_5aafd278-810c-48c1-bb29-2af91e7fa872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_55557827-27cd-4e25-8728-136d06db4116" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityCurrentReportingStatus_55557827-27cd-4e25-8728-136d06db4116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aa5733fa-c9c7-4add-a3c4-54588a38ac1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityInteractiveDataCurrent_aa5733fa-c9c7-4add-a3c4-54588a38ac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_26ce05f0-6d0e-41a5-9b8d-cf43df0b380e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityFilerCategory_26ce05f0-6d0e-41a5-9b8d-cf43df0b380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_849ce495-329b-4ed7-baac-70f100992114" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntitySmallBusiness_849ce495-329b-4ed7-baac-70f100992114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ebae871d-e94b-4e29-a07f-7ebfff62078f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityEmergingGrowthCompany_ebae871d-e94b-4e29-a07f-7ebfff62078f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9b6445fc-f71e-41a5-a1bb-b8a20a019e60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityShellCompany_9b6445fc-f71e-41a5-a1bb-b8a20a019e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b3bcc9c3-fa2f-4310-832d-5afbef76457c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b3bcc9c3-fa2f-4310-832d-5afbef76457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a1a9cefc-a6c9-4844-b2be-bf64f784bea5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_EntityCentralIndexKey_a1a9cefc-a6c9-4844-b2be-bf64f784bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1aea6048-4b97-4370-848e-d8e8c51255ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_CurrentFiscalYearEndDate_1aea6048-4b97-4370-848e-d8e8c51255ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_db57a0bb-b65e-4f09-b966-98e64e6f1d37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_DocumentFiscalYearFocus_db57a0bb-b65e-4f09-b966-98e64e6f1d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_caf3260f-a824-4322-ac1b-2f8a1f7b4215" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_DocumentFiscalPeriodFocus_caf3260f-a824-4322-ac1b-2f8a1f7b4215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5fb34a05-4ae6-4457-94f6-c938747d8dec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c9031b-3245-48a9-bceb-9264d8782e89" xlink:to="loc_dei_AmendmentFlag_5fb34a05-4ae6-4457-94f6-c938747d8dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a855a4e-ac36-4c47-9b80-54ae253d378f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a855a4e-ac36-4c47-9b80-54ae253d378f" xlink:to="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfaf2ecd-8459-40b7-a22b-70a3bd36dc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfaf2ecd-8459-40b7-a22b-70a3bd36dc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_abe7c70a-68d7-4d45-a1d5-4349ada61b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_abe7c70a-68d7-4d45-a1d5-4349ada61b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a224e479-f88c-4629-b45e-4f9836a8bc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:to="loc_us-gaap_InventoryNet_a224e479-f88c-4629-b45e-4f9836a8bc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a45097ba-0601-4392-8151-3eb12501bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a45097ba-0601-4392-8151-3eb12501bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d1d4526a-7d1a-46eb-a9db-578e53599f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:to="loc_us-gaap_OtherAssetsCurrent_d1d4526a-7d1a-46eb-a9db-578e53599f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0369f7c2-feee-49a0-9e3e-eadbcfd1c549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5d265489-815e-418b-8939-d25c2b0965c6" xlink:to="loc_us-gaap_AssetsCurrent_0369f7c2-feee-49a0-9e3e-eadbcfd1c549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0f117439-8bbd-4b8b-9fd6-7d38f621ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0f117439-8bbd-4b8b-9fd6-7d38f621ce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_2bca5c40-473b-4d0d-9f3c-85665c2b1897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_2bca5c40-473b-4d0d-9f3c-85665c2b1897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e21895ac-d9fb-4129-a5e6-182ceaa3c96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e21895ac-d9fb-4129-a5e6-182ceaa3c96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8eab8cdf-4bff-442e-b365-2efe6bc777e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8eab8cdf-4bff-442e-b365-2efe6bc777e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_3621a053-5450-4a22-a155-6d4b06befc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_3621a053-5450-4a22-a155-6d4b06befc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a674a141-adcd-424a-8f36-89b2125a0c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a674a141-adcd-424a-8f36-89b2125a0c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_555ebc18-a134-4016-9fe8-2751291c7650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d57f73db-a683-4aff-8122-7d0e5bb49863" xlink:to="loc_us-gaap_Assets_555ebc18-a134-4016-9fe8-2751291c7650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a855a4e-ac36-4c47-9b80-54ae253d378f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_25f9d831-94d3-4db6-a2fd-46ff338887b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_25f9d831-94d3-4db6-a2fd-46ff338887b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c353fee0-29c8-4c27-b3f4-4fd526da1214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_25f9d831-94d3-4db6-a2fd-46ff338887b2" xlink:to="loc_us-gaap_AccountsPayableCurrent_c353fee0-29c8-4c27-b3f4-4fd526da1214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ce844512-6442-476d-9ca1-45bf6cb43b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_25f9d831-94d3-4db6-a2fd-46ff338887b2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ce844512-6442-476d-9ca1-45bf6cb43b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_64f92713-92a6-4514-a166-39805460038a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_25f9d831-94d3-4db6-a2fd-46ff338887b2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_64f92713-92a6-4514-a166-39805460038a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de53120a-220e-459d-b5bf-48c1f571d9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_25f9d831-94d3-4db6-a2fd-46ff338887b2" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de53120a-220e-459d-b5bf-48c1f571d9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8be2448e-b776-49b8-a89b-d5c6191d30a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_25f9d831-94d3-4db6-a2fd-46ff338887b2" xlink:to="loc_us-gaap_LiabilitiesCurrent_8be2448e-b776-49b8-a89b-d5c6191d30a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8179ce78-38d1-4dd3-94df-63da677e607d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8179ce78-38d1-4dd3-94df-63da677e607d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0a54d921-8bef-4ed8-89f8-7aa1da9e4eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0a54d921-8bef-4ed8-89f8-7aa1da9e4eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_51942de6-9081-444e-911d-fdaa706a3054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_51942de6-9081-444e-911d-fdaa706a3054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8b7e0e14-1b31-4400-b62b-574af9ccc8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8b7e0e14-1b31-4400-b62b-574af9ccc8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9457aa47-6e81-44d5-87f7-32b63acaf5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_PreferredStockValue_9457aa47-6e81-44d5-87f7-32b63acaf5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_b8c5418a-3151-4ab9-a170-2523e382ccf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_CommonStockValueOutstanding_b8c5418a-3151-4ab9-a170-2523e382ccf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a48684ff-569e-4c77-a9ae-fffd0ceed8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a48684ff-569e-4c77-a9ae-fffd0ceed8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_466ac661-54fc-4540-afce-18e36e65326c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_466ac661-54fc-4540-afce-18e36e65326c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5302f99b-5353-4965-8dee-2c25cd7ba633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5302f99b-5353-4965-8dee-2c25cd7ba633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e6ea463d-e0dd-479e-ac8a-655b1669e110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_StockholdersEquity_e6ea463d-e0dd-479e-ac8a-655b1669e110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8fe401aa-b6c0-4745-ae12-8688e8fe0566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_MinorityInterest_8fe401aa-b6c0-4745-ae12-8688e8fe0566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e71d60e9-aaac-46cc-8e78-736b584c34d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_32749a00-2015-41cb-8263-22120f038b82" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e71d60e9-aaac-46cc-8e78-736b584c34d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bf1487c-6a59-4d99-ae41-fc0387cfe381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06247561-373c-47cd-a13f-caa6c96bcc71" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bf1487c-6a59-4d99-ae41-fc0387cfe381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_90e526ba-69a0-44be-b57e-495253e99f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_90e526ba-69a0-44be-b57e-495253e99f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_633357f5-452f-4395-9652-21f80ebba1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_633357f5-452f-4395-9652-21f80ebba1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6ecb8575-d698-4fd2-b9cc-8c6705238146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6ecb8575-d698-4fd2-b9cc-8c6705238146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_49d5d817-a588-4b73-878c-a44b95d2e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_49d5d817-a588-4b73-878c-a44b95d2e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fc8012bd-4270-47cd-8fc5-4b0fa75115b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fc8012bd-4270-47cd-8fc5-4b0fa75115b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7d2a8f0a-c704-405c-8544-198e7bca6e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7d2a8f0a-c704-405c-8544-198e7bca6e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a6705f80-ac1d-4de7-b8b0-ef457866d55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a6705f80-ac1d-4de7-b8b0-ef457866d55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_46a9871d-7eac-43b4-8e04-93043f1b891e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_CommonStockSharesIssued_46a9871d-7eac-43b4-8e04-93043f1b891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c4121f1f-fe3c-4a15-9644-73869e71fb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1331236-cd69-4e69-9a54-f2d174ed11d7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c4121f1f-fe3c-4a15-9644-73869e71fb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5b7001c6-ddd3-4aed-a01a-062360cbe86b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5b7001c6-ddd3-4aed-a01a-062360cbe86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_954c00b6-1c9a-43ea-899e-74cc57546ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_LaborAndRelatedExpense_954c00b6-1c9a-43ea-899e-74cc57546ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_9efd3a8e-a629-42c0-898c-b8b0ea9808ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_SuppliesExpense_9efd3a8e-a629-42c0-898c-b8b0ea9808ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_47b44a7c-c782-49f5-ab7f-84479f7504ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_ProfessionalFees_47b44a7c-c782-49f5-ab7f-84479f7504ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense_ee0d14a2-14df-4ca7-807f-3995d2c2b9c0" xlink:href="sgry-20230331.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_sgry_OperatingAndFinanceLeaseExpense_ee0d14a2-14df-4ca7-807f-3995d2c2b9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_23ac2cd8-76cf-4788-8833-365a1562a532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_23ac2cd8-76cf-4788-8833-365a1562a532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_9e75acb3-b9ab-40c6-b53c-1c1dad80ebbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_9e75acb3-b9ab-40c6-b53c-1c1dad80ebbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c0a0efe8-3f14-4a5a-a645-3ec8b3604db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c0a0efe8-3f14-4a5a-a645-3ec8b3604db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_665f41aa-cf44-4361-81b8-85591c41afe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_665f41aa-cf44-4361-81b8-85591c41afe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_73fbf93b-5d90-45c3-87bf-a40e64d3e592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_73fbf93b-5d90-45c3-87bf-a40e64d3e592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_0fd64a56-0bc4-4d7f-bedf-019f44eb382f" xlink:href="sgry-20230331.xsd#sgry_GrantRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ff25e23-d271-48d4-a060-870d6598420f" xlink:to="loc_sgry_GrantRevenue_0fd64a56-0bc4-4d7f-bedf-019f44eb382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_6b41259a-6dcb-48ab-b952-e90036bfd9b3" xlink:href="sgry-20230331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_6b41259a-6dcb-48ab-b952-e90036bfd9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b8f75557-970e-4ee0-8135-4656936968a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b8f75557-970e-4ee0-8135-4656936968a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5c125826-50ef-43b4-8a3e-89e49ddcfeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5c125826-50ef-43b4-8a3e-89e49ddcfeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_1c14b07f-1c46-4afc-bf43-c18ff430d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_1c14b07f-1c46-4afc-bf43-c18ff430d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f97b0399-3861-494d-bdc2-b353d0f5cd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_OperatingExpenses_f97b0399-3861-494d-bdc2-b353d0f5cd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a657fd10-0796-496e-b037-4861543b3af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_OperatingIncomeLoss_a657fd10-0796-496e-b037-4861543b3af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_350205ad-12ab-41d3-a845-b8d10bca3bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_350205ad-12ab-41d3-a845-b8d10bca3bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_43f1a48b-26d1-461e-9788-7ee8d6a2f34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_43f1a48b-26d1-461e-9788-7ee8d6a2f34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea05b05b-439b-47cb-bd80-7bfe7f100251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ea05b05b-439b-47cb-bd80-7bfe7f100251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8fad5e34-3668-4f05-97ae-46474ff55697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_ProfitLoss_8fad5e34-3668-4f05-97ae-46474ff55697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e0f09f02-a8c8-4510-b79f-01a4d2f95c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e0f09f02-a8c8-4510-b79f-01a4d2f95c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_51f68580-70e4-41e8-add4-803f85b5be13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_NetIncomeLoss_51f68580-70e4-41e8-add4-803f85b5be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_114c2296-8de3-479b-bf60-a501c67f5876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_114c2296-8de3-479b-bf60-a501c67f5876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_39eab1d3-a635-497c-bd0b-e484567475f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_114c2296-8de3-479b-bf60-a501c67f5876" xlink:to="loc_us-gaap_EarningsPerShareBasic_39eab1d3-a635-497c-bd0b-e484567475f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0571f9d9-e96e-4558-bb1b-89539f57a46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_114c2296-8de3-479b-bf60-a501c67f5876" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0571f9d9-e96e-4558-bb1b-89539f57a46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0ed8cb7-a794-4cf0-8039-0b6784aba057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee9f8db7-e71f-4984-9d86-6a3939729a1e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0ed8cb7-a794-4cf0-8039-0b6784aba057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2ac1bcb-6620-4c2b-ad5d-218b927a14c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0ed8cb7-a794-4cf0-8039-0b6784aba057" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2ac1bcb-6620-4c2b-ad5d-218b927a14c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e17f4f96-b7a9-4559-9842-60cdd3fa83c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d0ed8cb7-a794-4cf0-8039-0b6784aba057" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e17f4f96-b7a9-4559-9842-60cdd3fa83c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_30fd9259-8121-41b4-b1a6-4b03054116cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4cfcd293-26ca-40dd-9fcc-a55b162a9588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_30fd9259-8121-41b4-b1a6-4b03054116cb" xlink:to="loc_us-gaap_ProfitLoss_4cfcd293-26ca-40dd-9fcc-a55b162a9588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_021b1465-dd1e-4bfc-a601-939bafa28da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_30fd9259-8121-41b4-b1a6-4b03054116cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_021b1465-dd1e-4bfc-a601-939bafa28da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_98fd4d9b-9115-488a-b892-8691f2b07202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_021b1465-dd1e-4bfc-a601-939bafa28da9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_98fd4d9b-9115-488a-b892-8691f2b07202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0fa085f3-2a49-404f-84e6-3ff571689553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_30fd9259-8121-41b4-b1a6-4b03054116cb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0fa085f3-2a49-404f-84e6-3ff571689553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_698c0673-6231-4645-a104-85eca9856cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_30fd9259-8121-41b4-b1a6-4b03054116cb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_698c0673-6231-4645-a104-85eca9856cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_183efa3e-d079-40d3-8b57-52f58152f980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_30fd9259-8121-41b4-b1a6-4b03054116cb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_183efa3e-d079-40d3-8b57-52f58152f980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6d211268-43eb-4be4-aa99-0437d4db52fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_dd55916e-c654-490d-98a0-f184bc55acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6d211268-43eb-4be4-aa99-0437d4db52fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_dd55916e-c654-490d-98a0-f184bc55acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e01ae26d-47e7-43dc-9f23-8ca747c9e577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_28c64a20-365b-4d0c-8851-842ae2cfbaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e01ae26d-47e7-43dc-9f23-8ca747c9e577" xlink:to="loc_us-gaap_StatementTable_28c64a20-365b-4d0c-8851-842ae2cfbaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b410648-257b-4573-98c9-a6b0ede48e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_28c64a20-365b-4d0c-8851-842ae2cfbaff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b410648-257b-4573-98c9-a6b0ede48e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b410648-257b-4573-98c9-a6b0ede48e8c" xlink:to="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2a5561b2-47fb-46da-b60a-e8dc8c582f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_CommonStockMember_2a5561b2-47fb-46da-b60a-e8dc8c582f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a59e9435-8b8f-4743-bb9a-44e21d987311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a59e9435-8b8f-4743-bb9a-44e21d987311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ed1961c-970f-41c1-87d6-3b3d9a2201c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ed1961c-970f-41c1-87d6-3b3d9a2201c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a86a058-823d-42ca-b231-437582c7fb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_RetainedEarningsMember_4a86a058-823d-42ca-b231-437582c7fb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e8b8cb37-5df9-4c81-9fd5-bb4a678c1717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45a42751-58ef-4b31-850d-e98cb5d49ee5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e8b8cb37-5df9-4c81-9fd5-bb4a678c1717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cc8e198-cf5f-43aa-867e-e5448f1a0466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_28c64a20-365b-4d0c-8851-842ae2cfbaff" xlink:to="loc_us-gaap_StatementLineItems_1cc8e198-cf5f-43aa-867e-e5448f1a0466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cc8e198-cf5f-43aa-867e-e5448f1a0466" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9b74ac36-0f5f-4b8c-a7c9-65d04bcca58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9b74ac36-0f5f-4b8c-a7c9-65d04bcca58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d10f79f9-7d7b-4a72-b3d6-e1bb2ed2c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d10f79f9-7d7b-4a72-b3d6-e1bb2ed2c4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab5220f2-ec18-4502-bc31-942801545de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab5220f2-ec18-4502-bc31-942801545de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70870964-b6ad-4fa4-b22b-f2b22ac3850d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70870964-b6ad-4fa4-b22b-f2b22ac3850d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_67814559-2ed6-41f7-b32b-ec0c12858827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_67814559-2ed6-41f7-b32b-ec0c12858827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34ad0832-e9e3-4f97-98bd-2327577a24d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34ad0832-e9e3-4f97-98bd-2327577a24d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_56a1fafc-f41e-45e3-ae9c-bb7ec965eff3" xlink:href="sgry-20230331.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_56a1fafc-f41e-45e3-ae9c-bb7ec965eff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_daa7838c-6efa-49f3-a1d7-450c3059e517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_daa7838c-6efa-49f3-a1d7-450c3059e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a97582b7-8545-4b56-a94d-b58b0e4e6a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a97582b7-8545-4b56-a94d-b58b0e4e6a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99e0b259-9938-4da7-a0f2-72461b584fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7d825e57-b93d-4cc5-8edc-f65fcdab5d5d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99e0b259-9938-4da7-a0f2-72461b584fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgry-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6ba9279c-c908-4b18-a385-d364d8dfc6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_febd4f2d-b1f4-4442-9c3c-2ba67da74b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ba9279c-c908-4b18-a385-d364d8dfc6d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_febd4f2d-b1f4-4442-9c3c-2ba67da74b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_14a7b7c5-94f1-498f-be64-d40a6bfc8d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_febd4f2d-b1f4-4442-9c3c-2ba67da74b8d" xlink:to="loc_us-gaap_ProfitLoss_14a7b7c5-94f1-498f-be64-d40a6bfc8d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_febd4f2d-b1f4-4442-9c3c-2ba67da74b8d" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d3ce46f1-cff5-4ed8-a886-4d7130d4e97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d3ce46f1-cff5-4ed8-a886-4d7130d4e97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_99932cdf-4cd4-4704-b183-c7a692d753e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:to="loc_us-gaap_OperatingLeaseExpense_99932cdf-4cd4-4704-b183-c7a692d753e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet_2be42678-c8a1-4bca-a82a-1c2eeff3473c" xlink:href="sgry-20230331.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:to="loc_sgry_NoncashInterestIncomeExpenseNet_2be42678-c8a1-4bca-a82a-1c2eeff3473c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_298d0f92-ff1a-4b9a-b688-dab1e08d0949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:to="loc_us-gaap_ShareBasedCompensation_298d0f92-ff1a-4b9a-b688-dab1e08d0949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_bd8db60a-9ed4-4eaa-b8b2-5bba08d20daf" xlink:href="sgry-20230331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_bd8db60a-9ed4-4eaa-b8b2-5bba08d20daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4df8fe8a-3306-4cc3-8536-6f33c51906a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4df8fe8a-3306-4cc3-8536-6f33c51906a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_46d704e5-9668-495a-b04f-0c34b25289af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_114d38d8-0185-4fb5-9170-200a627e24b7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_46d704e5-9668-495a-b04f-0c34b25289af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69f140e6-19bd-49a4-933d-9fc44298fffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_febd4f2d-b1f4-4442-9c3c-2ba67da74b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69f140e6-19bd-49a4-933d-9fc44298fffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_173b9b57-7544-4556-a2ac-5739c196e5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69f140e6-19bd-49a4-933d-9fc44298fffa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_173b9b57-7544-4556-a2ac-5739c196e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_70cae229-1cdc-4465-b3d1-b93943da011f" xlink:href="sgry-20230331.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69f140e6-19bd-49a4-933d-9fc44298fffa" xlink:to="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_70cae229-1cdc-4465-b3d1-b93943da011f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_aa81de3b-d0c1-411e-9574-0084da88e181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69f140e6-19bd-49a4-933d-9fc44298fffa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_aa81de3b-d0c1-411e-9574-0084da88e181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_169d7922-3359-4048-b585-5e5206cdc786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_febd4f2d-b1f4-4442-9c3c-2ba67da74b8d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_169d7922-3359-4048-b585-5e5206cdc786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ba9279c-c908-4b18-a385-d364d8dfc6d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c87a4411-4501-4c2a-9ffa-7780b32da3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c87a4411-4501-4c2a-9ffa-7780b32da3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f569633c-871d-4129-a260-c6709103b3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f569633c-871d-4129-a260-c6709103b3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_b30e97ae-fad3-40a0-94be-5f1acab7e4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_b30e97ae-fad3-40a0-94be-5f1acab7e4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_822c8b50-157c-477a-86fc-220ffa32438d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_822c8b50-157c-477a-86fc-220ffa32438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f30f868d-6a68-4a4b-9511-b46420cc4f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f30f868d-6a68-4a4b-9511-b46420cc4f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_394c3c0c-7446-453c-bf4e-cf6800366844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_394c3c0c-7446-453c-bf4e-cf6800366844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8626bedc-e36f-437f-94b1-76582305d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ee89502-13d7-4a6f-8781-a197ba95a4eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8626bedc-e36f-437f-94b1-76582305d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ba9279c-c908-4b18-a385-d364d8dfc6d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bdd967c6-868d-4f89-8d19-2febaec5c504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bdd967c6-868d-4f89-8d19-2febaec5c504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88c00d6c-71e1-4e9d-937c-e01872660230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88c00d6c-71e1-4e9d-937c-e01872660230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_978ff945-c45d-4bf5-b827-64333c9b90cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_978ff945-c45d-4bf5-b827-64333c9b90cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_524b538b-9a29-4217-b365-69a831b6cef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_524b538b-9a29-4217-b365-69a831b6cef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_1a0b8afb-a5bc-4c4a-8730-2d6a71cbbf57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_1a0b8afb-a5bc-4c4a-8730-2d6a71cbbf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_81aa2663-5cab-41b3-8caa-ef74cc9e130a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_81aa2663-5cab-41b3-8caa-ef74cc9e130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7815899a-c8b2-4c9e-98f0-5e4db2e8b461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93b4833d-c459-4e67-afac-a1f6e2115b96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7815899a-c8b2-4c9e-98f0-5e4db2e8b461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e55bd79-a7f0-4880-90a2-95c95ea7acfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ba9279c-c908-4b18-a385-d364d8dfc6d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e55bd79-a7f0-4880-90a2-95c95ea7acfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d92b07f2-5b2c-4335-9544-7079ed168d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ba9279c-c908-4b18-a385-d364d8dfc6d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d92b07f2-5b2c-4335-9544-7079ed168d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c75bbe9-b2ca-428c-9d6f-2d5e8ad5fd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ba9279c-c908-4b18-a385-d364d8dfc6d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c75bbe9-b2ca-428c-9d6f-2d5e8ad5fd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f2117949-4481-4519-b047-b3b82a69596a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_86d4cd06-d816-45d0-92ca-be61ef1ae163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f2117949-4481-4519-b047-b3b82a69596a" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_86d4cd06-d816-45d0-92ca-be61ef1ae163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="simple" xlink:href="sgry-20230331.xsd#AcquisitionsandDisposals"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5f82d4d5-ce94-4172-87b0-3458145a5378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_ef30d664-fd91-452d-9fc4-9805f55ecb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5f82d4d5-ce94-4172-87b0-3458145a5378" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_ef30d664-fd91-452d-9fc4-9805f55ecb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_91dc2314-45b0-42e9-abb8-fec3132a3525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_0f8c7df0-a082-4d9a-b387-72dccac761ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_91dc2314-45b0-42e9-abb8-fec3132a3525" xlink:to="loc_us-gaap_LongTermDebtTextBlock_0f8c7df0-a082-4d9a-b387-72dccac761ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Leases" xlink:type="simple" xlink:href="sgry-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d1e91cb2-4ce4-4651-b8e2-cbe3c480b1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_28ff39bb-0399-42ae-b3dc-370d6f733dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1e91cb2-4ce4-4651-b8e2-cbe3c480b1c4" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_28ff39bb-0399-42ae-b3dc-370d6f733dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_81104e55-0dfd-4469-93d4-65aae1503a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1e91cb2-4ce4-4651-b8e2-cbe3c480b1c4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_81104e55-0dfd-4469-93d4-65aae1503a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivities"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_285575a1-714e-4777-99ba-f68642fc123a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_38aad585-d932-415d-b4c6-7cb4d1febc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_285575a1-714e-4777-99ba-f68642fc123a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_38aad585-d932-415d-b4c6-7cb4d1febc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="simple" xlink:href="sgry-20230331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_25413438-7541-4473-907b-561dc3b9f190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_92b09b2d-4362-4562-8fd8-c5684ba24507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_25413438-7541-4473-907b-561dc3b9f190" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_92b09b2d-4362-4562-8fd8-c5684ba24507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="simple" xlink:href="sgry-20230331.xsd#OtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f45cda15-d706-4cef-93c0-99ef5d0c747b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_98509055-a56f-47cc-8a6a-fa2905fe1002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_f45cda15-d706-4cef-93c0-99ef5d0c747b" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_98509055-a56f-47cc-8a6a-fa2905fe1002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgry-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a9a2510d-2f84-454e-bb08-5d4fa7cc00e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3a61da7e-44cb-4d42-a74c-73a0b1be2674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a9a2510d-2f84-454e-bb08-5d4fa7cc00e7" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3a61da7e-44cb-4d42-a74c-73a0b1be2674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="simple" xlink:href="sgry-20230331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e26a1335-dbde-4559-b081-1e7f0535bdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_51d21b5e-7de4-44f0-8e47-bc35139a32a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e26a1335-dbde-4559-b081-1e7f0535bdfa" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_51d21b5e-7de4-44f0-8e47-bc35139a32a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgry-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a631c678-313d-4eeb-bec2-b6295255b480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_d253633a-aaf8-4e68-9e1c-f76e8aa7c9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a631c678-313d-4eeb-bec2-b6295255b480" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_d253633a-aaf8-4e68-9e1c-f76e8aa7c9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bebf3881-86ab-4c8d-b0dd-5f490c955775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bebf3881-86ab-4c8d-b0dd-5f490c955775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f4d843fe-ad1b-4f57-a179-a5e654bce5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f4d843fe-ad1b-4f57-a179-a5e654bce5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f87ae3f6-cb36-47d1-869c-85c63803cd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_UseOfEstimates_f87ae3f6-cb36-47d1-869c-85c63803cd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e4ea9be8-47fc-49cc-abd3-76163f0f8548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e4ea9be8-47fc-49cc-abd3-76163f0f8548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_d5937978-3797-46ee-b941-8922ff48d4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_d5937978-3797-46ee-b941-8922ff48d4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_cb693a2e-a7d0-46ea-9b91-7d7b7f946fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_cb693a2e-a7d0-46ea-9b91-7d7b7f946fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_b27ba4a6-9d1e-4ee8-99c2-c05aadd6d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_b27ba4a6-9d1e-4ee8-99c2-c05aadd6d3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_cd4ec988-5451-4388-b125-957d7dca964a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_cd4ec988-5451-4388-b125-957d7dca964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_0147e0b1-b78b-4bbe-886f-4d568e3a00a4" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_0147e0b1-b78b-4bbe-886f-4d568e3a00a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8356cc47-548a-4f15-b70d-85b511903151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8356cc47-548a-4f15-b70d-85b511903151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_734e4ed9-5c97-414b-aa06-ae4787d83685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27fd5f25-64b3-4280-b895-9f57b43c7da8" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_734e4ed9-5c97-414b-aa06-ae4787d83685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f42af55f-b557-400d-be25-2a9a35edbdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8fbaf36f-6c64-41c0-972a-5758be319758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f42af55f-b557-400d-be25-2a9a35edbdc3" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8fbaf36f-6c64-41c0-972a-5758be319758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_f0ae18b4-6e08-4539-abfa-ac3daf78f561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f42af55f-b557-400d-be25-2a9a35edbdc3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_f0ae18b4-6e08-4539-abfa-ac3daf78f561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_b827ed98-6fb7-475d-8299-9e4ae7331618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f42af55f-b557-400d-be25-2a9a35edbdc3" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_b827ed98-6fb7-475d-8299-9e4ae7331618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_08c9fefc-a9e5-4b52-8188-c546a5d21773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f42af55f-b557-400d-be25-2a9a35edbdc3" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_08c9fefc-a9e5-4b52-8188-c546a5d21773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_99657766-ced7-4f2d-93b3-a780f54494f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_10319244-f691-4532-91d1-b91382e06e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_99657766-ced7-4f2d-93b3-a780f54494f6" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_10319244-f691-4532-91d1-b91382e06e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesTables" xlink:type="simple" xlink:href="sgry-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8c464143-9638-4ebf-8663-ae685add2eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_6d9fc81b-0376-43a8-8d8a-687f22b482ff" xlink:href="sgry-20230331.xsd#sgry_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8c464143-9638-4ebf-8663-ae685add2eed" xlink:to="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_6d9fc81b-0376-43a8-8d8a-687f22b482ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_618da469-82d9-482c-a50b-09e98412a66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8c464143-9638-4ebf-8663-ae685add2eed" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_618da469-82d9-482c-a50b-09e98412a66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea82cb71-0190-4162-92e4-a5b3bd15f293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_74a2404d-425c-45a7-b2fb-1a63be10f79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea82cb71-0190-4162-92e4-a5b3bd15f293" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_74a2404d-425c-45a7-b2fb-1a63be10f79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_66e32145-a697-4b11-b12d-e08a74e0f7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea82cb71-0190-4162-92e4-a5b3bd15f293" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_66e32145-a697-4b11-b12d-e08a74e0f7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_6a450ed9-bc9b-4e57-909d-3e01fc635996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea82cb71-0190-4162-92e4-a5b3bd15f293" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_6a450ed9-bc9b-4e57-909d-3e01fc635996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="sgry-20230331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f79ab48b-8926-4e49-9f8d-b9cee80e93c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b81ca025-7e58-4995-a904-ffdb944eba0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f79ab48b-8926-4e49-9f8d-b9cee80e93c1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b81ca025-7e58-4995-a904-ffdb944eba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sgry-20230331.xsd#OtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e197ec8e-4a52-4ace-9403-4afb3bc902e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_edf3d87a-1e44-4364-b4ae-a9038ab7f344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e197ec8e-4a52-4ace-9403-4afb3bc902e1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_edf3d87a-1e44-4364-b4ae-a9038ab7f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="sgry-20230331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_44b163de-cc4b-40b2-a5d2-02c30b354278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_5399f074-b726-4de5-b5fe-613f4cc919b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_44b163de-cc4b-40b2-a5d2-02c30b354278" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_5399f074-b726-4de5-b5fe-613f4cc919b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_556ca53c-0703-4207-99ce-c9a3cb0b07f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_44b163de-cc4b-40b2-a5d2-02c30b354278" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_556ca53c-0703-4207-99ce-c9a3cb0b07f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b9fedf35-b4a2-45ed-ba55-07d19e766caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_44b163de-cc4b-40b2-a5d2-02c30b354278" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b9fedf35-b4a2-45ed-ba55-07d19e766caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1babf7de-88ae-4048-89ff-191ba0c10288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_6aa7486e-d610-4e43-8546-bdda9caf79bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1babf7de-88ae-4048-89ff-191ba0c10288" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_6aa7486e-d610-4e43-8546-bdda9caf79bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af9972a8-e12c-44b4-be20-69cc4800f570" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_6aa7486e-d610-4e43-8546-bdda9caf79bc" xlink:to="loc_srt_ProductOrServiceAxis_af9972a8-e12c-44b4-be20-69cc4800f570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_af9972a8-e12c-44b4-be20-69cc4800f570" xlink:to="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_095803b5-5ca7-49ed-898d-5a397ba4195f" xlink:href="sgry-20230331.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:to="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_095803b5-5ca7-49ed-898d-5a397ba4195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember_07301b6a-9fdd-4b56-8b61-0354ce8f72e6" xlink:href="sgry-20230331.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f971abee-cc2e-4ba5-8dad-4290926ee38d" xlink:to="loc_sgry_FacilitiesSurgicalHospitalsMember_07301b6a-9fdd-4b56-8b61-0354ce8f72e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_6aa7486e-d610-4e43-8546-bdda9caf79bc" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned_6daebe27-e3ae-4e54-8a2c-bf76b92d0c23" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwned_6daebe27-e3ae-4e54-8a2c-bf76b92d0c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_c2cb4004-53f4-4ceb-a972-0bcc41485b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_c2cb4004-53f4-4ceb-a972-0bcc41485b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_11a15d1e-1839-44f0-8d2b-abcf1d6a7edc" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_11a15d1e-1839-44f0-8d2b-abcf1d6a7edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_df58452d-c0da-44db-93b0-adb8c398b662" xlink:href="sgry-20230331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_70287621-102c-4981-9cd1-2d7bcd6d4b78" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_df58452d-c0da-44db-93b0-adb8c398b662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c456968c-a057-4d83-ba49-8b372ef9eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c456968c-a057-4d83-ba49-8b372ef9eae2" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fe6c0ca0-5173-455d-bba1-e32a52906554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fe6c0ca0-5173-455d-bba1-e32a52906554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_78ec0b90-372a-45a2-a54f-d7ad9932b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fe6c0ca0-5173-455d-bba1-e32a52906554" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_78ec0b90-372a-45a2-a54f-d7ad9932b42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d49781f6-7601-467a-827f-c5022bd08879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78ec0b90-372a-45a2-a54f-d7ad9932b42b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d49781f6-7601-467a-827f-c5022bd08879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d077cb0-6b7b-46d9-9515-5dd402a8aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d077cb0-6b7b-46d9-9515-5dd402a8aae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05abb968-e342-4fb2-969e-be4caa73fc69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d077cb0-6b7b-46d9-9515-5dd402a8aae3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05abb968-e342-4fb2-969e-be4caa73fc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_22831304-8a12-4c38-9498-9a814cab983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05abb968-e342-4fb2-969e-be4caa73fc69" xlink:to="loc_us-gaap_SalesRevenueNetMember_22831304-8a12-4c38-9498-9a814cab983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5127d5ee-32e7-40ed-920a-67a3cd10fe58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:to="loc_srt_ProductOrServiceAxis_5127d5ee-32e7-40ed-920a-67a3cd10fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5127d5ee-32e7-40ed-920a-67a3cd10fe58" xlink:to="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:href="sgry-20230331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_029fbbd8-5934-4bdb-988e-130121cc756e" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:to="loc_sgry_SurgicalFacilityServicesMember_029fbbd8-5934-4bdb-988e-130121cc756e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_d08b8ae8-2b28-4ade-94e7-5816d9e5933c" xlink:href="sgry-20230331.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_fce69108-0d18-4061-9987-2fd3b6f8ab30" xlink:to="loc_sgry_AncillaryServicesMember_d08b8ae8-2b28-4ade-94e7-5816d9e5933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_e18104e6-07d5-4f8d-9641-18eccc6838a2" xlink:href="sgry-20230331.xsd#sgry_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7f4c0393-43c1-4979-8c1f-fec4a854340d" xlink:to="loc_sgry_OtherServicesMember_e18104e6-07d5-4f8d-9641-18eccc6838a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_fdc03780-e742-4f3b-8533-c94afa7031b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_981c462d-5403-4b22-8a03-189caf6b8f3a" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_fdc03780-e742-4f3b-8533-c94afa7031b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3926b795-c6e3-4fda-a9a5-3732c729d1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_fdc03780-e742-4f3b-8533-c94afa7031b1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3926b795-c6e3-4fda-a9a5-3732c729d1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ab38484-7137-48e0-9504-878b561232ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ab38484-7137-48e0-9504-878b561232ef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a98be025-683c-4b5c-ba5b-fff3eab2d8f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:to="loc_srt_ProductOrServiceAxis_a98be025-683c-4b5c-ba5b-fff3eab2d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a98be025-683c-4b5c-ba5b-fff3eab2d8f7" xlink:to="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:href="sgry-20230331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember_21a70881-1d29-46e8-b093-91dced9912c1" xlink:href="sgry-20230331.xsd#sgry_PrivateInsuranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_sgry_PrivateInsuranceMember_21a70881-1d29-46e8-b093-91dced9912c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_418f3a1d-73a8-4717-92cf-c922500c56b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_us-gaap_GovernmentContractMember_418f3a1d-73a8-4717-92cf-c922500c56b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember_07ccd032-bfbb-4752-8047-b91bdcb2e656" xlink:href="sgry-20230331.xsd#sgry_SelfPayRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_sgry_SelfPayRevenueMember_07ccd032-bfbb-4752-8047-b91bdcb2e656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember_879e62ce-d234-427a-b03d-465f9f815cd1" xlink:href="sgry-20230331.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_68640427-cb79-4e88-97e7-5f2bcfb03497" xlink:to="loc_sgry_OtherPatientServiceRevenueSourcesMember_879e62ce-d234-427a-b03d-465f9f815cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_d8b568ab-3a44-40c3-bebb-d3442dacb114" xlink:href="sgry-20230331.xsd#sgry_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_340e2d9a-f02e-4aaf-b29c-f62584753bd7" xlink:to="loc_sgry_OtherServicesMember_d8b568ab-3a44-40c3-bebb-d3442dacb114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e911665a-5649-4572-bdf9-ed3e3ae47613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a4c4fd59-1c0e-4b5f-93d1-dc1550f233a3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e911665a-5649-4572-bdf9-ed3e3ae47613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_57daf5d5-bd02-4731-8ba4-d8e0ba68ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e911665a-5649-4572-bdf9-ed3e3ae47613" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_57daf5d5-bd02-4731-8ba4-d8e0ba68ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aadb9873-531a-4314-bfe2-108649f7c635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aadb9873-531a-4314-bfe2-108649f7c635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c756e9d1-a7d7-44a6-8c00-bed6d7dfebc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_aadb9873-531a-4314-bfe2-108649f7c635" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c756e9d1-a7d7-44a6-8c00-bed6d7dfebc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c77f78d5-f194-4490-b0f7-6d04aac57d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c756e9d1-a7d7-44a6-8c00-bed6d7dfebc7" xlink:to="loc_us-gaap_SalesRevenueNetMember_c77f78d5-f194-4490-b0f7-6d04aac57d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_34d86de9-25b8-4672-9e91-74cf73fc6cf8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d29440d2-5323-47b1-afdf-42e747aa8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d29440d2-5323-47b1-afdf-42e747aa8f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_49c9b5ed-2bc4-453c-b413-7778e65fd481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7241d01-5215-4c55-91cb-dc678dc6d6cf" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_49c9b5ed-2bc4-453c-b413-7778e65fd481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c22dc749-7747-4f84-b980-669542d327f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4a45e4ba-3376-4b71-a629-24144d7dcbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c22dc749-7747-4f84-b980-669542d327f3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4a45e4ba-3376-4b71-a629-24144d7dcbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_6ef65e11-29c0-45a5-b47d-5a1b9dde4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c22dc749-7747-4f84-b980-669542d327f3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_6ef65e11-29c0-45a5-b47d-5a1b9dde4bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a08e0e5b-c025-44e3-aef5-dcd6c7044902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c22dc749-7747-4f84-b980-669542d327f3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a08e0e5b-c025-44e3-aef5-dcd6c7044902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_a46fc632-29d8-49ee-8248-35b244f65cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c22dc749-7747-4f84-b980-669542d327f3" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_a46fc632-29d8-49ee-8248-35b244f65cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d856aefb-5d54-4a68-a3fb-06f57a078e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_040a63c4-4125-4561-b2fa-5aca9820c697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d856aefb-5d54-4a68-a3fb-06f57a078e49" xlink:to="loc_us-gaap_GoodwillRollForward_040a63c4-4125-4561-b2fa-5aca9820c697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d6ea58f5-4fc0-4f19-9e7d-bc95beca5899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_040a63c4-4125-4561-b2fa-5aca9820c697" xlink:to="loc_us-gaap_Goodwill_d6ea58f5-4fc0-4f19-9e7d-bc95beca5899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_14557fa8-fc16-48f0-8c54-9c88af59ea2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_040a63c4-4125-4561-b2fa-5aca9820c697" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_14557fa8-fc16-48f0-8c54-9c88af59ea2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_bf2adc4a-d4f0-43d3-8761-1bdc1c655a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_040a63c4-4125-4561-b2fa-5aca9820c697" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_bf2adc4a-d4f0-43d3-8761-1bdc1c655a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_de591c2c-492c-45e8-bca1-837407f4b864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_040a63c4-4125-4561-b2fa-5aca9820c697" xlink:to="loc_us-gaap_Goodwill_de591c2c-492c-45e8-bca1-837407f4b864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d61af054-70d5-4e13-a42d-8b8024fb8960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestRollForward_beb15787-526c-47a8-898a-ff699b77624a" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d61af054-70d5-4e13-a42d-8b8024fb8960" xlink:to="loc_sgry_RedeemableNoncontrollingInterestRollForward_beb15787-526c-47a8-898a-ff699b77624a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_fb213413-ebff-4825-b5e4-96734649588a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_beb15787-526c-47a8-898a-ff699b77624a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_fb213413-ebff-4825-b5e4-96734649588a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_ed709f7c-c624-412a-a913-7c999fe07020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_beb15787-526c-47a8-898a-ff699b77624a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_ed709f7c-c624-412a-a913-7c999fe07020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_b0bc3e48-46c9-44ee-8610-c5085c821647" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_beb15787-526c-47a8-898a-ff699b77624a" xlink:to="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_b0bc3e48-46c9-44ee-8610-c5085c821647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_fc7001f4-e06f-40cb-b711-36872758140d" xlink:href="sgry-20230331.xsd#sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_beb15787-526c-47a8-898a-ff699b77624a" xlink:to="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_fc7001f4-e06f-40cb-b711-36872758140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4882c526-df48-4be7-a390-789f41d27e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_beb15787-526c-47a8-898a-ff699b77624a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4882c526-df48-4be7-a390-789f41d27e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c969a90-ae5c-403e-aac5-2477bf600e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_4137ea1a-e37c-4bd5-9afc-1f9e0afe65dd" xlink:href="sgry-20230331.xsd#sgry_GrantRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c969a90-ae5c-403e-aac5-2477bf600e04" xlink:to="loc_sgry_GrantRevenue_4137ea1a-e37c-4bd5-9afc-1f9e0afe65dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UnrecognizedGrantFundsReceived_05ee7eab-df49-4050-8189-16b158d18bed" xlink:href="sgry-20230331.xsd#sgry_UnrecognizedGrantFundsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c969a90-ae5c-403e-aac5-2477bf600e04" xlink:to="loc_sgry_UnrecognizedGrantFundsReceived_05ee7eab-df49-4050-8189-16b158d18bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_833d3acc-6c5b-4838-a769-7aebc2217646" xlink:href="sgry-20230331.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c969a90-ae5c-403e-aac5-2477bf600e04" xlink:to="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_833d3acc-6c5b-4838-a769-7aebc2217646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c1ebab9a-7a2d-47e7-b14d-868003a8316c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c1ebab9a-7a2d-47e7-b14d-868003a8316c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1507a76-5c69-4b08-8e3b-7e33a43ad63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1507a76-5c69-4b08-8e3b-7e33a43ad63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1507a76-5c69-4b08-8e3b-7e33a43ad63b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d1b4a576-ebd6-46e4-a832-6c411d6bd1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:to="loc_us-gaap_SecuredDebtMember_d1b4a576-ebd6-46e4-a832-6c411d6bd1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8ed8e068-a407-48ec-8554-ff85feec2e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c354e9c-4f47-4a94-b729-c7ec090e225e" xlink:to="loc_us-gaap_SeniorNotesMember_8ed8e068-a407-48ec-8554-ff85feec2e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a26515e8-0e80-47cd-be3f-37d159445c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_a26515e8-0e80-47cd-be3f-37d159445c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a26515e8-0e80-47cd-be3f-37d159445c50" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_b1ba8641-9227-4f29-b7b0-ebfd8ad98fc1" xlink:href="sgry-20230331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_b1ba8641-9227-4f29-b7b0-ebfd8ad98fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_580bd716-f2a3-44fa-aec4-45feec9caebe" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_580bd716-f2a3-44fa-aec4-45feec9caebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_d1f12ef3-25fc-4a1e-b15d-9b97d6ab84ef" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e9e26b3-4adc-4634-a919-15bfbfddc8dd" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_d1f12ef3-25fc-4a1e-b15d-9b97d6ab84ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_867a2cb7-e697-4b86-9dd8-f062847e945b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_867a2cb7-e697-4b86-9dd8-f062847e945b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9541a7f3-0b82-43ac-b261-95fe6e5cc876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_867a2cb7-e697-4b86-9dd8-f062847e945b" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9541a7f3-0b82-43ac-b261-95fe6e5cc876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9541a7f3-0b82-43ac-b261-95fe6e5cc876" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ae2e0964-2d62-444a-aff3-faf7ec476f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ae2e0964-2d62-444a-aff3-faf7ec476f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0ff56f19-73ce-483a-b03e-2e92d7a31db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69a73a64-a365-472f-b86e-0a470eb49c42" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0ff56f19-73ce-483a-b03e-2e92d7a31db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32aa9461-328f-4b30-a12f-372051c3ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32aa9461-328f-4b30-a12f-372051c3ef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0359eb8-3a82-46d6-8193-a81c672cae82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32aa9461-328f-4b30-a12f-372051c3ef9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0359eb8-3a82-46d6-8193-a81c672cae82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bf659222-5b2f-4395-a1e4-3978ddf38703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0359eb8-3a82-46d6-8193-a81c672cae82" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bf659222-5b2f-4395-a1e4-3978ddf38703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6c6f0081-a2ac-4a39-91db-436c10c981e4" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f662e5fe-b66f-4529-ad4a-8d7f75f3890e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:to="loc_us-gaap_LongTermDebt_f662e5fe-b66f-4529-ad4a-8d7f75f3890e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8125c68b-1d73-403a-8fab-4ad176cdd6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_317aab9d-6b12-4bfd-aaa5-5437aac1f2aa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8125c68b-1d73-403a-8fab-4ad176cdd6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_32869312-d1bf-4b23-bdc0-71c3ee7a0f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e875a082-827e-4556-8e17-3f51af7d1337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_32869312-d1bf-4b23-bdc0-71c3ee7a0f14" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e875a082-827e-4556-8e17-3f51af7d1337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e875a082-827e-4556-8e17-3f51af7d1337" xlink:to="loc_srt_ConsolidatedEntitiesAxis_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_43c159bd-ce2b-4370-be94-0d80128ef37a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_516f10f4-3b15-4d1f-91a3-63d9c73f3c5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_43c159bd-ce2b-4370-be94-0d80128ef37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c97d07e7-21d9-4ae8-9f44-d77955085ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_43c159bd-ce2b-4370-be94-0d80128ef37a" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c97d07e7-21d9-4ae8-9f44-d77955085ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e875a082-827e-4556-8e17-3f51af7d1337" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities_24f38388-5bcd-429d-afe6-fa560939d2c6" xlink:href="sgry-20230331.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:to="loc_sgry_VariableInterestEntityNumberOfFacilities_24f38388-5bcd-429d-afe6-fa560939d2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ae7c5f48-0201-4a96-97e4-ba660b415b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:to="loc_us-gaap_Assets_ae7c5f48-0201-4a96-97e4-ba660b415b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c362a969-6ca6-49fa-9dd6-297af4e59479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8fc2967a-0d58-4c49-acd4-95be37c9c800" xlink:to="loc_us-gaap_Liabilities_c362a969-6ca6-49fa-9dd6-297af4e59479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#AcquisitionsandDisposalsAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_660dae7c-e974-402c-bc2d-03b7fb3e8994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ba011441-e2f7-411a-9905-110b0772b84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_660dae7c-e974-402c-bc2d-03b7fb3e8994" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ba011441-e2f7-411a-9905-110b0772b84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_963d1af3-8a1b-42f1-9c92-397ee214d98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ba011441-e2f7-411a-9905-110b0772b84c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_963d1af3-8a1b-42f1-9c92-397ee214d98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_963d1af3-8a1b-42f1-9c92-397ee214d98d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesAndPhysicianPracticesMember_f1668242-43bf-4b79-825b-fb45a2fa97fc" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesAndPhysicianPracticesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_SurgicalFacilitiesAndPhysicianPracticesMember_f1668242-43bf-4b79-825b-fb45a2fa97fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember_35419f01-82ce-442d-9df9-af0d4bdb4ed3" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_SurgicalFacilitiesMember_35419f01-82ce-442d-9df9-af0d4bdb4ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ExistingSurgicalFacilityMember_a440e2ce-fb63-4e77-92e9-0e51e7ce5957" xlink:href="sgry-20230331.xsd#sgry_ExistingSurgicalFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_ExistingSurgicalFacilityMember_a440e2ce-fb63-4e77-92e9-0e51e7ce5957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember_4666330e-db36-4382-8551-38d1013a8cdb" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84592945-a961-44c6-8e8d-c6d131b28a12" xlink:to="loc_sgry_SurgicalFacilitiesExistingMarketsMember_4666330e-db36-4382-8551-38d1013a8cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ba011441-e2f7-411a-9905-110b0772b84c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_aa1e687a-9df8-4185-9df2-3d0ac418cd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_aa1e687a-9df8-4185-9df2-3d0ac418cd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7a03595b-fb8b-49c0-9196-78b8081f8985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7a03595b-fb8b-49c0-9196-78b8081f8985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4c302bdc-a36a-42cb-b693-723c2756207c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4c302bdc-a36a-42cb-b693-723c2756207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6c4aea49-abbe-4d0f-a3e2-50f2d482721a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_Goodwill_6c4aea49-abbe-4d0f-a3e2-50f2d482721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_358f2d08-f4da-4620-bafc-ac7a346dd2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_358f2d08-f4da-4620-bafc-ac7a346dd2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a76749eb-9220-4a39-b824-c3fcd0c1bf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a76749eb-9220-4a39-b824-c3fcd0c1bf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_5cde1c1d-2279-4e6f-9602-7284c1302ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_5cde1c1d-2279-4e6f-9602-7284c1302ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_939ab02d-6fed-4e0f-af13-9e0e8f11fc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_939ab02d-6fed-4e0f-af13-9e0e8f11fc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredPaymentsToAcquireEquityMethodInvestments_426d991e-f317-47ac-96d4-d400726f684f" xlink:href="sgry-20230331.xsd#sgry_DeferredPaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_58d5b011-bf60-4cd2-bd14-f65b574306d5" xlink:to="loc_sgry_DeferredPaymentsToAcquireEquityMethodInvestments_426d991e-f317-47ac-96d4-d400726f684f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ec90f8ad-0438-4623-a5e3-ef8bec45b45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ec90f8ad-0438-4623-a5e3-ef8bec45b45b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6122a931-77f0-4bb5-a5cf-26233178298f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6122a931-77f0-4bb5-a5cf-26233178298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6122a931-77f0-4bb5-a5cf-26233178298f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OneSurgicalFacilityMember_230b3f81-5d7a-4883-acf3-7ff092f5638e" xlink:href="sgry-20230331.xsd#sgry_OneSurgicalFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:to="loc_sgry_OneSurgicalFacilityMember_230b3f81-5d7a-4883-acf3-7ff092f5638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2022DisposalsMember_347eb324-70d6-4c4a-a8de-f922b6cc4fef" xlink:href="sgry-20230331.xsd#sgry_A2022DisposalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b048baab-f8d4-40c3-8c88-464b4c1df33a" xlink:to="loc_sgry_A2022DisposalsMember_347eb324-70d6-4c4a-a8de-f922b6cc4fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6defb441-238e-4b4d-b66f-16017ea2c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6defb441-238e-4b4d-b66f-16017ea2c62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_017a738e-b98e-4ff2-8104-61bb81d16eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6defb441-238e-4b4d-b66f-16017ea2c62c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_017a738e-b98e-4ff2-8104-61bb81d16eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9d4b4c37-d267-4282-97ad-2095518e6ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_017a738e-b98e-4ff2-8104-61bb81d16eee" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_9d4b4c37-d267-4282-97ad-2095518e6ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bc179d24-967d-4dfd-ab31-eaf129cac350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bc179d24-967d-4dfd-ab31-eaf129cac350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f595abe-f2ed-424d-80e9-5df5f4fc0a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bc179d24-967d-4dfd-ab31-eaf129cac350" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f595abe-f2ed-424d-80e9-5df5f4fc0a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_68eb4a42-8337-45a7-b71d-93df16e0e110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f595abe-f2ed-424d-80e9-5df5f4fc0a15" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_68eb4a42-8337-45a7-b71d-93df16e0e110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1dc6cf03-c4d4-404d-82c0-bdf25fd1ca0d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_e3e6f53d-946b-438b-84b6-b8a3bc8d3432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_e3e6f53d-946b-438b-84b6-b8a3bc8d3432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ef2135da-6a52-47a3-a260-8ee9ac0e708d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ef2135da-6a52-47a3-a260-8ee9ac0e708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_9d0e0edf-2f8b-4be6-bbfc-4e2aeeec6f62" xlink:href="sgry-20230331.xsd#sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_9d0e0edf-2f8b-4be6-bbfc-4e2aeeec6f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_63e1d233-0c80-424f-af53-2d3fae78a517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_63e1d233-0c80-424f-af53-2d3fae78a517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_00ebb97d-00b6-45f9-bda6-f0ad4f880bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_510fb669-6c00-4b88-9943-2a0b882cea06" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_00ebb97d-00b6-45f9-bda6-f0ad4f880bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtSummaryofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8aa0c735-3998-4d14-82f4-4537d48c1350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8aa0c735-3998-4d14-82f4-4537d48c1350" xlink:to="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5662e215-6ac3-425f-8b43-fdb7547b62c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5662e215-6ac3-425f-8b43-fdb7547b62c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5662e215-6ac3-425f-8b43-fdb7547b62c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_715d9662-1c7c-4fab-af8a-175c8d795ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:to="loc_us-gaap_SecuredDebtMember_715d9662-1c7c-4fab-af8a-175c8d795ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ad18f86d-59af-4820-aa29-efb72c95d14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:to="loc_us-gaap_SeniorNotesMember_ad18f86d-59af-4820-aa29-efb72c95d14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember_07dd9f5f-7431-43b0-a90e-4983e31d2885" xlink:href="sgry-20230331.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0b34a35-23bf-454d-99fd-054f6a64a0d3" xlink:to="loc_sgry_NotesPayableAndSecuredLoansMember_07dd9f5f-7431-43b0-a90e-4983e31d2885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6ebd19e7-3f83-472b-8f00-438eeac2f7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:to="loc_us-gaap_DebtInstrumentAxis_6ebd19e7-3f83-472b-8f00-438eeac2f7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6ebd19e7-3f83-472b-8f00-438eeac2f7b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_13ff0851-a471-48d7-802f-62baf0505e7d" xlink:href="sgry-20230331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_13ff0851-a471-48d7-802f-62baf0505e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_dd37b8d0-6a36-41db-b867-9aa91fdaf37c" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_dd37b8d0-6a36-41db-b867-9aa91fdaf37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_03ee4d98-3e36-4e76-8014-32882842ef7c" xlink:href="sgry-20230331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc2878b8-919a-4ff5-b7d4-0e10e15c59be" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_03ee4d98-3e36-4e76-8014-32882842ef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d99b337-048a-4449-ba64-1b4dca31ff37" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0224a161-17be-40c6-a82c-e5036f897c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0224a161-17be-40c6-a82c-e5036f897c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_56caf7a3-5216-43d2-acc1-62cf046e13c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_FinanceLeaseLiability_56caf7a3-5216-43d2-acc1-62cf046e13c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_487bb180-8558-4812-bbcb-7cf19e55bf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_487bb180-8558-4812-bbcb-7cf19e55bf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_494b1627-6086-4eba-8170-a5df66e2fe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_494b1627-6086-4eba-8170-a5df66e2fe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_53d851df-bf6f-4bb3-be5d-61ee4c1e99cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_53d851df-bf6f-4bb3-be5d-61ee4c1e99cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_aad4ab00-cea4-4b29-8cc1-e85925ce456e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_aad4ab00-cea4-4b29-8cc1-e85925ce456e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_874b0155-1bd5-4ded-a29f-0ad5d84c1198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_874b0155-1bd5-4ded-a29f-0ad5d84c1198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_66020496-ebd8-4bdd-9164-7b1eeaff4696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e164c0e-32cf-41f3-a2b2-410feccc3f5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_66020496-ebd8-4bdd-9164-7b1eeaff4696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtSummaryofLongtermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_33622850-b8dd-4c67-9602-04ce3141bf17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_33622850-b8dd-4c67-9602-04ce3141bf17" xlink:to="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_11674495-84cb-48e1-b5f4-1664a4fc2156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:to="loc_us-gaap_CreditFacilityAxis_11674495-84cb-48e1-b5f4-1664a4fc2156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_11674495-84cb-48e1-b5f4-1664a4fc2156" xlink:to="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d9bc6020-b123-4eca-be6a-16bdbd705b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d9bc6020-b123-4eca-be6a-16bdbd705b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_2aed804a-aab8-4e88-9e58-f0841f60e041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ecbc737e-f921-4cbd-9327-1e331b91de3b" xlink:to="loc_us-gaap_LetterOfCreditMember_2aed804a-aab8-4e88-9e58-f0841f60e041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_feb98690-c303-4291-91df-06b59b78a09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_feb98690-c303-4291-91df-06b59b78a09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_da126b85-bcc0-47dc-b6b3-3d8a6dc50b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_feb98690-c303-4291-91df-06b59b78a09d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_da126b85-bcc0-47dc-b6b3-3d8a6dc50b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b61b4a9c-0974-4838-b984-008549e31d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_da126b85-bcc0-47dc-b6b3-3d8a6dc50b8a" xlink:to="loc_us-gaap_SecuredDebtMember_b61b4a9c-0974-4838-b984-008549e31d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ae9f3cc-362a-45d9-be0f-1948c06d1f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ae9f3cc-362a-45d9-be0f-1948c06d1f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4a12c9a-f388-4c50-8567-216993131ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ae9f3cc-362a-45d9-be0f-1948c06d1f69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4a12c9a-f388-4c50-8567-216993131ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c915125d-d1a6-4a08-aba0-3bc0b9cf4caf" xlink:href="sgry-20230331.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4a12c9a-f388-4c50-8567-216993131ec8" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c915125d-d1a6-4a08-aba0-3bc0b9cf4caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e503bab1-ba69-49fe-8e01-e43890268ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3b70123a-816b-4503-a39a-06ab592fb9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dbd685cd-e09a-4b26-b927-5598c18a71c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c438ce1-b427-4617-b4c4-6511211b1c58" xlink:to="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity_a6aaa9e7-8174-4143-8dff-dcf745504a08" xlink:href="sgry-20230331.xsd#sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:to="loc_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity_a6aaa9e7-8174-4143-8dff-dcf745504a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_161dd7a2-954c-4c03-8800-a10ae80f4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_161dd7a2-954c-4c03-8800-a10ae80f4fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1ac75f24-b73c-4130-9706-17acdb57791b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e71144-1e7f-4b6c-b606-80937f718036" xlink:to="loc_us-gaap_LineOfCredit_1ac75f24-b73c-4130-9706-17acdb57791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cd631234-3015-4c2d-a486-13dfa5d2f567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_055776d3-1044-4b12-be50-9abb7dd19dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd631234-3015-4c2d-a486-13dfa5d2f567" xlink:to="loc_us-gaap_AssetsAbstract_055776d3-1044-4b12-be50-9abb7dd19dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd30afc5-3b84-483d-b05a-e3f9d3ed7b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_055776d3-1044-4b12-be50-9abb7dd19dab" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd30afc5-3b84-483d-b05a-e3f9d3ed7b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_36b5500c-8ab6-4745-ba9e-8d8985b8d8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_055776d3-1044-4b12-be50-9abb7dd19dab" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_36b5500c-8ab6-4745-ba9e-8d8985b8d8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset_2764313f-ac82-491a-87a3-a257a6a1c3fc" xlink:href="sgry-20230331.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_055776d3-1044-4b12-be50-9abb7dd19dab" xlink:to="loc_sgry_LeaseRightOfUseAsset_2764313f-ac82-491a-87a3-a257a6a1c3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_1d959ba2-948f-429c-93ae-7fe329332c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd631234-3015-4c2d-a486-13dfa5d2f567" xlink:to="loc_us-gaap_LiabilitiesAbstract_1d959ba2-948f-429c-93ae-7fe329332c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_0b6dc89b-4556-4bf4-a861-fb6fb41eff28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1d959ba2-948f-429c-93ae-7fe329332c1c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_0b6dc89b-4556-4bf4-a861-fb6fb41eff28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_374ae816-9cb2-4682-8d8f-caecdb293318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_0b6dc89b-4556-4bf4-a861-fb6fb41eff28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_374ae816-9cb2-4682-8d8f-caecdb293318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6708a05-012d-4999-bd72-e0f1cb4633c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_0b6dc89b-4556-4bf4-a861-fb6fb41eff28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6708a05-012d-4999-bd72-e0f1cb4633c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7fd6c4b0-a67f-4c14-9631-0e01f0272055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_0b6dc89b-4556-4bf4-a861-fb6fb41eff28" xlink:to="loc_us-gaap_OperatingLeaseLiability_7fd6c4b0-a67f-4c14-9631-0e01f0272055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_1bf64e42-c7c1-48ed-af87-0e33fc95806e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1d959ba2-948f-429c-93ae-7fe329332c1c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_1bf64e42-c7c1-48ed-af87-0e33fc95806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_85854ea6-e188-4864-9b22-610e0395e05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1bf64e42-c7c1-48ed-af87-0e33fc95806e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_85854ea6-e188-4864-9b22-610e0395e05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6fa7d3da-fe8b-4639-9234-67905dda7a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1bf64e42-c7c1-48ed-af87-0e33fc95806e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6fa7d3da-fe8b-4639-9234-67905dda7a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_dafac612-cbf4-4550-9f20-dc76cb52151a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1bf64e42-c7c1-48ed-af87-0e33fc95806e" xlink:to="loc_us-gaap_FinanceLeaseLiability_dafac612-cbf4-4550-9f20-dc76cb52151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability_0ab77b81-482b-4edc-9f55-8d8d653a14ec" xlink:href="sgry-20230331.xsd#sgry_LeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1d959ba2-948f-429c-93ae-7fe329332c1c" xlink:to="loc_sgry_LeaseLiability_0ab77b81-482b-4edc-9f55-8d8d653a14ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_215baa47-e20c-467e-8493-4f0a3a1ca025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd631234-3015-4c2d-a486-13dfa5d2f567" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_215baa47-e20c-467e-8493-4f0a3a1ca025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3707633d-cf4a-48ec-9970-d8587d2c35b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd631234-3015-4c2d-a486-13dfa5d2f567" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3707633d-cf4a-48ec-9970-d8587d2c35b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7610d027-4fca-4034-bd18-5609444de987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd631234-3015-4c2d-a486-13dfa5d2f567" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7610d027-4fca-4034-bd18-5609444de987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_caa315f1-9cb6-4290-9d76-ddb3fe65360b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd631234-3015-4c2d-a486-13dfa5d2f567" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_caa315f1-9cb6-4290-9d76-ddb3fe65360b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#LeasesLeaseExpenseandCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5bd1b96c-3f87-4822-8c3c-8898a4266f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:to="loc_us-gaap_OperatingLeaseCost_5bd1b96c-3f87-4822-8c3c-8898a4266f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost1Abstract_1c8b3106-1e42-4e04-ba9e-6d64214ec032" xlink:href="sgry-20230331.xsd#sgry_FinanceLeaseCost1Abstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:to="loc_sgry_FinanceLeaseCost1Abstract_1c8b3106-1e42-4e04-ba9e-6d64214ec032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3c4e8f0e-9626-4c43-91aa-2451322ad5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_1c8b3106-1e42-4e04-ba9e-6d64214ec032" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3c4e8f0e-9626-4c43-91aa-2451322ad5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_beb9a415-a1be-4ff0-ad65-37d370b92396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_1c8b3106-1e42-4e04-ba9e-6d64214ec032" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_beb9a415-a1be-4ff0-ad65-37d370b92396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_a924449e-1aec-4f69-994a-db530ebb8ca1" xlink:href="sgry-20230331.xsd#sgry_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_1c8b3106-1e42-4e04-ba9e-6d64214ec032" xlink:to="loc_sgry_FinanceLeaseCost_a924449e-1aec-4f69-994a-db530ebb8ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost_32af23d4-015a-4d1b-bbe8-3ff1ff24569c" xlink:href="sgry-20230331.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:to="loc_sgry_VariableAndShortTermLeaseCost_32af23d4-015a-4d1b-bbe8-3ff1ff24569c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_274af331-4968-43ff-9146-f847e376bd09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:to="loc_us-gaap_LeaseCost_274af331-4968-43ff-9146-f847e376bd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CashFlowLesseeAbstract_9436ee5f-1b1c-4ea2-8fb2-d1a6a83a4cee" xlink:href="sgry-20230331.xsd#sgry_CashFlowLesseeAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:to="loc_sgry_CashFlowLesseeAbstract_9436ee5f-1b1c-4ea2-8fb2-d1a6a83a4cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f79238eb-c6ad-4fb0-b977-97b39530ce56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_CashFlowLesseeAbstract_9436ee5f-1b1c-4ea2-8fb2-d1a6a83a4cee" xlink:to="loc_us-gaap_OperatingLeasePayments_f79238eb-c6ad-4fb0-b977-97b39530ce56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0c26bdb6-20a0-423a-9880-912bc513d294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_CashFlowLesseeAbstract_9436ee5f-1b1c-4ea2-8fb2-d1a6a83a4cee" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0c26bdb6-20a0-423a-9880-912bc513d294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1a9e3876-44ee-46b4-b06b-3ca038a1b19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_CashFlowLesseeAbstract_9436ee5f-1b1c-4ea2-8fb2-d1a6a83a4cee" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1a9e3876-44ee-46b4-b06b-3ca038a1b19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_738b1f3b-2a4b-4a46-ae28-5d43db2165f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_738b1f3b-2a4b-4a46-ae28-5d43db2165f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_810c994b-eb66-4055-9c9e-e34fbadcf771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a266c34b-f726-4e3b-aea7-05955e7535ab" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_810c994b-eb66-4055-9c9e-e34fbadcf771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9a1287b9-8b36-4e85-aab1-b79c363ee8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a4777e90-ca70-46f6-a486-3d8103495abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9a1287b9-8b36-4e85-aab1-b79c363ee8f5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a4777e90-ca70-46f6-a486-3d8103495abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_01c99bf4-ed4a-4d69-b243-fe538a19312d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a4777e90-ca70-46f6-a486-3d8103495abf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_01c99bf4-ed4a-4d69-b243-fe538a19312d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_01c99bf4-ed4a-4d69-b243-fe538a19312d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapOneMember_1b276c21-d8c6-487b-a82e-11e89c970e80" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapOneMember_1b276c21-d8c6-487b-a82e-11e89c970e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapTwoMember_c80b0981-0ab7-461d-b48e-9de558259f2e" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapTwoMember_c80b0981-0ab7-461d-b48e-9de558259f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapThreeMember_ca64e20c-f317-40fd-b7ef-422ea0cd41e5" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapThreeMember_ca64e20c-f317-40fd-b7ef-422ea0cd41e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapOneMember_7f18a9c7-5bd7-4986-aa53-00a0edbba92f" xlink:href="sgry-20230331.xsd#sgry_InterestRateCapOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_InterestRateCapOneMember_7f18a9c7-5bd7-4986-aa53-00a0edbba92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapTwoMember_6ae0f7b7-a6a7-4e4f-97ea-a8e6428935f5" xlink:href="sgry-20230331.xsd#sgry_InterestRateCapTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_InterestRateCapTwoMember_6ae0f7b7-a6a7-4e4f-97ea-a8e6428935f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFourMember_df914778-7bca-4b6d-8b34-9109990c4ed2" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapFourMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapFourMember_df914778-7bca-4b6d-8b34-9109990c4ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFiveMember_90971004-f52f-4fa2-92bf-e9bb231951e4" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapFiveMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapFiveMember_90971004-f52f-4fa2-92bf-e9bb231951e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapSixMember_efdaa1a7-cc55-4100-b1c3-bebb0a067055" xlink:href="sgry-20230331.xsd#sgry_PayFixedSwapSixMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_PayFixedSwapSixMember_efdaa1a7-cc55-4100-b1c3-bebb0a067055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapOneMember_8efd3e66-e9e0-411e-8e3d-690aaecf13ed" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapOneMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_ReceiveFixedSwapOneMember_8efd3e66-e9e0-411e-8e3d-690aaecf13ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapTwoMember_60e7faa2-7c42-4557-a13c-af3672841305" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapTwoMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_ReceiveFixedSwapTwoMember_60e7faa2-7c42-4557-a13c-af3672841305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapThreeMember_44d3802b-ec3f-41a2-ad7a-cbed82599401" xlink:href="sgry-20230331.xsd#sgry_ReceiveFixedSwapThreeMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2473f6a-7231-4edf-ac3b-3cc5a33bd226" xlink:to="loc_sgry_ReceiveFixedSwapThreeMember_44d3802b-ec3f-41a2-ad7a-cbed82599401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a4777e90-ca70-46f6-a486-3d8103495abf" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_4c71ed16-f53b-4d28-8bcd-c25b45b9803f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_4c71ed16-f53b-4d28-8bcd-c25b45b9803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0ed21341-9b6f-410d-81b5-6088c73f899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0ed21341-9b6f-410d-81b5-6088c73f899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c9ab3d32-5f96-47b0-8421-be1fb1d48bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f0df9b94-83d4-472a-9d0a-38824f8ffca5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c9ab3d32-5f96-47b0-8421-be1fb1d48bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9cb985c-9b0c-468b-9718-771be9ecbc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9cb985c-9b0c-468b-9718-771be9ecbc3d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cf96f4c6-e05f-413c-ab40-3467036bf199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cf96f4c6-e05f-413c-ab40-3467036bf199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cf96f4c6-e05f-413c-ab40-3467036bf199" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:to="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member_8e9fbb29-9d61-47f9-a0f5-90393e494c37" xlink:href="sgry-20230331.xsd#sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:to="loc_sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member_8e9fbb29-9d61-47f9-a0f5-90393e494c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:href="sgry-20230331.xsd#sgry_SixUndersignedInterestRateSwapsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestRateSwapMember_1a20e420-24b7-468a-baf2-540f404072a6" xlink:to="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member_076910f5-d222-4bb5-b7e0-84b6714a8cc4" xlink:href="sgry-20230331.xsd#sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:to="loc_sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member_076910f5-d222-4bb5-b7e0-84b6714a8cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member_6591464d-8d9b-4655-af2a-55d3c5d88a20" xlink:href="sgry-20230331.xsd#sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_SixUndersignedInterestRateSwapsMember_4cfc6880-88fe-4f51-8c50-900ee28fa86b" xlink:to="loc_sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member_6591464d-8d9b-4655-af2a-55d3c5d88a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_5c70c862-5f33-4d48-bd7e-eaeb00eb335c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e632c8a2-d728-4acc-9e07-841b7f8f06f8" xlink:to="loc_us-gaap_InterestRateCapMember_5c70c862-5f33-4d48-bd7e-eaeb00eb335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_68bcebc6-9734-4b07-ae8c-c166ba9db580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_us-gaap_HedgingDesignationAxis_68bcebc6-9734-4b07-ae8c-c166ba9db580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_68bcebc6-9734-4b07-ae8c-c166ba9db580" xlink:to="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3779b30e-8974-4287-860c-a4c2344974bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3779b30e-8974-4287-860c-a4c2344974bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e3af3045-c084-4d0d-a86b-a6383635f140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_39def9c9-2861-4688-a7a0-1fe38f8af628" xlink:to="loc_us-gaap_NondesignatedMember_e3af3045-c084-4d0d-a86b-a6383635f140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c5103e2b-50ae-4413-a095-ee31562a97a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_us-gaap_VariableRateAxis_c5103e2b-50ae-4413-a095-ee31562a97a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_27762218-fc79-4bbf-b048-be4669b7d5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c5103e2b-50ae-4413-a095-ee31562a97a2" xlink:to="loc_us-gaap_VariableRateDomain_27762218-fc79-4bbf-b048-be4669b7d5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fca356cb-9148-4d3f-b920-e818ac90e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_27762218-fc79-4bbf-b048-be4669b7d5c5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_fca356cb-9148-4d3f-b920-e818ac90e13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e34a164-3eef-44e5-b898-d578909935f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_srt_RangeAxis_0e34a164-3eef-44e5-b898-d578909935f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7403b963-904d-430b-8ce8-7f85a897e9e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0e34a164-3eef-44e5-b898-d578909935f8" xlink:to="loc_srt_RangeMember_7403b963-904d-430b-8ce8-7f85a897e9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fc159f7b-a0ec-4128-8ebf-264b38f4c31a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7403b963-904d-430b-8ce8-7f85a897e9e1" xlink:to="loc_srt_MinimumMember_fc159f7b-a0ec-4128-8ebf-264b38f4c31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_badacf1f-1d98-422b-a0ef-34d4c1ee8262" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_70a20a46-70c8-4b07-89dd-acb51f838fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_70a20a46-70c8-4b07-89dd-acb51f838fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_6a7ca0d2-dde7-4bec-aabe-d6da7b222b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_6a7ca0d2-dde7-4bec-aabe-d6da7b222b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeVariableInterestRate_2dff0907-ed1b-43d2-92ee-61f0d8878dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeVariableInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_DerivativeVariableInterestRate_2dff0907-ed1b-43d2-92ee-61f0d8878dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities_2fe8823e-3095-4a73-8d82-53b654a89bef" xlink:href="sgry-20230331.xsd#sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities_2fe8823e-3095-4a73-8d82-53b654a89bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_4f10a209-79b0-4cf4-ba46-f4dcef2dc806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_9beb501d-9f51-41e4-8b3a-7da25f667ef3" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_4f10a209-79b0-4cf4-ba46-f4dcef2dc806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2ecaa224-6d3f-45e4-91d7-9774a404c598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2ecaa224-6d3f-45e4-91d7-9774a404c598" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:to="loc_us-gaap_HedgingDesignationAxis_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2200b5e7-656d-4d2b-8f71-ff832e6aaa6c" xlink:to="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a3d951a8-b558-4d7c-adba-86b480e64ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:to="loc_us-gaap_NondesignatedMember_a3d951a8-b558-4d7c-adba-86b480e64ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2a644ae8-999e-4c0b-8156-1882817dea89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_09969d7f-b944-48c7-b2ed-9ce0a313e7ff" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2a644ae8-999e-4c0b-8156-1882817dea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_98e04f4f-fe47-4c52-8bf3-4abc9cabc005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_98e04f4f-fe47-4c52-8bf3-4abc9cabc005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_98e04f4f-fe47-4c52-8bf3-4abc9cabc005" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_fac48907-53a1-47fd-b59b-e130145ecbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_fac48907-53a1-47fd-b59b-e130145ecbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2a0ac266-b8ae-4625-88f7-7903cfc5b318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_214e5f64-95b7-4c70-9511-83be879f91a4" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2a0ac266-b8ae-4625-88f7-7903cfc5b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e0cfcad1-ea8a-4cc5-96d5-5a3dd6eb5d3d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_ceb51eca-e3e5-470e-80f8-036e33470f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:to="loc_us-gaap_InterestRateCapMember_ceb51eca-e3e5-470e-80f8-036e33470f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_86cf8270-fccb-42dc-bd2b-662ff8b5b39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_22b0ac4a-eef7-423c-a192-31e8b1cad01e" xlink:to="loc_us-gaap_InterestRateSwapMember_86cf8270-fccb-42dc-bd2b-662ff8b5b39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_bb5fc373-5916-4619-8cca-973545a79696" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_8cb59deb-5566-4801-a571-95374289904e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_8cb59deb-5566-4801-a571-95374289904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_3413f0a3-0b62-489f-9bb3-f0410b7040ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_f463d65b-fa20-42d9-aa7c-2b8fd6119570" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_3413f0a3-0b62-489f-9bb3-f0410b7040ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4708c556-cf9f-4a67-8cb3-515179cea338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_303cd526-5a10-4a89-81c9-3a9b757cb137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4708c556-cf9f-4a67-8cb3-515179cea338" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_303cd526-5a10-4a89-81c9-3a9b757cb137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_02fa385f-c992-4fee-b1ec-26efb442393b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_303cd526-5a10-4a89-81c9-3a9b757cb137" xlink:to="loc_us-gaap_HedgingDesignationAxis_02fa385f-c992-4fee-b1ec-26efb442393b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_02fa385f-c992-4fee-b1ec-26efb442393b" xlink:to="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8cf1d6b8-3e77-47dd-acfa-77178f5455e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:to="loc_us-gaap_NondesignatedMember_8cf1d6b8-3e77-47dd-acfa-77178f5455e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26738b95-ee97-4a1f-b403-f14e549e54ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_52bfee7f-e681-4aa5-b92c-a2989c9cd361" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26738b95-ee97-4a1f-b403-f14e549e54ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_303cd526-5a10-4a89-81c9-3a9b757cb137" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0cc6ef26-5e4b-40ad-8e75-f8705399e278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_0cc6ef26-5e4b-40ad-8e75-f8705399e278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_73867e35-7138-43f0-9415-b68545897131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_73867e35-7138-43f0-9415-b68545897131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_dbac5d6e-0577-45ec-b661-e21ff5714ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_dbac5d6e-0577-45ec-b661-e21ff5714ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_601f02bf-fdf1-4750-b321-b45c776280f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_601f02bf-fdf1-4750-b321-b45c776280f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a69faab0-cbbe-494a-91a6-b92296513843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_55d8f959-d66a-440a-b997-2084efa3c06f" xlink:to="loc_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a69faab0-cbbe-494a-91a6-b92296513843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#EarningsPerShareSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7af7adc5-4ce3-45d4-8203-ead1985ff9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0b187cf0-4797-4b6e-aa18-d3fc63f8141e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7af7adc5-4ce3-45d4-8203-ead1985ff9eb" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0b187cf0-4797-4b6e-aa18-d3fc63f8141e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75aa5e0e-79fc-46f2-b6c6-fd3676b57287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0b187cf0-4797-4b6e-aa18-d3fc63f8141e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75aa5e0e-79fc-46f2-b6c6-fd3676b57287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75aa5e0e-79fc-46f2-b6c6-fd3676b57287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c0f968c1-d6d8-4a9d-85bf-b0c653038625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c0f968c1-d6d8-4a9d-85bf-b0c653038625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b930b5a8-5ca6-4835-9cc9-999186085cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8624b66-bf86-44c6-b96a-c6b4131f94b8" xlink:to="loc_us-gaap_RestrictedStockMember_b930b5a8-5ca6-4835-9cc9-999186085cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0b187cf0-4797-4b6e-aa18-d3fc63f8141e" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_9ac2944a-1017-4648-90b6-7d38f15efe58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_NetIncomeLossAbstract_9ac2944a-1017-4648-90b6-7d38f15efe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_773b8590-f3e4-4a5b-82ac-9ccca142c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9ac2944a-1017-4648-90b6-7d38f15efe58" xlink:to="loc_us-gaap_NetIncomeLoss_773b8590-f3e4-4a5b-82ac-9ccca142c6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0719e94e-7d48-4e7c-b792-c6cf69f9bcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0719e94e-7d48-4e7c-b792-c6cf69f9bcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86c38862-b4c2-45b4-8cbe-eb89f297a316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a6ac7867-0923-4cfe-ab94-414a4e7b82a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86c38862-b4c2-45b4-8cbe-eb89f297a316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6dfd5718-61ce-4552-83e2-8e5ec6657582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:to="loc_us-gaap_EarningsPerShareBasic_6dfd5718-61ce-4552-83e2-8e5ec6657582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e17fd6d6-89d5-4c9d-bfe0-01c0ee9d3401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_74b97343-140c-4391-a992-1f3b6436f65c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e17fd6d6-89d5-4c9d-bfe0-01c0ee9d3401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_246af275-bfdb-4e9c-9805-7e668e52cc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_992fcf0c-dae1-4e49-8e52-6d32d8307b79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_246af275-bfdb-4e9c-9805-7e668e52cc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#OtherCurrentLiabilitiesSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca0421c6-cb34-4f22-b717-45cbaa3aef7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca0421c6-cb34-4f22-b717-45cbaa3aef7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers_53124256-5822-4251-bc1d-d81c6708392a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PayablesToCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:to="loc_srt_PayablesToCustomers_53124256-5822-4251-bc1d-d81c6708392a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent_8479c1b0-afb0-4739-9d6b-606507a2d2ae" xlink:href="sgry-20230331.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:to="loc_sgry_CostReportLiabilitiesCurrent_8479c1b0-afb0-4739-9d6b-606507a2d2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_c7c51c84-e3c1-4473-8847-e1fe00aae8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:to="loc_us-gaap_InterestPayableCurrent_c7c51c84-e3c1-4473-8847-e1fe00aae8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AcquisitionEscrowLiabilityCurrent_1836f371-428e-43ca-80c1-00fc4471d4a7" xlink:href="sgry-20230331.xsd#sgry_AcquisitionEscrowLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:to="loc_sgry_AcquisitionEscrowLiabilityCurrent_1836f371-428e-43ca-80c1-00fc4471d4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5ff413c8-4632-4d14-9139-df6881aa019e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5ff413c8-4632-4d14-9139-df6881aa019e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b6c8b9a7-7ae7-46da-8358-2d858c935925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2ced6436-86b6-43dd-abd1-4157c8693ae5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b6c8b9a7-7ae7-46da-8358-2d858c935925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8df0c33c-c8f5-4fe6-995a-adf16a8e9c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_a442336e-1d31-4954-9db0-1c84377f7999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8df0c33c-c8f5-4fe6-995a-adf16a8e9c9c" xlink:to="loc_us-gaap_SelfInsuranceReserve_a442336e-1d31-4954-9db0-1c84377f7999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_04f7fc3c-5568-44f1-9475-ca85a151e058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8df0c33c-c8f5-4fe6-995a-adf16a8e9c9c" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_04f7fc3c-5568-44f1-9475-ca85a151e058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_d7000cf5-ff3f-4a62-ba68-782991e3e190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8df0c33c-c8f5-4fe6-995a-adf16a8e9c9c" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_d7000cf5-ff3f-4a62-ba68-782991e3e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_10a6354b-3e18-43a8-bbbc-1255899a87ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6424cc37-cc50-4512-a2a2-4086e4713b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_10a6354b-3e18-43a8-bbbc-1255899a87ea" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6424cc37-cc50-4512-a2a2-4086e4713b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_10a6354b-3e18-43a8-bbbc-1255899a87ea" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3d9b4be0-33c2-49fb-9d85-256e74157b2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:to="loc_srt_ConsolidationItemsAxis_3d9b4be0-33c2-49fb-9d85-256e74157b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_3d9b4be0-33c2-49fb-9d85-256e74157b2f" xlink:to="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_afa434c2-5b53-4508-9bcf-4c24ef7e7860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:to="loc_us-gaap_OperatingSegmentsMember_afa434c2-5b53-4508-9bcf-4c24ef7e7860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2003512d-2ea9-477e-b139-f39907e0e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_612ab96a-8d62-44d4-ba7c-48958185beea" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2003512d-2ea9-477e-b139-f39907e0e46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_49579199-b7de-4561-b302-b48dde996da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_49579199-b7de-4561-b302-b48dde996da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_49579199-b7de-4561-b302-b48dde996da8" xlink:to="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_23094003-5852-4d35-a9da-15973fa876ed" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:to="loc_sgry_SurgicalFacilityServicesMember_23094003-5852-4d35-a9da-15973fa876ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_769d5d9d-a61d-41de-b345-15c16c188526" xlink:href="sgry-20230331.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bda9ff2d-5a8b-484f-bbd7-35a97690f2d7" xlink:to="loc_sgry_AncillaryServicesMember_769d5d9d-a61d-41de-b345-15c16c188526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9f79b2a5-65bc-4756-9dd1-76e23233fa9d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6d5e82b-da1d-41f7-b00f-9d1c74188f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6d5e82b-da1d-41f7-b00f-9d1c74188f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_b85c2a23-2b36-43cf-aaca-652a83f0a845" xlink:href="sgry-20230331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_b85c2a23-2b36-43cf-aaca-652a83f0a845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_20f52e8e-bd83-44ef-ba98-b2e911740904" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7ce8cd35-2e07-416a-a3a9-1554b719f68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7ce8cd35-2e07-416a-a3a9-1554b719f68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_34688ff3-430c-4cb5-8796-5e5394f57a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_34688ff3-430c-4cb5-8796-5e5394f57a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_28cef182-04cb-4437-a753-14de9b433241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_28cef182-04cb-4437-a753-14de9b433241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_34ca3e02-a8b1-4677-a2fc-a506f4fa1e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_34ca3e02-a8b1-4677-a2fc-a506f4fa1e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f17bc369-36c4-46e7-925f-cbd2cdd60bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_ShareBasedCompensation_f17bc369-36c4-46e7-925f-cbd2cdd60bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_0818b4ae-3947-4f8d-bb43-d52095237a00" xlink:href="sgry-20230331.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_0818b4ae-3947-4f8d-bb43-d52095237a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_c64bc5ce-7195-425d-be3b-ab217dbf40d3" xlink:href="sgry-20230331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_c64bc5ce-7195-425d-be3b-ab217dbf40d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact_c12ac269-fc14-41fe-931d-1ceaf9da149a" xlink:href="sgry-20230331.xsd#sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact_c12ac269-fc14-41fe-931d-1ceaf9da149a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UndesignatedDerivativeActivity_ca2a818a-8b9a-4307-81d7-144518027450" xlink:href="sgry-20230331.xsd#sgry_UndesignatedDerivativeActivity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_UndesignatedDerivativeActivity_ca2a818a-8b9a-4307-81d7-144518027450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_68ac03dd-c05e-4b65-ae95-0856bea9f88b" xlink:href="sgry-20230331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_68ac03dd-c05e-4b65-ae95-0856bea9f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_d0e7f431-2148-492a-8868-ff40bd5e6d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_d0e7f431-2148-492a-8868-ff40bd5e6d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5a1f05ab-9257-40a3-9652-36d15e019b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5a1f05ab-9257-40a3-9652-36d15e019b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_caf8ee05-a3f4-4ee1-b83f-7f3e682216ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_caf8ee05-a3f4-4ee1-b83f-7f3e682216ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_58d137e1-160e-4722-9f39-98706d8df111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_us-gaap_LitigationSettlementExpense_58d137e1-160e-4722-9f39-98706d8df111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation_17c9690f-91db-4ef3-80ab-40ddd5644cf8" xlink:href="sgry-20230331.xsd#sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_4e925032-ed7a-468d-878f-875af58a6f0c" xlink:to="loc_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation_17c9690f-91db-4ef3-80ab-40ddd5644cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_23eac91c-4184-4f53-b814-e02f46cfd043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_23eac91c-4184-4f53-b814-e02f46cfd043" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f9508529-dd0c-4cb1-b48e-7815fe50ffa8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:to="loc_srt_ConsolidationItemsAxis_f9508529-dd0c-4cb1-b48e-7815fe50ffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f9508529-dd0c-4cb1-b48e-7815fe50ffa8" xlink:to="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_619f4f6d-e990-4b72-bbe6-cb13796efaac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:to="loc_us-gaap_OperatingSegmentsMember_619f4f6d-e990-4b72-bbe6-cb13796efaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0e258f39-d6f9-4b76-a117-d80ae47befb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e766c421-0845-43a3-9740-924efea9fa68" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0e258f39-d6f9-4b76-a117-d80ae47befb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1549626f-063c-4c70-93fa-0a0140e78534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1549626f-063c-4c70-93fa-0a0140e78534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1549626f-063c-4c70-93fa-0a0140e78534" xlink:to="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_e8eff3da-f908-4bf2-a5d8-c84ff438ac03" xlink:href="sgry-20230331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:to="loc_sgry_SurgicalFacilityServicesMember_e8eff3da-f908-4bf2-a5d8-c84ff438ac03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_78334f00-61d3-4820-b16c-09e0b63285e7" xlink:href="sgry-20230331.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ab3acb7e-589d-46b1-aa42-bb1d603ae13e" xlink:to="loc_sgry_AncillaryServicesMember_78334f00-61d3-4820-b16c-09e0b63285e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5275bc03-c94f-40ea-962f-c6f66e0d2003" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_adbdee25-07a3-40ee-9cfd-fb6dfb7e4a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:to="loc_us-gaap_Assets_adbdee25-07a3-40ee-9cfd-fb6dfb7e4a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b0fc2c8-779e-4704-b216-e6c3a3072a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c84afdf7-02b8-46ac-8f6d-f9dfac95df6c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b0fc2c8-779e-4704-b216-e6c3a3072a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgry-20230331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_36ea0275-8ff8-4936-ae44-7593af2f99e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_36ea0275-8ff8-4936-ae44-7593af2f99e2" xlink:to="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_62a383eb-0b4c-412e-af4c-1354823f57bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_62a383eb-0b4c-412e-af4c-1354823f57bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0068949a-e977-4532-acd0-bbff640e58ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_62a383eb-0b4c-412e-af4c-1354823f57bc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0068949a-e977-4532-acd0-bbff640e58ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8e175232-4906-461b-8467-35ee4b835724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0068949a-e977-4532-acd0-bbff640e58ed" xlink:to="loc_us-gaap_SubsequentEventMember_8e175232-4906-461b-8467-35ee4b835724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f99e896e-15ff-4f03-be0f-3d158dc75729" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f99e896e-15ff-4f03-be0f-3d158dc75729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3c3c2ef8-a912-4094-bc99-3126abbd4063" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f99e896e-15ff-4f03-be0f-3d158dc75729" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3c3c2ef8-a912-4094-bc99-3126abbd4063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InDevelopmentDeNovoSurgicalFacilityMember_3ad32f00-f514-44d1-ae64-800767250164" xlink:href="sgry-20230331.xsd#sgry_InDevelopmentDeNovoSurgicalFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3c3c2ef8-a912-4094-bc99-3126abbd4063" xlink:to="loc_sgry_InDevelopmentDeNovoSurgicalFacilityMember_3ad32f00-f514-44d1-ae64-800767250164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d002825b-b459-4821-9704-8de4959b6efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d002825b-b459-4821-9704-8de4959b6efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6c09004e-53ad-4387-aa7f-cd2cad8d5c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d002825b-b459-4821-9704-8de4959b6efe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6c09004e-53ad-4387-aa7f-cd2cad8d5c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e927b283-12bc-4118-ba3a-0f9eb6cb19cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6c09004e-53ad-4387-aa7f-cd2cad8d5c71" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e927b283-12bc-4118-ba3a-0f9eb6cb19cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_464d7a3c-95ce-4e5f-89ef-6c1d97258951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_464d7a3c-95ce-4e5f-89ef-6c1d97258951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc090900-531e-425d-b0c6-e6f6476f6976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_464d7a3c-95ce-4e5f-89ef-6c1d97258951" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc090900-531e-425d-b0c6-e6f6476f6976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TwoSurgicalFacilitiesMember_194f8054-78bc-4c59-9647-dd3892b97213" xlink:href="sgry-20230331.xsd#sgry_TwoSurgicalFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc090900-531e-425d-b0c6-e6f6476f6976" xlink:to="loc_sgry_TwoSurgicalFacilitiesMember_194f8054-78bc-4c59-9647-dd3892b97213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f7c31157-e6c6-490f-a4c2-00f0028bd275" xlink:to="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed_70047b31-692a-4a7d-ae17-d42513d2aa99" xlink:href="sgry-20230331.xsd#sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:to="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed_70047b31-692a-4a7d-ae17-d42513d2aa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02e57e1a-e6e7-492a-8e90-bfec335abf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_02e57e1a-e6e7-492a-8e90-bfec335abf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ae482e78-d8b1-471b-9972-b4352f5a9c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_457f12b6-5ef4-43bc-bb87-79e199151f93" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ae482e78-d8b1-471b-9972-b4352f5a9c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828375920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 25, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Surgery Partners, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3620923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">340 Seven Springs Way, Suite&#160;600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brentwood<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">234-5900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGRY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,476,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836122560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 245.5<span></span>
</td>
<td class="nump">$ 282.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">452.9<span></span>
</td>
<td class="nump">456.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">71.8<span></span>
</td>
<td class="nump">71.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">29.3<span></span>
</td>
<td class="nump">31.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">69.4<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">868.9<span></span>
</td>
<td class="nump">921.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net of accumulated depreciation of $382.7 and $374.3, respectively</a></td>
<td class="nump">844.3<span></span>
</td>
<td class="nump">876.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangible assets, net</a></td>
<td class="nump">4,252.6<span></span>
</td>
<td class="nump">4,179.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to affiliates</a></td>
<td class="nump">191.6<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease assets</a></td>
<td class="nump">274.0<span></span>
</td>
<td class="nump">279.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Long-term deferred tax assets</a></td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">91.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">118.6<span></span>
</td>
<td class="nump">144.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,643.3<span></span>
</td>
<td class="nump">6,682.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">144.4<span></span>
</td>
<td class="nump">151.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">67.8<span></span>
</td>
<td class="nump">68.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">210.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">62.9<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">475.1<span></span>
</td>
<td class="nump">493.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, less current maturities</a></td>
<td class="nump">2,530.9<span></span>
</td>
<td class="nump">2,559.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use operating lease liabilities</a></td>
<td class="nump">268.8<span></span>
</td>
<td class="nump">271.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Non-controlling interests&#8212;redeemable</a></td>
<td class="nump">345.8<span></span>
</td>
<td class="nump">342.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 126,480,483 and 125,960,834, respectively</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,478.1<span></span>
</td>
<td class="nump">2,478.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">64.9<span></span>
</td>
<td class="nump">76.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(582.3)<span></span>
</td>
<td class="num">(557.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Surgery Partners, Inc. stockholders' equity</a></td>
<td class="nump">1,962.0<span></span>
</td>
<td class="nump">1,998.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests&#8212;non-redeemable</a></td>
<td class="nump">980.5<span></span>
</td>
<td class="nump">942.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">2,942.5<span></span>
</td>
<td class="nump">2,940.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 6,643.3<span></span>
</td>
<td class="nump">$ 6,682.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828348048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation on property and equipment</a></td>
<td class="nump">$ 382.7<span></span>
</td>
<td class="nump">$ 374.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">20,310,000<span></span>
</td>
<td class="nump">20,310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (shares)</a></td>
<td class="nump">126,480,483<span></span>
</td>
<td class="nump">125,960,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (shares)</a></td>
<td class="nump">126,480,483<span></span>
</td>
<td class="nump">125,960,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458835768512">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 666.2<span></span>
</td>
<td class="nump">$ 596.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">202.2<span></span>
</td>
<td class="nump">178.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188.4<span></span>
</td>
<td class="nump">171.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional and medical fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74.6<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_OperatingAndFinanceLeaseExpense', window );">Lease expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45.6<span></span>
</td>
<td class="nump">37.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">532.2<span></span>
</td>
<td class="nump">471.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32.0<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Transaction and integration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_GrantRevenue', window );">Grant funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Net loss (gain) on disposals, consolidations and deconsolidations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.5<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.0<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncomeExpense', window );">Other expense (income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">619.8<span></span>
</td>
<td class="nump">495.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46.4<span></span>
</td>
<td class="nump">100.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46.8)<span></span>
</td>
<td class="num">(56.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">(Loss) income before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26.1)<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Surgery Partners, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (24.9)<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net (loss) income per share attributable to common stockholders</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">125,206<span></span>
</td>
<td class="nump">87,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">125,206<span></span>
</td>
<td class="nump">90,272<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The impact of potentially dilutive securities for the three months ended March 31, 2023 was not considered because the effect would be anti-dilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_OperatingAndFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_OperatingAndFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836105568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Derivative activity, net of tax of $0</a></td>
<td class="num">(11.3)<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive (loss) income</a></td>
<td class="num">(10.1)<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to non-controlling interests</a></td>
<td class="num">(26.1)<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income attributable to Surgery Partners, Inc.</a></td>
<td class="num">$ (36.2)<span></span>
</td>
<td class="nump">$ 69.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458832916880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivative activity, tax</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836164512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Retained Deficit</div></th>
<th class="th"><div>Non-Controlling Interests&#8212; Non-Redeemable</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 1,969.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1,622.3<span></span>
</td>
<td class="num">$ (31.5)<span></span>
</td>
<td class="num">$ (502.7)<span></span>
</td>
<td class="nump">$ 880.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net (loss) income</a></td>
<td class="nump">32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive income (loss)</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet', window );">Acquisition and disposal of shares of non-controlling interests, net</a></td>
<td class="num">(29.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interests&#8212;non-redeemable holders</a></td>
<td class="num">(24.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="nump">$ 2,012.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">1,625.2<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="num">(490.5)<span></span>
</td>
<td class="nump">851.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2022</a></td>
<td class="nump">125,960,834<span></span>
</td>
<td class="nump">125,961,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 2,940.9<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">2,478.0<span></span>
</td>
<td class="nump">76.2<span></span>
</td>
<td class="num">(557.3)<span></span>
</td>
<td class="nump">942.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net (loss) income</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive income (loss)</a></td>
<td class="num">(11.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet', window );">Acquisition and disposal of shares of non-controlling interests, net</a></td>
<td class="nump">46.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interests&#8212;non-redeemable holders</a></td>
<td class="num">$ (30.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Mar. 31, 2023</a></td>
<td class="nump">126,480,483<span></span>
</td>
<td class="nump">126,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2023</a></td>
<td class="nump">$ 2,942.5<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 2,478.1<span></span>
</td>
<td class="nump">$ 64.9<span></span>
</td>
<td class="num">$ (582.3)<span></span>
</td>
<td class="nump">$ 980.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836398896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NoncashInterestIncomeExpenseNet', window );">Non-cash interest expense, net</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Net loss (gain) on disposals, consolidations and deconsolidations</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Equity in earnings of unconsolidated affiliates, net of distributions received</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants', window );">Medicare accelerated payments and deferred governmental grants</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(24.3)<span></span>
</td>
<td class="num">(18.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="num">(40.7)<span></span>
</td>
<td class="num">(31.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of equity investments</a></td>
<td class="num">(9.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sales of equity investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(70.7)<span></span>
</td>
<td class="num">(47.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(15.9)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings of long-term debt</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">Distributions to non-controlling interest holders</a></td>
<td class="num">(41.9)<span></span>
</td>
<td class="num">(36.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Receipts (payments) related to ownership transactions with non-controlling interest holders</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(41.2)<span></span>
</td>
<td class="num">(43.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(37.4)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">282.9<span></span>
</td>
<td class="nump">389.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 245.5<span></span>
</td>
<td class="nump">$ 378.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NoncashInterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NoncashInterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458835375040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Accounting Policies</a></td>
<td class="text">Organization and Summary of Accounting Policies<div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company owned or operated a portfolio of 145 surgical facilities, comprised of 127 ASCs and 18 surgical hospitals in 31 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in 92 of these surgical facilities and consolidated 118 of these facilities for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#8217;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the "2022 Annual Report on Form 10-K").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">656.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required. </span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's effective tax rate was 400.0% for the three months ended March&#160;31, 2023 compared to 2.9% for the three months ended March&#160;31, 2022. For the three months ended March&#160;31, 2023, the effective tax rate differed from the federal corporate tax rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and a discrete tax benefit of $1.8&#160;million related to the vesting of restricted stock awards. For the three months ended March 31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $4.6&#160;million related to the vesting of restricted stock awards, (b) $1.8&#160;million attributable to non-recurring earnings&#8217; impact on the Company&#8217;s valuation allowance, and (c) $1.0&#160;million related to entity divestitures. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions and disposals for the three months ended March&#160;31, 2023 is included in Note 2. "Acquisitions and Disposals."</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to goodwill for the three months ended March&#160;31, 2023 is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,137.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,217.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A detailed evaluation of potential impairment indicators was performed as of March&#160;31, 2023, which specifically considered recent increases in interest rates, inflation risk and market volatility. On the basis of available evidence as of March&#160;31, 2023, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company&#8217;s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests&#8212;Redeemable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to non-controlling interests&#8212;redeemable is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest&#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Medicare Accelerated Payments and Deferred Governmental Grants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received grant funds distributed under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) and other governmental assistance programs. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues. The Company estimates $1.1 million and $1.2 million of grant funds received qualified for recognition as a reduction in operating expenses for the three months ended March&#160;31, 2023 and 2022, respectively. There were no remaining unrecognized grant funds as of March 31, 2023. As of December&#160;31, 2022 approximately $3&#160;million of unrecognized grant funds received was reflected as a component of other current liabilities within the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received accelerated payments under the Medicare Accelerated and Advance Payment Program. The payments received were deferred and included in the condensed consolidated balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the remaining deferred accelerated payments was minimal. During the three months ended March 31, 2022, approximately $18&#160;million was repaid in </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">accordance with the terms of the program. These repayments are included as a component of the change in Medicare accelerated payments and deferred government grants in the condensed consolidated statements of cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policies for relief received under the CARES Act and other governmental assistance programs, including the recognition of grant funds, is unchanged from the policies described in Note 1 to the Company&#8217;s consolidated financial statements included in the 2022 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,353.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of March&#160;31, 2023, the Company's consolidated VIEs include seven surgical facilities and five physician practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of March&#160;31, 2023 and December&#160;31, 2022 were $69.9 million and $64.9 million, respectively, and the total liabilities of the consolidated VIEs were $44.5 million and $40.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458926284160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Disposals</a></td>
<td class="text">Acquisitions and Disposals <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company acquired a controlling interest in a surgical facility and a physician practice for aggregate cash consideration of $16.2&#160;million, net of cash acquired, and non-cash consideration of $1.3&#160;million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $12.0&#160;million and goodwill of $25.7&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company acquired a controlling interest in two surgical facilities which were previously accounted for as equity method investments for cash consideration of $24.5&#160;million, net of cash acquired. As a result of these transactions, the Company obtained control of the previously non-controlled surgical facilities, resulting in the consolidation of the previously non-consolidated entities. The previously held non-controlling were remeasured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data. The acquisition date fair value of the previously held non-controlling interests was $8.3&#160;million. As a result of stepping up its ownership interest, the Company recognized a loss of $2.9&#160;million included in net loss (gain) on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023. The net loss was determined based on the difference between the fair value of the Company's previously held non-controlling interests in the entities and the carrying values immediately prior to the transactions. In connection with the acquisitions, the Company preliminarily recognized non-controlling interests of $34.2&#160;million and goodwill of $65.6&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company acquired non-controlling interests in an existing surgical facility and an in-development de novo surgical facility for an aggregate cash purchase price of $12.4&#160;million, of which $2.8&#160;million was deferred and will be paid in April 2023. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. In April 2023, the Company obtained control of an existing non-controlled surgical facility due to an amendment to the facility operating agreement, resulting in the consolidation of the previously non-consolidated entity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company acquired a controlling interest in two surgical facilities, one of which was merged into an existing surgical facility, for aggregate cash consideration of $31.1&#160;million, net of cash acquired, and non-cash consideration of $2.6&#160;million. In connection with the acquisitions, the Company preliminarily recognized non-controlling interests of $10.6&#160;million and goodwill of $42.7&#160;million. During the three months ended March&#160;31, 2023, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Disposals</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company sold its interests in a surgical facility for a cash sales price of $8.8&#160;million, a portion of which was held in escrow pursuant to the purchase agreement. In connection with the sale, the Company recognized a pre-tax gain of $0.2&#160;million included in net loss (gain) on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company sold its interests in a surgical facility, which was previously accounted for as an equity method investment, for net cash proceeds of $11.5&#160;million, and recognized a pre-tax loss of $0.4&#160;million included in loss (gain) on disposals and consolidations, net in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">The Company contributed its interests in two surgical facilities as non-cash consideration for non-controlling interests in two new separate entities. As a result of these transactions, the Company lost control of the previously controlled surgical facilities but retains a non-controlling interest in each, resulting in the deconsolidation of the previously consolidated entities. The remaining non-controlling interests were accounted for as equity method investments, and initially measured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data, to measure the fair value of the retained non-controlling interests. The fair value determination was based on a combination of multiple valuation methods, which included discounted cash flow and market value approach, which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. The fair value of the investments of $9.8&#160;million was recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. Further, based on the valuation, the transactions resulted in a pretax net loss on deconsolidations of $5.6&#160;million, which is included in net loss (gain) on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2022. The gains were determined based on the difference between the fair value of the Company's retained interests in the entities and the carrying values of both the tangible and intangible assets of the entities immediately prior to the transactions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458837138320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,593.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,621.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,559.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $2.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and $2.1&#160;million as of March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">December&#160;31, 2022, respectively. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 13, 2023, the Company entered into an amendment to the credit agreement governing its revolving credit facility (the "Revolver"), which amended and supplemented the credit agreement, dated as of August 31, 2017 (the "Credit Agreement"), to provide a $203.8&#160;million increase in the outstanding commitments under the Revolver. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company's availability on its Revolver was $545.9 million (including outstanding letters of credit of $7.9 million). There were no outstanding borrowings under the Revolver as of both March&#160;31, 2023 and December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458832881632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">764.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense included in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">764.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense included in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458837159600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives and Hedging Activities</a></td>
<td class="text">Derivatives and Hedging Activities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2023 and 2022, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The key terms of interest rate swaps and interest rate caps outstanding are presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.352%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,366.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,518.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had nine interest rate swaps with a total net notional amount of $1.2&#160;billion. Of the nine interest rate swaps, three are pay-fixed, receive 1-Month LIBOR (subject to a minimum of 0.75%) interest rate swaps designated in cash flow hedging relationships with a total notional amount of $1.2&#160;billion and a termination date of March 31, 2025. The remaining six interest rate </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">swaps are undesignated and consist of three pay-fixed, receive 1-Month LIBOR (subject to a minimum of 1.00%) interest rate swaps and three pay 1-Month LIBOR (subject to a minimum of 1.00%), receive-fixed interest rate swaps with a termination date of November 30, 2023. The pay-floating, receive-fixed swaps are designed to economically offset the undesignated pay-fixed, receive-floating swaps. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had two interest rate caps designated in cash flow hedging relationships with a total notional amount of $166.1&#160;million. The interest rate caps each have a termination date of March 31, 2025. During the three months ended March 31, 2023, the Company partially terminated a previously undesignated portion of one of its interest rate caps. In connection with the termination, the Company received $8.6&#160;million, which is included as a component of operating activities in the condensed consolidated statements of cash flows for the three months ended March 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Within the Company&#8217;s condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives and the undesignated swaps are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Cash settlements related to the undesignated swaps will offset and are classified as operating activities in the condensed consolidated cash flows. Within the Company&#8217;s condensed consolidated balance sheets, the interest rate caps, including the undesignated portion, are recorded at fair value. The cash flows related to the interest rate caps, including the undesignated portion, are classified as operating activities in the condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps are determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt. Over the next 12 months, the Company estimates that an additional $33.6 million will be reclassified as a decrease to interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The balance  is related to the financing component of the pay-fixed, receive floating interest rate swaps.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:54.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss recognized in income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss reclassified from accumulated OCI into income (effective portion) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0xLTEtMS04MjAwNA_eaac48d6-4a38-4801-99ed-58a72d155519">Interest expense, net</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.4 million and $5.3 million for the three months ended March&#160;31, 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458833634768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to Surgery Partners, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Loss) income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for the three months ended March 31, 2023, was not considered because the effect would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458837138320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">Other Current Liabilities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458832881392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Professional, General and Workers' Compensation Liability Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were $22.1 million and $20.8 million, respectively. Expected insurance recoveries of $12.7 million as of both March&#160;31, 2023 and December&#160;31, 2022 are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 4, 2017, a purported Company stockholder filed an action in the Delaware Court of Chancery (the "Delaware Action"). That action is captioned Witmer v. H.I.G. Capital, L.L.C., et al., C.A. No. 2017-0862. The plaintiff in the Delaware Action asserted claims against (i) certain current and former members of the Company&#8217;s Board of Directors (together, the "Directors"); (ii) H.I.G. Capital, LLC and certain of its affiliates (collectively, "H.I.G."); and (iii) Bain Capital Private Equity, L.P. and certain of its affiliates (collectively, "Bain Capital" and, together with the Directors and H.I.G., the "Defendants"). The parties to the Delaware Action negotiated a final stipulation of settlement (the &#8220;Settlement Stipulation&#8221;), which governs the terms of the settlement of the Delaware Action, and which they filed with the Court of Chancery on November 22, 2021. On February 11, 2022, the Court of Chancery approved the settlement of the Delaware Action as memorialized in the Settlement Stipulation. That decision became final and non-appealable on March 14, 2022. The case is now closed. Pursuant to the settlement, the Company received $32.8&#160;million in March 2022, which was included in litigation settlement in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Acquired Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the federal physician self-referral law, or Stark Law, the statute commonly known as the federal Anti-Kickback statute, the federal False Claims Act, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Potential Physician Investor Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458833599488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in&#160;two&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment includes the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of the Company's corporate general and administrative functions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) on disposals, consolidations and deconsolidations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlements and regulatory change impact </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Undesignated derivative activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $12.5 million and $7.1 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $0.3 million for the three months ended March&#160;31, 2023, with no comparable costs for the three months ended March 31, 2022.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes an $8.5&#160;million loss for the three months ended March 31, 2023 related to a surgical facility with a book value of the asset group in excess of the fair value based on a letter of intent.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes a litigation settlement loss of $3.0 million and a gain of $32.8 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount also includes other litigation costs of $0.6 million and $2.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. Additionally, the three months ended March 31, 2023, includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,049.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,001.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,643.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,682.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458833587568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, the Company completed the sale of two surgical facilities for cash proceeds of $23.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, the Company acquired non-controlling interests in an in-development de novo surgical facility for a purchase price of $6.1&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828229952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#8217;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the "2022 Annual Report on Form 10-K").</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div>The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">GoodwillGoodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestPolicyTextBlock', window );">Non-Controlling Interests&#8212;Redeemable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests&#8212;Redeemable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest Entities<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span>". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458832916624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">656.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div>(1)Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Rollforward of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to goodwill for the three months ended March&#160;31, 2023 is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,137.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,217.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Schedule of Rollforward of Noncontrolling Interest - Redeemable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to non-controlling interests&#8212;redeemable is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest&#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,353.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458833709520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,593.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,621.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,559.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $2.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and $2.1&#160;million as of March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>December&#160;31, 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458837152640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Components of Right-of-use Assets and Liabilities Related to Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">764.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense and Cash Flow Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense included in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458830142912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding</a></td>
<td class="text">During 2023 and 2022, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The key terms of interest rate swaps and interest rate caps outstanding are presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.352%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,366.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,518.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The balance  is related to the financing component of the pay-fixed, receive floating interest rate swaps.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of Effect of Interest Rate Swaps</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:54.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss recognized in income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss reclassified from accumulated OCI into income (effective portion) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0xLTEtMS04MjAwNA_eaac48d6-4a38-4801-99ed-58a72d155519">Interest expense, net</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.4 million and $5.3 million for the three months ended March&#160;31, 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458833629168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share</a></td>
<td class="text">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): <div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to Surgery Partners, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Loss) income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for the three months ended March 31, 2023, was not considered because the effect would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458837011536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Summary of Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836437328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Revenue and Operating Income</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) on disposals, consolidations and deconsolidations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlements and regulatory change impact </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Undesignated derivative activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $12.5 million and $7.1 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $0.3 million for the three months ended March&#160;31, 2023, with no comparable costs for the three months ended March 31, 2022.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes an $8.5&#160;million loss for the three months ended March 31, 2023 related to a surgical facility with a book value of the asset group in excess of the fair value based on a letter of intent.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes a litigation settlement loss of $3.0 million and a gain of $32.8 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount also includes other litigation costs of $0.6 million and $2.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. Additionally, the three months ended March 31, 2023, includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Schedule of Reconciliation of Assets from Segment to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,049.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,001.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,643.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,682.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Financial Information by Reportable Segment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828367840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Organization (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>facility </div>
<div>state</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest', window );">Number of surgical facilities owned, majority interest</a></td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated', window );">Number of surgical facilities owned, consolidated</a></td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember', window );">Facilities, Ambulatory Surgery Centers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember', window );">Facilities, Surgical Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned, Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwnedConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned, Majority Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458825461488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details) - Revenue Source - Revenue<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Patent service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">98.50%<span></span>
</td>
<td class="nump">98.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">95.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Other service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458825686928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 666.2<span></span>
</td>
<td class="nump">$ 596.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember', window );">Patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 656.4<span></span>
</td>
<td class="nump">$ 587.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember', window );">Patient service revenues | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember', window );">Private insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 335.6<span></span>
</td>
<td class="nump">$ 300.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember', window );">Private insurance | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">51.10%<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 287.8<span></span>
</td>
<td class="nump">$ 249.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">43.80%<span></span>
</td>
<td class="nump">42.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember', window );">Self-pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember', window );">Self-pay | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember', window );">Other | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember', window );">Other service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836151136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (percent)</a></td>
<td class="nump">400.00%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax benefits related to vesting of restricted stock awards</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Tax benefits attributable to non-recurring earnings' impact on the valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Tax benefits related to the sale of partnership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458829394272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 4,137.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions, including post acquisition adjustments</a></td>
<td class="nump">91.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Disposals</a></td>
<td class="num">(11.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 4,217.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828152512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestRollForward', window );"><strong>Non-Controlling Interests - Redeemable [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">$ 342.0<span></span>
</td>
<td class="nump">$ 330.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to non-controlling interests&#8212;redeemable</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests', window );">Acquisition of shares of non-controlling interests, net&#8212;redeemable</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interest&#8212;redeemable holders</a></td>
<td class="num">(11.7)<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 345.8<span></span>
</td>
<td class="nump">$ 341.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828250368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Medicare Accelerated Payments and Deferred Governmental Grants (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_GrantRevenue', window );">Grant funds</a></td>
<td class="num">$ (1.1)<span></span>
</td>
<td class="num">$ (1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_UnrecognizedGrantFundsReceived', window );">Unrecognized grant funds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments', window );">Repayments of grants received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_UnrecognizedGrantFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Grant Funds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_UnrecognizedGrantFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828028368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior secure term loan | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,370.1<span></span>
</td>
<td class="nump">$ 1,370.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior secure term loan | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,353.0<span></span>
</td>
<td class="nump">1,359.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 185.0<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025 | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 181.5<span></span>
</td>
<td class="nump">183.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="nump">320.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 326.4<span></span>
</td>
<td class="nump">$ 326.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458828160896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Variable Interest Entities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>facility</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>physician_practice</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_VariableInterestEntityNumberOfFacilities', window );">Number of facilities included in VIE</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,643.3<span></span>
</td>
<td class="nump">$ 6,682.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.9<span></span>
</td>
<td class="nump">64.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.5<span></span>
</td>
<td class="nump">$ 40.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_VariableInterestEntityNumberOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Number of Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_VariableInterestEntityNumberOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458825340272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Acquisitions (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>facility</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="nump">$ 40.7<span></span>
</td>
<td class="nump">$ 31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,217.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,137.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesAndPhysicianPracticesMember', window );">Surgical Facility and Physician Practice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Noncash consideration</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Recognized non-controlling interests</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember', window );">Surgical Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Noncash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Recognized non-controlling interests</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 65.6<span></span>
</td>
<td class="nump">$ 42.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of facilities acquired | facility</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Non-controlling interest, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss', window );">Net (loss) gain on fair value of non-controlling interest</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_ExistingSurgicalFacilityMember', window );">Existing Surgical Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_DeferredPaymentsToAcquireEquityMethodInvestments', window );">Payments for acquisitions, deferred</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember', window );">Surgical Facilities, Existing Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of facilities acquired | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredPaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Payments To Acquire Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredPaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesAndPhysicianPracticesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesAndPhysicianPracticesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_ExistingSurgicalFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_ExistingSurgicalFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458829303536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Disposals and Deconsolidations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>business_entity </div>
<div>facility</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_OneSurgicalFacilityMember', window );">One Surgical Facility | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain (loss) on disposals and deconsolidations</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_A2022DisposalsMember', window );">2022 Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain (loss) on disposals and deconsolidations</a></td>
<td class="num">$ (5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_A2022DisposalsMember', window );">2022 Disposals | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain (loss) on disposals and deconsolidations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration', window );">Number of surgical facilities contributed as non-cash consideration | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Fair value of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_A2022DisposalsMember', window );">2022 Disposals | Disposed of by Sale | Series of Individually Immaterial Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of facilities acquired | business_entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_OneSurgicalFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_OneSurgicalFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_A2022DisposalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_A2022DisposalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458830533856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary of Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 553.5<span></span>
</td>
<td class="nump">$ 585.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs and discounts</a></td>
<td class="num">(9.7)<span></span>
</td>
<td class="num">(10.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total debt</a></td>
<td class="nump">2,593.8<span></span>
</td>
<td class="nump">2,621.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current maturities</a></td>
<td class="nump">62.9<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="nump">2,530.9<span></span>
</td>
<td class="nump">2,559.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior secure term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">1,370.1<span></span>
</td>
<td class="nump">1,370.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized fair value discount</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 185.0<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="nump">320.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember', window );">Notes payable and other secured loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 174.9<span></span>
</td>
<td class="nump">$ 171.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458829453680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details) - Secured Debt - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 13, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Availability on line of credit instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | The Revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity', window );">Line of credit facility, increase in borrowing capacity</a></td>
<td class="nump">$ 203,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount of line of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Availability on line of credit instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Increase In Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458829436608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 274.0<span></span>
</td>
<td class="nump">$ 279.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">490.6<span></span>
</td>
<td class="nump">529.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_LeaseRightOfUseAsset', window );">Total leased assets</a></td>
<td class="nump">764.6<span></span>
</td>
<td class="nump">808.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">38.0<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term</a></td>
<td class="nump">268.8<span></span>
</td>
<td class="nump">271.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">306.8<span></span>
</td>
<td class="nump">307.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term</a></td>
<td class="nump">532.1<span></span>
</td>
<td class="nump">564.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">553.5<span></span>
</td>
<td class="nump">585.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 860.3<span></span>
</td>
<td class="nump">$ 893.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property and equipment, net of accumulated depreciation of $382.7 and $374.3, respectively<span></span>
</td>
<td class="text">Property and equipment, net of accumulated depreciation of $382.7 and $374.3, respectively<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Less: Current maturities<span></span>
</td>
<td class="text">Less: Current maturities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Long-term debt, less current maturities<span></span>
</td>
<td class="text">Long-term debt, less current maturities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836082416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Expense and Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_FinanceLeaseCost1Abstract', window );"><strong>Finance lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_FinanceLeaseCost', window );">Total finance lease costs</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_VariableAndShortTermLeaseCost', window );">Variable and short-term lease costs</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_CashFlowLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash outflows from finance leases</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash outflows from finance leases</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for finance lease obligations</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 89.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost1 [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_VariableAndShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable And Short-Term Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_VariableAndShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458830258912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">$ 85.2<span></span>
</td>
<td class="nump">$ 113.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">(34.5)<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount</a></td>
<td class="nump">1,366.1<span></span>
</td>
<td class="nump">1,518.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapOneMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="nump">435.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapTwoMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">330.0<span></span>
</td>
<td class="nump">330.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapThreeMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="nump">435.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapOneMember', window );">Interest rate cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">157.2<span></span>
</td>
<td class="nump">159.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapTwoMember', window );">Interest rate cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">159.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFourMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">165.0<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFiveMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapSixMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapOneMember', window );">Receive-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">(165.0)<span></span>
</td>
<td class="num">(165.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapTwoMember', window );">Receive-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">(120.0)<span></span>
</td>
<td class="num">(120.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapThreeMember', window );">Receive-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">$ (150.0)<span></span>
</td>
<td class="num">$ (150.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458827891616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | $</a></td>
<td class="nump">$ 1,366.1<span></span>
</td>
<td class="nump">$ 1,518.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Amount estimated to be reclassified as a reduction to interest expense over next 12 months | $</a></td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | $</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member', window );">Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 0.75% | Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | $</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member', window );">Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 0.75% | Derivatives in cash flow hedging relationships | LIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Variable interest rate of derivative instrument (percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_SixUndersignedInterestRateSwapsMember', window );">Six Undersigned Interest Rate Swaps | Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member', window );">Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 1.00% | Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member', window );">Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 1.00% | Derivatives in cash flow hedging relationships | LIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Variable interest rate of derivative instrument (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member', window );">Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00% | Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member', window );">Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00% | Derivatives in cash flow hedging relationships | LIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Variable interest rate of derivative instrument (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Caps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | $</a></td>
<td class="nump">$ 166.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Caps | Derivatives not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities', window );">Gain on termination | $</a></td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Terminated Derivative Instrument, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_SixUndersignedInterestRateSwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_SixUndersignedInterestRateSwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458827925520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">$ 85.2<span></span>
</td>
<td class="nump">$ 113.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Other long-term assets | Interest Rate Caps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Other long-term assets | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Other long-term liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships | Other long-term assets | Interest Rate Caps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships | Other long-term assets | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">70.6<span></span>
</td>
<td class="nump">85.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships | Other long-term liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">$ 28.3<span></span>
</td>
<td class="nump">$ 31.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458830263184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax', window );">Amortization of accumulated OCI related</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest expense, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss recognized in income</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">(Loss) gain recognized in OCI (effective portion)</a></td>
<td class="num">(5.2)<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Loss (gain) reclassified from accumulated OCI into income (effective portion)</a></td>
<td class="num">$ (6.1)<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes reclassification from accumulated other comprehensive income (AOCI) for gain (loss) recognized in other comprehensive income (OCI) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624177-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836404336">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Summary (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Surgery Partners, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (24.9)<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding- basic (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">125,206<span></span>
</td>
<td class="nump">87,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding- diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">125,206<span></span>
</td>
<td class="nump">90,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>(Loss) income per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>(Loss) income per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>(Loss) income per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The impact of potentially dilutive securities for the three months ended March 31, 2023 was not considered because the effect would be anti-dilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458827933072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Liabilities - Summary (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use operating lease liabilities</a></td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="nump">$ 36.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PayablesToCustomers', window );">Amounts due to patients and payors</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_CostReportLiabilitiesCurrent', window );">Cost report liabilities</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_AcquisitionEscrowLiabilityCurrent', window );">Acquisition escrow</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">66.7<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="nump">$ 210.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_AcquisitionEscrowLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Escrow Liability Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_AcquisitionEscrowLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CostReportLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Report Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CostReportLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PayablesToCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to customer by broker-dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Rule 15c3-1<br> -Number 240<br> -Section 15c3-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PayablesToCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458833989104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Professional, general and workers' compensation insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Expected insurance recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="num">$ (3.0)<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458825506032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 666.2<span></span>
</td>
<td class="nump">$ 596.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">(Loss) income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.1)<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.8<span></span>
</td>
<td class="nump">56.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts', window );">Transaction, integration and acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Net loss (gain) on disposals, consolidations and deconsolidations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact', window );">Litigation settlements and regulatory change impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="num">(30.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_UndesignatedDerivativeActivity', window );">Undesignated derivative activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Transaction and integration costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Start-up costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">(Loss) gain on litigation settlement</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Other litigation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation', window );">Additional interest expense for Florida LOP regulation change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember', window );">Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Net loss (gain) on disposals, consolidations and deconsolidations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649.0<span></span>
</td>
<td class="nump">578.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.3)<span></span>
</td>
<td class="num">(24.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="num">$ (24.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Integration Related Costs, And Merger Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Before Interest Taxes Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Impact Of Change In Letter Of Protection Regulation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_UndesignatedDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undesignated Derivative Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_UndesignatedDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458830268128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 6,643.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,682.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,049.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,001.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">41.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">552.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 639.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140458836418000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>facility</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Disposed of by Sale | Two Surgical Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed', window );">Number of interests sold | facility</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">$ 23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | In-Development De Novo Surgical Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_TwoSurgicalFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_TwoSurgicalFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=sgry_InDevelopmentDeNovoSurgicalFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=sgry_InDevelopmentDeNovoSurgicalFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>sgry-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgry="http://www.surgerypartners.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgry-20230331.xsd" xlink:type="simple"/>
    <context id="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d41fd45700a4164beb54fee998d920a_I20230425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2023-04-25</instant>
        </period>
    </context>
    <context id="ieddfc3852ec1452ba8c4688dd114cee6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic87dcd9813304e79b4016a38d95a6b26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa47a92aabfb4f198bd892ae1c73b47e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e5a939bdb244adf9d443c23ec72a6eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65ee09ce3e1544a3a10503ec164f9559_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i419bf181460249fe83b08bb14c6fc0dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1bfc86bd81947fd8321bee696e14ba8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic77b33bfc579485d9d202b8fa5835ebb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id73c97f747ea40c89ca7360664151a1d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9656398a8cdc4c2684fa3528cd1fd737_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i394eeacceb884d9dac0bffe547fcfd9b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74c7ebcc457244ff879740e6b5842dc7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iace256156ecb46e7a7879df0ee315f58_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i559d3e62ec804801a7d58ea449905c65_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8748cab7c3f340cebd27f76f35614534_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i53d01a25902b4073a79e1ac8105bab03_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97e64b243cb74e08990bb73929ab0a6c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1f16ef7c61754a9f9f05d6a9e5783680_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0eb096987544bb6a2a82e082c5b28e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4215fc76964f4337aa436bd3e933e2e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1faa6a90751245b287153e4d2de4bf31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba00892a7dbf473f9ebd08d01e3af4c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4ad6ada487b44178e469d7d80790c65_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i05afb4f94a984b2c822ccdd467908600_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f5ba699a656478ba51b4056199d52d2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic8759e8dfad94c5fa466de092b896d4f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib68f4679b2c94c25b3f7f0f693b6ec14_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4b423adca5e4dd9968d29cc90df2d4e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3357462c707d4acfb10096d245e66a3a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3cb9d22b38ff4ca790e312d6a32e41d2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d30c499f0834cf2882c4d2c725d4e29_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7b158a1a0b39401183f6b663f67d5119_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesAmbulatorySurgeryCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e67a4ba4b7b45ec9fb013fdd2a9a8c7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesSurgicalHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93fbb84ab8e54bf68ae45319f7ceed8e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i330b18e5ad5743db8b6302ffdf866646_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i194a9154acd5484889805e9286e14672_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5333aa040ad4421ea9ff5171113791b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i347c2e534f60472f9aa78f23e2b7662d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i24a958c4d33242709d5e6b4c8a16d451_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i174f2ef7f43b4017be096fd6960d0dd8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13bc8547fc6249f391018e3c36ac7ae5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0cec9a12adb2490880d03b5e2db3fb51_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib1e91e1eeba04f3cb636ac9f9e9c742e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifdc7653a276442c2895ba6dc6f426066_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaf0554ebc49d4fcb999fb93084ca8790_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i99b023be21c94ca6b3fda57d05624b2b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic894bd77f5d24d9f8d642bd4486553b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a3a0d5b4af849048366464b85a609df_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a1d727596c449d1aa589faede2c444c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieb44bf1e649f4f9797567c55c11d2a57_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4fdfeafd2b2b44c581d7ae62c305a05b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i35c8b6e80870471584d0662cd5e62ce1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia3533ff5f75840c8b83b791c1edd4b8b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i56c5f1fcb27242be90a9519d3a5daa49_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb60ee5f491a4d759f3f80d61bc39428_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45c5bb7aafa14f84b6d67420515600b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibaad3032980a44f9b79dd84b65b8a8f3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie11e527c61994fc4b8612c9529f84738_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4059e6a11b044239991a9cd274ca93af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ccbab58e225409b8f397b22aaa0921a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i690afa60488b471bad71d09dde1be1f5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3cb842e8e10b4aa2b02cfaeca3e9e29e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i567b65cfc1644f8ca0a4e2059d874857_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39473dc95e60480a8548a0f5e95a4826_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i86c371e19dfa4eec95e299e3a708563a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if395609fbdf14ab7bd54498a1f593d2b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06a12e5fa6f448c88de9a7f5391b609d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68d8f30c03d949d484d4aa733ea4240d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia6b4ddef7045437ba1eaade0bc4fe400_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae41732101204d4c86f049ad4216697b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b22c450786b4f0091dc4d4eae7d1675_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9bc921c9b0344e5bb467bc42eaf8791_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e3330b0a2e34c18a19a93f183c72e49_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i323cf8e399eb45778ab71e463913d7f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6455bc1ca084f939e75bb4558e43b7d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idacc70d8240e4b39bd9280d74b6d9b33_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i08eb459530bf461880a8962c3bbf26b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i195064f2c74144fa80d098a0e694c828_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c30227944194e40b8bf2475f00b0c1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fa03c70c0ed47c68e5d1597b922d233_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic20dd80291ba42deb6354c4af9a710ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife322ebfae344c06aadeb5444f977b01_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesAndPhysicianPracticesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia038e278a48340bda3280d3d858e408e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesAndPhysicianPracticesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9b9dc705bdaf4307a20eb8262bdc4a27_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0289c146748495ea969e604a4ecc4a0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i602c53397d114d5783de58eea6a301e1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:ExistingSurgicalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i79df32098d2a43b6b68b90171d47d5e8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:ExistingSurgicalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe2f8852d0e443be810017d409db5c10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3637827bd8fa46638845369ff6cefb32_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec7a6a99212642aab1d11f46ef8b71e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:OneSurgicalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia62b48e259754cf8b5b649d1146431d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d5a67a56b014b7b8024c968af016c48_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5360c902c0454970be9a1279e60a08c7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:A2022DisposalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie31e09c8a7f742a7be738ff2b92bbe76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie8a68d29d5ed4fd982d2f908018f3c10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife734a9e9b7c478480dcde8c8c378846_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8254371571844ad8161e4d28a3392c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9d1e8e2eb6f4636a25ae23bd08dab22_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i23e712005c5d48dc978669d2c705456c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4be4e474695442ff8609d04af8b53bf2_D20230113-20230113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-13</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <context id="i615ae79f54e248ed8c11df419a474567_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d03e45ac72242afb2e27ac00a7fede9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4ba191127c0e418d98b7c137b8b3b012_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffd37df4ed4f4e928da39c9e8a3b97d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b122a7729f846aa83ebcbf74914d1ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8fdfc90ff3a14df4942da87910339b7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iefe42526145740de8a9b4f2c4ab6be7b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idc4d54f90673412ab5865efd54bf31bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a3ddfc6326b430ba42803e01d9ea155_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia7aaa64d2b9647c0880375718f91f9aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0ee0c2d30114fa7a498e11d518d5e86_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6cc717c4e3294018b3a17b8db7550574_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d3958dd7b5c43feb0b399d644cfcd76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaef97110d9b04fc3800be00674d398a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6363d1608b80467fabaff6452dee18c1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id0f20c8303b34ed89344ee532d50feb5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03ac93228961451d928a5d157461cb0c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3ad3beb2f31c412db347647224886c3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d43b1d96bd4419da9eece9e1cdddd7c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2552dc67907f4497afcc3243f335c0da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie53660b17d444b948667db475ff5f35b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if32f04ce941249ddbd22432651106a15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic698993ebca540e6a16d6647445084ef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i372b7962442b41a2ad5aae90be62bfd9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id13b3e0bc44448129d260b0bf3a9c405_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i83325c5100f64cd79cec11f2d4874566_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46fd0fed21334b48980d887244b2c6db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8302a05487cc46e38e8ff3204b1ef2ad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e445dd464d44ade88f9c43c91d57652_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i033d3f1806b744ce9eadad25192e34c5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:SixUndersignedInterestRateSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3af8b13e57f44b27bb771a94d96d89aa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic1065326829d4decbc61f91f23875e3b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb4cece3ff2e407f9fb299708f2e854b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6bca9cce39a74eb380fb5d884f2da248_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0a74f9aadc8a47c890d7ae741d0d1e9e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i517ad963d7114f93893b2d189dc801a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8812d79ba0e7406a8a6f1c6d561cc07a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29099c90b3434f62bb442dd9874e5c47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if5cac67689284faabfc9916d5cb46d63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic979a115883d4f5592bb7c07055ffbf5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icd3a9b4bf3a2433f898c5e81d44b1b91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9adfa3e753a42ca88143d956ce95e86_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89a6a63c9b104ac2a07649af064d610e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbafff4d10d840b2955f9a765fcf5409_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6c827cd5ece5427082bea6ecb15df8c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i886a6e64b9a743b0aca7c22e739b1e1d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ica8d344040734175a530bc09317337aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd4a8d2749ec405c9d0f00d16b8d1584_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i363d451cc1cb4d0c96744998ea60df5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i759de978c1164030aaf39f8ac3180d79_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6eab5cbc43744770be5708852cdd239c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ife80b1a65af94f9b863703998b3c1df8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifab134fcb68746328d5adb54f4ab2b41_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e51254b066146b68172b2d7e45eabf9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i570ad1cc62c24af1a4a594dacdc9450a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i879bc0eafd88419c89015946c25ea837_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib9989159902245b3958bc162627b001a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2157333f54a64133b4ed6c8fe0d8ed07_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6579947ad8ee4c769d03065a92a8c1d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f25d93459534f5c84a4cb1633eb1ef7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iac3c71c2dd4b44f78bf883755b6def96_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic762e7cc857a43c1a2f037d3352477ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33fb3f237a04410498509c0ce5185504_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i16570392805a4746b263e0633c73a07a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b3621d88dc14df6923e768f491fc566_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iccc84e42df6a4279be1365d3ba61b0e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78f9f79b8aa34e08805a3d3c55374c19_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:TwoSurgicalFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="i0801f484705247ca9f81ed5e46fa3718_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">sgry:InDevelopmentDeNovoSurgicalFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="facility">
        <measure>sgry:facility</measure>
    </unit>
    <unit id="state">
        <measure>sgry:state</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="physician_practice">
        <measure>sgry:physician_practice</measure>
    </unit>
    <unit id="business_entity">
        <measure>sgry:business_entity</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>sgry:interest_rate_swap</measure>
    </unit>
    <unit id="segment">
        <measure>sgry:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV80LTEtMS0xLTgyMDA0_d402282c-9490-48f3-8578-45644d412be1">0001638833</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV81LTEtMS0xLTgyMDA0_d89f2bea-8c17-4822-a155-a6bfca2746b7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV85LTEtMS0xLTgyMDA0_1e0a7011-c59b-428c-b200-de71c24d27cc">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV8xMC0xLTEtMS04MjAwNA_172cb7cb-2aae-4691-9ab0-09063478a680">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80L2ZyYWc6MGY4ZWQ1MmUzMmZiNDcxOGFiNDc2N2YwYmQ4MjJkYjcvdGFibGU6MTRkYWYzNjE1ZmEwNGIzNjkxM2M4YzE2Mzk3YWMxMWEvdGFibGVyYW5nZToxNGRhZjM2MTVmYTA0YjM2OTEzYzhjMTYzOTdhYzExYV8xMS0xLTEtMS04MjAwNA_735ff264-dfd3-4cdc-889b-e80e46bae865">false</dei:AmendmentFlag>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0xLTEtMS04MjAwNA_eaac48d6-4a38-4801-99ed-58a72d155519">http://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNet</us-gaap:OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzM4_8c7f44ae-4bd9-429d-8ad8-ce4f130e9864">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzUz_022cb0f8-de3c-4df6-8343-6ecd622cd26e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yOTg_893bc05a-7fd9-40b7-8e7e-4fe949019158">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzU0_d5cb52fb-9982-43ec-9f0f-e831394e67aa">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQx_db350650-8fae-4609-94b4-c9d501703a1d">001-37576</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ3_afbf416c-c57c-4cb5-8ed7-e247b7e5f45d">Surgery Partners, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6MDVlMjE5NWVhZGI3NGIzZTk0NjJmZThhOGQ1YTEwNDcvdGFibGVyYW5nZTowNWUyMTk1ZWFkYjc0YjNlOTQ2MmZlOGE4ZDVhMTA0N18wLTAtMS0xLTgyMDA0_75e510b8-3eca-4fb1-a058-9cace73f903c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6MDVlMjE5NWVhZGI3NGIzZTk0NjJmZThhOGQ1YTEwNDcvdGFibGVyYW5nZTowNWUyMTk1ZWFkYjc0YjNlOTQ2MmZlOGE4ZDVhMTA0N18wLTItMS0xLTgyMDA0_6d458f7f-96de-41c4-b03d-466380b24e02">47-3620923</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ4_05221ff5-abb1-44ac-8e3f-2f703c5221b2">340 Seven Springs Way, Suite&#160;600</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ2_12f70043-fd10-4728-8608-8ab9ef5a4a70">Brentwood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQ5_5c046435-3d86-4657-9b4b-0e6f5f61e7f5">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQw_8ee1a829-679f-4e84-87ca-4fc88a438b3f">37027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzUw_debaad5b-9ff9-4614-839a-8d0178d79f4e">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQz_a1f1d446-2935-4ce6-b88b-7110090dab90">234-5900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6Y2I4MGFlZTA1M2QzNDQ1ZWIwNjdhN2E4NDI4MmQ2OWEvdGFibGVyYW5nZTpjYjgwYWVlMDUzZDM0NDVlYjA2N2E3YTg0MjgyZDY5YV8xLTAtMS0xLTgyMDA0_0a29adef-fba1-4c93-8b22-5febbe6e7f3e">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6Y2I4MGFlZTA1M2QzNDQ1ZWIwNjdhN2E4NDI4MmQ2OWEvdGFibGVyYW5nZTpjYjgwYWVlMDUzZDM0NDVlYjA2N2E3YTg0MjgyZDY5YV8xLTItMS0xLTgyMDA0_d2f73b05-7822-4247-92c6-e7b5ea73baa2">SGRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6Y2I4MGFlZTA1M2QzNDQ1ZWIwNjdhN2E4NDI4MmQ2OWEvdGFibGVyYW5nZTpjYjgwYWVlMDUzZDM0NDVlYjA2N2E3YTg0MjgyZDY5YV8xLTQtMS0xLTgyMDA0_d1e72c3d-4086-4981-b45b-e2ac4e01fda0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzQy_a3a9f0f5-0352-4867-af89-4217ad8dfdfd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMzUx_00cdf9d6-6ea7-4fe7-be44-9e252003a1e6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6ZGVlYmZjZDEyOGFlNGFmMzljYmFhYzYwNGFkZjZjNWEvdGFibGVyYW5nZTpkZWViZmNkMTI4YWU0YWYzOWNiYWFjNjA0YWRmNmM1YV8wLTAtMS0xLTgyMDA0L3RleHRyZWdpb246NzU2ZjVhYjEzMzA0NDRlMmI0YTNkYzliOWUxODg3NDdfNA_016c1e97-5f61-45e4-9f00-effcb5ad1fbb">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6ZGVlYmZjZDEyOGFlNGFmMzljYmFhYzYwNGFkZjZjNWEvdGFibGVyYW5nZTpkZWViZmNkMTI4YWU0YWYzOWNiYWFjNjA0YWRmNmM1YV8xLTItMS0xLTgyMDA0L3RleHRyZWdpb246NTRiMGVmYmIyYWFjNGFkZmE2Njk2MDUzZjhmZDgwY2FfMzA_7b233eb3-cb4c-4557-bce2-67e38729d50e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGFibGU6ZGVlYmZjZDEyOGFlNGFmMzljYmFhYzYwNGFkZjZjNWEvdGFibGVyYW5nZTpkZWViZmNkMTI4YWU0YWYzOWNiYWFjNjA0YWRmNmM1YV8yLTItMS0xLTgyMDA0L3RleHRyZWdpb246ZDYxNjE4ZjVlNzE5NDBlZTk2ZjExMGI3Zjg5ODFiMGZfMjg_ea8ed59f-3e82-4d33-a7a0-e7e905a264b9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF80OTQ3ODAyMzI3MzU3_dcd222b5-7459-4563-bac1-ccf0a7bd2dba">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4d41fd45700a4164beb54fee998d920a_I20230425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xL2ZyYWc6ZWNkZjA1MDQxMDc2NGNhZjllNDI1N2E5YmU1MzcwMGQvdGV4dHJlZ2lvbjplY2RmMDUwNDEwNzY0Y2FmOWU0MjU3YTliZTUzNzAwZF8yMjgx_60e75b9a-c1a3-4f1b-a1d7-12e5f26baa8f"
      unitRef="shares">126476669</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNC0yLTEtMS04MjAwNA_4f0a4c84-2de7-45d1-8bc9-9cc958ffd423"
      unitRef="usd">245500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNC00LTEtMS04MjAwNA_bd8a1fa8-a05c-4f96-b8e3-a05efe4d8bd9"
      unitRef="usd">282900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNS0yLTEtMS04MjAwNA_ad6e04fa-a57e-448e-b36d-74bb09d7d804"
      unitRef="usd">452900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNS00LTEtMS04MjAwNA_2057dfa4-0cf6-4960-945d-f4a4534e7852"
      unitRef="usd">456300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNi0yLTEtMS04MjAwNA_48e4945b-901a-4eb5-96be-e4ecffb61935"
      unitRef="usd">71800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNi00LTEtMS04MjAwNA_45c729e2-d2b4-41b4-869d-2037d0595236"
      unitRef="usd">71400000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNy0yLTEtMS04MjAwNA_34e7c9ad-47cd-4231-8e0a-8d352bcd8a6d"
      unitRef="usd">29300000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNy00LTEtMS04MjAwNA_c969968e-94d5-4206-9b98-4d7010bdc721"
      unitRef="usd">31400000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOC0yLTEtMS04MjAwNA_b07f19cb-0a17-46d3-a104-c82d7d354638"
      unitRef="usd">69400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOC00LTEtMS04MjAwNA_c4d33ed3-10f8-46ba-8163-4be67c15f889"
      unitRef="usd">79000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOS0yLTEtMS04MjAwNA_9b8cfc24-779c-42c2-8d55-4942cb9e8d96"
      unitRef="usd">868900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfOS00LTEtMS04MjAwNA_bdc824c7-1630-45cb-983a-04d371eab84a"
      unitRef="usd">921000000.0</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo0YjdmODFhOGRiNTE0ZDI4YWE0MWM5MGRkMThjZjc2N182Mw_019c9bca-df7a-4f84-8f22-a44fb9a99681"
      unitRef="usd">382700000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo0YjdmODFhOGRiNTE0ZDI4YWE0MWM5MGRkMThjZjc2N183MA_a8e20036-e75f-4e18-b7af-59c0da7ac9a6"
      unitRef="usd">374300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtMi0xLTEtODIwMDQ_e1c90e44-2d16-4729-a1f0-0fbea6eb2c0f"
      unitRef="usd">844300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTAtNC0xLTEtODIwMDQ_8920889a-457b-4480-9ac7-776cac8d38a0"
      unitRef="usd">876600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTEtMi0xLTEtODIwMDQ_f2a784b9-a088-48f6-af7b-93a1e5f87113"
      unitRef="usd">4252600000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTEtNC0xLTEtODIwMDQ_95b0089b-bd87-4dd2-8e7d-05dba93f89f1"
      unitRef="usd">4179400000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTItMi0xLTEtODIwMDQ_2ac0e09b-59c4-43d5-a204-27d2fb12c857"
      unitRef="usd">191600000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTItNC0xLTEtODIwMDQ_f5904ebd-69e6-4b75-a6f2-fb2f88ad3f9a"
      unitRef="usd">190300000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTMtMi0xLTEtODIwMDQ_c76178b4-871f-41a8-8a36-5e45798e3acf"
      unitRef="usd">274000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTMtNC0xLTEtODIwMDQ_40bf8205-bf48-4774-908b-6d7bb23bcdad"
      unitRef="usd">279100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTQtMi0xLTEtODIwMDQ_a4ee74d6-be90-4f45-b533-139ba401f1ce"
      unitRef="usd">93300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTQtNC0xLTEtODIwMDQ_795dc63d-3092-4ed0-8955-fd29acc5b3b0"
      unitRef="usd">91500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTUtMi0xLTEtODIwMDQ_657b055f-be24-46f6-a677-9843a7364f89"
      unitRef="usd">118600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTUtNC0xLTEtODIwMDQ_60d66d41-00f3-46bc-9a58-6f63418d8eb7"
      unitRef="usd">144200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTYtMi0xLTEtODIwMDQ_ade213a8-5e53-4c31-b197-cf7f883a30c3"
      unitRef="usd">6643300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMTYtNC0xLTEtODIwMDQ_13a48bb2-990f-4415-9a62-bda951c9ae70"
      unitRef="usd">6682100000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjAtMi0xLTEtODIwMDQ_249f62b5-3ebb-43bb-bb82-64b0a00c2074"
      unitRef="usd">144400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjAtNC0xLTEtODIwMDQ_a241d29c-8a1a-448a-887d-59ed9fd732c3"
      unitRef="usd">151600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjEtMi0xLTEtODIwMDQ_c0c817b5-8430-4851-8047-edcf6369ab38"
      unitRef="usd">67800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjEtNC0xLTEtODIwMDQ_9aa0f7b9-062a-4b2a-b3f0-c3e1e58e5596"
      unitRef="usd">68900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjMtMi0xLTEtODIwMDQ_7c0920bb-45cd-4428-b5a2-bbaf709abac0"
      unitRef="usd">200000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjMtNC0xLTEtODIwMDQ_9fe5aab8-3163-4c37-8583-5399d90b63b4"
      unitRef="usd">210100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjQtMi0xLTEtODIwMDQ_9dc435ee-ea8f-4650-9df7-636dee304ec4"
      unitRef="usd">62900000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjQtNC0xLTEtODIwMDQ_3e84c354-e90f-41aa-909e-d9827afdf8bb"
      unitRef="usd">62800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjUtMi0xLTEtODIwMDQ_451d0172-e687-4e4b-8a53-b2c9b0d3a36a"
      unitRef="usd">475100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjUtNC0xLTEtODIwMDQ_9f7e128b-354b-4bac-8123-23df62726978"
      unitRef="usd">493400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjYtMi0xLTEtODIwMDQ_97de9482-1021-410f-b0a9-24d3f739101f"
      unitRef="usd">2530900000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjYtNC0xLTEtODIwMDQ_00a87cdc-c20f-4aac-986e-bdbf96219964"
      unitRef="usd">2559000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjctMi0xLTEtODIwMDQ_4ddcb943-ebf2-42a6-b1b5-73ad99598a55"
      unitRef="usd">268800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjctNC0xLTEtODIwMDQ_4b9270b2-2329-48f4-918f-cb805542eeb9"
      unitRef="usd">271400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjgtMi0xLTEtODIwMDQ_849b3675-490b-422e-bbef-76e5fe8fe0da"
      unitRef="usd">80200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMjgtNC0xLTEtODIwMDQ_b4d5318d-bd8d-4f77-a03e-9581f4d2cf8a"
      unitRef="usd">75400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzAtMi0xLTEtODIwMDQ_1d9a3b04-483e-42d2-88ed-8764f8a1d973"
      unitRef="usd">345800000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzAtNC0xLTEtODIwMDQ_0b288e89-d2d4-457f-8947-ec229b3172bc"
      unitRef="usd">342000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV8yMQ_a1dcd0ca-9e93-4698-9dfc-d9f742110e00"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV8yMQ_dc0f6bb5-ab8c-4b58-880e-4731d45e0504"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV81NQ_9bfded86-1031-45b5-b566-9c1bf833f30c"
      unitRef="shares">20310000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV81NQ_eee24c0d-e4fa-4bb3-83cd-6236dc5aea6d"
      unitRef="shares">20310000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_bcf2bfb8-a977-466c-8b2e-715004685f36"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_cbc59b6c-ec76-4a55-b641-348cc4819251"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_d85c780a-bf20-4496-9ca1-015ce824e506"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjoyMjdjMGIxZDgyN2M0MzY1YTYxMzkxZGU4YTI3Y2RiMV85MA_f4f17f26-2276-4e6d-aec3-a378d9c65038"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtMi0xLTEtODIwMDQ_a56293fc-9400-45b4-9b1b-ef276aecde41"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzMtNC0xLTEtODIwMDQ_6413a105-51a0-447b-9064-33a8e68f416e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF8xOA_9e3881e4-f15b-4b41-b1f4-14b791ce0737"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF8xOA_dd988d44-1bee-4397-b18b-3965a2d0a883"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF81Mg_2aaa6386-0a1d-4c24-a8e5-3bd16693c442"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF81Mg_6c7ffdb8-f40d-471e-8235-6457c14b3b8f"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF84OA_776d7313-7fe3-4d59-9bcf-7313eb3ec5e8"
      unitRef="shares">126480483</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF84OA_d1fb450b-b1be-4c2e-886a-d610cf7103ea"
      unitRef="shares">126480483</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF85NQ_12daadbd-88af-4967-a8c2-a1998ab5e72b"
      unitRef="shares">125960834</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMC0xLTEtODIwMDQvdGV4dHJlZ2lvbjo3YzM5ZjQyNjk4M2E0N2I0YjhmNzkyZmIyYzMzNTU3ZF85NQ_b24a6a7d-ded2-4693-a614-0c6b637ef659"
      unitRef="shares">125960834</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtMi0xLTEtODIwMDQ_7b17fc34-5179-4be5-a7ac-3d4276c853eb"
      unitRef="usd">1300000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzQtNC0xLTEtODIwMDQ_0efbeb1d-4ccf-42a6-b882-287ed1be751e"
      unitRef="usd">1300000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzUtMi0xLTEtODIwMDQ_76f3f860-9ef1-4808-8501-0e8b87d27228"
      unitRef="usd">2478100000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzUtNC0xLTEtODIwMDQ_bde3eb1b-03fb-4885-81ae-aa5c6005a73f"
      unitRef="usd">2478000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzYtMi0xLTEtODIwMDQ_e2b85ccb-c6ae-4b05-98d6-b241115eb79f"
      unitRef="usd">64900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzYtNC0xLTEtODIwMDQ_9228dd3b-1249-4a2b-8401-f835993152e1"
      unitRef="usd">76200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzctMi0xLTEtODIwMDQ_cdbd449c-e64d-4dd8-96c7-859b02ba2e48"
      unitRef="usd">-582300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzctNC0xLTEtODIwMDQ_2ff73547-b9ac-4da6-8cca-3e1a11e03df4"
      unitRef="usd">-557300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzgtMi0xLTEtODIwMDQ_b17f9597-51d8-4af0-9486-fa88266906a5"
      unitRef="usd">1962000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzgtNC0xLTEtODIwMDQ_6bee3928-8b37-487f-82e7-499f1a16a9a2"
      unitRef="usd">1998200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzktMi0xLTEtODIwMDQ_32c1ab14-60fe-4d5c-a9ec-eb3b568b1551"
      unitRef="usd">980500000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfMzktNC0xLTEtODIwMDQ_399117bb-3131-4144-b784-35cdba6f66ef"
      unitRef="usd">942700000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDAtMi0xLTEtODIwMDQ_1d999397-9e1b-49b0-a503-c68f039a8358"
      unitRef="usd">2942500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDAtNC0xLTEtODIwMDQ_1e965199-f927-466f-beb5-ce48d1c2ddca"
      unitRef="usd">2940900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDEtMi0xLTEtODIwMDQ_0434635b-13e6-4ffd-a19b-563aefa44dcd"
      unitRef="usd">6643300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xMy9mcmFnOjMxYjY5NWVkMjYyMTRlNjM4NTZjYjExZjFlZDRhYTg2L3RhYmxlOjU5Mzg3OGJmMWQwYjRlZmQ4Mjc3ZTcyOTNlNDQxMzE1L3RhYmxlcmFuZ2U6NTkzODc4YmYxZDBiNGVmZDgyNzdlNzI5M2U0NDEzMTVfNDEtNC0xLTEtODIwMDQ_31337741-e7c6-407e-b51a-1cc4802e3ab7"
      unitRef="usd">6682100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMy0yLTEtMS04MjAwNA_4738197f-dad8-4490-8726-1131211b7677"
      unitRef="usd">666200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMy00LTEtMS04MjAwNA_ee79cdaf-1674-4fa9-8b96-95a0d6b6447b"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNS0yLTEtMS04MjAwNA_8f563ca3-0265-4102-aa42-987915ccf8e3"
      unitRef="usd">202200000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNS00LTEtMS04MjAwNA_ed2361fb-d102-4108-bc05-24ae3634eaba"
      unitRef="usd">178900000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:SuppliesExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNi0yLTEtMS04MjAwNA_b54a059e-54c6-4fcb-9621-75be8f408705"
      unitRef="usd">188400000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNi00LTEtMS04MjAwNA_57d990f7-bf00-4eee-9300-9a68ab2e4089"
      unitRef="usd">171600000</us-gaap:SuppliesExpense>
    <us-gaap:ProfessionalFees
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNy0yLTEtMS04MjAwNA_fc0719c1-e754-4c27-8896-c6da16d4b259"
      unitRef="usd">74600000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfNy00LTEtMS04MjAwNA_fcef044a-6134-4cf2-8e0f-c93d170c9f45"
      unitRef="usd">63600000</us-gaap:ProfessionalFees>
    <sgry:OperatingAndFinanceLeaseExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOC0yLTEtMS04MjAwNA_4547c386-cfb2-4af8-bc84-bae689728c40"
      unitRef="usd">21400000</sgry:OperatingAndFinanceLeaseExpense>
    <sgry:OperatingAndFinanceLeaseExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOC00LTEtMS04MjAwNA_f156fdd7-5648-4cf3-a015-16729365b88f"
      unitRef="usd">20000000.0</sgry:OperatingAndFinanceLeaseExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOS0yLTEtMS04MjAwNA_d19b53ec-b32b-4137-a3de-89ddfb254f1e"
      unitRef="usd">45600000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfOS00LTEtMS04MjAwNA_f543dea9-3107-4341-a599-0fcc32f178a8"
      unitRef="usd">37300000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTAtMi0xLTEtODIwMDQ_71a45c13-53e4-4ff9-8c4f-f5b8a8e13f3b"
      unitRef="usd">532200000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTAtNC0xLTEtODIwMDQ_9a20176a-b353-4395-9e66-9a83f105be20"
      unitRef="usd">471400000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTEtMi0xLTEtODIwMDQ_42d5109a-f4de-44e6-adc6-905cf342e5f4"
      unitRef="usd">32000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTEtNC0xLTEtODIwMDQ_26153c51-fe44-4997-a05e-577463ee89dd"
      unitRef="usd">29500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTItMi0xLTEtODIwMDQ_9a63f5c7-5c43-42cc-9389-ed8754e16167"
      unitRef="usd">33700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTItNC0xLTEtODIwMDQ_9c855cd7-5557-40c3-b4b2-617c4ad00d07"
      unitRef="usd">27400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTMtMi0xLTEtODIwMDQ_45864894-f936-47d5-99ca-3c91f036dea9"
      unitRef="usd">12500000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTMtNC0xLTEtODIwMDQ_a62dee08-d3e4-44b1-8710-7204090bf380"
      unitRef="usd">7100000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <sgry:GrantRevenue
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTQtMi0xLTEtODIwMDQ_acddd4bd-dbc9-4a96-9d0b-82b3a130022f"
      unitRef="usd">1100000</sgry:GrantRevenue>
    <sgry:GrantRevenue
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTQtNC0xLTEtODIwMDQ_31eb8449-12c9-4e8f-a4c8-540d7a872ba0"
      unitRef="usd">1200000</sgry:GrantRevenue>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTUtMi0xLTEtODIwMDQ_9d88d424-a9d4-467b-b521-4f40a9d9141f"
      unitRef="usd">-10500000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTUtNC0xLTEtODIwMDQ_70a7d233-ff9c-453e-8bfb-dc289bb9b295"
      unitRef="usd">100000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTYtMi0xLTEtODIwMDQ_2c579ada-eb66-4b91-8877-706a64dc3b8d"
      unitRef="usd">3300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTYtNC0xLTEtODIwMDQ_31b7f1f4-056d-4601-b860-9fdca5ebe133"
      unitRef="usd">3100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTctMi0xLTEtODIwMDQ_ddd88054-f5fe-409e-83b3-08521663e45d"
      unitRef="usd">-3000000.0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTctNC0xLTEtODIwMDQ_31972981-bb6d-4b69-9285-f10c5b7e7ce2"
      unitRef="usd">32800000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTktMi0xLTEtODIwMDQ_f63e320a-496a-4203-aa2b-3e91815b61ab"
      unitRef="usd">300000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMTktNC0xLTEtODIwMDQ_4f9b5655-2b8e-46d9-8990-02b4a3c00296"
      unitRef="usd">-2400000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjAtMi0xLTEtODIwMDQ_696b7967-f98f-4498-81bd-9fc2130ab51b"
      unitRef="usd">619800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjAtNC0xLTEtODIwMDQ_15256e53-3e77-41bd-a350-81292764dd4c"
      unitRef="usd">495800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjEtMi0xLTEtODIwMDQ_cc6b14cc-6187-4733-9d56-7cb41c9b159a"
      unitRef="usd">46400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjEtNC0xLTEtODIwMDQ_e318cf64-8fc9-44a5-a51a-8a5bf10c1beb"
      unitRef="usd">100400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjItMi0xLTEtODIwMDQ_5d41b906-63f7-4d6d-855b-c36a91672cd3"
      unitRef="usd">-46800000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjItNC0xLTEtODIwMDQ_7d857e88-0d79-4dd1-82ea-4435fb877cf6"
      unitRef="usd">-56300000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjMtMi0xLTEtODIwMDQ_05864361-8ce6-45c5-9ce9-605bc51c5372"
      unitRef="usd">-400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjMtNC0xLTEtODIwMDQ_39664994-cdc5-4cc0-bce4-6c971bbcf53f"
      unitRef="usd">44100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjQtMi0xLTEtODIwMDQ_89734329-97b0-4641-9c4c-dadef759a59b"
      unitRef="usd">-1600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjQtNC0xLTEtODIwMDQ_d4d972c9-a53e-466e-8e64-c73bc7ab94a6"
      unitRef="usd">1300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjUtMi0xLTEtODIwMDQ_0879b225-9535-4b9a-9377-bc5f5f6844ea"
      unitRef="usd">1200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjUtNC0xLTEtODIwMDQ_dbe2456e-2b4a-4aa3-abd0-19b919b073ac"
      unitRef="usd">42800000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjYtMi0xLTEtODIwMDQ_d348ac7c-7d11-45b9-883b-4c812424dce4"
      unitRef="usd">26100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjYtNC0xLTEtODIwMDQ_b2623d75-e28e-48ee-abe1-2f697b0650e1"
      unitRef="usd">30600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjctMi0xLTEtODIwMDQ_f3f12ac0-aa7a-4995-ab94-68160200a587"
      unitRef="usd">-24900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMjctNC0xLTEtODIwMDQ_cd56bb52-eaf3-48ce-88c8-97a9cfe1aae3"
      unitRef="usd">12200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzItMi0xLTEtODIwMDQ_bdd099a3-4793-4050-ae57-cffc527e32e0"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzItNC0xLTEtODIwMDQ_22b60dff-6dd4-4d40-b1e4-e1ef0c5af217"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtMi0xLTEtODIwMDQ_2aee640c-d5ee-4c65-9d06-3183f99eb627"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtNC0xLTEtODIwMDQ_a86f7bca-360e-408d-a5c7-69577988ff87"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzUtMi0xLTEtODIwMDQ_a300e41b-47ea-4740-983a-8b6e0048f8fd"
      unitRef="shares">125206000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzUtNC0xLTEtODIwMDQ_386bfd3b-4425-46f2-8043-691f12df08e4"
      unitRef="shares">87995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtMi0xLTEtODIwMDQ_1da8f9b1-483f-4542-85c2-5ef648da6eb7"
      unitRef="shares">125206000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtNC0xLTEtODIwMDQ_b606e16c-d033-4319-9dd0-f2ca51061163"
      unitRef="shares">90272000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfMy0yLTEtMS04MjAwNA_0879b225-9535-4b9a-9377-bc5f5f6844ea"
      unitRef="usd">1200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfMy00LTEtMS04MjAwNA_dbe2456e-2b4a-4aa3-abd0-19b919b073ac"
      unitRef="usd">42800000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjBiNmFlYjk0MTFmZjRmMTViNGRjZTRkNmVlMjFlYWQyXzEwNDQ1MzYwNDYzOTE0_4e3956f4-3115-42d0-91b5-ea3a04d88abb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjBiNmFlYjk0MTFmZjRmMTViNGRjZTRkNmVlMjFlYWQyXzEwNDQ1MzYwNDYzOTE0_705b3542-1ebf-402e-9973-6bf41f1393d3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS0yLTEtMS04MjAwNA_161cd937-cdb7-4837-9a86-3dc53e7eefdb"
      unitRef="usd">-11300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNS00LTEtMS04MjAwNA_4ac75ab6-79a6-4ddc-810f-4af6b45a6d65"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNi0yLTEtMS04MjAwNA_1b014676-6e53-4998-929c-f7783b4e2588"
      unitRef="usd">-10100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNi00LTEtMS04MjAwNA_2fcd02e7-758e-41aa-b40c-3fc619ddf784"
      unitRef="usd">99600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNy0yLTEtMS04MjAwNA_b56f99e5-8a71-46bc-b006-63dddf16be4c"
      unitRef="usd">26100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfNy00LTEtMS04MjAwNA_d7e450dd-1763-4ef3-835a-2d9880a205d1"
      unitRef="usd">30600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfOC0yLTEtMS04MjAwNA_c8d4b64b-2c47-4030-965f-29a895088fda"
      unitRef="usd">-36200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xOS9mcmFnOjk1ZjlmNTczZWJkYTRmOWY5MDk3NWExMWJlNWFkZTQ4L3RhYmxlOjUxNTBiN2UzYjg3YjRkZjFhYjhiYmRkMGM4YzViYWU3L3RhYmxlcmFuZ2U6NTE1MGI3ZTNiODdiNGRmMWFiOGJiZGQwYzhjNWJhZTdfOC00LTEtMS04MjAwNA_8d3b1839-df7f-4cfc-a800-456512c5170a"
      unitRef="usd">69000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaa47a92aabfb4f198bd892ae1c73b47e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0xLTEtMS04MjYxMw_5575a845-c9e1-4885-8c06-9e9e972cf59f"
      unitRef="shares">89333000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa47a92aabfb4f198bd892ae1c73b47e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0zLTEtMS04MjYxMw_431f816a-fe21-4840-b090-9e0494b10512"
      unitRef="usd">900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e5a939bdb244adf9d443c23ec72a6eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy01LTEtMS04MjYxMw_390c7ac3-52d1-45f0-af2d-ebf9bc7f072b"
      unitRef="usd">1622300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65ee09ce3e1544a3a10503ec164f9559_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy03LTEtMS04MjYxMw_f8dab29e-3377-4b5e-aa7c-0065dfb4131e"
      unitRef="usd">-31500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i419bf181460249fe83b08bb14c6fc0dc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy05LTEtMS04MjYxMw_93850cd6-5274-4a74-b292-4302b128f9a1"
      unitRef="usd">-502700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1bfc86bd81947fd8321bee696e14ba8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0xMS0xLTEtODI2MTM_50d61b9c-2eb0-4f94-8762-2e33c1af489c"
      unitRef="usd">880600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfMy0xMy0xLTEtODU1MTY_53c931c7-4c1b-4b29-9261-64d793d08a9e"
      unitRef="usd">1969600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ic77b33bfc579485d9d202b8fa5835ebb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNC05LTEtMS04MjYxMw_c50fceb1-a84a-4bb0-adba-b8a0f54deb6c"
      unitRef="usd">12200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNC0xMS0xLTEtODI2MTM_19264287-d74c-4014-9e55-451b40386d2d"
      unitRef="usd">20000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNC0xMy0xLTEtODU1MTY_af4cf467-7bdd-4120-b91c-aea2cf2eadfc"
      unitRef="usd">32200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id73c97f747ea40c89ca7360664151a1d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNS0xLTEtMS04MjYxMw_01d14915-0b5c-4f54-a749-1b6716ef4b3c"
      unitRef="shares">572000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9656398a8cdc4c2684fa3528cd1fd737_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNS01LTEtMS04MjYxMw_3de9c624-0a81-4cba-871e-0c10207fcaed"
      unitRef="usd">7700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNS0xMy0xLTEtODU1MTY_a5bdd112-79b5-4fdd-b87d-d44a4b4c632a"
      unitRef="usd">7700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i394eeacceb884d9dac0bffe547fcfd9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNi03LTEtMS04MjYxMw_8684ad31-7e11-4629-9d57-171144875b43"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNi0xMy0xLTEtODU1MTY_809ae90b-cafb-4b3b-88cc-c9d46fad5f7e"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i9656398a8cdc4c2684fa3528cd1fd737_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNy01LTEtMS04MjYxMw_0c9f29c3-bfac-4d3b-a8f9-936a86420ec5"
      unitRef="usd">-4800000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNy0xMS0xLTEtODI2MTM_1876c379-730e-4945-ba86-027062792724"
      unitRef="usd">-24300000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfNy0xMy0xLTEtODU1MTY_2d06f44f-2009-4aba-8386-e55a1af2d8bc"
      unitRef="usd">-29100000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i224774bd79304f84b212a1fea32b73ff_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOC0xMS0xLTEtODI2MTM_f1d56bc7-ed9f-4380-b24c-f959e417c6e4"
      unitRef="usd">24600000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOC0xMy0xLTEtODU1MTY_213195ec-96bc-4a76-9b34-334219597514"
      unitRef="usd">24600000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i74c7ebcc457244ff879740e6b5842dc7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0xLTEtMS04NTUxNg_a82b1866-740b-4f32-85f6-aa25874b1abc"
      unitRef="shares">89905000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74c7ebcc457244ff879740e6b5842dc7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0zLTEtMS04NTUxNg_b73c0467-cb34-41df-a04b-1e870e3e467d"
      unitRef="usd">900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iace256156ecb46e7a7879df0ee315f58_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS01LTEtMS04NTUxNg_9a8c0326-5beb-4026-a3b4-fcecbc273f96"
      unitRef="usd">1625200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i559d3e62ec804801a7d58ea449905c65_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS03LTEtMS04NTUxNg_33c4c6aa-d0db-4048-ac16-1010541bec14"
      unitRef="usd">25300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8748cab7c3f340cebd27f76f35614534_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS05LTEtMS04NTUxNg_1b5a532b-8ff0-4c7b-b53a-f3740a594392"
      unitRef="usd">-490500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53d01a25902b4073a79e1ac8105bab03_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0xMS0xLTEtODU1MTY_c442001e-d6dd-4a95-9eee-4581b7124c4e"
      unitRef="usd">851700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97e64b243cb74e08990bb73929ab0a6c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOjUzN2RkMjNmZmU0ZjQ2NDZhZGU3MWYyY2Y3NmI2ZDlhL3RhYmxlcmFuZ2U6NTM3ZGQyM2ZmZTRmNDY0NmFkZTcxZjJjZjc2YjZkOWFfOS0xMy0xLTEtODU1MTY_b4170dfa-cc1d-40e6-a5ca-59b030d3ae56"
      unitRef="usd">2012600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1f16ef7c61754a9f9f05d6a9e5783680_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0xLTEtMS04MjAwNA_5ee46090-100f-4689-937c-1fc8bb1ac96b"
      unitRef="shares">125961000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f16ef7c61754a9f9f05d6a9e5783680_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0zLTEtMS04MjAwNA_3a5820b4-358c-4980-b20f-92c44758b726"
      unitRef="usd">1300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0eb096987544bb6a2a82e082c5b28e5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy01LTEtMS04MjAwNA_eecc463d-80a6-4606-aed5-85a350a6c2b2"
      unitRef="usd">2478000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4215fc76964f4337aa436bd3e933e2e2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy03LTEtMS04MjAwNA_7a4da19b-c0b3-426c-a2a6-ce06e4c16089"
      unitRef="usd">76200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1faa6a90751245b287153e4d2de4bf31_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy05LTEtMS04MjAwNA_9230be2e-1e18-4237-a289-80a82876f243"
      unitRef="usd">-557300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba00892a7dbf473f9ebd08d01e3af4c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0xMS0xLTEtODIwMDQ_8d9c8a3c-58fd-48d6-8baf-54afd706f2c5"
      unitRef="usd">942700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfMy0xMy0xLTEtODIwMDQ_39b2e8e3-01f0-4b00-82b0-1de98121e419"
      unitRef="usd">2940900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ie4ad6ada487b44178e469d7d80790c65_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNC05LTEtMS04MjAwNA_c296c1ed-3ba5-4382-9eaf-63347727c1bb"
      unitRef="usd">-25000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNC0xMS0xLTEtODIwMDQ_5fc37412-ae3e-452d-8b57-48ff3cef7b19"
      unitRef="usd">18300000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNC0xMy0xLTEtODIwMDQ_b3648142-d5f8-40d4-8cf7-a6d2312b5575"
      unitRef="usd">-6700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i05afb4f94a984b2c822ccdd467908600_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNS0xLTEtMS04MjAwNA_3a1de5fc-0533-4989-be0a-43b1bf168fec"
      unitRef="shares">519000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5f5ba699a656478ba51b4056199d52d2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNS01LTEtMS04MjAwNA_6a906330-55f9-4ea9-b41a-cbdffcb2a85b"
      unitRef="usd">3700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNS0xMy0xLTEtODIwMDQ_c343c10e-78dc-4752-b286-df74cb034aa5"
      unitRef="usd">3700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic8759e8dfad94c5fa466de092b896d4f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNi03LTEtMS04MjAwNA_c9b82adb-69f8-4202-9abd-1d5b089ae760"
      unitRef="usd">-11300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNi0xMy0xLTEtODIwMDQ_95b30cb7-5a04-44e5-8a28-c88647b12541"
      unitRef="usd">-11300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i5f5ba699a656478ba51b4056199d52d2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNy01LTEtMS04MjAwNA_b197e6f6-44e3-46a2-9107-c17222a3bed6"
      unitRef="usd">-3600000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNy0xMS0xLTEtODIwMDQ_2877d8eb-824c-4000-8362-25649dfb79ed"
      unitRef="usd">49700000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfNy0xMy0xLTEtODIwMDQ_0ac24c48-c402-48be-a180-28d14ea3a07d"
      unitRef="usd">46100000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i78805302d2b14f6eb19882771a966ad5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOC0xMS0xLTEtODIwMDQ_549de89c-70b7-47e5-b987-58c323e270d4"
      unitRef="usd">30200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOC0xMy0xLTEtODIwMDQ_8d809269-7c37-4d8c-a11b-f7f0361c6b11"
      unitRef="usd">30200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib68f4679b2c94c25b3f7f0f693b6ec14_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0xLTEtMS04MjAwNA_ad73764d-10f5-496b-8734-e0c8af0884dd"
      unitRef="shares">126480000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib68f4679b2c94c25b3f7f0f693b6ec14_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0zLTEtMS04MjAwNA_784927ae-83c9-4092-8ee0-a99356fdd700"
      unitRef="usd">1300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4b423adca5e4dd9968d29cc90df2d4e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS01LTEtMS04MjAwNA_f68a4ff3-4844-4467-97a2-a53b88aec8a8"
      unitRef="usd">2478100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3357462c707d4acfb10096d245e66a3a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS03LTEtMS04MjAwNA_e48dbbe3-460b-43e0-ba28-839a5ba29826"
      unitRef="usd">64900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cb9d22b38ff4ca790e312d6a32e41d2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS05LTEtMS04MjAwNA_1e64f2da-27dd-4105-a942-dba50f0427da"
      unitRef="usd">-582300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d30c499f0834cf2882c4d2c725d4e29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0xMS0xLTEtODIwMDQ_6f889558-375c-47ff-87ca-5526f59d1abc"
      unitRef="usd">980500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yMi9mcmFnOmZkZDQyOTRjODRlOTQ0ZTM5OGMyMzQxODc2NDY4ODNiL3RhYmxlOmY3M2E5M2NjMjYwZjQzN2FiNWQyZTRmZjc4OTZhMTY2L3RhYmxlcmFuZ2U6ZjczYTkzY2MyNjBmNDM3YWI1ZDJlNGZmNzg5NmExNjZfOS0xMy0xLTEtODIwMDQ_12868292-028c-4a5e-9bce-084fe3b234be"
      unitRef="usd">2942500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMy0yLTEtMS04MjAwNA_01d76b5d-b809-413a-85b1-ca73934be022"
      unitRef="usd">1200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMy00LTEtMS04MjAwNA_31932d9d-0e7b-4945-b4bb-9844592a2565"
      unitRef="usd">42800000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNS0yLTEtMS04MjAwNA_34c63081-88f3-4fde-afbb-bad19b4a093e"
      unitRef="usd">33700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNS00LTEtMS04MjAwNA_dc2e3664-b8ca-45df-afea-9742efcceef2"
      unitRef="usd">27400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi0yLTEtMS04NjY0Nw_7157d91e-7f6d-474e-be12-9ce6011b7ccf"
      unitRef="usd">9000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi00LTEtMS04NjY0Nw_d8fd45a9-9f76-4869-a41c-e7209b577553"
      unitRef="usd">8600000</us-gaap:OperatingLeaseExpense>
    <sgry:NoncashInterestIncomeExpenseNet
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi0yLTEtMS04MjAwNA_1e72732c-b8cc-413a-905f-b4e6f24f809d"
      unitRef="usd">-6500000</sgry:NoncashInterestIncomeExpenseNet>
    <sgry:NoncashInterestIncomeExpenseNet
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNi00LTEtMS04MjAwNA_a1db8d53-7282-4e2d-ad4b-8d2a8a9d9ad3"
      unitRef="usd">-6100000</sgry:NoncashInterestIncomeExpenseNet>
    <us-gaap:ShareBasedCompensation
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNy0yLTEtMS04MjAwNA_4e8b0839-551d-47aa-9c68-7c2315a26599"
      unitRef="usd">4200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNy00LTEtMS04MjAwNA_666a1e96-538e-4b35-8098-9ba343a6e9d0"
      unitRef="usd">3700000</us-gaap:ShareBasedCompensation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfOC0yLTEtMS04MjAwNA_970f46aa-b215-486b-a379-765117d40dbe"
      unitRef="usd">-10500000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfOC00LTEtMS04MjAwNA_b939b01b-302b-4d1d-bd75-1c0a93e42e72"
      unitRef="usd">100000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTAtMi0xLTEtODIwMDQ_1f5f996c-4ae3-4f32-8f76-6c1d932d2294"
      unitRef="usd">-1800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTAtNC0xLTEtODIwMDQ_8455649c-f3ea-44ff-92d2-b0fbd7250acb"
      unitRef="usd">1000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTEtMi0xLTEtODIwMDQ_6bcc6bfd-eb12-4457-9a2b-784dca81d3e6"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTEtNC0xLTEtODIwMDQ_eb3d3a4d-320d-489f-ad63-3e1583510ff4"
      unitRef="usd">900000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTQtMi0xLTEtODIwMDQ_1ad7b57e-b958-4039-b14f-9fc586b3b9d5"
      unitRef="usd">-8800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTQtNC0xLTEtODIwMDQ_39e4a51f-f0e8-46b5-aa15-45e867b1a6a0"
      unitRef="usd">-2000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTUtMi0xLTEtODIwMDQ_3362fc6d-e8bf-4504-9eab-fd8700943473"
      unitRef="usd">-1200000</sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants>
    <sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTUtNC0xLTEtODIwMDQ_907c9b8f-0b98-49b4-a71e-b9d0c37f796a"
      unitRef="usd">-18000000.0</sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTctMi0xLTEtODIwMDQ_0e3b654e-f85e-499f-a911-8a8653cf1b3c"
      unitRef="usd">-3800000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTctNC0xLTEtODIwMDQ_876db0fd-c639-4700-a35c-cf99dc96813a"
      unitRef="usd">-7200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTgtMi0xLTEtODIwMDQ_ab63219e-9d3d-447e-928d-c22c92abfbce"
      unitRef="usd">74500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMTgtNC0xLTEtODIwMDQ_5ff705c0-afd0-498b-bba9-025b374f12f9"
      unitRef="usd">79800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjEtMi0xLTEtODIwMDQ_4101df1a-341e-46b9-adc8-5d3ec7416203"
      unitRef="usd">24300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjEtNC0xLTEtODIwMDQ_1ab6d682-115e-4885-a90b-597c3a1aa908"
      unitRef="usd">18200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjItMi0xLTEtODIwMDQ_82bb5021-746d-4082-9a38-3301b655c189"
      unitRef="usd">40700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjItNC0xLTEtODIwMDQ_1a6e8271-5198-44c0-95be-15848c046809"
      unitRef="usd">31100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjMtMi0xLTEtODIwMDQ_3f4cdb28-a505-4045-be6b-9e84d5de6c62"
      unitRef="usd">8000000.0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjMtNC0xLTEtODIwMDQ_c87b6781-4225-432c-a009-df989a1e6edb"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjQtMi0xLTEtODIwMDQ_19d6a3ef-a0e3-4e68-9988-ef8bff0323f2"
      unitRef="usd">9600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjQtNC0xLTEtODIwMDQ_cedccd85-6bcc-4585-9540-10bed5fe6315"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjUtMi0xLTEtODIwMDQ_da0264a5-316c-47ba-8d82-67e7968ace0a"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjUtNC0xLTEtODIwMDQ_fb487279-8e39-4793-ac7e-15bff7c10749"
      unitRef="usd">11500000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjYtMi0xLTEtODIwMDQ_09610741-f072-4285-ac1a-b7dae7a2bdec"
      unitRef="usd">4100000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjYtNC0xLTEtODIwMDQ_7798fa21-4dce-4485-a51a-636881e8fced"
      unitRef="usd">9300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjctMi0xLTEtODIwMDQ_3cb873d8-047c-4e97-94cc-c7caf5ba6863"
      unitRef="usd">-70700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMjctNC0xLTEtODIwMDQ_bbacabc7-b9a5-4066-bc42-16d1d4bdf3d5"
      unitRef="usd">-47100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtMi0xLTEtODIwMDQ_519687bc-8465-4d23-84c8-f54800c1adc4"
      unitRef="usd">15900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtNC0xLTEtODIwMDQ_1066e445-7372-4777-b2a5-f136bad54b89"
      unitRef="usd">17000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzEtMi0xLTEtODIwMDQ_ef317b0c-b362-4035-b132-f74e83a52410"
      unitRef="usd">15900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzEtNC0xLTEtODIwMDQ_b41f7c8d-fb81-42d9-8284-1e21d32bf429"
      unitRef="usd">11900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtMi0xLTEtODk2MTU_08ef02a6-7c3c-4ae5-b027-eea4dc02ea43"
      unitRef="usd">1300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzAtNC0xLTEtODk2MTU_157488dc-f3ed-4b30-90f1-c8fe4b40f163"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzYtMi0xLTEtODIwMDQ_f53bda1c-ffb3-4a0c-9931-a583c5f27d75"
      unitRef="usd">41900000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzYtNC0xLTEtODIwMDQ_1756f5dc-90e1-4562-89e6-3477cee70fdf"
      unitRef="usd">36200000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzctMi0xLTEtODIwMDQ_22df0328-5b9c-4f76-9d0b-2c3b2d1e6fc5"
      unitRef="usd">5100000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzctNC0xLTEtODIwMDQ_2261140c-7e60-4c78-8d5e-6acb251f8035"
      unitRef="usd">-3100000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzgtMi0xLTEtODIwMDQ_9f14670e-86b5-4847-9d87-39ad927e8444"
      unitRef="usd">-3100000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzgtNC0xLTEtODIwMDQ_ecc9d7d5-e299-4864-86d1-97f7279967ef"
      unitRef="usd">700000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzktMi0xLTEtODIwMDQ_d8faab32-342b-497b-8de8-a9d2da6515ee"
      unitRef="usd">-41200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfMzktNC0xLTEtODIwMDQ_ad757b7e-eb3e-4d6f-962b-4963bba87097"
      unitRef="usd">-43700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDAtMi0xLTEtODIwMDQ_3de84d02-8c0f-4f21-a444-131b10fa2ab7"
      unitRef="usd">-37400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDAtNC0xLTEtODIwMDQ_595c2260-e12c-47eb-963c-f4a8d2402047"
      unitRef="usd">-11000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDEtMi0xLTEtODIwMDQ_38bf2454-72b9-4e09-a81d-915091cc69bf"
      unitRef="usd">282900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDEtNC0xLTEtODIwMDQ_1ce527c7-6826-44a5-8efb-5726571dec2c"
      unitRef="usd">389900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDItMi0xLTEtODIwMDQ_a2d8ca10-91cb-4755-b3f6-c4a780e5b7bb"
      unitRef="usd">245500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i97e64b243cb74e08990bb73929ab0a6c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8yNS9mcmFnOjNkOTgzYmYyYjBmOTQ5ZWU4NjYxNDYwNWQxY2EyOWMyL3RhYmxlOmU3ZmMzYTA0ZjQ0MTQzMGM4ZDA2MzdkOWU1MmM4MzRkL3RhYmxlcmFuZ2U6ZTdmYzNhMDRmNDQxNDMwYzhkMDYzN2Q5ZTUyYzgzNGRfNDItNC0xLTEtODIwMDQ_40c3a74b-76d6-404f-a616-dc4c899131b3"
      unitRef="usd">378900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNTQ_fc84f001-d107-49dc-b4ee-e6f840994e53">Organization and Summary of Accounting Policies&lt;div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company owned or operated a portfolio of 145 surgical facilities, comprised of 127 ASCs and 18 surgical hospitals in 31 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in 92 of these surgical facilities and consolidated 118 of these facilities for financial reporting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#x2019;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the "2022 Annual Report on Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of revenues by service type as a percentage of total revenues follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Surgical facilities revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Ancillary services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient service revenues.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#x2019;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Private insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;656.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;666.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#x2019; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#x2019;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's effective tax rate was 400.0% for the three months ended March&#160;31, 2023 compared to 2.9% for the three months ended March&#160;31, 2022. For the three months ended March&#160;31, 2023, the effective tax rate differed from the federal corporate tax rate of 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#x2019;s valuation allowance attributable to interest expense limitations, and a discrete tax benefit of $1.8&#160;million related to the vesting of restricted stock awards. For the three months ended March 31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#x2019;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $4.6&#160;million related to the vesting of restricted stock awards, (b) $1.8&#160;million attributable to non-recurring earnings&#x2019; impact on the Company&#x2019;s valuation allowance, and (c) $1.0&#160;million related to entity divestitures. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions and disposals for the three months ended March&#160;31, 2023 is included in Note 2. "Acquisitions and Disposals."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to goodwill for the three months ended March&#160;31, 2023 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,137.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions, including post acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,217.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A detailed evaluation of potential impairment indicators was performed as of March&#160;31, 2023, which specifically considered recent increases in interest rates, inflation risk and market volatility. On the basis of available evidence as of March&#160;31, 2023, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company&#x2019;s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks even though hedge accounting does not apply or the Company elects not to apply hedge accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-Controlling Interests&#x2014;Redeemable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#x2019; or physician minority members&#x2019;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to non-controlling interests&#x2014;redeemable is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of shares of non-controlling interests, net&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions to non-controlling interest&#x2014;redeemable holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Medicare Accelerated Payments and Deferred Governmental Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company received grant funds distributed under the Coronavirus Aid, Relief and Economic Security Act (the &#x201c;CARES Act&#x201d;) and other governmental assistance programs. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues. The Company estimates $1.1 million and $1.2 million of grant funds received qualified for recognition as a reduction in operating expenses for the three months ended March&#160;31, 2023 and 2022, respectively. There were no remaining unrecognized grant funds as of March 31, 2023. As of December&#160;31, 2022 approximately $3&#160;million of unrecognized grant funds received was reflected as a component of other current liabilities within the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company received accelerated payments under the Medicare Accelerated and Advance Payment Program. The payments received were deferred and included in the condensed consolidated balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the remaining deferred accelerated payments was minimal. During the three months ended March 31, 2022, approximately $18&#160;million was repaid in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;accordance with the terms of the program. These repayments are included as a component of the change in Medicare accelerated payments and deferred government grants in the condensed consolidated statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policies for relief received under the CARES Act and other governmental assistance programs, including the recognition of grant funds, is unchanged from the policies described in Note 1 to the Company&#x2019;s consolidated financial statements included in the 2022 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,353.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,359.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of March&#160;31, 2023, the Company's consolidated VIEs include seven surgical facilities and five physician practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of March&#160;31, 2023 and December&#160;31, 2022 were $69.9 million and $64.9 million, respectively, and the total liabilities of the consolidated VIEs were $44.5 million and $40.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTAyMQ_f442c3a9-75d2-47ad-984c-80d48a658bac"
      unitRef="facility">145</sgry:NumberOfSurgicalFacilitiesOwned>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="i7b158a1a0b39401183f6b663f67d5119_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA1OA_174e6408-c95a-48d1-b22f-bf322d30fcaa"
      unitRef="facility">127</sgry:NumberOfSurgicalFacilitiesOwned>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="i4e67a4ba4b7b45ec9fb013fdd2a9a8c7_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA3MA_12b5619d-b2db-405e-acdf-f80c7ab5b90a"
      unitRef="facility">18</sgry:NumberOfSurgicalFacilitiesOwned>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5NQ_e621ebda-89a3-45e1-a5df-d6ac20b746ae"
      unitRef="state">31</us-gaap:NumberOfStatesInWhichEntityOperates>
    <sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTI5NA_5d1ef008-be49-4b9a-a342-9da6d2fa3988"
      unitRef="facility">92</sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest>
    <sgry:NumberOfSurgicalFacilitiesOwnedConsolidated
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTM0MQ_15801e32-c7e4-498e-b0de-cc0ac9d5ebec"
      unitRef="facility">118</sgry:NumberOfSurgicalFacilitiesOwnedConsolidated>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMjQ_ce38c3f8-80ba-4975-aaea-121fe0b6310d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#x2019;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the "2022 Annual Report on Form 10-K").&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMTQ_b2f2e687-5fef-4c51-afb3-5276c271a213">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwOTI_e69d479b-c6b3-4717-b98c-ecf3e86b67d2">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNzQ_8f02eb63-ab64-4670-8a21-cb0c34f9e66f">&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient service revenues.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#x2019;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwODQ_c172ef3a-bc7d-44ed-818b-7e1ac937eec9">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of revenues by service type as a percentage of total revenues follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Surgical facilities revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Ancillary services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Private insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;656.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;666.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types.</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93fbb84ab8e54bf68ae45319f7ceed8e_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfMy0yLTEtMS04MjAwNA_eb711367-a812-4938-a6d2-125e1b4e8018"
      unitRef="number">0.960</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i330b18e5ad5743db8b6302ffdf866646_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfMy00LTEtMS04MjAwNA_17334063-a04b-4554-acad-5326f5ff3b48"
      unitRef="number">0.957</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i194a9154acd5484889805e9286e14672_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNC0yLTEtMS04MjAwNA_eb5a6d1c-63c1-493b-820c-89c982f240f4"
      unitRef="number">0.025</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5333aa040ad4421ea9ff5171113791b9_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNC00LTEtMS04MjAwNA_6b93e7a6-268d-40b0-a62d-0c2abc937882"
      unitRef="number">0.029</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i347c2e534f60472f9aa78f23e2b7662d_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNS0yLTEtMS04MjAwNA_cd5d7ea9-5094-4969-92b5-2de207097e34"
      unitRef="number">0.985</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i24a958c4d33242709d5e6b4c8a16d451_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNS00LTEtMS04MjAwNA_08195f5b-6286-4a6f-851d-525095d8643c"
      unitRef="number">0.986</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i174f2ef7f43b4017be096fd6960d0dd8_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNi0yLTEtMS04MjAwNA_5ded17d8-31cf-42f7-bb31-d7dd8b90f735"
      unitRef="number">0.015</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i13bc8547fc6249f391018e3c36ac7ae5_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNi00LTEtMS04MjAwNA_0972e317-4fa1-4f2e-8a87-ab20bca57487"
      unitRef="number">0.014</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0cec9a12adb2490880d03b5e2db3fb51_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNy0yLTEtMS04MjAwNA_59b412ad-c0a1-43ba-9172-7d8c93f77cfd"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib1e91e1eeba04f3cb636ac9f9e9c742e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjkyN2Q1NmRhZjJmMTQ4OTNhMDA3NDA5OTU0ZTJmZjU2L3RhYmxlcmFuZ2U6OTI3ZDU2ZGFmMmYxNDg5M2EwMDc0MDk5NTRlMmZmNTZfNy00LTEtMS04MjAwNA_a349f79b-934d-49ba-bdd7-09233bf80b85"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifdc7653a276442c2895ba6dc6f426066_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC0yLTEtMS04MjAwNA_72bd2336-c7b1-4a5d-aab9-d36359856c47"
      unitRef="usd">335600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaf0554ebc49d4fcb999fb93084ca8790_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC00LTEtMS04MjAwNA_e6b3b569-b386-48de-b001-57b24e4fd7fa"
      unitRef="number">0.511</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i99b023be21c94ca6b3fda57d05624b2b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC02LTEtMS04MjAwNA_4933af6b-b3d3-4fb8-9c57-44e3616f4c78"
      unitRef="usd">300200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic894bd77f5d24d9f8d642bd4486553b9_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNC04LTEtMS04MjAwNA_f4cbb0e6-82e3-4640-9eab-f1a051b00b8e"
      unitRef="number">0.511</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6a3a0d5b4af849048366464b85a609df_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS0yLTEtMS04MjAwNA_773c798e-03b6-48ee-b4ca-b0c256d002b3"
      unitRef="usd">287800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a1d727596c449d1aa589faede2c444c_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS00LTEtMS04MjAwNA_da9f0fc9-823c-4997-8b56-8dedac881d8f"
      unitRef="number">0.438</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieb44bf1e649f4f9797567c55c11d2a57_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS02LTEtMS04MjAwNA_742dd573-8fbc-466c-a4c4-673980781c00"
      unitRef="usd">249000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4fdfeafd2b2b44c581d7ae62c305a05b_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNS04LTEtMS04MjAwNA_7185f815-19b4-4fa0-83ec-6fc68f3d2796"
      unitRef="number">0.424</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i35c8b6e80870471584d0662cd5e62ce1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi0yLTEtMS04MjAwNA_7f4d20ff-d489-40c9-a722-ed64cd6e3b7c"
      unitRef="usd">15600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia3533ff5f75840c8b83b791c1edd4b8b_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi00LTEtMS04MjAwNA_15c849b2-8aae-4c1a-9c26-b0f34a15f64a"
      unitRef="number">0.024</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i56c5f1fcb27242be90a9519d3a5daa49_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi02LTEtMS04MjAwNA_c5128157-7403-497f-8bb8-400434278bc9"
      unitRef="usd">16800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibb60ee5f491a4d759f3f80d61bc39428_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNi04LTEtMS04MjAwNA_9f0983fa-c75f-4c6e-adeb-b31f606b23d9"
      unitRef="number">0.029</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i45c5bb7aafa14f84b6d67420515600b5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy0yLTEtMS04MjAwNA_c1582bb5-1403-4682-b25c-ed94360f6ab1"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibaad3032980a44f9b79dd84b65b8a8f3_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy00LTEtMS04MjAwNA_c34bf31e-8a19-447f-8ccc-794942940244"
      unitRef="number">0.027</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie11e527c61994fc4b8612c9529f84738_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy02LTEtMS04MjAwNA_b95adbe6-4fcd-4401-8a8f-73ca90165e3d"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4059e6a11b044239991a9cd274ca93af_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfNy04LTEtMS04MjAwNA_87ac1b0d-9519-4952-bd28-458696a5a475"
      unitRef="number">0.036</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5ccbab58e225409b8f397b22aaa0921a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC0yLTEtMS04MjAwNA_e3c7708d-6da7-43ab-a04a-b7364a5e2067"
      unitRef="usd">656400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i690afa60488b471bad71d09dde1be1f5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC00LTEtMS04MjAwNA_60399ebc-02f5-4e41-b12f-83adee3c2930"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3cb842e8e10b4aa2b02cfaeca3e9e29e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC02LTEtMS04MjAwNA_f10026a7-9989-4322-a69d-85d4bf10a767"
      unitRef="usd">587700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i567b65cfc1644f8ca0a4e2059d874857_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOC04LTEtMS04MjAwNA_d2e44993-9896-4087-a133-3cba4c2b8b1b"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i39473dc95e60480a8548a0f5e95a4826_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOS0yLTEtMS04MjAwNA_f10eff37-f60c-458c-9b0d-1da097bff7be"
      unitRef="usd">9800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i86c371e19dfa4eec95e299e3a708563a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfOS02LTEtMS04MjAwNA_637e0146-61af-41b3-9ecf-e39afbda9a54"
      unitRef="usd">8500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfMTAtMi0xLTEtODIwMDQ_349972d2-bbee-484d-9132-90895de9a99d"
      unitRef="usd">666200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjg4OTIxM2I1YTI1MzRiZTViODI5YjkwZDYyY2ZiZjUxL3RhYmxlcmFuZ2U6ODg5MjEzYjVhMjUzNGJlNWI4MjliOTBkNjJjZmJmNTFfMTAtNi0xLTEtODIwMDQ_3561db90-b31e-4558-b33c-ef072a15b248"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMDY_6faaa47b-77e7-469b-b000-e5f184a16c34">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#x2019; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#x2019;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.&lt;/span&gt;&lt;/div&gt;The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMDI_104f7220-a146-4a76-b1f2-268643374e56">&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTIyNDk_20123c50-fbdb-4bd7-9e76-cfe9a4b44608"
      unitRef="number">4.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTIyOTE_ac7cd998-8cde-4cc9-9184-b0663f9776b5"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1ODA4Ng_6a2f3297-e3ce-465c-a56e-4da167dbe489"
      unitRef="usd">-1800000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMzg0ODI5MDcyMTAzNQ_348e7826-c51e-46c2-a72a-a9044d677a76"
      unitRef="usd">-4600000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMzg0ODI5MDcyMTA0OQ_acedf43f-62b0-42ec-b705-c6a5bee95c85"
      unitRef="usd">-1800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMzg0ODI5MDcyMTA2Mw_bcdfe9d6-cdb6-4b91-b7ea-c048cc677552"
      unitRef="usd">-1000000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwODA_42b10398-ec5b-4361-aa67-0a73d0d49ba4">GoodwillGoodwill represents the excess of the fair value of the consideration provided in an acquisition plus the fair value of any non-controlling interests over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNjI_c4c10082-67c7-482e-be0d-252ae1db2364">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to goodwill for the three months ended March&#160;31, 2023 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,137.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions, including post acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,217.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMC0yLTEtMS04MjAwNA_6ba4f746-9925-40fc-88d5-06db2fa9e02e"
      unitRef="usd">4137100000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMS0yLTEtMS04MjAwNA_a0158620-6c56-4576-bb26-98cf76415a5c"
      unitRef="usd">91300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMi0yLTEtMS04NjQyNA_7421ac16-4ac6-48e2-9672-1a07011ec48f"
      unitRef="usd">11100000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:Goodwill
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjA5NTk1OWU2ZWUxYjQ4OWI5Yzg4NDI5NTk5NGE2YmMwL3RhYmxlcmFuZ2U6MDk1OTU5ZTZlZTFiNDg5YjljODg0Mjk1OTk0YTZiYzBfMy0yLTEtMS04MjAwNA_25918f6b-e964-4d97-a6ee-323fd234aac7"
      unitRef="usd">4217300000</us-gaap:Goodwill>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNDc_0f0ad54f-2fd7-43cf-94d5-07abb5f480bd">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks even though hedge accounting does not apply or the Company elects not to apply hedge accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <sgry:RedeemableNoncontrollingInterestPolicyTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxNDU_01035b22-8bbd-4174-a427-5d0bf4c86433">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-Controlling Interests&#x2014;Redeemable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#x2019; or physician minority members&#x2019;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</sgry:RedeemableNoncontrollingInterestPolicyTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNjM_469deaf9-66bf-4118-81f1-8889de7e8948">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to non-controlling interests&#x2014;redeemable is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of shares of non-controlling interests, net&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions to non-controlling interest&#x2014;redeemable holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfMy0yLTEtMS04MjAwNA_f10447ab-08f2-4f90-9736-f4af784341b9"
      unitRef="usd">342000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfMy00LTEtMS04MjAwNA_e9b10a21-0b22-49b5-a9f1-0998d7bcf9d7"
      unitRef="usd">330200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNC0yLTEtMS04MjAwNA_ca0a6d07-1345-43d0-8794-654fc7901a94"
      unitRef="usd">7800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNC00LTEtMS04MjAwNA_0262e533-91c6-4d18-b010-622ff28c3021"
      unitRef="usd">10600000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNS0yLTEtMS04MjAwNA_b08f2177-ffb7-4b2f-b816-afa05da5d253"
      unitRef="usd">7700000</sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests>
    <sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNS00LTEtMS04MjAwNA_926d8e22-6f28-4977-8bf4-7afde915e0e3"
      unitRef="usd">12300000</sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests>
    <sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNi0yLTEtMS04MjAwNA_47e1a2db-f776-42a7-8cb1-1e8a66d4171c"
      unitRef="usd">11700000</sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNi00LTEtMS04MjAwNA_be34f6fd-7db6-4785-8227-13ca2397cee9"
      unitRef="usd">11600000</sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNy0yLTEtMS04MjAwNA_b14254d8-8cd8-47fe-9b61-7cc7b15ce6ab"
      unitRef="usd">345800000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i97e64b243cb74e08990bb73929ab0a6c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOjI4ZDhmNzZmY2ZmMDQ5YTk4NGJmZmRhNTU3Njg1YWVlL3RhYmxlcmFuZ2U6MjhkOGY3NmZjZmYwNDlhOTg0YmZmZGE1NTc2ODVhZWVfNy00LTEtMS04MjAwNA_02a789ee-c560-4687-953a-71b103b49db3"
      unitRef="usd">341500000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <sgry:GrantRevenue
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTc5MjM_095c1312-9043-49a9-aee9-4c250fdfe2e7"
      unitRef="usd">1100000</sgry:GrantRevenue>
    <sgry:GrantRevenue
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1MTAyMw_75c70224-1d4b-4b7c-b2f8-52f61e28d320"
      unitRef="usd">1200000</sgry:GrantRevenue>
    <sgry:UnrecognizedGrantFundsReceived
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1MTIxNw_83fdfdf5-72c5-4bc1-95f2-cda99fa4acbd"
      unitRef="usd">3000000</sgry:UnrecognizedGrantFundsReceived>
    <sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMTA5OTUxMTY1MTM2MA_27c0dd20-7f05-43db-bbb1-bd23e6950a6a"
      unitRef="usd">18000000</sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMzM_a5d25924-ddec-4943-8bcd-4201ac1405a9">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwNDQ_7876eff1-5df7-4242-8c23-757ac2c442f7">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,353.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,359.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="if395609fbdf14ab7bd54498a1f593d2b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy0yLTEtMS04MjAwNA_fdb7ea72-bb6d-4873-bf74-b20ff024b5af"
      unitRef="usd">1370100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i06a12e5fa6f448c88de9a7f5391b609d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy00LTEtMS04MjAwNA_16423808-e476-4bae-9874-9757f1f9631f"
      unitRef="usd">1370000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i68d8f30c03d949d484d4aa733ea4240d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy02LTEtMS04MjAwNA_ce9127b0-f435-47cb-a372-6e04d15c5f54"
      unitRef="usd">1353000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia6b4ddef7045437ba1eaade0bc4fe400_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfMy04LTEtMS04MjAwNA_267c5074-7490-4222-9048-883d60761ed1"
      unitRef="usd">1359700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iae41732101204d4c86f049ad4216697b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOmNhZGZiNDBmNmE2NzQ4ZGI5Njg5MTg1NjljMjUwOTY4XzQ_fdc4efbc-40b7-49de-86f5-8683a4794e74"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i4b22c450786b4f0091dc4d4eae7d1675_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC0yLTEtMS04MjAwNA_66afc026-c3fc-4b61-8613-2fdbe1e59ee4"
      unitRef="usd">185000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia9bc921c9b0344e5bb467bc42eaf8791_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC00LTEtMS04MjAwNA_1a57df2c-1391-4c6b-9de9-0c52f216c471"
      unitRef="usd">185000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8e3330b0a2e34c18a19a93f183c72e49_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC02LTEtMS04MjAwNA_75df6f42-6708-43ce-869f-f2d4d2fcaf45"
      unitRef="usd">181500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i323cf8e399eb45778ab71e463913d7f4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNC04LTEtMS04MjAwNA_3db257d3-663f-4493-a877-4abd8c1bdd3a"
      unitRef="usd">183400000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id6455bc1ca084f939e75bb4558e43b7d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjU5OGNiNjE4NDVlMzRiNmNiN2UzZWUwNTczMTg3YTU2XzQ_09d685b2-3421-402e-9045-828dd189add1"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="idacc70d8240e4b39bd9280d74b6d9b33_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS0yLTEtMS04MjAwNA_9e1a89aa-d6f6-409e-a1a7-620ccdb10422"
      unitRef="usd">320000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i08eb459530bf461880a8962c3bbf26b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS00LTEtMS04MjAwNA_2fe91aca-f1f4-4cb5-8b17-f858d1a68f93"
      unitRef="usd">320000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i195064f2c74144fa80d098a0e694c828_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS02LTEtMS04MjAwNA_4673c2f4-f62e-4814-965a-8f93e2dd1789"
      unitRef="usd">326400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0c30227944194e40b8bf2475f00b0c1d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RhYmxlOmQzYTVkODE2ZTZiYjQ1ODZhN2ZkZjM1MDMwMzU0ZGU5L3RhYmxlcmFuZ2U6ZDNhNWQ4MTZlNmJiNDU4NmE3ZmRmMzUwMzAzNTRkZTlfNS04LTEtMS04MjAwNA_ed974a3b-bca5-418e-89db-ec945146494d"
      unitRef="usd">326800000</us-gaap:LongTermDebt>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIxMTI_c2a1b25d-7450-47ec-a934-6e36a9fe5fcb">Variable Interest Entities&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <sgry:VariableInterestEntityNumberOfFacilities
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE3MDQ_e8f06487-64c9-4bd2-9998-44f67e08b36c"
      unitRef="facility">7</sgry:VariableInterestEntityNumberOfFacilities>
    <sgry:VariableInterestEntityNumberOfFacilities
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE3MzE_f720aad8-3cac-4d9e-b8c1-f518b13da682"
      unitRef="physician_practice">5</sgry:VariableInterestEntityNumberOfFacilities>
    <us-gaap:Assets
      contextRef="i7fa03c70c0ed47c68e5d1597b922d233_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE5MzM_642b6869-78cc-4c37-a1c0-04c555964b4d"
      unitRef="usd">69900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic20dd80291ba42deb6354c4af9a710ba_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjE5NDA_09b8d207-e48e-431f-8b34-7b3cde8c5263"
      unitRef="usd">64900000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i7fa03c70c0ed47c68e5d1597b922d233_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwMTQ_2ac497d7-e408-4419-8c85-ebc65f27ca56"
      unitRef="usd">44500000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic20dd80291ba42deb6354c4af9a710ba_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zMS9mcmFnOjIxYjBhNTFkNWUzNTRjN2M5YjVjZjIxNWE2ODVhNDgxL3RleHRyZWdpb246MjFiMGE1MWQ1ZTM1NGM3YzliNWNmMjE1YTY4NWE0ODFfMjIwMjE_37974085-7b25-4ff2-bc33-42b27ce61420"
      unitRef="usd">40900000</us-gaap:Liabilities>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNDM0Mw_30f19a4c-9523-49ea-ac7c-648351c32e27">Acquisitions and Disposals &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;The Company acquired a controlling interest in a surgical facility and a physician practice for aggregate cash consideration of $16.2&#160;million, net of cash acquired, and non-cash consideration of $1.3&#160;million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $12.0&#160;million and goodwill of $25.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;The Company acquired a controlling interest in two surgical facilities which were previously accounted for as equity method investments for cash consideration of $24.5&#160;million, net of cash acquired. As a result of these transactions, the Company obtained control of the previously non-controlled surgical facilities, resulting in the consolidation of the previously non-consolidated entities. The previously held non-controlling were remeasured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data. The acquisition date fair value of the previously held non-controlling interests was $8.3&#160;million. As a result of stepping up its ownership interest, the Company recognized a loss of $2.9&#160;million included in net loss (gain) on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023. The net loss was determined based on the difference between the fair value of the Company's previously held non-controlling interests in the entities and the carrying values immediately prior to the transactions. In connection with the acquisitions, the Company preliminarily recognized non-controlling interests of $34.2&#160;million and goodwill of $65.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;The Company acquired non-controlling interests in an existing surgical facility and an in-development de novo surgical facility for an aggregate cash purchase price of $12.4&#160;million, of which $2.8&#160;million was deferred and will be paid in April 2023. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. In April 2023, the Company obtained control of an existing non-controlled surgical facility due to an amendment to the facility operating agreement, resulting in the consolidation of the previously non-consolidated entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company acquired a controlling interest in two surgical facilities, one of which was merged into an existing surgical facility, for aggregate cash consideration of $31.1&#160;million, net of cash acquired, and non-cash consideration of $2.6&#160;million. In connection with the acquisitions, the Company preliminarily recognized non-controlling interests of $10.6&#160;million and goodwill of $42.7&#160;million. During the three months ended March&#160;31, 2023, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, the Company sold its interests in a surgical facility for a cash sales price of $8.8&#160;million, a portion of which was held in escrow pursuant to the purchase agreement. In connection with the sale, the Company recognized a pre-tax gain of $0.2&#160;million included in net loss (gain) on disposals, consolidations and deconsolidations in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;The Company sold its interests in a surgical facility, which was previously accounted for as an equity method investment, for net cash proceeds of $11.5&#160;million, and recognized a pre-tax loss of $0.4&#160;million included in loss (gain) on disposals and consolidations, net in the condensed consolidated statements of operations for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;The Company contributed its interests in two surgical facilities as non-cash consideration for non-controlling interests in two new separate entities. As a result of these transactions, the Company lost control of the previously controlled surgical facilities but retains a non-controlling interest in each, resulting in the deconsolidation of the previously consolidated entities. The remaining non-controlling interests were accounted for as equity method investments, and initially measured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data, to measure the fair value of the retained non-controlling interests. The fair value determination was based on a combination of multiple valuation methods, which included discounted cash flow and market value approach, which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. The fair value of the investments of $9.8&#160;million was recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. Further, based on the valuation, the transactions resulted in a pretax net loss on deconsolidations of $5.6&#160;million, which is included in net loss (gain) on disposals, consolidations and deconsolidations in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2022. The gains were determined based on the difference between the fair value of the Company's retained interests in the entities and the carrying values of both the tangible and intangible assets of the entities immediately prior to the transactions.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ife322ebfae344c06aadeb5444f977b01_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNzE0NjgyNTU5NDgxMQ_5840c088-e9c0-47ee-ae7c-fd92d5d36f0e"
      unitRef="usd">16200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ife322ebfae344c06aadeb5444f977b01_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfOTQ3_a03e324b-5316-4ae0-8bd2-1993cfb9dace"
      unitRef="usd">1300000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ia038e278a48340bda3280d3d858e408e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTE1Mw_34001e42-79c9-42a3-ad6a-6ebef75eb69c"
      unitRef="usd">12000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:Goodwill
      contextRef="ia038e278a48340bda3280d3d858e408e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTE3Mg_16e2272a-1aeb-40b5-8d6f-9f1cabc24e18"
      unitRef="usd">25700000</us-gaap:Goodwill>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzI5ODUzNDkwNTU5Mw_a3fc57f9-337f-4532-bed3-2b8cefa2cfe6"
      unitRef="facility">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNzE0NjgyNTU5NTAxNQ_021d0263-39bc-4095-bd9d-a8f09345c538"
      unitRef="usd">24500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i9b9dc705bdaf4307a20eb8262bdc4a27_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3MTg3MA_6f1e5548-fbb9-4b7f-b9a0-02555afb32ff"
      unitRef="usd">8300000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss
      contextRef="i00b2025fe03c49249c24ec196217cc8f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk2OTA3MA_adc8189b-1be8-424a-823b-bcca8e6b5720"
      unitRef="usd">2900000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ia0289c146748495ea969e604a4ecc4a0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3MjQ2NA_4c236e8a-9bca-45af-a35b-70deaf8b70ff"
      unitRef="usd">34200000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:Goodwill
      contextRef="ia0289c146748495ea969e604a4ecc4a0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3MjQ4NA_5bcce062-41a9-4d97-a094-60c909ddc649"
      unitRef="usd">65600000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i602c53397d114d5783de58eea6a301e1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3NDY0Mw_ec3ab212-d53f-471c-95a4-83944373018a"
      unitRef="usd">12400000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <sgry:DeferredPaymentsToAcquireEquityMethodInvestments
      contextRef="i79df32098d2a43b6b68b90171d47d5e8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk3NDY1Nw_1360d78b-c635-4883-91f7-1074860b6f9c"
      unitRef="usd">2800000</sgry:DeferredPaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTA5OTUxMTYzMjgxMw_98432af4-0681-4d7d-92a8-d21e65ba2e78"
      unitRef="facility">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ibe2f8852d0e443be810017d409db5c10_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTA5OTUxMTYzMjgxOQ_65435f74-5f76-4744-9ac9-6955cb6f6ff1"
      unitRef="facility">1</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNzE0NjgyNTU5NTMzMg_ee529020-0c51-4971-802a-b8376f98bfa8"
      unitRef="usd">31100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ib038f9531cff44e18ddbb6737c41b947_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTA5OTUxMTYzMzA4NA_63002c4c-4926-47ce-a31d-48f270d045d5"
      unitRef="usd">2600000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i3637827bd8fa46638845369ff6cefb32_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTU0NQ_f4d18fb8-c463-46dd-a4c2-e8f84366c700"
      unitRef="usd">10600000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:Goodwill
      contextRef="i3637827bd8fa46638845369ff6cefb32_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMTU2NA_6d6288f7-2fa1-420a-9e22-0d4999910cd2"
      unitRef="usd">42700000</us-gaap:Goodwill>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="iec7a6a99212642aab1d11f46ef8b71e8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk2OTkwMA_d059aa02-907b-4e07-baf0-b09a4d2ee10c"
      unitRef="usd">8800000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="iec7a6a99212642aab1d11f46ef8b71e8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfNjA0NzMxMzk2OTk4OA_15e2def0-2610-46e5-a362-4d9c4b88f4e5"
      unitRef="usd">200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjU3Ng_f7c94af2-2d91-4d0e-926e-af1d7d7352f0"
      unitRef="usd">11500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjU5MQ_e85aa547-a8c9-48b0-a07f-6f203f1fff91"
      unitRef="usd">-400000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <sgry:DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration
      contextRef="ib7040aa13d814518b2392558d57d1ae2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYwNA_bd6f9b45-dde9-450e-afda-d3bad12f1b70"
      unitRef="facility">2</sgry:DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ia62b48e259754cf8b5b649d1146431d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYzMw_7292dcca-4f86-40a6-b08c-f9c668be57fb"
      unitRef="business_entity">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i9d5a67a56b014b7b8024c968af016c48_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYwNg_4ee072e5-d6cc-44fa-a29a-2f6a1502f89b"
      unitRef="usd">9800000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i5360c902c0454970be9a1279e60a08c7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNC9mcmFnOjVkN2I5ZmM2YzA1ZDQ3N2ZiM2E0ZTFlNDhhNzQ3ODMwL3RleHRyZWdpb246NWQ3YjlmYzZjMDVkNDc3ZmIzYTRlMWU0OGE3NDc4MzBfMzg0ODI5MDcwNjYyMA_a04f39d2-44a8-4377-8206-cd4552ce768f"
      unitRef="usd">-5600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTE5Nw_58562afd-506e-4944-88f0-daca508b50a7">Long-Term Debt&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable and other secured loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,621.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,530.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,559.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes unamortized fair value discount of $2.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and $2.1&#160;million as of March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On January 13, 2023, the Company entered into an amendment to the credit agreement governing its revolving credit facility (the "Revolver"), which amended and supplemented the credit agreement, dated as of August 31, 2017 (the "Credit Agreement"), to provide a $203.8&#160;million increase in the outstanding commitments under the Revolver. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company's availability on its Revolver was $545.9 million (including outstanding letters of credit of $7.9 million). There were no outstanding borrowings under the Revolver as of both March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTE4Mg_065c5b2f-8503-472b-88d6-4a046cb227f7">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable and other secured loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,621.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,530.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,559.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes unamortized fair value discount of $2.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and $2.1&#160;million as of March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;December&#160;31, 2022, respectively.</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie31e09c8a7f742a7be738ff2b92bbe76_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMi0yLTEtMS04MjAwNA_565e24e7-6ce8-478f-971d-b313869ab404"
      unitRef="usd">1370100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie8a68d29d5ed4fd982d2f908018f3c10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMi00LTEtMS04MjAwNA_3ba4c971-4fb0-478a-a050-b1b06fe7c15b"
      unitRef="usd">1370000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iae41732101204d4c86f049ad4216697b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMy0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjM0MWFkMjNjY2U0OTRlMGRhOTNmZjg1ZDQ0MWY1Zjc3XzQ_fdc4efbc-40b7-49de-86f5-8683a4794e74"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iae41732101204d4c86f049ad4216697b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMy0yLTEtMS04MjAwNA_66bcab8c-36b3-4557-9825-89b4d5e8ccd2"
      unitRef="usd">185000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ife734a9e9b7c478480dcde8c8c378846_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMy00LTEtMS04MjAwNA_47f6ac14-babd-4b78-98eb-63c9bb169a4f"
      unitRef="usd">185000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id6455bc1ca084f939e75bb4558e43b7d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNC0wLTEtMS04MjAwNC90ZXh0cmVnaW9uOjYyNThhOWVhNjMyNDRlNDg5Y2I5MTAxZjA3N2U0MWI2XzQ_09d685b2-3421-402e-9045-828dd189add1"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id6455bc1ca084f939e75bb4558e43b7d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNC0yLTEtMS04MjAwNA_a906a913-6e66-42fd-8020-2096951af0f6"
      unitRef="usd">320000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic8254371571844ad8161e4d28a3392c2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNC00LTEtMS04MjAwNA_e186b43f-530c-4f6f-a3bd-53521cf8abc3"
      unitRef="usd">320000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie9d1e8e2eb6f4636a25ae23bd08dab22_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNS0yLTEtMS04MjAwNA_b3909872-fe7f-4809-9aca-90d55c69b3ac"
      unitRef="usd">174900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i23e712005c5d48dc978669d2c705456c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNS00LTEtMS04MjAwNA_e0cd38d2-f8ec-4bba-8626-23170572c938"
      unitRef="usd">171300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNi0yLTEtMS04MjAwNA_43c4fec7-ca68-4053-9416-33e151a743c9"
      unitRef="usd">553500000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNi00LTEtMS04MjAwNA_af591794-7552-4cb0-b431-c5cd49f6f395"
      unitRef="usd">585700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNy0yLTEtMS04MjAwNA_f9dae3fd-d396-4dd9-b48e-e0872e3fa67d"
      unitRef="usd">9700000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfNy00LTEtMS04MjAwNA_af998bea-bba0-4d98-b71e-5afb80bb6852"
      unitRef="usd">10200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOC0yLTEtMS04MjAwNA_2b773edb-753e-4539-9ebc-64286ecf033a"
      unitRef="usd">2593800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOC00LTEtMS04MjAwNA_dfefae5c-b53c-4b0e-ade7-48759274f942"
      unitRef="usd">2621800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOS0yLTEtMS04MjAwNA_9dc435ee-ea8f-4650-9df7-636dee304ec4"
      unitRef="usd">62900000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfOS00LTEtMS04MjAwNA_3e84c354-e90f-41aa-909e-d9827afdf8bb"
      unitRef="usd">62800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMTAtMi0xLTEtODIwMDQ_ab1e2d18-c30f-41bd-8746-c61a532c9536"
      unitRef="usd">2530900000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RhYmxlOjU5N2U0N2E4M2E0OTRhZTU4OTEwZmIzMzgxMzA2NjliL3RhYmxlcmFuZ2U6NTk3ZTQ3YTgzYTQ5NGFlNTg5MTBmYjMzODEzMDY2OWJfMTAtNC0xLTEtODIwMDQ_28151d88-a0e7-4fe5-970f-e06cc8084c95"
      unitRef="usd">2559000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ie31e09c8a7f742a7be738ff2b92bbe76_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTIy_c89c8327-9c26-4aa6-9565-ad2431a32560"
      unitRef="usd">2000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ie8a68d29d5ed4fd982d2f908018f3c10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTA5OTUxMTYyOTAwMA_c534175b-fa79-4cc4-8b74-b4fa84360929"
      unitRef="usd">2100000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <sgry:LineOfCreditFacilityIncreaseInBorrowingCapacity
      contextRef="i4be4e474695442ff8609d04af8b53bf2_D20230113-20230113"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTA5OTUxMTYyOTU0NA_2062535e-a2f6-4ba7-a3f1-75ebe869065d"
      unitRef="usd">203800000</sgry:LineOfCreditFacilityIncreaseInBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i615ae79f54e248ed8c11df419a474567_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTA1Mw_e304282a-8dd7-4377-8385-beeb8cb5e019"
      unitRef="usd">545900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i4d03e45ac72242afb2e27ac00a7fede9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTEwMA_90bfeb5e-2e21-46b3-9268-1434a38cd876"
      unitRef="usd">7900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i4ba191127c0e418d98b7c137b8b3b012_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTExNg_9156d910-5a1a-42c3-83f8-12803c246298"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="iffd37df4ed4f4e928da39c9e8a3b97d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8zNy9mcmFnOmU5NzFjYmVlNWU5ODRmM2U5NGQ5OWI0ZTAxOWEzNjE0L3RleHRyZWdpb246ZTk3MWNiZWU1ZTk4NGYzZTk0ZDk5YjRlMDE5YTM2MTRfMTExNg_d4480cde-1e74-4417-b738-495009ea51cd"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTEzNQ_0cc7951f-f9f0-4294-85e9-0ea9b03eab4c">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;529.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;764.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;860.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense included in the condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTEzNQ_c9cc57c5-4bcc-44fc-8ef0-2b4e88b8e8aa">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;529.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;764.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;860.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense included in the condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <sgry:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTE0MQ_b423d0a9-fce8-4740-a678-779c1ef8411a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_7c005afa-3e58-4e7f-9e35-bde35d2b6b33"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC0yLTEtMS04MjAwNA_bb72f3a8-6952-4333-a969-a036084797e3"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;529.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;764.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_979d2398-2538-463c-b590-3942d73c3f40"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS0yLTEtMS04MjAwNA_ad866618-2dd3-4eb2-b40a-b7a62c8aa011"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_54337ff7-9fdb-4ec0-a3e4-049905eea9de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtMi0xLTEtODIwMDQ_84d0388f-e7f4-4233-a332-5945c10e1f30"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_4b478872-0407-48a7-8d8a-424fbbb7633f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtMi0xLTEtODIwMDQ_b47c4f49-652d-4ae9-82e8-3c4c53c5d905"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;860.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgry:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMy00LTEtMS04MjAwNA_c0d017ec-74ac-4647-8696-6862a54a8921"
      unitRef="usd">274000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMy02LTEtMS04MjAwNA_55845dd7-4869-4ecc-ba15-bbc25c49b1fd"
      unitRef="usd">279100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC00LTEtMS04MjAwNA_4f21b3d6-2dd4-41e6-9ef7-e899bf908b14"
      unitRef="usd">490600000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNC02LTEtMS04MjAwNA_03e7f332-7ea2-43ba-a9e8-a3a5ee4d237c"
      unitRef="usd">529600000</us-gaap:FinanceLeaseRightOfUseAsset>
    <sgry:LeaseRightOfUseAsset
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNS00LTEtMS04MjAwNA_786d7b02-9fbb-4823-9a7a-aa8e2e195035"
      unitRef="usd">764600000</sgry:LeaseRightOfUseAsset>
    <sgry:LeaseRightOfUseAsset
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfNS02LTEtMS04MjAwNA_d3a4627b-5571-4897-bba5-2eebd38ed373"
      unitRef="usd">808700000</sgry:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS00LTEtMS04MjAwNA_501a2948-edfb-4c9b-a696-a6bf16245d23"
      unitRef="usd">38000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfOS02LTEtMS04MjAwNA_85c57cbb-499f-474a-9946-e6f87d96c285"
      unitRef="usd">36500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTAtNC0xLTEtODIwMDQ_1e8131ac-9a4d-4c8b-8967-0ba0f8f3db15"
      unitRef="usd">268800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTAtNi0xLTEtODIwMDQ_2af6597e-e1e8-4a8f-975a-c1c72ada6cfa"
      unitRef="usd">271400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTEtNC0xLTEtODIwMDQ_8b5db528-074d-4852-b092-4a395b1e452a"
      unitRef="usd">306800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTEtNi0xLTEtODIwMDQ_3f8b3606-25f9-4c5b-8efc-ca2fff6be998"
      unitRef="usd">307900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtNC0xLTEtODIwMDQ_73d4ad1c-d08d-41bc-8189-2ab4806ba059"
      unitRef="usd">21400000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTMtNi0xLTEtODIwMDQ_4e2ec62c-cf09-4059-b198-784dbc868a7c"
      unitRef="usd">20900000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtNC0xLTEtODIwMDQ_a47af8a3-ca57-4b63-a131-4fe599b151b6"
      unitRef="usd">532100000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTQtNi0xLTEtODIwMDQ_4185b66d-35f4-4128-bfa9-496392e77d2a"
      unitRef="usd">564800000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTUtNC0xLTEtODIwMDQ_a3d7121f-e60f-409c-97b3-917060fc6fb2"
      unitRef="usd">553500000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTUtNi0xLTEtODIwMDQ_29c181eb-2483-4e0c-9186-e1cc97714826"
      unitRef="usd">585700000</us-gaap:FinanceLeaseLiability>
    <sgry:LeaseLiability
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTYtNC0xLTEtODIwMDQ_e3b2fc06-ece9-46c6-877f-c00e13d117b3"
      unitRef="usd">860300000</sgry:LeaseLiability>
    <sgry:LeaseLiability
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOmE4NzU0ZGVhNTdjNjQ2MDFiOWY4ZTUxOWZlMWJmNzc5L3RhYmxlcmFuZ2U6YTg3NTRkZWE1N2M2NDYwMWI5ZjhlNTE5ZmUxYmY3NzlfMTYtNi0xLTEtODIwMDQ_309c0d04-4185-46b9-aa78-fa2566ed742b"
      unitRef="usd">893600000</sgry:LeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RleHRyZWdpb246ODU2ZTdhYmZlOTk4NDExNmFlNmFhMjgyZDY1ZjJkOTFfMTE0Mg_5ad0917c-b8f5-4cd3-b521-4e10e9d9e797">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense included in the condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfMi0yLTEtMS04MjAwNA_c337e375-a67e-491a-a47c-8370e33a831d"
      unitRef="usd">16400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfMi00LTEtMS04MjAwNA_cd43ce0b-1720-4eaf-afb7-cadaff89f16f"
      unitRef="usd">16100000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNC0yLTEtMS04MjAwNA_52eadc15-69c6-41f3-9281-42f7f3bfdf11"
      unitRef="usd">9400000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNC00LTEtMS04MjAwNA_26e465f5-2e5f-4eaf-8af8-c53e1b8c2bac"
      unitRef="usd">9200000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNS0yLTEtMS04MjAwNA_4843d182-d235-4322-ac61-5c230929964d"
      unitRef="usd">12300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNS00LTEtMS04MjAwNA_29da0316-c3a6-497e-81d0-6bb746ea1dbf"
      unitRef="usd">9900000</us-gaap:FinanceLeaseInterestExpense>
    <sgry:FinanceLeaseCost
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNi0yLTEtMS04MjAwNA_eba8d3f5-176f-4c16-a197-6e8d809e8ed2"
      unitRef="usd">21700000</sgry:FinanceLeaseCost>
    <sgry:FinanceLeaseCost
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNi00LTEtMS04MjAwNA_e7b37fa8-e0aa-4511-9432-73525a4b2270"
      unitRef="usd">19100000</sgry:FinanceLeaseCost>
    <sgry:VariableAndShortTermLeaseCost
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNy0yLTEtMS04MjAwNA_22681007-3936-48b2-97ec-688a0a2ac37b"
      unitRef="usd">5200000</sgry:VariableAndShortTermLeaseCost>
    <sgry:VariableAndShortTermLeaseCost
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfNy00LTEtMS04MjAwNA_5c11a7c2-378c-4b43-a12f-2dfb1b82d9ef"
      unitRef="usd">4400000</sgry:VariableAndShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfOC0yLTEtMS04MjAwNA_0fa42936-c7a3-4392-a803-12768179bedd"
      unitRef="usd">43300000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjdkOTgzNDc5NjM2ZTQ5ZTQ4NDUyYTZhY2E5MjRlYWJmL3RhYmxlcmFuZ2U6N2Q5ODM0Nzk2MzZlNDllNDg0NTJhNmFjYTkyNGVhYmZfOC00LTEtMS04MjAwNA_679b3519-40d1-4cf7-b820-7615ed8da13e"
      unitRef="usd">39600000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfMy0xLTEtMS04MjAwNA_08fab6f6-2803-4418-87eb-ed2610bf05bd"
      unitRef="usd">16100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfMy0zLTEtMS04MjAwNA_1e0a5d70-0352-4e17-aa44-9f4062241f47"
      unitRef="usd">15600000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNC0xLTEtMS04MjAwNA_baa47103-c54e-445c-aacc-0f61d2c7f1fa"
      unitRef="usd">11700000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNC0zLTEtMS04MjAwNA_ac83e286-c1f0-4922-8ff3-600ef12b9959"
      unitRef="usd">9800000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNS0xLTEtMS04MjAwNA_b7f28632-15f9-4175-b223-1c08799d804f"
      unitRef="usd">6400000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfNS0zLTEtMS04MjAwNA_a1c48df9-af69-42aa-a82b-cd75f9dca65f"
      unitRef="usd">6000000.0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOC0xLTEtMS04MjAwNA_7278d136-4a93-4b27-8250-c08facd97c03"
      unitRef="usd">8900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOC0zLTEtMS04MjAwNA_4d560588-df76-4d36-a382-fdbfcb5e3138"
      unitRef="usd">22000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOS0xLTEtMS04MjAwNA_48ec38e9-d900-4f2a-9450-34ceb9e997ae"
      unitRef="usd">15400000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80MC9mcmFnOjg1NmU3YWJmZTk5ODQxMTZhZTZhYTI4MmQ2NWYyZDkxL3RhYmxlOjlhZmVjYWE2NWVjNDRlNTU5ODFmNjIyNGE1OGY4YzIzL3RhYmxlcmFuZ2U6OWFmZWNhYTY1ZWM0NGU1NTk4MWY2MjI0YTU4ZjhjMjNfOS0zLTEtMS04MjAwNA_8e38924e-272d-4321-b0e1-e28deb082b15"
      unitRef="usd">89300000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNTAxMw_c031c677-a520-4bfc-9a90-b14db32eb740">Derivatives and Hedging Activities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2023 and 2022, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The key terms of interest rate swaps and interest rate caps outstanding are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 28, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,366.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,518.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company had nine interest rate swaps with a total net notional amount of $1.2&#160;billion. Of the nine interest rate swaps, three are pay-fixed, receive 1-Month LIBOR (subject to a minimum of 0.75%) interest rate swaps designated in cash flow hedging relationships with a total notional amount of $1.2&#160;billion and a termination date of March 31, 2025. The remaining six interest rate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;swaps are undesignated and consist of three pay-fixed, receive 1-Month LIBOR (subject to a minimum of 1.00%) interest rate swaps and three pay 1-Month LIBOR (subject to a minimum of 1.00%), receive-fixed interest rate swaps with a termination date of November 30, 2023. The pay-floating, receive-fixed swaps are designed to economically offset the undesignated pay-fixed, receive-floating swaps. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company had two interest rate caps designated in cash flow hedging relationships with a total notional amount of $166.1&#160;million. The interest rate caps each have a termination date of March 31, 2025. During the three months ended March 31, 2023, the Company partially terminated a previously undesignated portion of one of its interest rate caps. In connection with the termination, the Company received $8.6&#160;million, which is included as a component of operating activities in the condensed consolidated statements of cash flows for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Within the Company&#x2019;s condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives and the undesignated swaps are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Cash settlements related to the undesignated swaps will offset and are classified as operating activities in the condensed consolidated cash flows. Within the Company&#x2019;s condensed consolidated balance sheets, the interest rate caps, including the undesignated portion, are recorded at fair value. The cash flows related to the interest rate caps, including the undesignated portion, are classified as operating activities in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Our interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps are determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#x2019;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#x2019;s variable-rate debt. Over the next 12 months, the Company estimates that an additional $33.6 million will be reclassified as a decrease to interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate caps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate caps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The balance  is related to the financing component of the pay-fixed, receive floating interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Loss) gain recognized in OCI (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss reclassified from accumulated OCI into income (effective portion) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0xLTEtMS04MjAwNA_eaac48d6-4a38-4801-99ed-58a72d155519"&gt;Interest expense, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.4 million and $5.3 million for the three months ended March&#160;31, 2023 and 2022, respectively.</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMzI5ODUzNDg5MzA0MA_6ace8335-0914-44ed-bd5d-8cafd130d946">During 2023 and 2022, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The key terms of interest rate swaps and interest rate caps outstanding are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 28, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,366.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,518.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i2b122a7729f846aa83ebcbf74914d1ea_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMi00LTEtMS04OTIyNg_5e776f9e-16d2-473e-bd41-c50bf8d0d59f"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i8fdfc90ff3a14df4942da87910339b7d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMi04LTEtMS04OTIyNg_2927ed26-f4ce-42ea-951e-ac8b0f7d4113"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="iefe42526145740de8a9b4f2c4ab6be7b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMy00LTEtMS04OTIyNg_29bab942-f899-4adc-ac51-b84bbe935b47"
      unitRef="usd">330000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="idc4d54f90673412ab5865efd54bf31bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMy04LTEtMS04OTIyNg_221faae4-e46d-4024-bb28-e02e3bd71ad5"
      unitRef="usd">330000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i1a3ddfc6326b430ba42803e01d9ea155_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNC00LTEtMS04OTIyNg_8dfa1d68-74b4-44a1-87c6-ee77eb6f0dfe"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ia7aaa64d2b9647c0880375718f91f9aa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNC04LTEtMS04OTIyNg_374c0c9a-9ba4-4279-9f85-c13ff9bf596b"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="id0ee0c2d30114fa7a498e11d518d5e86_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNS00LTEtMS04OTIyNg_5a7591e6-f1e9-4d48-9eed-c732e8ba4c8e"
      unitRef="usd">157200000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i6cc717c4e3294018b3a17b8db7550574_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNS04LTEtMS04OTIyNg_127bbb23-1af2-4d77-8d26-3d2299c1ad65"
      unitRef="usd">159100000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i0d3958dd7b5c43feb0b399d644cfcd76_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNi00LTEtMS04OTIyNg_696b72a0-8620-42c3-887b-37b6052d8b2e"
      unitRef="usd">8900000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="iaef97110d9b04fc3800be00674d398a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNi04LTEtMS04OTIyNg_feb05990-1f0c-4834-b6bb-265668ffe783"
      unitRef="usd">159100000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i6363d1608b80467fabaff6452dee18c1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNy00LTEtMS04OTIyNg_30ff7335-435a-4999-94b4-79ee74f7cde3"
      unitRef="usd">165000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="id0f20c8303b34ed89344ee532d50feb5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfNy04LTEtMS04OTIyNg_574c2fd1-50ae-4e1c-82a3-f6db2c7873c8"
      unitRef="usd">165000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i03ac93228961451d928a5d157461cb0c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOC00LTEtMS04OTIyNg_1fda5d12-7898-4736-937e-f6d9e52aac06"
      unitRef="usd">120000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i3ad3beb2f31c412db347647224886c3c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOC04LTEtMS04OTIyNg_2d698c08-10c9-43b1-8dd7-cc7b8609a94e"
      unitRef="usd">120000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i8d43b1d96bd4419da9eece9e1cdddd7c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOS00LTEtMS04OTIyNg_d2a750a6-f303-4513-b2d6-b55aa5c73f8b"
      unitRef="usd">150000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i2552dc67907f4497afcc3243f335c0da_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfOS04LTEtMS04OTIyNg_77c3f8b5-c72d-4fb5-b7d8-ea3354f5de44"
      unitRef="usd">150000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ie53660b17d444b948667db475ff5f35b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTAtNC0xLTEtODkyMjY_82c5f8d4-9cf5-4f86-a0fd-d4dbcdaac84d"
      unitRef="usd">165000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="if32f04ce941249ddbd22432651106a15_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTAtOC0xLTEtODkyMjY_0ce97118-e6ff-4ba8-a7a4-b2a5ca4c49f7"
      unitRef="usd">165000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic698993ebca540e6a16d6647445084ef_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTEtNC0xLTEtODkyMjY_c6867962-5666-436c-ab9d-a8001fe79f23"
      unitRef="usd">120000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i372b7962442b41a2ad5aae90be62bfd9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTEtOC0xLTEtODkyMjY_e96a317b-d595-45df-8ffe-7e80c628393f"
      unitRef="usd">120000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="id13b3e0bc44448129d260b0bf3a9c405_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTItNC0xLTEtODkyMjY_c131c76f-a742-4b06-a769-ae37f109ad32"
      unitRef="usd">150000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i83325c5100f64cd79cec11f2d4874566_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTItOC0xLTEtODkyMjY_313dfb89-b97f-4e70-aee0-dbec528e4bc6"
      unitRef="usd">150000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTMtNC0xLTEtOTA0MzY_ce68380f-8f09-4cd0-846a-c3a3da8af36b"
      unitRef="usd">1366100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOjY4ZWFkOWFkODgzNTRiZGU5NTI5MWM3MDc3MzRhOTE4L3RhYmxlcmFuZ2U6NjhlYWQ5YWQ4ODM1NGJkZTk1MjkxYzcwNzczNGE5MThfMTMtOC0xLTEtOTA0Mzg_6c3d9098-4207-44d4-847a-5e1eec6d75e1"
      unitRef="usd">1518200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i46fd0fed21334b48980d887244b2c6db_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTIxMQ_da76f8e6-e799-4821-8ac7-d596ce4f639e"
      unitRef="interest_rate_swap">9</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i46fd0fed21334b48980d887244b2c6db_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTI3Nw_aebe842d-af26-4d3f-be84-76c2c849323d"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i46fd0fed21334b48980d887244b2c6db_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTM1Ng_1441a3e3-2910-4266-9f60-132f285a3561"
      unitRef="interest_rate_swap">9</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i8302a05487cc46e38e8ff3204b1ef2ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTM4MA_3e0f428d-8213-4b46-8847-45c1afd97ae6"
      unitRef="interest_rate_swap">3</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="i8e445dd464d44ade88f9c43c91d57652_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTQ0NQ_3ffc5e97-8dcd-43da-b70a-6ef682d0ef65"
      unitRef="number">0.0075</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8302a05487cc46e38e8ff3204b1ef2ad_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTU0Nw_1383eea2-f2c5-4ae8-97d3-591dac428fad"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i033d3f1806b744ce9eadad25192e34c5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTU5NA_9848966a-3537-4235-9795-8e4fcb5463f3"
      unitRef="interest_rate_swap">6</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i3af8b13e57f44b27bb771a94d96d89aa_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTY0OQ_fd6807b3-f303-46a6-92f3-c3277100458d"
      unitRef="interest_rate_swap">3</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="ic1065326829d4decbc61f91f23875e3b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTcxMA_12387927-d8ac-46f5-a0d5-745a82987687"
      unitRef="number">0.0100</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="idb4cece3ff2e407f9fb299708f2e854b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTczOA_27b975c2-f403-4a11-8bc9-dd17b8441899"
      unitRef="interest_rate_swap">3</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="i6bca9cce39a74eb380fb5d884f2da248_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTc4NA_63bb71fc-70e0-4584-967a-aea2812a187d"
      unitRef="number">0.0100</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i0a74f9aadc8a47c890d7ae741d0d1e9e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTA5OTUxMTYzNDExMw_73dd42c0-480a-4f1f-8595-55e7a3ae8d90"
      unitRef="interest_rate_swap">2</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0a74f9aadc8a47c890d7ae741d0d1e9e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTA5OTUxMTYzNDE0OQ_945d3e57-2b05-42aa-9836-9268f66df76d"
      unitRef="usd">166100000</us-gaap:DerivativeNotionalAmount>
    <sgry:ProceedsFromTerminatedDerivativeInstrumentOperatingActivities
      contextRef="i517ad963d7114f93893b2d189dc801a1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNjA0NzMxMzk2MjMzMw_0b2f60b7-4087-44e8-963c-7612ced3622d"
      unitRef="usd">8600000</sgry:ProceedsFromTerminatedDerivativeInstrumentOperatingActivities>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNjA0NzMxMzk2MTY5NA_4ef60cb2-9725-4015-88b1-8c0e218dc58c"
      unitRef="usd">-33600000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNTAxMQ_7d550073-4d6d-46c0-a625-d6c906ef0edc">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate caps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate caps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The balance  is related to the financing component of the pay-fixed, receive floating interest rate swaps.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i8812d79ba0e7406a8a6f1c6d561cc07a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMy04LTEtMS04MzMyNQ_83dce34d-57e2-4f93-937c-668bea794861"
      unitRef="usd">9000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i29099c90b3434f62bb442dd9874e5c47_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMy00LTEtMS04MjAwNA_6e2531f9-54b1-4731-aba0-4014a61f0110"
      unitRef="usd">6200000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="if5cac67689284faabfc9916d5cb46d63_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMy04LTEtMS04MjAwNA_e9c35a3b-66f6-4b27-a136-550e97b86d3d"
      unitRef="usd">8500000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic979a115883d4f5592bb7c07055ffbf5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNC02LTEtMS04MjAwNA_d2551b0b-f94a-4116-967e-481920f713ee"
      unitRef="usd">6200000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="icd3a9b4bf3a2433f898c5e81d44b1b91_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNC0xMC0xLTEtODIwMDQ_2b3096d6-4b15-4472-94bc-5ec0a2eee384"
      unitRef="usd">8500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ia9adfa3e753a42ca88143d956ce95e86_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNy00LTEtMS04MjAwNA_8212fd13-aa24-498b-a65a-fd3b6c0ea926"
      unitRef="usd">8400000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i89a6a63c9b104ac2a07649af064d610e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfNy04LTEtMS04MjAwNA_3b8b563f-6f25-4af2-8fed-1507d46aefd6"
      unitRef="usd">10400000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="icbafff4d10d840b2955f9a765fcf5409_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOC00LTEtMS04MjAwNA_6979c285-a67d-4cd6-b524-f43642d8ba40"
      unitRef="usd">70600000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i6c827cd5ece5427082bea6ecb15df8c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOC04LTEtMS04MjAwNA_eb06ab72-c83d-41a0-94fb-0c4858661ce3"
      unitRef="usd">85500000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i886a6e64b9a743b0aca7c22e739b1e1d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOS02LTEtMS04MjAwNA_d4567ad6-cca2-455b-b8c4-f7058c99d440"
      unitRef="usd">28300000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ica8d344040734175a530bc09317337aa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfOS0xMC0xLTEtODIwMDQ_908aac8c-f569-47c6-ae9f-4ca506848052"
      unitRef="usd">31900000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtNC0xLTEtODIwMDQ_81dfc5b7-2f55-47c8-92ca-a639fb078fd7"
      unitRef="usd">85200000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtNi0xLTEtODIwMDQ_caa13c3f-3deb-4534-ad7c-d458aba2c1e9"
      unitRef="usd">34500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtOC0xLTEtODIwMDQ_0ca74934-0121-400b-9150-fdfbc608f4ff"
      unitRef="usd">113400000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmVhMDJjMWJjNzRkNzRkMmJiNDY4NDUxNTc2YmY4NmQ4L3RhYmxlcmFuZ2U6ZWEwMmMxYmM3NGQ3NGQyYmI0Njg0NTE1NzZiZjg2ZDhfMTAtMTAtMS0xLTgyMDA0_7a278b85-5a47-4324-a2f3-a84d7e462fd3"
      unitRef="usd">40400000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNTAxMg_36c00bf6-2cc5-4d23-969a-0a9bfa67c633">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Loss) gain recognized in OCI (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss reclassified from accumulated OCI into income (effective portion) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0xLTEtMS04MjAwNA_eaac48d6-4a38-4801-99ed-58a72d155519"&gt;Interest expense, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.4 million and $5.3 million for the three months ended March&#160;31, 2023 and 2022, respectively.</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="icd4a8d2749ec405c9d0f00d16b8d1584_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfMy0zLTEtMS04MjAwNA_47e0ec70-c1ff-4634-937c-1cae675bd04c"
      unitRef="usd">-600000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i363d451cc1cb4d0c96744998ea60df5c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfMy01LTEtMS04MjAwNA_cbf527a9-3b4f-4dd2-ad5f-15780aceff48"
      unitRef="usd">-100000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i759de978c1164030aaf39f8ac3180d79_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNi0zLTEtMS04MjAwNA_990037cc-c727-4451-acc2-07f0a0360146"
      unitRef="usd">-5200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6eab5cbc43744770be5708852cdd239c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNi01LTEtMS04MjAwNA_cec73fc5-6735-40ae-bf17-46f3e7ce9a7f"
      unitRef="usd">50400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i759de978c1164030aaf39f8ac3180d79_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy0zLTEtMS04MjAwNA_2f1ad4e8-0572-4672-be79-03cc68647856"
      unitRef="usd">6100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6eab5cbc43744770be5708852cdd239c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RhYmxlOmViMWQ2NzViMjViYzRlMTliODRkMDFhYmJhZDhlNzZmL3RhYmxlcmFuZ2U6ZWIxZDY3NWIyNWJjNGUxOWI4NGQwMWFiYmFkOGU3NmZfNy01LTEtMS04MjAwNA_77d8a0d8-46cd-49aa-992a-fb1675c3bf93"
      unitRef="usd">-6400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfNDgwNQ_21c74d0b-188f-41a4-9d71-fba1933c5bb1"
      unitRef="usd">5400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80My9mcmFnOjc2OGRhYTMyYWMxOTRlNDU5YzMzNmRhMDFjOTRkYWNkL3RleHRyZWdpb246NzY4ZGFhMzJhYzE5NGU0NTljMzM2ZGEwMWM5NGRhY2RfMTA5OTUxMTYzNTEyNQ_a9c1823d-5cde-468a-807b-7714e930a9da"
      unitRef="usd">5300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RleHRyZWdpb246OGM5MDYzODY2OTA3NDllMjgzYmY4YWMyY2ExYzcyNTBfMTMzNg_841342bb-a7f2-4be0-99ab-4889b15b871f">Earnings Per Share&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to Surgery Partners, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The impact of potentially dilutive securities for the three months ended March 31, 2023, was not considered because the effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RleHRyZWdpb246OGM5MDYzODY2OTA3NDllMjgzYmY4YWMyY2ExYzcyNTBfMTMzOQ_f3af74c0-7f51-451e-ad48-c6cf514abd84">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): &lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to Surgery Partners, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The impact of potentially dilutive securities for the three months ended March 31, 2023, was not considered because the effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMy0xLTEtMS04MjAwNA_f3f12ac0-aa7a-4995-ab94-68160200a587"
      unitRef="usd">-24900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMy0zLTEtMS04MjAwNA_cd56bb52-eaf3-48ce-88c8-97a9cfe1aae3"
      unitRef="usd">12200000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOC0xLTEtMS04MjAwNA_40a07f52-7e6d-4451-8462-736c1a2b8959"
      unitRef="shares">125206000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOC0zLTEtMS04MjAwNA_de54a245-36a5-430a-982b-8bb192fdf610"
      unitRef="shares">87995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOS0xLTEtMS04MjAwNA_252996ba-afcd-481f-9d6e-f3beac8aae3c"
      unitRef="shares">125206000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfOS0zLTEtMS04MjAwNA_d3fb2777-b30a-4f9b-adda-073d47062ee4"
      unitRef="shares">90272000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTItMS0xLTEtODIwMDQ_cd830a76-d0e3-48be-8e60-b7460bdaa3ea"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTItMy0xLTEtODIwMDQ_ee0b33e6-e28b-43d3-8f87-c5604d26d8eb"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTMtMS0xLTEtODIwMDQ_5ea318ff-8ffd-4885-8cf1-d95005ffc0e5"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTMtMy0xLTEtODIwMDQ_299b70d3-be0a-49aa-a617-2b0d1b4c3260"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ife80b1a65af94f9b863703998b3c1df8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTYtMS0xLTEtODIwMDQ_60f29c26-9267-4a8c-a725-077b94093ffe"
      unitRef="shares">1338000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifab134fcb68746328d5adb54f4ab2b41_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTYtMy0xLTEtODIwMDQ_f33d01ca-32ce-4cad-ad1d-41cf98812f21"
      unitRef="shares">1634000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5e51254b066146b68172b2d7e45eabf9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTctMS0xLTEtODIwMDQ_f836c76d-a8ec-4317-a621-97d121976edd"
      unitRef="shares">67000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i570ad1cc62c24af1a4a594dacdc9450a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80Ni9mcmFnOjhjOTA2Mzg2NjkwNzQ5ZTI4M2JmOGFjMmNhMWM3MjUwL3RhYmxlOmM5NWZkMzgxZTQzOTQxMmI4NzgzY2M4MGFiYzcxZTQwL3RhYmxlcmFuZ2U6Yzk1ZmQzODFlNDM5NDEyYjg3ODNjYzgwYWJjNzFlNDBfMTctMy0xLTEtODIwMDQ_3e74e5a2-4b9e-4714-becb-0f3c06584870"
      unitRef="shares">643000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RleHRyZWdpb246OGFiNzFlZjJjMDg3NDVmYjkyYzI3NzIzYjE3MTY0MWZfMTA4_ddc3f76e-f002-421b-aa7a-692c5080ea7c">Other Current Liabilities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of other current liabilities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts due to patients and payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost report liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition escrow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RleHRyZWdpb246OGFiNzFlZjJjMDg3NDVmYjkyYzI3NzIzYjE3MTY0MWZfMTEx_abd5e144-0211-4884-842e-7ff1d14c605c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of other current liabilities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts due to patients and payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost report liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition escrow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy0yLTEtMS04MjAwNA_cfbe713a-c4de-493e-92c1-e369c63793fa"
      unitRef="usd">38000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy00LTEtMS04MjAwNA_22bccde8-93e4-4cbb-9e78-72cc01f33952"
      unitRef="usd">36500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <srt:PayablesToCustomers
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy0yLTEtMS04MzU2NQ_295d6d18-bd01-4699-8a13-e76c0713d631"
      unitRef="usd">30000000.0</srt:PayablesToCustomers>
    <srt:PayablesToCustomers
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfMy00LTEtMS04MzU2NQ_8d766d9c-d5e2-4911-9ae2-dfd98cd0b85d"
      unitRef="usd">31900000</srt:PayablesToCustomers>
    <sgry:CostReportLiabilitiesCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC0yLTEtMS04ODQ1NA_4cf1d48f-14bf-401c-a7fb-3802af55ec5d"
      unitRef="usd">24200000</sgry:CostReportLiabilitiesCurrent>
    <sgry:CostReportLiabilitiesCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC00LTEtMS04ODQ1NA_316958c8-3832-4f23-b304-90edd51ce4c6"
      unitRef="usd">23500000</sgry:CostReportLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNS0yLTEtMS04MzU5NQ_a0798bdc-b2da-4473-a0da-6e448ea1f385"
      unitRef="usd">23700000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNS00LTEtMS04MzU5NQ_e3f1f414-0928-45d7-a0a4-d5cf8e2eb767"
      unitRef="usd">19400000</us-gaap:InterestPayableCurrent>
    <sgry:AcquisitionEscrowLiabilityCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC0yLTEtMS04MjAwNA_311d1da9-e139-4e54-91a3-7c5779a04a64"
      unitRef="usd">17400000</sgry:AcquisitionEscrowLiabilityCurrent>
    <sgry:AcquisitionEscrowLiabilityCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfNC00LTEtMS04MjAwNA_13030c05-660f-4eff-b75f-2bc0e08ce27b"
      unitRef="usd">28800000</sgry:AcquisitionEscrowLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOC0yLTEtMS04MjAwNA_f7723037-737c-4c82-a523-cc083a34b016"
      unitRef="usd">66700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOC00LTEtMS04MjAwNA_2b23ba10-f9bc-459a-8e14-1c0ed28f631f"
      unitRef="usd">70000000.0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOS0yLTEtMS04MjAwNA_a400735c-1f83-4e3c-bc6f-69500dd3ad46"
      unitRef="usd">200000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF80OS9mcmFnOjhhYjcxZWYyYzA4NzQ1ZmI5MmMyNzcyM2IxNzE2NDFmL3RhYmxlOjExNWIxN2FhNzIzODQ1NTNhMzE4NjVjOGY5YzVkODNmL3RhYmxlcmFuZ2U6MTE1YjE3YWE3MjM4NDU1M2EzMTg2NWM4ZjljNWQ4M2ZfOS00LTEtMS04MjAwNA_c6ed5620-44b6-4f83-97fc-bcff93af4103"
      unitRef="usd">210100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfODc3NQ_4cd614eb-3952-42ec-84f4-0f63d145a739">Commitments and Contingencies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Professional, General and Workers' Compensation Liability Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were $22.1 million and $20.8 million, respectively. Expected insurance recoveries of $12.7 million as of both March&#160;31, 2023 and December&#160;31, 2022 are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Laws and Regulations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholder Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On December 4, 2017, a purported Company stockholder filed an action in the Delaware Court of Chancery (the "Delaware Action"). That action is captioned Witmer v. H.I.G. Capital, L.L.C., et al., C.A. No. 2017-0862. The plaintiff in the Delaware Action asserted claims against (i) certain current and former members of the Company&#x2019;s Board of Directors (together, the "Directors"); (ii) H.I.G. Capital, LLC and certain of its affiliates (collectively, "H.I.G."); and (iii) Bain Capital Private Equity, L.P. and certain of its affiliates (collectively, "Bain Capital" and, together with the Directors and H.I.G., the "Defendants"). The parties to the Delaware Action negotiated a final stipulation of settlement (the &#x201c;Settlement Stipulation&#x201d;), which governs the terms of the settlement of the Delaware Action, and which they filed with the Court of Chancery on November 22, 2021. On February 11, 2022, the Court of Chancery approved the settlement of the Delaware Action as memorialized in the Settlement Stipulation. That decision became final and non-appealable on March 14, 2022. The case is now closed. Pursuant to the settlement, the Company received $32.8&#160;million in March 2022, which was included in litigation settlement in the condensed consolidated statements of operations for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the federal physician self-referral law, or Stark Law, the statute commonly known as the federal Anti-Kickback statute, the federal False Claims Act, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Potential Physician Investor Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SelfInsuranceReserve
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTAwNg_c23c7bc8-17c6-4eff-a9f9-98ecfff8344d"
      unitRef="usd">22100000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTAxMw_97276daa-3d5f-4312-b4b3-895c024fc02b"
      unitRef="usd">20800000</us-gaap:SelfInsuranceReserve>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTA2NA_71d65bbc-14f9-42f3-aa8f-f7a979ac2493"
      unitRef="usd">12700000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMTA2NA_ab97f010-c96f-4251-8d41-4ecd03276456"
      unitRef="usd">12700000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i879bc0eafd88419c89015946c25ea837_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81Mi9mcmFnOjIwNWNkNTAzZmFlNjQ2NTViMzU3MTQwZjIyYTcyMjBiL3RleHRyZWdpb246MjA1Y2Q1MDNmYWU2NDY1NWIzNTcxNDBmMjJhNzIyMGJfMzQ1Ng_16bea11f-ed57-4f4f-ad69-37c636e7035a"
      unitRef="usd">32800000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTY0MA_475c2179-99c8-435d-9956-177ec1c3d54f">Segment Reporting&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company currently operates in&#160;two&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment includes the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of the Company's corporate general and administrative functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present financial information for each reportable segment (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;666.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciliation of Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transaction, integration and acquisition costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss (gain) on disposals, consolidations and deconsolidations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Litigation settlements and regulatory change impact &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Undesignated derivative activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes transaction and integration costs of $12.5 million and $7.1 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $0.3 million for the three months ended March&#160;31, 2023, with no comparable costs for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes an $8.5&#160;million loss for the three months ended March 31, 2023 related to a surgical facility with a book value of the asset group in excess of the fair value based on a letter of intent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes a litigation settlement loss of $3.0 million and a gain of $32.8 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount also includes other litigation costs of $0.6 million and $2.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. Additionally, the three months ended March 31, 2023, includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,049.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,643.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,682.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash purchases of property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjE_f3647f98-d9a4-4e0f-b96f-107ee02e8cdd"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTY0OA_784603d1-c2b9-4d43-a49d-da1712053e05">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present financial information for each reportable segment (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;666.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciliation of Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transaction, integration and acquisition costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss (gain) on disposals, consolidations and deconsolidations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Litigation settlements and regulatory change impact &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Undesignated derivative activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes transaction and integration costs of $12.5 million and $7.1 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $0.3 million for the three months ended March&#160;31, 2023, with no comparable costs for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes an $8.5&#160;million loss for the three months ended March 31, 2023 related to a surgical facility with a book value of the asset group in excess of the fair value based on a letter of intent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes a litigation settlement loss of $3.0 million and a gain of $32.8 million for the three months ended March&#160;31, 2023 and 2022, respectively. This amount also includes other litigation costs of $0.6 million and $2.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. Additionally, the three months ended March 31, 2023, includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMy0yLTEtMS04MjAwNA_3f34dc88-5622-461d-ae9f-c1a960a4b4dd"
      unitRef="usd">649000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib9989159902245b3958bc162627b001a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMy00LTEtMS04MjAwNA_1f7f2a12-98ae-4c55-9cec-c2e94d6519c4"
      unitRef="usd">578800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNC0yLTEtMS04MjAwNA_0a019978-d1d9-45d7-a414-6b4f92fb612b"
      unitRef="usd">17200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNC00LTEtMS04MjAwNA_251256de-c502-490a-be65-aa3724071f83"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNS0yLTEtMS04MjAwNA_15b850f8-2f64-42f3-b1b1-c9f8d76b44e1"
      unitRef="usd">666200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfNS00LTEtMS04MjAwNA_c52e81d3-3d53-4d9d-97fa-e19eea120076"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOC0yLTEtMS04MjAwNA_5d5e2e25-a9c8-44a0-9868-7306e00e037d"
      unitRef="usd">118800000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ib9989159902245b3958bc162627b001a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOC00LTEtMS04MjAwNA_6f5404ea-6418-44ed-ae55-35c49f907332"
      unitRef="usd">101000000.0</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOS0yLTEtMS04MjAwNA_1e0722cc-2e6f-410e-8c88-85771901b36d"
      unitRef="usd">-1400000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfOS00LTEtMS04MjAwNA_4648cae8-246c-4ab6-a695-42dc409e74a7"
      unitRef="usd">100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i2157333f54a64133b4ed6c8fe0d8ed07_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTAtMi0xLTEtODIwMDQ_9f58a3b6-98a9-43cf-9670-4b03a3323afc"
      unitRef="usd">-27300000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i6579947ad8ee4c769d03065a92a8c1d8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTAtNC0xLTEtODIwMDQ_d53eda87-eab8-4e18-ae48-ad68ccac85e0"
      unitRef="usd">-24000000.0</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTEtMi0xLTEtODIwMDQ_674558df-c91e-4726-a80e-ba21ef3b7075"
      unitRef="usd">90100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTEtNC0xLTEtODIwMDQ_62106f90-f305-4f7f-90f2-d97082be5e7c"
      unitRef="usd">77100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTQtMi0xLTEtODIwMDQ_09eac37d-1cd9-49eb-b4d8-2f7fb5edee61"
      unitRef="usd">-400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTQtNC0xLTEtODIwMDQ_3f7c981f-8756-460d-abe3-7e025f8f7a00"
      unitRef="usd">44100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTYtMi0xLTEtODIwMDQ_80c33c8c-f513-4f80-a2f6-42b7260645ce"
      unitRef="usd">26100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTYtNC0xLTEtODIwMDQ_d83d57f9-53e0-4446-89ad-2ff02e6fd991"
      unitRef="usd">30600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctMi0xLTEtODg0OTM_097e29b1-04db-4d74-a44e-d78bf8bcc775"
      unitRef="usd">-46800000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctNC0xLTEtODg0OTM_338bce20-8335-4175-89de-4910aff78309"
      unitRef="usd">-56300000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctMi0xLTEtODIwMDQ_e6672bb9-b43a-44d1-bb3e-513049d704cc"
      unitRef="usd">33700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTctNC0xLTEtODIwMDQ_eb59bec4-d9c8-48e3-854d-ca03ba042498"
      unitRef="usd">27400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTktMi0xLTEtODIwMDQ_c00e379b-5c21-4fee-a8f9-e4d069f37f34"
      unitRef="usd">4200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMTktNC0xLTEtODIwMDQ_2235edaa-24b6-4c80-a1b8-cd085e08c05d"
      unitRef="usd">3700000</us-gaap:ShareBasedCompensation>
    <sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjAtMi0xLTEtODIwMDQ_7406f638-c1d6-4789-a791-fb1dd9a5c21b"
      unitRef="usd">12800000</sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts>
    <sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjAtNC0xLTEtODIwMDQ_c996d8cf-1555-467f-86bb-496e59b0c7d8"
      unitRef="usd">7100000</sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjEtMi0xLTEtODIwMDQ_ac135a43-3098-4d3c-8f9c-ba3293fd01f6"
      unitRef="usd">-10500000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjEtNC0xLTEtODIwMDQ_2cacd61a-ebb5-49b8-b108-190fe3f2bfdc"
      unitRef="usd">100000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjItMi0xLTEtODg1MDQ_eb88042d-f81f-4efc-9885-fa57115d578d"
      unitRef="usd">-8000000.0</sgry:GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact>
    <sgry:GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjItNC0xLTEtODg1MDQ_0a821ae1-18ce-4a9d-9f33-0bcbed0cc22a"
      unitRef="usd">30800000</sgry:GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact>
    <sgry:UndesignatedDerivativeActivity
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjMtMi0xLTEtODg1MjU_ba08c98c-a06a-4d0b-b73e-899f09059467"
      unitRef="usd">-600000</sgry:UndesignatedDerivativeActivity>
    <sgry:UndesignatedDerivativeActivity
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjMtNC0xLTEtODg1MzI_0e0f964e-4c74-41d9-a259-186fe58d5e29"
      unitRef="usd">0</sgry:UndesignatedDerivativeActivity>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjUtMi0xLTEtODIwMDQ_e37add40-dfe3-42f3-aa5a-8538816a807b"
      unitRef="usd">90100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmE1OGQ0NjIyZjJhNDRjNjZiNzY1NmVlNWQwN2ZhY2FmL3RhYmxlcmFuZ2U6YTU4ZDQ2MjJmMmE0NGM2NmI3NjU2ZWU1ZDA3ZmFjYWZfMjUtNC0xLTEtODIwMDQ_4c47b780-e3b6-4152-95b4-7f34e0a82c29"
      unitRef="usd">77100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjg5_e50d03c5-4fcc-42df-86ed-cab1d784d1a8"
      unitRef="usd">12500000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjk2_f6079df2-c4da-4376-b646-1b27b8ccc384"
      unitRef="usd">7100000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfODM0_ce10e24f-afc0-450f-aec8-666f46dc9433"
      unitRef="usd">300000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i2f25d93459534f5c84a4cb1633eb1ef7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NjY1MQ_980a17e4-8783-4a66-96e4-acf591afdb01"
      unitRef="usd">8500000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU0Nw_da99a8bf-2d65-40d9-b9f3-51e1c548a722"
      unitRef="usd">-3000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU2Ng_85ac19a2-d744-496e-8c30-93675af774ab"
      unitRef="usd">32800000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LitigationSettlementExpense
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU4Ng_878f572e-a47b-4b00-8c24-f1e50535713d"
      unitRef="usd">600000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTU5NA_500aebd0-8903-4619-b9b0-702f08ca2e08"
      unitRef="usd">2000000</us-gaap:LitigationSettlementExpense>
    <sgry:InterestExpenseImpactOfChangeInLetterOfProtectionRegulation
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfNjA0NzMxMzk1NTY4NQ_50440205-ba59-42dd-8307-e8e43a062b2e"
      unitRef="usd">4400000</sgry:InterestExpenseImpactOfChangeInLetterOfProtectionRegulation>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTYyNg_e945fde9-d8d8-4bd4-a9be-2b97c9997569">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,049.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,643.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,682.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="iac3c71c2dd4b44f78bf883755b6def96_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMi0yLTEtMS04MjAwNA_3dfdc8ab-2398-4c99-80e6-327087c689ef"
      unitRef="usd">6049200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic762e7cc857a43c1a2f037d3352477ab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMi00LTEtMS04MjAwNA_564b7791-7199-4f39-8899-7bb59a06106b"
      unitRef="usd">6001100000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i33fb3f237a04410498509c0ce5185504_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMy0yLTEtMS04MjAwNA_83a48a08-0421-4196-900c-d03ebf98f131"
      unitRef="usd">41400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i16570392805a4746b263e0633c73a07a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfMy00LTEtMS04MjAwNA_432d027e-e802-464c-8082-e28c41227769"
      unitRef="usd">41700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5b3621d88dc14df6923e768f491fc566_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNC0yLTEtMS04MjAwNA_9b7195cf-0d3b-4348-90e1-53653df76924"
      unitRef="usd">552700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iccc84e42df6a4279be1365d3ba61b0e9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNC00LTEtMS04MjAwNA_4e639bb3-dadf-47d8-8ecf-6e87b5517877"
      unitRef="usd">639300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ieddfc3852ec1452ba8c4688dd114cee6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNS0yLTEtMS04MjAwNA_dd1d3c89-8c10-466e-829e-496bca4673d0"
      unitRef="usd">6643300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic87dcd9813304e79b4016a38d95a6b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOjBlNGI2ZTcwM2U0MzQyZjA5NWQ0ZjI2MDU3YTE0MjgzL3RhYmxlcmFuZ2U6MGU0YjZlNzAzZTQzNDJmMDk1ZDRmMjYwNTdhMTQyODNfNS00LTEtMS04MjAwNA_1d7dbbd2-4766-4660-bd7e-a45100e83c5e"
      unitRef="usd">6682100000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RleHRyZWdpb246NGM0MWY2MWY1OWFjNGIyNmE4ZGRjNTNhZWE5MTUxMmRfMTYzMw_f0e3d31d-2b1e-453f-97c6-3a5b4def0f6c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash purchases of property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic7ed58833539487ea657bbe105c307f8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfMy0yLTEtMS04MjAwNA_0b25870c-2d58-4dd0-9c29-359efcc6fd58"
      unitRef="usd">23800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib9989159902245b3958bc162627b001a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfMy00LTEtMS04MjAwNA_0fa373fa-6554-4379-881e-a6e8fee32836"
      unitRef="usd">17700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4fb574e0f82342968c60caecccd3e8d8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNC0yLTEtMS04MjAwNA_94fb0fa4-c7b1-4efa-a539-369762d25483"
      unitRef="usd">500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i46ab2e94e0d94954bdb8ea21ef139882_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNC00LTEtMS04MjAwNA_54d0f9ae-68fb-4d46-9572-90c87eabf263"
      unitRef="usd">200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2157333f54a64133b4ed6c8fe0d8ed07_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNS0yLTEtMS04MjAwNA_0540bb0c-25c3-4f20-856e-8b03f5490aaa"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6579947ad8ee4c769d03065a92a8c1d8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNS00LTEtMS04MjAwNA_84445d23-9c0b-41bd-8c91-ae3e0af32720"
      unitRef="usd">300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNi0yLTEtMS04MjAwNA_1137b372-6576-4baf-851c-444455c3a88f"
      unitRef="usd">24300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie58c002acbf44177b5eb133f11c0bb12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81NS9mcmFnOjRjNDFmNjFmNTlhYzRiMjZhOGRkYzUzYWVhOTE1MTJkL3RhYmxlOmZkMzQzN2Q4ODY1YzQxYjk4MDM2ZWU3MDI2MzU3ZjgyL3RhYmxlcmFuZ2U6ZmQzNDM3ZDg4NjVjNDFiOTgwMzZlZTcwMjYzNTdmODJfNi00LTEtMS04MjAwNA_3fca4b7b-2551-4256-a020-d0f040a83ab6"
      unitRef="usd">18200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfNDQ_b61b4390-de48-4c3d-ab9e-0c512a506a64">Subsequent Events&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In April 2023, the Company completed the sale of two surgical facilities for cash proceeds of $23.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In April 2023, the Company acquired non-controlling interests in an in-development de novo surgical facility for a purchase price of $6.1&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <sgry:DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed
      contextRef="i78f9f79b8aa34e08805a3d3c55374c19_D20230401-20230430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfMzI5ODUzNDg4NDIyNA_f0c620de-d121-4441-b343-65c14b18d4cd"
      unitRef="facility">2</sgry:DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i78f9f79b8aa34e08805a3d3c55374c19_D20230401-20230430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfNjA0NzMxMzk1MzQwNQ_8d823184-786d-4b2f-bb39-1b9e2a594661"
      unitRef="usd">23000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i0801f484705247ca9f81ed5e46fa3718_D20230401-20230430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF81OC9mcmFnOjNmZmIyMGYwOWVhMDQzZDBiMzlhYjM5NzNhZmJhNTk1L3RleHRyZWdpb246M2ZmYjIwZjA5ZWEwNDNkMGIzOWFiMzk3M2FmYmE1OTVfNjA0NzMxMzk1MzYxNQ_459dff6b-71a8-442a-a996-b7416d65cd3a"
      unitRef="usd">6100000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtNC0xLTEtODIwMDQ_a86f7bca-360e-408d-a5c7-69577988ff87"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtNC0xLTEtODIwMDQ_a86f7bca-360e-408d-a5c7-69577988ff87"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtNC0xLTEtODIwMDQ_b606e16c-d033-4319-9dd0-f2ca51061163"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtNC0xLTEtODIwMDQ_b606e16c-d033-4319-9dd0-f2ca51061163"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtMi0xLTEtODIwMDQ_2aee640c-d5ee-4c65-9d06-3183f99eb627"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtMi0xLTEtODIwMDQ_2aee640c-d5ee-4c65-9d06-3183f99eb627"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtMi0xLTEtODIwMDQ_1da8f9b1-483f-4542-85c2-5ef648da6eb7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtMi0xLTEtODIwMDQ_1da8f9b1-483f-4542-85c2-5ef648da6eb7"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The impact of potentially dilutive securities for the three months ended March 31, 2023 was not considered because the effect would be anti-dilutive.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtNC0xLTEtODIwMDQ_a86f7bca-360e-408d-a5c7-69577988ff87"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtNC0xLTEtODIwMDQ_b606e16c-d033-4319-9dd0-f2ca51061163"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzMtMi0xLTEtODIwMDQ_2aee640c-d5ee-4c65-9d06-3183f99eb627"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RhYmxlOjlkOWUwMGMyMGRhZTQ5MTU4NjExYTE3ODE2YjkxYWVmL3RhYmxlcmFuZ2U6OWQ5ZTAwYzIwZGFlNDkxNTg2MTFhMTc4MTZiOTFhZWZfMzYtMi0xLTEtODIwMDQ_1da8f9b1-483f-4542-85c2-5ef648da6eb7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRkMTIxOTNjMWFjNDQ5Y2JhYWVjODcwYzBhN2MxYjdkL3NlYzo0ZDEyMTkzYzFhYzQ0OWNiYWFlYzg3MGMwYTdjMWI3ZF8xNi9mcmFnOmZmOWU4ZDk2Y2E2MjQyZWI4M2YwZmZlZTIxNTAxM2QwL3RleHRyZWdpb246ZmY5ZThkOTZjYTYyNDJlYjgzZjBmZmVlMjE1MDEzZDBfMzcx_0253f8d6-fe16-4ff1-8801-a2b7284ce219"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M\Q/+3O5Y<?#[D9L),R6A6$"H<SZ $4\59ZG%C99)?APYEUK+*+]<">X+93Z
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MK"8HW#NCL%^3NN$93<(I'<.N4UM>L[5X=+DYM]T,0VO1.*R2>!J['<5!!ZO
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MHQU;:>031L?CTA&?^(E_N5KEIDH&+IG7*!.HUS*VS8%33J$.FH=):D/)D1J
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M^I'-IZ_F1(MM_?7H3F@MROIPPQG(-@9P?RV$_G%B/DBU'R 7_P-02P,$%
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MW4RFW3B*FXE\Z,T\$RLJ7M$#$0J:3F!L2*.>U961L67OXK!WN.NQB/FXK<O
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MW) 8Q77= 2F[ ]+<'=PK&7$>Y[E7M#H6^H)%^5YW<9"N+&3%(&B(WQ@<;OV
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MC2(";X2(]D"LM>5E<%X2OS]4*_ 1Y-NN=KNT3-01D!@5V_QWTVAB&@VI(C[
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M#_#).!X6\G&$^G63;^WY]/-I.46\:P[*$\UEH&:D^H(-2#Q^EZ_T 0H[PP/
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MVA#W1XF'X_HGI]A\2-WKY@IVC1.DDMT>,22^GN.JB4F^+HT8(@K[[ \^1VE
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MW$F#[^[SF;UM45<CX6>2IY>M>$GN#UB1XI#1_70#\CY\D1Z\9E(.B77 <(+
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M4.T,E@N6GV275XO9!;<(HB?P'TG<_MA0_1AP=!'.+V8W:83#^"5G3)SI!U)
MI,+&5GR>S1<2^20\\0!8QVLXPG+(]/R</VYZD9-KA$M0<TT'P2?N+(6VI]NB
M("TO+_5XGS9#A#IF;*DD/OT1=Z&/G$C%;;E\3YJ\4OA@@=OA?X5FJ[>F,75^
MKYO.9K>ZG&8?T)DD=W3>^7++'5))X#-R6N7Z.DZ_N/CF[>V'=W=XRG_/OSE/
M>A77*9"QY!T:N7R:NN><Q)R".P&W5;IBC\_2X.*.=6]4$"^'K]6Y/L&0LN .
M)#YZ*"5:5Q)\^\MO/WW_=/XR"(Z4G@I?BJU=Z:5"I)S>"AN[2_ $?:XA$T=
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MUFSYZT;E).H80+_CG7+^#VP07H7_^G\!4$L#!!0    ( %1 HE;.VJ84D@<
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MBZL1,^$#4;APNO(?9>"ETZ7_F0L,W88$\'RMM6LN:(/V*]W][U!+ P04
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MM!/ _5(INYXX!]TC[/QO4$L#!!0    ( %1 HE;,HV)^00H  *TA   9
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MP&M5J'H!UZ:G<[&!)\6]^7QVBM9B#'=)++PW/YD]S4]8^59Q\S10\\TM?4$
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MZ$?\>BG=@6WV,IMWR85M&<=%1#:P:#88Y>_?3<^23P>TSD:MLT/L;WN/_Z2
M:P7+U@@9+O087(UPJ9N6J6?@U$MT6(15RR2"+L'UFFQJ*L&9A))Q(843:(&*
M '!F:VB-YHB%]<%':39)Z&]*23:;'#J,\<=.&#I+:77"Z=,832!5@5 .Z2Y)
MJB"C*FI/"MQ0Q6@;GT:!A-C\*^DY"&+0=H;79$V2)7A(X.AL,ATEO?0L\9YE
M&C15* R6KJ-3;G#/N#K6GN5@N3_A0^&B[UH)94%B2=!D\N$T C,4@V'B=!L,
MN-:.[!R&-=5/-#Z ]DNMW6[B#Q@K<OX;4$L#!!0    ( %1 HE:XT0W=$14
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M4NXIR^9T<@+?HH!SQ?#36 P_/5O2W@0?_Q"K_[FZ^(LG*6YFV@KW@-\4+DZ
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MVK<GQ#FI2BJK/ ^M%94^MRIF/\O<*I^N(M2A$5:[3\@2IIKV% A*9X1:X0
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M^=MH.)#E3JX.+ZSZ;0F<:-S#92>^YX+[=('K9V0DEM!XLD8JG*X3<YE9X^1
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M/+8T&MQ)2A?4&+OYN.#2U,-#:E%DF8)4P3W&D!!*%WE-[E0.!N^2>'".V!]
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M#UG*U=!9:9WW75=%*\BH:HD<.,XLA<RHQJY,7)5+H+$%9:GKM=L]-Z.,.\'
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M653WHJ-%;NO=0FBLGK:YP@<12+, YY="Z%W';% ]L8*_4$L#!!0    ( %1
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M8X$@SP2+2V<904R3XA]_*8EH.,#A%@=4.J!='=S2P=6)%I'IM*ZQP+,)9VO
ME;5$4P>:&^TMLZ&)VL:YX/(LE7YB]B=?XH3^APM.DQ#,B_T$; $N@H#EB:#)
M$CRPB :49. =F,M*"O.(*(LKS/E7=?XB5I8:X 93#C[B*-<6=RQ9OON+\!A<
MDT<!WEX3@6F4G4B@#_-K\/;-"7@#: +N:13)$+*)+616*C8[*#.X+#) 6S*X
MQWP 7'@*D(/<#O>K?O=K$E3NJ.UN2RXK0E%%*-)XPRUX<Q+DG(1%NM_ G"24
MR;;1LT H(B*&$WEF@[NNQ'M74@U^GJ4X(%-+=G!&^!.Q9K_\!'WGURX:#(&U
M2'$K4ER-[FXAI:Z)4W")(YP$!,SU5>HWSO)4LG *;F@BYRF.P%Q@0>2E0DB.
M4E68&?CG3B*"6SF=_=O%E&N2*4-@+::&%5/#WO+1_:++))0%U)5JX>]K?W61
M?II!=^0,X,1^:B91F)UMF%5&K>"\*CC/3&TWK@'-P2FX3=)<9*?@CCR1"*"N
M_'I#V'<K#8&UV/(KMOSC%KUODBE#8"VF1A53HU<6_:BCFCUWH^0+HU';Z&PP
MZB[Z<17<^(6BUU7^!Q/R]O<-^(.1Y_PLBU[/YDE6]D2BSX>RXN6-Q.O*H7>9
M?;?+$%B+D;.*D;/C%O:92:8,@;68@DXMKYS^ZE'9AU+AR/(FF0!<#L';E/!
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M!(>$*P-Y?L%D)Y0#]36G^GHW^Q]02P,$%     @ 5$"B5A3"C-%% P  : X
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M&JD.Q6%#<=A+\1/.89Z@BP0KE*AE?#AV[?"(XJG4R!^WI#H41PW%42_%KU1
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M2&XOK/H^4=T(6N@C_HH*03-]N44P14P)R/=K2L7^1GTU:+X2S?X%4$L#!!0
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M^9'FGRSE)X)MLJ]^'ID0+,X.UP0O2*H"Y/TE8^+E1'U(5'XX-OL/4$L#!!0
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M,6.A\U1//T$V<38=D0!A\20@-97_4\Q3RN+->XEYE(^,OO 0JS86$CPK +!
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M>$\0)%0I%K' DDBFX5^8#SFYF25X&@19FB5(>4@>= R2S$2*U1R;,EL#6?!
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M!;^H9:1SE.M7_;9_4! U4GVO<@#O>^"_>N#_=^&VC ,7QH,B)]"'2(KTZ'K
MN!9%8;_9._^HVJ\&E5(NO#N6&APYYU;N]'A +^VHHT@@,J[S.VVY6XY34SM$
M'.S?FC'+S@JO,/F,AC=6; 6*)! AI-<>XB$M\[$G7VBQLI/#B] XA]C'&$=%
MD$8 WT="Z-W"?* </B?_ E!+ P04    " !40*)67GI0)HP$  !3$@  &0
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M,P**'C$".+X1Z/.B828HWY'F_P%02P,$%     @ 5$"B5A(&7:P1 P  [0@
M !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULK99M;]HP$,>_BI554R>M
M>80$.HC4@J956K6JK-N+:2],.,"J$Z>V ^VWWSFA64K2="_V!FSG_G>_.S].
M]D+>JRV )H\IS]34VFJ=GSN.2K:04F6+'#+\LA8RI1J[<N.H7 )=E:*4.[[K
MADY*66;%DW+L1L8346C.,KB11!5I2N73)7"QGUJ>]3QPRS9;;0:<>)+3#2Q
MW^4W$GM.[67%4L@4$QF1L)Y:%][Y;&SL2X,?#/:JT28FDZ40]Z9SM9I:K@$"
M#HDV'BC^[6 &G!M'B/%P\&G5(8VPV7[V_KG,'7-94@4SP7^RE=Y.K9%%5K"F
M!=>W8O\%#OD,C;]$<%7^DGUE&[D620JE17H0(T'*LNJ?/A[JT!!X@U<$_D'@
M_ZL@. B",M&*K$QK3C6-)U+LB336Z,TTRMJ4:LR&9686%UKB5X8Z'7_36Y!D
M5D@)F29?&5TRSC0#1<[(HII9<CH'31E7'W#L;C$GIR<?R EA&;EFG.-<J(FC
M$<4X=))#V,LJK/]*V&LJ;1)X'XGO^D&'?-8OGT-2R_V7<@<+4%?!KZO@E_Z"
MWBHTLY\SE7"A"@GDU\52:8GK[7=7GI7C0;=CLP?/54X3F%JXR13('5CQ^W=>
MZ'[JROH_.7M1@Z"N0=#G/2XW\)E8GQ4*")X2DFJ6;0@'W"2$_RU-5Q$JS^/2
MLSDW=G$PFCB[9FJ52=@T">UA;?0">5 C#WJ1+U)19%J150%$"Y(C,9@^S5;8
M>1*R$[;R.6R2N$>PE4G4-/'L<3?LL(8=]L+.A-)X[N5"ZK?*.6R%]P>V?\38
M812\5M"P9@Q[&:\R#;BRM*D>77+H@@N[XD9'<&TC;VP/NN&B&B[JG^WDH6"*
ME:<_J 3577A1.W+4B%SAM8W\D3WJQAO5>*,W\!)9P(K (]ZP"JI5*,S!TH4Y
M:A&$8:N*H]9*C=QNR'$-.>Z%_"XTY5T\X]8.QG? $<ZXM85]S[6](R*G<1F9
MAP >]1N6*3Q(UJAS[0CSD=7E6G6TR,O[:2DTWG9E<XOO$9#& +^OA=#/'7/E
MU2^<^ ]02P,$%     @ 5$"B5IPXFV$, P  F H  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&ULK59=;]HP%/TK5E9MJ]02DD#:,8C4DDR;M$JH5;>'
M:0\FN8!5Q\YL ]V_G^V$++1I1#=>P'9\SO$]UQ]WO.7B0:X %'K,*9,39Z54
M,7)=F:X@Q[+'"V#ZRX*+'"O=%4M7%@)P9D$Y=?U^/W1S3)@3C>W83$1COE:4
M,)@))-=YCL7O:Z!\.W$\9S=P2Y8K90;<:%S@)=R!NB]F0O?<FB4C.3!).$,"
M%A/GRALEH9EO)WPCL)6--C*1S#E_,)TOV<3IFP4!A509!JS_-C %2@V17L:O
MBM.I)0VPV=ZQ?[*QZUCF6,*4T^\D4ZN)<^F@#!9X3=4MWWZ&*IZAX4LYE?87
M;<NY8>B@="T5SRNP7D%.6/F/'RL?&@#-TP[P*X!_*""H ,%3P. %P* "# X%
M#"N #=TM8[?&Q5CA:"SX%@DS6[.9AG7?HK5?A)E]<J>$_DHT3D53GN=$Z<0K
MB3#+T)0S1=@26$I HO<Q*$RH/$7GZ/XN1N]/3M$)(@S=$$IUGN7857H1ALI-
M*\'K4M!_0=!#-UIB)5'",LA:\--N?-"!=W7PM0/^SH%KOY/P!HL>"KPSY/=]
MOVT]A\.#%GC\?^I)-SR&]"7XGAE!O1T"RQ?\TW:(B4PIEVL!Z,?57"JAC_G/
MMBU0B@S:1<S5-Y(%3F'BZ+M-@MB $[U]XX7]CVW^'Y,L/B99<B2RO4P-ZDP-
MNMBCF> +D.:ZQO0,Z0R!P-3FS-S,(.0[E/)</R<2VQN9,)TWS%) U5K:\M8I
M^=J\E62A)3//U2;R_9XW=C?-?!Q3,6E1[/<N:\4]GX>US\-.GY/'0K]ID.T9
MF/(-"'TBVCSLI'NMAR7912,BS^]=//'PF(K)\)F'>XI['H:UAV&GAU^)(LMR
M&TI0BH*Y8-J\"Y^)!WXC@:4GY:0/C4GGP1-'#N%).M?\VM/K-I[@',32UCY2
M'\$U4^5;5(_6Y=65K2J>C$^]45Q627]IRII-/Q5+O0D1A86F[/<N=*I$60>5
M'<4+^]#/N=)E@VVN=.D(PDS0WQ><JUW'"-3%:/0'4$L#!!0    ( %1 HE:D
M6V#'HP<  'DR   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+6;:V_;
M-A2&_PKA%4,*)+9$RK<L,>!$+18@68.XW3X4^T!+C*U-$EV*SF78CQ]UL2F9
M%&NM3#\TEDR^TGEUQ/.0LBZ>*?L[6Q/"P4L2I]EE;\WYYGPPR((U27#6IQN2
MBF\>*4LP%YML-<@VC."PZ)3$ ^@XHT&"H[0WNRCVW;/9!=WR.$K)/0/9-DDP
M>[TB,7V^[+F]W8Z':+7F^8[![&*#5V1!^)?-/1-;@[U*&"4DS2*: D8>+WMS
M]]SW4-ZA:/%[1)ZSVF>0A[*D].]\XR:\[#GY&9&8!#R7P.+/$[DF<9PKB?/X
M5HGV]L?,.]8_[]0_%L&+8)8X(]<T_B,*^?JR-^F!D#SB;<P?Z/.OI IHF.L%
M-,Z*_\%SU=;I@6";<9I4G<49)%%:_L4OE1&U#A"V=(!5!WC0 ;4= 54=T+%'
M\*H.7N%,&4KA@X\YGETP^@Q8WEJHY1\*,XO>(OPHS:_[@C/Q;23Z\=F"K,15
MY."!;"CC4;H"9V ADBO<Q@301R"_?R+IE@"<AN#3AC!<M+U) YH0<.(3CJ,X
M>P_>@2@%=U$<BVN:70RX.,/\.(.@.INK\FQ@R]FXX(ZF?)V!#VE(0DW_:W-_
M9.@_$,[L[8$[>ZZ@4? .LSY [BF #H3@R\(')^_>Z\[K>!FTDP%9Z:U&SO_A
MLVI$B_;)@ I=='0R?)TO,\[$S?FG[F*6:IY>+1^QSK,-#LAE3PQ)&6%/I#?[
M^2=WY/RB<]"FF&])K.&BMW?1,ZG/?MLF2\+RFX?N;Y3J4F?@7\-5OS+J=O6S
M%!L68OGH_S2#%X.GNDF6#M<P:;@W:=@QU6[2LHKEU>#KK6@.;CA),FWB#6T:
M95/,MR36\'2T]W1D3+QJC-:.N\:>71TKQ4:UU!J-1OW#]%);#:?U5HT8Q_L8
MQ\88Y^%?HBB2$'RXNOGLSW6A&@6ZAEJ*C6M!3)V^,ZW_.PA;[3$>M_5H6##9
M6S QWCH/)*!I$,51>:^(<>; E'.=*Q.;KM@4\RV)-;R<[KV<&M/IY)9F ENB
MDF.61 Q!9+?%\8O^7C)*=K5RJJ3+F=/W#G)*;>1Y?5>?1JXCT<\Q%RHQK:AB
MQ9RS:+GE>"FPCU.0TO1,9!EG5*"<&)RCE!,1#-<SG?$P70VIU!J.P%$MVM(2
M73/D]$<MIM1XV#6:<E-%"LB+F%MEY!2D1%NLS3J=HW;52SSJ3PZ#5EL-1WW4
M$C.4,4-CS#X1IQA4XTE.^#C)B_(_Q0YM[$:]SK%#)2J$^N/#V-56<%R[4YJQ
M2^1UC2PX^_!M&_'7LWSN& )Q+^07O32B2@!M_%;)MU)K7'NEFFH:U3UJ1B]1
MU36SZF>&1;C%%/RTN,E7K)8%@? FBXKM@+;=_%:AM5*K1^E"]3906XU;AT-)
MI*X1SHKA,!;E )RL<)2^!R+J,,HV-,-Q=BH,2#,:1V%A3U;X$Y+F3JT]5E&U
M4FO8X_2'A_:HK41-:?-'TJ5KQLM;D0FK,CLRPGE,RAE-[@0CJVV,.66O(%CC
M="5J:"*BTH^;5E&T4JM/<Y1L&6DKQ:3%#TFBKAE%OZ0AR:)5BG/R"@F+GG"^
MAE4N98DQ11N\53AU5=:L5\ J_+'BD-,2NB10UPAEQU"X6:%SI)/.'*[I<B2(
MNY(>73,^UH;/XCZHCZ#M(Z95?G15-A0CIC(DJ*U:1TPH 1*: 7+!,>-GVTU[
MK&:!KK%"E?F<&OU42V>6#MGT1/(C-/-C-:/(2TA>06+=H*EURE6FRTBI?-=5
MJV%C+#LT0(7$AE(S, F)T R)G_B:L'H\[1?=*AU"E?O40:YJI%_M:@8LR1":
MR7 >A@7[X'@__=DQ(1#S1/ QIDR4?G#[Z7Y7  M;B@*H]<4J-4(=-1Y.'&T=
MLFFAQ$MHQLO%EJVB0!CX$><+%OP5+,0QHD _KS:+=?;'IIIO2ZUII&13:%XN
M_7]K/M J?%I5\VVI-0V5, O-,/LFL&\^9F>_-=PZ42J[K6,V?900#,T0+)\%
M+N0CCHZWO54FMJKFVU)KNBLY&YJ7>G_L*0FTBN!6U7Q;:DUC);A#,[B;'I68
MNW:V;:J0R<@[G*M %<^'XTD;LR$)Z,@,Z$?,T\P*G1_BJH3NNA-E :=J5C?%
M=5JF(TBB-W+?H$@BJ^NX5M5\6VI-0R7R(S/R'Y,^5ED?J:RO31^5]MO3I_;C
M!S/O:TO9/$^H&#-S"3,K=W;![D\AWF(*@.04 'EO6,*0U2F!537?EEK36#DE
M0.;E:E,),W?M;)MFU7FL/*#0MVIY/H,DJ",SJ!\S!EG%;J3!;E>96&M:M2ZQ
M(TG3:/P6%<PJ0%M5\VVI-0V5 (U^>*':K-#9/77569<]:JOV[)%0B\Q0.X]C
M0/-5.FV85JG6JIIO2ZWY<SU)R9[SAB7*LPK05M5\6VI-8R60>^:U\"/N/K-"
M9_?4I>\S.%8>$7B:57384JD\2<L>?(/!V[,*T%;5?%MJ34,ED'O?6X#_?OI8
M!>]*;?2]]"F;38WI,ZC])C\A;%6\VY"!@&Y37O[^?+]W__[$O'AKX&#_M7ON
MEV]!2)GRI8P[S%91FH&8/ I)IS\6"<W*]QS*#4XWQ2__EY1SFA0?UP2'A.4-
MQ/>/E/+=1GZ _=LFL_\ 4$L#!!0    ( %1 HE:H_I@=( 0  -$5   9
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M/E@>/R>UEW^D:1K'28+-Z'CL=3#&YBU)X,>OAGD#!I8',OW97..KC5?(TW6
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !40*)6ZZVUU!,$   K(@
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M0";2')01N<'K^)!:R(=^"1>JW%T_@2Y8 AN+J4B]>/;+ H2!3HPHCX2>19*
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M&^IM!'K;8+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
M;T>]G4!O1[V=0&]'O9U ;Q]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3
MZ%VCWC6!WC7J7?^GWBF?]S'=>VYK?/Y_4ITO]\;[XZ_+V\G!2[CB'."'],LW
M4$L#!!0    ( %1 HE8HM&@3PP$  (D>   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W9R6[",!0%T%]!V5;$>( . C9MMRV+_H";/" BB2W;4/C[.F&06M&H
MB$J]FT2)[7=?;.EL,G[;6?*];576?I(L0[ /C/EL297VJ;%4QY&Y<94.\=$M
MF-792B^(B<%@Q#)3!ZI#/S0UDNGXB>9Z78;>\S:^]H6I)XFCTB>]Q_W$)FN2
M:&O+(M,ACK--G7]+Z1\2TKBRG>.7A?4W<4+"SB8T(S\''-:];LBY(J?>3+OP
MHJLXBVU+YL.N))]VESC3HYG/BXQRDZVKN"3UUI'._9(H5&6Z+WK3G1SB#M/^
MRJ_.;\MT!<:9,V>LCR?FZ/*XXY$TJ_LV%B(7BNY//"7&TE=_'S6GG5/^R^RX
MO1_&K=KS\*R]7;_'7\_X5/_"/@1('Q*D#P72QQ"DCQ%('[<@?=R!]'$/T@<?
MH#2"(BI'(96CF,I14.4HJG(45CF*JQP%5HXBJT"15:#(*E!D%2BR"A19!8JL
M D56@2*K0)%5H,@J4625*+)*%%DEBJP215:)(JM$D56BR"I19)4HLBH4616*
MK I%5H4BJT*15:'(JE!D52BR*A19%8JL0Q19A_\IZ[LQJ[_^.=K<TTH7]3&?
MM7^@IY]02P$"% ,4    " !40*)6!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %1 HE:1Q+?M[0
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( %1 HE:97)PC$ 8  )PG   3              "  <L!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 5$"B5N"#Z4O;!0  W1X  !@
M             ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( %1 HE;3<KW^ZP8  (P<   8              " @1T.  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !40*)6(:X&0%$#   7
M"P  &               @($^%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ 5$"B5E'_3G<+!P  &QP  !@              ("!Q1@
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( %1 HE:T2U'B
M6P,  -T)   8              " @08@  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !40*)6+,T8&(H"  #A!0  &
M@(&7(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 5$"B
M5O\,$:O_!@  VRX  !@              ("!5R8  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( %1 HE;)GU(C) <  &,>   8
M      " @8PM  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !40*)6!R2J7'L>   67P  &               @('F-   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 5$"B5L[:IA22!P  L1L  !D
M             ("!EU,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !40*)6UU0U/3P$  !>"0  &0              @(%@6P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %1 HE;IQ16]& 4
M ) 5   9              " @=-?  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ 5$"B5LRC8GY!"@  K2$  !D              ("!
M(F4  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !40*)6
M?TQZ%=\#  #N"   &0              @(&:;P  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( %1 HE81[KG+Q@(  "H&   9
M      " @;!S  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ 5$"B5O!6G!O)"P  6QX  !D              ("!K78  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !40*)6.V>&5T(&  #L#P
M&0              @(&M@@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( %1 HE;FEW?4>@(  )T%   9              " @2:)  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 5$"B5KC1#=T1
M%0  +T$  !D              ("!UXL  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !40*)6U)AZR7H%   F#P  &0
M@($?H0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %1
MHE8[856U,P,  /8&   9              " @="F  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ 5$"B5HNVU=7#!   NPP  !D
M         ("!.JH  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " !40*)6M(2X%JP%   .$0  &0              @($TKP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %1 HE:#U&HDF0,  ",(
M   9              " @1>U  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ 5$"B5B2CE%#1 @  ) 8  !D              ("!Y[@
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !40*)6SYHL
MRN\%  !_#P  &0              @('ONP  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( %1 HE:['I)0\0(  !L*   9
M  " @17"  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M5$"B5L*3//.F P  DA$  !D              ("!/<4  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !40*)6/6I6%5@%  #;(P  &0
M            @($:R0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( %1 HE8K4 "'.P,  , (   9              " @:G.  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 5$"B5K?'SBRO @
M>P8  !D              ("!&](  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !40*)6Q]M&(#@#   Q"0  &0              @($!
MU0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %1 HE9*
M/6YW!P,  &X)   9              " @7#8  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ 5$"B5GY2#)2H!   R1L  !D
M     ("!KML  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %1 HE9W\A@W5 ,  !H0   9              "
M@6'S  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 5$"B
M5K;L23)B!   ,1(  !D              ("![/8  'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !40*)6#^<]?!D$   .#P  &0
M        @(&%^P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( %1 HE;""'*;) 4  $0F   9              " @=7_  !X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 5$"B5J^#/ (@!@  '"P
M !D              ("!, 4! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !40*)6> \<>V$$  #;&0  &0              @(&'"P$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( %1 HE9I<6-0
M#@0  (@.   9              " @1\0 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ 5$"B5EYZ4":,!   4Q(  !D
M ("!9!0! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !4
M0*)6$@9=K!$#  #M"   &0              @($G&0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( %1 HE:<.)MA# ,  )@*   9
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M;',O+G)E;'-02P$"% ,4    " !40*)6ZZVUU!,$   K(@  #P
M    @ $+- $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 5$"B5J&7ZI3)
M 0  H!X  !H              ( !2S@! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 5$"B5BBT:!/# 0  B1X  !,
M ( !3#H! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #L .P 4$   0#P!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>180</ContextCount>
  <ElementCount>258</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</Role>
      <ShortName>Organization and Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisitions and Disposals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposals</Role>
      <ShortName>Acquisitions and Disposals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Derivatives and Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivities</Role>
      <ShortName>Derivatives and Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Organization and Summary of Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Organization and Summary of Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/LongTermDebt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Derivatives and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables</Role>
      <ShortName>Derivatives and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/DerivativesandHedgingActivities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/EarningsPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/SegmentReporting</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Organization and Summary of Accounting Policies - Medicare Accelerated Payments and Deferred Governmental Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Medicare Accelerated Payments and Deferred Governmental Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails</Role>
      <ShortName>Acquisitions and Disposals - Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Acquisitions and Disposals - Disposals and Deconsolidations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails</Role>
      <ShortName>Acquisitions and Disposals - Disposals and Deconsolidations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Long-Term Debt - Summary of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails</Role>
      <ShortName>Long-Term Debt - Summary of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails</Role>
      <ShortName>Leases - Lease Expense and Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Earnings Per Share - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails</Role>
      <ShortName>Earnings Per Share - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Other Current Liabilities - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails</Role>
      <ShortName>Other Current Liabilities - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/CommitmentsandContingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails</Role>
      <ShortName>Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails</Role>
      <ShortName>Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sgry-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/SubsequentEvents</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept LondonInterbankOfferedRateLIBORMember in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. sgry-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="sgry-20230331.htm">sgry-20230331.htm</File>
    <File>a2023q1exhibit311.htm</File>
    <File>a2023q1exhibit312.htm</File>
    <File>a2023q1exhibit321.htm</File>
    <File>sgry-20230331.xsd</File>
    <File>sgry-20230331_cal.xml</File>
    <File>sgry-20230331_def.xml</File>
    <File>sgry-20230331_lab.xml</File>
    <File>sgry-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="567">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgry-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 2,
    "http://fasb.org/us-gaap/2022": 567,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 180,
   "dts": {
    "calculationLink": {
     "local": [
      "sgry-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgry-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sgry-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgry-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgry-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sgry-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 442,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 14
   },
   "keyCustom": 32,
   "keyStandard": 226,
   "memberCustom": 37,
   "memberStandard": 32,
   "nsprefix": "sgry",
   "nsuri": "http://www.surgerypartners.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.surgerypartners.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Acquisitions and Disposals",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposals",
     "shortName": "Acquisitions and Disposals",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Long-Term Debt",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.surgerypartners.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.surgerypartners.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Derivatives and Hedging Activities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivities",
     "shortName": "Derivatives and Hedging Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.surgerypartners.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Other Current Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilities",
     "shortName": "Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.surgerypartners.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.surgerypartners.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.surgerypartners.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Organization and Summary of Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Organization and Summary of Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables",
     "shortName": "Organization and Summary of Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.surgerypartners.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.surgerypartners.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Derivatives and Hedging Activities (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables",
     "shortName": "Derivatives and Hedging Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.surgerypartners.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.surgerypartners.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:NumberOfSurgicalFacilitiesOwned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "facility",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
     "shortName": "Organization and Summary of Accounting Policies - Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:NumberOfSurgicalFacilitiesOwned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "facility",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i0cec9a12adb2490880d03b5e2db3fb51_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i0cec9a12adb2490880d03b5e2db3fb51_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i5ccbab58e225409b8f397b22aaa0921a_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ic87dcd9813304e79b4016a38d95a6b26_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Rollforward of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ic87dcd9813304e79b4016a38d95a6b26_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ie72d31b8aced4bdfa7dc4d743c36cdb9_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgry:GrantRevenue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Organization and Summary of Accounting Policies - Medicare Accelerated Payments and Deferred Governmental Grants (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails",
     "shortName": "Organization and Summary of Accounting Policies - Medicare Accelerated Payments and Deferred Governmental Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ic87dcd9813304e79b4016a38d95a6b26_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "sgry:UnrecognizedGrantFundsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "if395609fbdf14ab7bd54498a1f593d2b_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "if395609fbdf14ab7bd54498a1f593d2b_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:VariableInterestEntityNumberOfFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "facility",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:VariableInterestEntityNumberOfFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "facility",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
     "shortName": "Acquisitions and Disposals - Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ife322ebfae344c06aadeb5444f977b01_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Acquisitions and Disposals - Disposals and Deconsolidations (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
     "shortName": "Acquisitions and Disposals - Disposals and Deconsolidations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "iec7a6a99212642aab1d11f46ef8b71e8_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Long-Term Debt - Summary of Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
     "shortName": "Long-Term Debt - Summary of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i615ae79f54e248ed8c11df419a474567_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Long-Term Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
     "shortName": "Long-Term Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i615ae79f54e248ed8c11df419a474567_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails",
     "shortName": "Leases - Schedule of Components of Right-of-use Assets and Liabilities Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails",
     "shortName": "Leases - Lease Expense and Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails",
     "shortName": "Derivatives and Hedging Activities - Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i2b122a7729f846aa83ebcbf74914d1ea_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
     "shortName": "Derivatives and Hedging Activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
     "shortName": "Derivatives and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i8812d79ba0e7406a8a6f1c6d561cc07a_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
     "shortName": "Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Earnings Per Share - Summary (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails",
     "shortName": "Earnings Per Share - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ife80b1a65af94f9b863703998b3c1df8_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Other Current Liabilities - Summary (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails",
     "shortName": "Other Current Liabilities - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "srt:PayablesToCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SelfInsuranceReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SelfInsuranceReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails",
     "shortName": "Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "ieddfc3852ec1452ba8c4688dd114cee6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
     "shortName": "Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "iac3c71c2dd4b44f78bf883755b6def96_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.surgerypartners.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i78f9f79b8aa34e08805a3d3c55374c19_D20230401-20230430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sgry:DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "facility",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "iaa47a92aabfb4f198bd892ae1c73b47e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "iaa47a92aabfb4f198bd892ae1c73b47e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Summary of Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies",
     "shortName": "Organization and Summary of Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20230331.htm",
      "contextRef": "i68d7d565d7f447e5a8a74b0c791c3bbe_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgry_A2017SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Senior Secured Credit Facility [Member]",
        "label": "2017 Senior Secured Credit Facility [Member]",
        "terseLabel": "The Revolver"
       }
      }
     },
     "localname": "A2017SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_A2017TermLoanMaturing2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Term Loan, Maturing 2024 [Member]",
        "label": "2017 Term Loan, Maturing 2024 [Member]",
        "verboseLabel": "Senior secure term loan"
       }
      }
     },
     "localname": "A2017TermLoanMaturing2024Member",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_A2022DisposalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Disposals",
        "label": "2022 Disposals [Member]",
        "terseLabel": "2022 Disposals"
       }
      }
     },
     "localname": "A2022DisposalsMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_AcquisitionEscrowLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Escrow Liability Current",
        "label": "Acquisition Escrow Liability Current",
        "terseLabel": "Acquisition escrow"
       }
      }
     },
     "localname": "AcquisitionEscrowLiabilityCurrent",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_AncillaryServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary Services [Member]",
        "label": "Ancillary Services [Member]",
        "terseLabel": "Ancillary Services"
       }
      }
     },
     "localname": "AncillaryServicesMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Components of Right-of-use Assets and Liabilities Related to Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Integration Related Costs, And Merger Costs",
        "label": "Business Combination, Integration Related Costs, And Merger Costs",
        "terseLabel": "Transaction, integration and acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCostsAndMergerCosts",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments",
        "label": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments",
        "terseLabel": "Repayments of grants received"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CostReportLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Report Liabilities, Current",
        "label": "Cost Report Liabilities, Current",
        "terseLabel": "Cost report liabilities"
       }
      }
     },
     "localname": "CostReportLiabilitiesCurrent",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredPaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Payments To Acquire Equity Method Investments",
        "label": "Deferred Payments To Acquire Equity Method Investments",
        "terseLabel": "Payments for acquisitions, deferred"
       }
      }
     },
     "localname": "DeferredPaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed",
        "label": "Disposal Group, Not Discontinued Operation, Number Of Businesses Disposed",
        "terseLabel": "Number of interests sold"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationNumberOfBusinessesDisposed",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration",
        "label": "Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration",
        "terseLabel": "Number of surgical facilities contributed as non-cash consideration"
       }
      }
     },
     "localname": "DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Before Interest Taxes Depreciation And Amortization",
        "label": "Earnings Before Interest Taxes Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "EarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_ExistingSurgicalFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Existing Surgical Facility",
        "label": "Existing Surgical Facility [Member]",
        "terseLabel": "Existing Surgical Facility"
       }
      }
     },
     "localname": "ExistingSurgicalFacilityMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_FacilitiesAmbulatorySurgeryCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities, Ambulatory Surgery Centers [Member]",
        "label": "Facilities, Ambulatory Surgery Centers [Member]",
        "terseLabel": "Facilities, Ambulatory Surgery Centers"
       }
      }
     },
     "localname": "FacilitiesAmbulatorySurgeryCentersMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_FacilitiesSurgicalHospitalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities, Surgical Hospitals [Member]",
        "label": "Facilities, Surgical Hospitals [Member]",
        "terseLabel": "Facilities, Surgical Hospitals"
       }
      }
     },
     "localname": "FacilitiesSurgicalHospitalsMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_FinanceLeaseCost1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost1 [Abstract]",
        "label": "Finance Lease, Cost1 [Abstract]",
        "terseLabel": "Finance lease costs:"
       }
      }
     },
     "localname": "FinanceLeaseCost1Abstract",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_GainLossOnDispositionOfAssetsAndDeconsolidation": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition of Assets And Deconsolidation",
        "label": "Gain (Loss) On Disposition Of Assets And Deconsolidation",
        "negatedLabel": "Net loss (gain) on disposals, consolidations and deconsolidations",
        "negatedTerseLabel": "Net loss (gain) on disposals, consolidations and deconsolidations"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsAndDeconsolidation",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact",
        "label": "Gain (Loss) Related to Litigation Settlement And Regulatory Change Impact",
        "negatedLabel": "Litigation settlements and regulatory change impact"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GrantRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Revenue",
        "label": "Grant Revenue",
        "negatedTerseLabel": "Grant funds"
       }
      }
     },
     "localname": "GrantRevenue",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_HealthcareOrganizationPatientServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Organization, Patient Service [Member]",
        "label": "Healthcare Organization, Patient Service [Member]",
        "terseLabel": "Patient service revenues",
        "verboseLabel": "Patent service revenues"
       }
      }
     },
     "localname": "HealthcareOrganizationPatientServiceMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_InDevelopmentDeNovoSurgicalFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-Development De Novo Surgical Facility",
        "label": "In-Development De Novo Surgical Facility [Member]",
        "terseLabel": "In-Development De Novo Surgical Facility"
       }
      }
     },
     "localname": "InDevelopmentDeNovoSurgicalFacilityMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants",
        "label": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants",
        "terseLabel": "Medicare accelerated payments and deferred governmental grants"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_InterestExpenseImpactOfChangeInLetterOfProtectionRegulation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Impact Of Change In Letter Of Protection Regulation",
        "label": "Interest Expense, Impact Of Change In Letter Of Protection Regulation",
        "terseLabel": "Additional interest expense for Florida LOP regulation change"
       }
      }
     },
     "localname": "InterestExpenseImpactOfChangeInLetterOfProtectionRegulation",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_InterestRateCapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Cap One",
        "label": "Interest Rate Cap One [Member]",
        "terseLabel": "Interest rate cap"
       }
      }
     },
     "localname": "InterestRateCapOneMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_InterestRateCapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Cap Two",
        "label": "Interest Rate Cap Two [Member]",
        "terseLabel": "Interest rate cap"
       }
      }
     },
     "localname": "InterestRateCapTwoMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-of-Use Asset",
        "label": "Lease, Right-Of-Use Asset",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_LineOfCreditFacilityIncreaseInBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Increase In Borrowing Capacity",
        "label": "Line Of Credit Facility, Increase In Borrowing Capacity",
        "terseLabel": "Line of credit facility, increase in borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseInBorrowingCapacity",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net",
        "label": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net",
        "terseLabel": "Acquisition and disposal of shares of non-controlling interests, net"
       }
      }
     },
     "localname": "NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NoncashInterestIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Interest Income (Expense), Net",
        "label": "Noncash Interest Income (Expense), Net",
        "negatedTerseLabel": "Non-cash interest expense, net"
       }
      }
     },
     "localname": "NoncashInterestIncomeExpenseNet",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NotesPayableAndSecuredLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable and Secured Loans [Member]",
        "label": "Notes Payable and Secured Loans [Member]",
        "terseLabel": "Notes payable and other secured loans"
       }
      }
     },
     "localname": "NotesPayableAndSecuredLoansMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned",
        "label": "Number of Surgical Facilities Owned",
        "terseLabel": "Number of surgical facilities owned"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwned",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwnedConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned, Consolidated",
        "label": "Number Of Surgical Facilities Owned, Consolidated",
        "terseLabel": "Number of surgical facilities owned, consolidated"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwnedConsolidated",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned, Majority Interest",
        "label": "Number Of Surgical Facilities Owned, Majority Interest",
        "terseLabel": "Number of surgical facilities owned, majority interest"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwnedMajorityInterest",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_OneSurgicalFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Surgical Facility",
        "label": "One Surgical Facility [Member]",
        "terseLabel": "One Surgical Facility"
       }
      }
     },
     "localname": "OneSurgicalFacilityMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_OperatingAndFinanceLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Expense",
        "label": "Operating And Finance Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseExpense",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_OtherPatientServiceRevenueSourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Patient Service Revenue Sources [Member]",
        "label": "Other Patient Service Revenue Sources [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPatientServiceRevenueSourcesMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_OtherServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Services [Member]",
        "label": "Other Services [Member]",
        "verboseLabel": "Other service revenues"
       }
      }
     },
     "localname": "OtherServicesMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Five Member",
        "label": "Pay-fixed Swap Five [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapFiveMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Four Member",
        "label": "Pay-fixed Swap Four [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapFourMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap One Member",
        "label": "Pay-fixed Swap One [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapOneMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Six Member",
        "label": "Pay-fixed Swap Six [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapSixMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Three Member",
        "label": "Pay-fixed Swap Three [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapThreeMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Two Member",
        "label": "Pay-fixed Swap Two [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapTwoMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PrivateInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Insurance [Member]",
        "label": "Private Insurance [Member]",
        "terseLabel": "Private insurance"
       }
      }
     },
     "localname": "PrivateInsuranceMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ProceedsFromTerminatedDerivativeInstrumentOperatingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Terminated Derivative Instrument, Operating Activities",
        "label": "Proceeds from Terminated Derivative Instrument, Operating Activities",
        "terseLabel": "Gain on termination"
       }
      }
     },
     "localname": "ProceedsFromTerminatedDerivativeInstrumentOperatingActivities",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_ReceiveFixedSwapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receive-fixed Swap One Member",
        "label": "Receive-fixed Swap One [Member]",
        "terseLabel": "Receive-fixed swap"
       }
      }
     },
     "localname": "ReceiveFixedSwapOneMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ReceiveFixedSwapThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receive-fixed Swap Three Member",
        "label": "Receive-fixed Swap Three [Member]",
        "terseLabel": "Receive-fixed swap"
       }
      }
     },
     "localname": "ReceiveFixedSwapThreeMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ReceiveFixedSwapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receive-fixed Swap Two Member",
        "label": "Receive-fixed Swap Two [Member]",
        "terseLabel": "Receive-fixed swap"
       }
      }
     },
     "localname": "ReceiveFixedSwapTwoMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "label": "Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to non-controlling interest\u2014redeemable holders"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests",
        "label": "Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests",
        "terseLabel": "Acquisition of shares of non-controlling interests, net\u2014redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_RedeemableNoncontrollingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Policy Text Block]",
        "label": "Redeemable Noncontrolling Interest [Policy Text Block]",
        "terseLabel": "Non-Controlling Interests\u2014Redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestPolicyTextBlock",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgry_RedeemableNoncontrollingInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Roll Forward]",
        "label": "Redeemable Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Non-Controlling Interests - Redeemable [Roll Forward]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestRollForward",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_SelfPayRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self-Pay Revenue [Member]",
        "label": "Self-Pay Revenue [Member]",
        "terseLabel": "Self-pay"
       }
      }
     },
     "localname": "SelfPayRevenueMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SeniorUnsecuredNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2025",
        "label": "Senior Unsecured Notes Due 2025 [Member]",
        "verboseLabel": "6.750% senior unsecured notes due 2025"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2025Member",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SeniorUnsecuredNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes, Due 2027",
        "label": "Senior Unsecured Notes, Due 2027 [Member]",
        "terseLabel": "10.000% senior unsecured notes due 2027"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2027Member",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SixUndersignedInterestRateSwapsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Undersigned Interest Rate Swaps",
        "label": "Six Undersigned Interest Rate Swaps [Member]",
        "terseLabel": "Six Undersigned Interest Rate Swaps"
       }
      }
     },
     "localname": "SixUndersignedInterestRateSwapsMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilitiesAndPhysicianPracticesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facilities And Physician Practices",
        "label": "Surgical Facilities And Physician Practices [Member]",
        "terseLabel": "Surgical Facility and Physician Practice"
       }
      }
     },
     "localname": "SurgicalFacilitiesAndPhysicianPracticesMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilitiesExistingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facilities, Existing Markets",
        "label": "Surgical Facilities, Existing Markets [Member]",
        "terseLabel": "Surgical Facilities, Existing Markets"
       }
      }
     },
     "localname": "SurgicalFacilitiesExistingMarketsMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facilities",
        "label": "Surgical Facilities [Member]",
        "terseLabel": "Surgical Facilities"
       }
      }
     },
     "localname": "SurgicalFacilitiesMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilityServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facility Services [Member]",
        "label": "Surgical Facility Services [Member]",
        "terseLabel": "Surgical Facility Services"
       }
      }
     },
     "localname": "SurgicalFacilityServicesMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00%",
        "label": "Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00% [Member]",
        "terseLabel": "Three Interest Rate Swaps That Pay 1-Month LIBOR Subject To Minimum Of 1.00%"
       }
      }
     },
     "localname": "ThreeInterestRateSwapsThatPay1MonthLIBORSubjectToMinimumOf100Member",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Pay-fixed Interest Rate Swaps Member",
        "label": "Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 0.75% [Member]",
        "terseLabel": "Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 0.75%"
       }
      }
     },
     "localname": "ThreePayFixedInterestRateSwapsSubjectToMinimumOf075Member",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Pay-fixed, Receive 1-Month LIBOR, Subject To Minimum Of 1.00%",
        "label": "Three Pay-fixed, Receive 1-Month LIBOR, Subject To Minimum Of 1.00% [Member]",
        "terseLabel": "Three Pay-fixed Interest Rate Swaps Subject To Minimum Of 1.00%"
       }
      }
     },
     "localname": "ThreePayFixedReceive1MonthLIBORSubjectToMinimumOf100Member",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_TwoSurgicalFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Surgical Facilities [Member]",
        "label": "Two Surgical Facilities [Member]",
        "terseLabel": "Two Surgical Facilities"
       }
      }
     },
     "localname": "TwoSurgicalFacilitiesMember",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_UndesignatedDerivativeActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated Derivative Activity",
        "label": "Undesignated Derivative Activity",
        "negatedTerseLabel": "Undesignated derivative activity"
       }
      }
     },
     "localname": "UndesignatedDerivativeActivity",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_UnrecognizedGrantFundsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Grant Funds Received",
        "label": "Unrecognized Grant Funds Received",
        "terseLabel": "Unrecognized grant funds received"
       }
      }
     },
     "localname": "UnrecognizedGrantFundsReceived",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesMedicareAcceleratedPaymentsandDeferredGovernmentalGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_VariableAndShortTermLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable And Short-Term Lease, Cost",
        "label": "Variable And Short-Term Lease, Cost",
        "terseLabel": "Variable and short-term lease costs"
       }
      }
     },
     "localname": "VariableAndShortTermLeaseCost",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_VariableInterestEntityNumberOfFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Number of Facilities",
        "label": "Variable Interest Entity, Number Of Facilities",
        "terseLabel": "Number of facilities included in VIE"
       }
      }
     },
     "localname": "VariableInterestEntityNumberOfFacilities",
     "nsuri": "http://www.surgerypartners.com/20230331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r225",
      "r398",
      "r399",
      "r402",
      "r403",
      "r443",
      "r482",
      "r486",
      "r585",
      "r588",
      "r589",
      "r633",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r225",
      "r398",
      "r399",
      "r402",
      "r403",
      "r443",
      "r482",
      "r486",
      "r585",
      "r588",
      "r589",
      "r633",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r225",
      "r261",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r283",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r586",
      "r587",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r225",
      "r261",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r283",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r586",
      "r587",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r371",
      "r454",
      "r470",
      "r484",
      "r485",
      "r513",
      "r526",
      "r533",
      "r590",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PayablesToCustomers": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to customer by broker-dealer.",
        "label": "Broker-Dealer, Payable to Customer",
        "terseLabel": "Amounts due to patients and payors"
       }
      }
     },
     "localname": "PayablesToCustomers",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r285",
      "r455",
      "r514",
      "r532",
      "r582",
      "r583",
      "r592",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r285",
      "r455",
      "r514",
      "r532",
      "r582",
      "r583",
      "r592",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r364",
      "r371",
      "r372",
      "r373",
      "r374",
      "r450",
      "r454",
      "r470",
      "r484",
      "r485",
      "r513",
      "r526",
      "r533",
      "r580",
      "r590",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r364",
      "r371",
      "r372",
      "r373",
      "r374",
      "r450",
      "r454",
      "r470",
      "r484",
      "r485",
      "r513",
      "r526",
      "r533",
      "r580",
      "r590",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r483",
      "r487",
      "r497",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of property.",
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r483",
      "r487",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.",
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r22",
      "r531"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r196",
      "r463",
      "r475",
      "r476"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r33",
      "r36",
      "r120",
      "r442",
      "r471",
      "r472",
      "r542",
      "r543",
      "r544",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r531"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r554",
      "r555",
      "r556",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities outstanding not included in the computation of (loss) income per share as their effect is antidilutive (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r165",
      "r175",
      "r195",
      "r221",
      "r269",
      "r275",
      "r281",
      "r292",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r398",
      "r402",
      "r418",
      "r531",
      "r586",
      "r587",
      "r606"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r190",
      "r200",
      "r221",
      "r292",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r398",
      "r402",
      "r418",
      "r531",
      "r586",
      "r587",
      "r606"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r138",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r396",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r108",
      "r109",
      "r396",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "terseLabel": "Recognized non-controlling interests"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Start-up costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Transaction and integration costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Non-controlling interest, fair value"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss",
        "terseLabel": "Net (loss) gain on fair value of non-controlling interest"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r58",
      "r192",
      "r498"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r53",
      "r58",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r159"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "negatedTerseLabel": "Amount estimated to be reclassified as a reduction to interest expense over next 12 months"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r312",
      "r313",
      "r481",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r554",
      "r555",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)",
        "terseLabel": "Common stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 126,480,483 and 125,960,834, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r37",
      "r207",
      "r209",
      "r217",
      "r460",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income attributable to Surgery Partners, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r115",
      "r116",
      "r131",
      "r207",
      "r209",
      "r216",
      "r459",
      "r466"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Comprehensive income attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r114",
      "r131",
      "r207",
      "r209",
      "r215",
      "r458",
      "r465"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r156",
      "r157",
      "r288",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r156",
      "r157",
      "r288",
      "r477",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r156",
      "r157",
      "r288",
      "r480",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r70",
      "r71",
      "r156",
      "r157",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Revenue by service type as a proportion of total revenues (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r156",
      "r157",
      "r288",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r121",
      "r123",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r82",
      "r274",
      "r275",
      "r276",
      "r277",
      "r283",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "verboseLabel": "All other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r68",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r166",
      "r167",
      "r174",
      "r225",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r427",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r167",
      "r174",
      "r348"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r28",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r29",
      "r225",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r427",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r29",
      "r99",
      "r100",
      "r101",
      "r102",
      "r160",
      "r161",
      "r164",
      "r173",
      "r225",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r427",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r162",
      "r337",
      "r349",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: unamortized debt issuance costs and discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "terseLabel": "Unamortized fair value discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Long-term deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r56",
      "r105",
      "r387",
      "r392",
      "r393",
      "r553"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r56",
      "r264"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeNotionalAmount",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Loss recognized in income"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r143",
      "r144",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivatives and Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeNotionalAmount",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "negatedTerseLabel": "Derivative liability, notional amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount",
        "totalLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeVariableInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.",
        "label": "Derivative, Variable Interest Rate",
        "terseLabel": "Variable interest rate of derivative instrument (percent)"
       }
      }
     },
     "localname": "DerivativeVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r134",
      "r136",
      "r137",
      "r146",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives in cash flow hedging relationships"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r362",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r308",
      "r550",
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "verboseLabel": "Pre-tax gain (loss) on disposals and deconsolidations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r218",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r239",
      "r241",
      "r244",
      "r245",
      "r246",
      "r250",
      "r413",
      "r414",
      "r461",
      "r468",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r218",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r241",
      "r244",
      "r245",
      "r246",
      "r250",
      "r413",
      "r414",
      "r461",
      "r468",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Net (loss) income per share attributable to common stockholders",
        "verboseLabel": "(Loss) income per share:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r594",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "negatedTerseLabel": "Tax benefits related to vesting of restricted stock awards"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r185",
      "r211",
      "r212",
      "r213",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r238",
      "r252",
      "r293",
      "r352",
      "r375",
      "r376",
      "r377",
      "r389",
      "r390",
      "r412",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r442",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r339",
      "r417",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.",
        "label": "Estimated Insurance Recoveries",
        "terseLabel": "Expected insurance recoveries"
       }
      }
     },
     "localname": "EstimatedInsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r150",
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r339",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r415",
      "r447",
      "r448",
      "r449",
      "r509",
      "r510",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r339",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r339",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r339",
      "r365",
      "r370",
      "r415",
      "r448",
      "r509",
      "r510",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r339",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r447",
      "r448",
      "r449",
      "r509",
      "r510",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r431",
      "r435",
      "r530"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "sgry_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r433",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r429",
      "r440"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "sgry_LeaseLiability",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease obligations",
        "totalLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability [Abstract]",
        "terseLabel": "Finance lease liabilities:"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r432",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "sgry_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r431",
      "r435",
      "r530"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "sgry_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation settlements",
        "netLabel": "(Loss) gain on litigation settlement",
        "verboseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r193",
      "r296",
      "r456",
      "r507",
      "r531",
      "r566",
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r298",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions, including post acquisition adjustments"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r306",
      "r307",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r300",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Disposals"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Formal agreement with government or its agency.",
        "label": "Government Contract [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "GovernmentContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r136",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r222",
      "r394"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "(Loss) income before income taxes",
        "totalLabel": "(Loss) income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r39",
      "r56",
      "r85",
      "r170",
      "r180",
      "r266"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "negatedTerseLabel": "Equity in earnings of unconsolidated affiliates, net of distributions received"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r223",
      "r237",
      "r238",
      "r267",
      "r382",
      "r391",
      "r395",
      "r469"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r378",
      "r379",
      "r384",
      "r385",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Tax benefits attributable to non-recurring earnings' impact on the valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "negatedTerseLabel": "Tax benefits related to the sale of partnership interests"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedTerseLabel": "Interest expense, net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCapMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.",
        "label": "Interest Rate Cap [Member]",
        "terseLabel": "Interest Rate Caps"
       }
      }
     },
     "localname": "InterestRateCapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r197",
      "r499",
      "r531"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r182",
      "r478",
      "r479"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment Owned, at Fair Value",
        "terseLabel": "Fair value of investments"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in and advances to affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r439",
      "r530"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense and Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24",
      "r221",
      "r292",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r399",
      "r402",
      "r403",
      "r418",
      "r505",
      "r586",
      "r606",
      "r607"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r169",
      "r179",
      "r531",
      "r552",
      "r565",
      "r601"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r191",
      "r221",
      "r292",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r399",
      "r402",
      "r403",
      "r418",
      "r531",
      "r586",
      "r606",
      "r607"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r14",
      "r167",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amount of line of credit outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Availability on line of credit instrument"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Other litigation costs"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r167",
      "r176",
      "r338",
      "r350",
      "r509",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, less current maturities",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Less: Current maturities",
        "verboseLabel": "Current maturities of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r29",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r11",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisitions and Disposals"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposals"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r32",
      "r168",
      "r178",
      "r221",
      "r292",
      "r318",
      "r321",
      "r322",
      "r323",
      "r329",
      "r330",
      "r418"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests\u2014non-redeemable"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to non-controlling interests\u2014non-redeemable holders"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r54",
      "r57"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r40",
      "r57",
      "r171",
      "r181",
      "r189",
      "r205",
      "r208",
      "r213",
      "r221",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r243",
      "r269",
      "r274",
      "r280",
      "r283",
      "r292",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r414",
      "r418",
      "r506",
      "r586"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income attributable to Surgery Partners, Inc.",
        "totalLabel": "Net (loss) income attributable to Surgery Partners, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r118",
      "r130",
      "r205",
      "r208",
      "r237",
      "r238",
      "r544"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net income attributable to non-controlling interests",
        "negatedTerseLabel": "Less: Net income attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to non-controlling interests\u2014redeemable"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r118",
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "terseLabel": "Noncash consideration"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r112",
      "r352",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interests\u2014 Non-Redeemable"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedging instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of facilities acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of interest rate swaps"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes reclassification from accumulated other comprehensive income (AOCI) for gain (loss) recognized in other comprehensive income (OCI) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.",
        "label": "OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Cost of revenues"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r269",
      "r274",
      "r280",
      "r283",
      "r506"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r436",
      "r530"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "sgry_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current",
        "verboseLabel": "Right-of-use operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Right-of-use operating lease liabilities",
        "verboseLabel": "Long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r434",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "sgry_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Right-of-use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LeasesScheduleofComponentsofRightofuseAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r199",
      "r531"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Derivative activity, net of tax of $0"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivative activity, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r201",
      "r202",
      "r404",
      "r405",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "(Loss) gain recognized in OCI (effective portion)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r202",
      "r204",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedTerseLabel": "Loss (gain) reclassified from accumulated OCI into income (effective portion)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax",
        "terseLabel": "Amortization of accumulated OCI related"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r38",
      "r98",
      "r206",
      "r209",
      "r214",
      "r419",
      "r424",
      "r425",
      "r457",
      "r464",
      "r542",
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Summary of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r531"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonrecurringIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature.",
        "label": "Other Nonrecurring (Income) Expense",
        "terseLabel": "Other expense (income), net"
       }
      }
     },
     "localname": "OtherNonrecurringIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "negatedTerseLabel": "Distributions to non-controlling interest holders"
       }
      }
     },
     "localname": "PaymentsOfDividendsMinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Payments for acquisitions, net of cash acquired",
        "terseLabel": "Payments for acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchases of equity investments",
        "terseLabel": "Payments to acquire equity method investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment",
        "terseLabel": "Total cash purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r531"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r198",
      "r294",
      "r295",
      "r500"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Borrowings of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "terseLabel": "Receipts (payments) related to ownership transactions with non-controlling interest holders"
       }
      }
     },
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sales of equity investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from disposals of facilities and other assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Revenue Source"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional and medical fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r189",
      "r205",
      "r208",
      "r219",
      "r221",
      "r229",
      "r237",
      "r238",
      "r269",
      "r274",
      "r280",
      "r283",
      "r292",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r397",
      "r400",
      "r401",
      "r414",
      "r418",
      "r462",
      "r506",
      "r527",
      "r528",
      "r544",
      "r586"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r578",
      "r602",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "terseLabel": "Accumulated depreciation on property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r579",
      "r604"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $382.7 and $374.3, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesScheduleofInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Assets from Segment to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Revenue and Operating Income"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r93",
      "r94",
      "r96",
      "r97"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Non-controlling interests\u2014redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of Rollforward of Noncontrolling Interest - Redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted shares"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r103",
      "r177",
      "r474",
      "r476",
      "r531"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r185",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r238",
      "r293",
      "r375",
      "r376",
      "r377",
      "r389",
      "r390",
      "r412",
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r260",
      "r261",
      "r273",
      "r278",
      "r279",
      "r285",
      "r286",
      "r288",
      "r361",
      "r362",
      "r455"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r438",
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for finance lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r438",
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r288",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amounts and Fair Values of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r142",
      "r143",
      "r145",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r64",
      "r66",
      "r241",
      "r242",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r507",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Rollforward of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of Effect of Interest Rate Swaps"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r80",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r76",
      "r77",
      "r80",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Financial Information by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r122",
      "r124",
      "r126",
      "r127",
      "r128",
      "r398",
      "r399",
      "r402",
      "r403",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r67",
      "r70",
      "r71",
      "r72",
      "r156",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Revenues"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r310",
      "r311",
      "r507",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r269",
      "r272",
      "r277",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]",
        "terseLabel": "Reconciliation of Adjusted EBITDA:"
       }
      }
     },
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SelfInsuranceReserve": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.",
        "label": "Self Insurance Reserve",
        "terseLabel": "Professional, general and workers' compensation insurance reserve"
       }
      }
     },
     "localname": "SelfInsuranceReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongtermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Series of Individually Immaterial Business Acquisitions"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r187",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r309",
      "r310",
      "r311",
      "r507",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingScheduleofSegmentRevenueandOperatingIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r98",
      "r185",
      "r211",
      "r212",
      "r213",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r238",
      "r252",
      "r293",
      "r352",
      "r375",
      "r376",
      "r377",
      "r389",
      "r390",
      "r412",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r442",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r252",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r98",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r103",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r19",
      "r20",
      "r84",
      "r531",
      "r552",
      "r565",
      "r601"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Surgery Partners, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r112",
      "r113",
      "r129",
      "r185",
      "r186",
      "r212",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r293",
      "r352",
      "r375",
      "r376",
      "r377",
      "r389",
      "r390",
      "r412",
      "r419",
      "r420",
      "r425",
      "r442",
      "r472",
      "r473",
      "r552",
      "r565",
      "r601"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r426",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r426",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r426",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r426",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r444",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Summary of Investment Holdings [Line Items]",
        "terseLabel": "Summary of Investment Holdings [Line Items]"
       }
      }
     },
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period.",
        "label": "Summary of Investment Holdings [Table]",
        "terseLabel": "Summary of Investment Holdings [Table]"
       }
      }
     },
     "localname": "SummaryOfInvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r122",
      "r398",
      "r399",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r240",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "verboseLabel": "Weighted average shares outstanding- diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r239",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted average shares outstanding- basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Footnote": "5",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(C)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "5",
   "Subparagraph": "Schedule III",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r537": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r538": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(ii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Rule 15c3-1",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15c3-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001638833-23-000070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001638833-23-000070-xbrl.zip
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M3WG 6_^UW_A92OA YN0_4$L#!!0    ( %1 HE89T#0O"0@  %4C   5
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MU>IFO5COQ=>*:/O"\EW#JK!1EHCJL$:V*ANK6N_97O.PH^P3X%<71I(G,+K
MI>Z<H9T0LAM(UF'$-7*7? '(P9RS%.L;UCK-+QB,TY1CMW/KA71[=#RK'?>]
M[]Y0D_:]PK>;ZC/$$F%/!F!?N:K*3E@UE5^HXT]B^R2V3V)[36R'Y()3B%T8
M"NR(].K'T-N=H7JDY%Z)[>\HM7"&[24WO:#M4"L]/M[VKT]Z_-APOM:=R_?Q
M<^N.N!#5)7DD649,CMRY-;ZJ/W8K_*LI9*I$5NK/3WG$+=6-9W4A;J_F>_\
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M'@<52+ B,D&%(=P$0JU'RAM+R.+;#'=S0TF>DAZOS2CE4X)!.4'NI#:6)>N
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MHTX+%O;DXW[SZ+35;(T:VW^W6Z?'5T>G?\*H[]KUTQU<W]ZY.MK^$Q;677Y
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M@MN#<#P<E\JJ'6;-KP%O;4:8.Y[4)Q0-_=_7G^IXW!>+EM9L I2_'#*^O?R
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MA2BK.IBO+PMRLY+C/]U^OQD'VVG/?BL(-Q/"3??NB=1IX;U#7@*N<8<%,CJ
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M'KI4\\XC#P87=0/;F3N6S&5F%A- IWGA'=&S-&.J!91^GX!2L-(]SA4<?6:
MG(2$+.8.D:@5CBS"1V&>K<,+CA8<+3B:<=3Z2(4D0D;ON(S**D#2D'",C(@D
M]&/C:.D8-3>0)1,@:ZSVF%&)A(O 5S&\LLQQE#S(WE/%DI'#%N?B_I5R"] 6
MH"U >PEHA3"!14FCUYAK3*P*0D?+N0'ST$M1"&N=L91-8"ECGGMI+0HX9"SE
M&EE/)"*88,&)B[YR7HIKPC0+D!8@+4!ZCR,AK;CVUBG/$N/81Q>H2DHF!CR6
M"\9O1M+2+;Y&D"HF()4X806C#NF4,.)>.>0$LR@QQ;$5AC-#EU:YP2O3WM29
M0V +G!8X?<9P.@LO90'(*!4&4\>Q8E:92*S7P&.<=9@57EIG$+T4,#,\5?><
M4XQ)1$'F7CC6"&1BC(@+39PBE'L>EU:U(',K)5J@M$!I@=*JZ(&*DCO*F7>*
M1ZS!LG=. 6TQ *16^N)+76"<G8A><IPH'))%WA/ 61PELL);) SLF3@P&X5<
M6J7+F-!K I@6#VFKZ*<_J@4'_X;6E]6_X,=XR)>NY6->?R-=7?W+]?Y8_?&<
MM_E:=8L?4S%\)IB&MCWMQU?C%W_FRD=M>_ZJU:DTMOK2GR>V=]CJC.<GIY1-
M/%)UO^''?WYMA<%1UO$5/-3S46C7Z,ZCCU>JCR8$-/R,DQ4BZ8T?XQ5RXV<_
MNZQ8P>3F;_[LJC__3)&;[_DRQJK,W:3U^&/5*_2.*ZO,Z\_GU1"V(&/-\ZIN
M==67%9BZ'GT\<;$WE]C4YQYC2E+N,:B\)$J +9A,PB)(:Z)0FDF-AXR4T!)C
M^E.>>0(CI1MBB\+8CO>_ L\$WOFFU?SX_CQS1^"*?'OOX AX(9WDF?#9]_T\
M1KIUWCS^&WCF%MO_N$D.UO_=;KX].&E^/Q3-DXUOS>.#-.:8PXI::U^;:Y]$
MC%QB@Q%(/R$N=2ZFI3PBR6OGB/5&NMRD7BP;.5T98.'+ =U;?^L&9#,;V,_2
M4+XC+!6?8RTPZOL$1C$K-,6.(R:T1]Q4.7J 5H9ZSI703M$<5S2WH_""3P6?
M'A:?/(X.&VDTP!-W3EIJ-8U84R\<U5$\-CX]>T?>XX$7F0"O&+WGD@6DL95
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M)JV-$!HQ)7(=T9205MXB(:A,P@1BG5]:-1JOB,),"Y06*)TCE,80DF=:T'P
M):BSVG.I=0B$<)@N67RI"XRS$^%+A&JIJ:$(4PTX:T5$QOF(L.8I,D<9=S$[
M4X'!/@NDK<*?_J@6'/P;6E]6_X(?XR%?NI:/>?V-='7U+]?[8_7'<][V:X^G
MXC2K^&Z,C4YW$*O4KK..!4T;5%W*.B%VAOW*.M5TVOQV:G5LQ[=L&T8);YS
MP/LK-S[BZ$:"PTA.N\.$RU>]V+:#UI?XY]=6&!R-@>;2MT8BQA=?L0Y&<#:X
M^2MU%0'!MY(!OSK"RS_S:"N,XH%08I@GUG-NO+/YS$)ACVUNU:O")RJ6QE\Z
MZHV?X-0>1N1ZT7Y&-L$#OK+MK_:\O_3'E7DX:77& U(41CPYS3?.2DIWF14U
M,2GJFDD9:B@ =K=7U=A_!8@0>_FO8$BV+D-I'/7RYO=?OY:.6EK=J](ANZF1
M4XJSXOSUAUV]3O)/"1+730" Q(>=MQL[^XUW:SM[S8V=W>7&9O/U2J,^V';]
ML%]O-]<WFKL;ZPUXM;O]S^;ZVA[\LKL'_VQM-/=V&]MO&J_7=O_5>///]L?=
M&CQ.=<%7K0'<S-_B 7_[, ;L9=@.VVW;ZS=:G0;<NIW#N'^?^8GN )C5MGB!
MW=4^[/-83OOQU?C%G[E(7]N>OVIUJJ>HOO3GB>T= O2, #_G04]LP]7]AA^/
M0,F8%2U(QJ51./+HQB/(6JD@:X)3##]3;(5*>>/'>(7<\3/!Q9V^^;/!$KQB
MU%T']"2#9;>Z["\"R7^9$S+#GYJI/[W&!AVNXJ<QN:94NMIO]V!+B8TM^+NC
M?F,#=IIP$8]^A3,_XE1>\B[<Q+.OH=KUGN>?AO;/^, O;>+H+ NQWLDAYE;/
M_-KVCQJIW?W:;Z1>]Z31/8V9"W8.&]FF_0)62NR_NLUJNG-9H%M<8VY+M5Z#
MG%.UE7HLK^O=;,TX -J6RWC?:0W](J'RWDF4=9NNVSMJKWO")W*XWN[1GC([
M]%VOFUJ#7$B^-@[2YN[(07K<_+R]=_A]_V3_?/_X[Y/MO??BX.,'WCS>_]9<
MW__:_/C^VS[=.-_^N'5^X2#]P Y.MK[O[ZWA@^/W>&OO_7>X/C]87Z-;W\/G
M[8\?R-;)%M_ZOO-YRD&Z%T[VOS>/MM9W3N"9X!XPKN]'G[?6X5T*]][[< [C
M_=Y\NY.VSO'YQ&D^)D%))P)R&AO$";-("T>0MXJ9[!R%+31']$]G=RY\888"
M-L\2;*+0'F-JO0.P(4HY$1UA+!'BL7-D6,F:CL&&%K!Y.+#!$V##B&$TF(!P
M5 YQPP5RW#ED-.?"4$MACUA:Y71%UPAMGI7-<$.;BG!\UA]4)R3Y:*470:%\
MJQUS^XD1VZNJZ<%O/IL7I[WNEU8V]]UY/>V+6E]CGC49"5VA3U:4\7:+:SV>
MPH)JV1]-4.Q)/AS_7KWQ$$;$HE9EJ3_MOBQ*>-V.58Q#)ZQ=DFC9(V?8(YN[
M4X2<<2\9U@1IG5/ 4HC()M@CG0W$.&ZQ87%IE<VAPW3]&'G1W(?BL$5SYZ^Y
MD^PV>!J9E!Q,:6\1%R&!YD:+C.(TIHH1@"E-U0JOD>;.LQ_; I"19BX(G2EL
M.Q<3:\1OISERZ$'IZH)5R:\_"]D>6QS_9!EN#$58P&L6\&I=T X8#VY^_:2(
M4,&0B%22 7'%(W*14&1\E)@0I[Q/2ZMF95X5DFH455XT]:%81]'4.6@JGM#4
MH%/@PAIDDI*(:VF0Y<2CJ"@V3B@E!%M:U=?T;'L>;2@6B66,^TV,B<;/&[H6
MRZD6;..&/I99H..<C6$CZQ&@U:FYSH)@VJ33@P!X*49]-IW\\!328)&0XU$F
MRI/&)BRMROMG:!2?1VTU=P[LHVCNX[&1<755$IP.@B%%-44\TH!LX [I0 %Z
M33 VL*RY]RY457P>=]7!86HB<G:8(G62E_[P-*:X/Q:"D$QDG>;JT7]G8;Z^
M),N"8[/@V'0<%(_:8<T,$H)D_X<%!N*E1LI31H2E4ABSM,KO'P=5_!^U5=6Y
M^S^*JLY#52<IAY32DF@D$DQ'Q!T3".P#C8RSC#,KHPDX-ZVO4^O=E^8 B8-&
MN]OO-WX[M*W.[PW0NS#N7+M\*4V[ZM.98T)RRNKE-XN/I-Z4Y#I+ZRV(.D=)
M;G>&78JKA/CMM-;OQT'5N_BJC L,S@"#VZ^G&(M1.'$)/,51(K(?V"'+E$%*
M"D)4X#CDRA9D#@6$BM/D<55YEB*+<^,L184?7H4GF8PSS#A,'&*8.L0#6!XN
M*(% =M:PR&E4=&D57^,\6>366HM"8M9CBKU>##\BH.VW>#=B\J(-L$=N(WA#
M[=BQ,(?^WSW[;>0"_CMV8FH5-_!,F1U[:X.MUD2=K222,3*7V,K5MA.C2.?S
M:>E)R$D?E!J>\\BF,SMFK@E;7"?U,RD>(&"UZ.L\];7Y>J*M)Q="<N-18M$B
MSE-"!K04.9R @E"!09197^L4[_7"G"C#<YM<)"G:7@<>H)\K<IUUKE2YLRFU
MVBUXV:]B2_)?A,OM<7,R5VQ]B:%X5&I.7*[BWQ#WLBV6.QX/E\)6'!QU 1&_
MQ%&R7C,.MM-Z*^?B=4)_NW>E,7*!R)D@<F.*TDCGO70I(-C**$"D4,A8L-.4
MYL%;30*+,EMG-6E\7'2ZKJZ5HM-/IM.3M"<Z%ICE 3&* ^+:)&2#9(A%(C03
M!*?$LTY/MP-:9(]+G5G.ZR/;.8Q5+<A+J>25P[$Z&0)RXX#AY+3R'PS'>M"=
MH7-R='S4ROK3&ISU2O)Y23Z_7-G >WB8P9@&YU*>A0@OU-'BI<VSE[-(UN/P
MW\W.6+8[/T1;ML>9ML?WTUX\&X#FJ(B<$1IQS QRA"=DDA=:.N9,$#FWI$[U
M68H*U\Z55U3X\51XDN$R$[D5)*&$(ZBP= )9FP,$1-12.6*EQ4NK]/Z.O?K1
MW$4A)5LQP$AZ$7BLC^W,>6-HG-KS80&F83C4Z.CQL OC[N0/;+MQV+-5*?YR
M EEK1]YUL5'3T#=>!&L7:^#=: E4@1;#!?#VDOS?5N(O #D30'Z8XCB,29J\
M#"AJEP 6,4<F6H=2T ICPQE7[/J*E^6D\CEH^ /EF14-?S(-GZ1 !BMOG$X(
M.P,4R#B.K"+9J G8,Y64D18T7%_#@9Y$Q5^83V9[<!1[OW3V%3?-,W'35.+^
M40GDM3W-+8-*YNVL,.>GB R.S$G!(TI:1)1; R-K"$'::BF83\0QG_-@BK/F
M^2KR8SIKBB+/29&G8K&4# XG6+B2&<3!"D&6"8]\,B9X(S5AP%=4K6KPS]-E
M0\6*JCEG:=ZV]/53>V=NW;SIV4'AW$.P0.:YF=*[D<3_/O_0S_&H/Q!P[8?0
M"P+.A("'4U3&.LDH,1&9P +*XD.&:EC;E'I#K4O.1T! /N\6S;?J<;8H;IN7
MJ_ISC]0JJO]@JC])?D1*"@L/E"<%#%:,=L@Y:Q"FPC'%$Z')@.J;^YLQCZ7Z
M(VHT'LAH49M*K^=M_SS2-1ZN7]^3#O)9A=?=KAUDJXHT+>U:'CUBKAZ+Y/JM
M]MU9SQ^!C5\EF("% ]O<X+QRR,;_/6N=YL.)XHZM^:GS1,^RT4'37G<MQ\KV
MXKN15-^U;6>PU@D;8\$6 C,+@3F>3A/A()60B$6,DY@#;@RRP6LD HM><2*!
M;RZM4K["ZA%37I2W?@?*17D?27DGK0]BG0Q24T1(/D/16B!KL$/"*,\LL?"+
MKHZ*:Y+D]:P8ZPUD9!P(E[J]*YD>/](_*D>L':K&W?):2[!,;8C)WV=]&&$?
MR&>5^9;ME=$GH:#;3.BV.45--'5.8$J0XKFI"P:<,Y9IQ$!B3@KAB<Y%3?$U
MI1)+K-MS4-^'IR9%?>>GOM/D1$9-%4&"Y#@V[C$RPD5$A.8@5RXU!O5EY%[U
MP>H7QU9K<M+KPGR%D3/M1TW3S$J2]:/0M<ISTJVBW(:Q;<5YLDCGOF,9YR3]
M70"P[03OA+/L+HW#2H@%V69"MJWI&/S$?7!4(RNP &*2&\%'Z9")F@<1HO22
MYCS#.B4I%;VM^:'M;?06;,H3.X"[?QN\2JUO,:#OL=<M^CRC/D\R%:^5DTH3
MQ"D%?<Z=G"S&!H5DM+$DRAC<$NBNIH3^62.=?@GNE,MG.W%<4NQ'N9GB/EEL
M]\D-580*HLV$:-=40C!!6A83X%BN9QJE1L9HC6+2+B7,*,O-O,TU73:+YZ2N
MFELKQ\F-BELHREP4>HJBQ.!]T +ELGZ("WAE!,>(8!>#2%$R(N9&48I3Y>Y.
ME3XL\WF2E6*/U<:/4C#O(3%ONM1!L)A*;@5B)%=F5\XB'31%4D5EI+8^8EM'
MLZRH=MW9S.U5NZCP3"H\25N2XUI199".56Z@8<AZE<^ P Q1GF#%S=(J(;7J
M\O0"W"K#(@;715,7C\I">E3>='N74:V2[^98O"7?YXZ MC]=M<#(#%H$):PH
MXC1'W'EBD5/!1F6I V'E1KLU.=,N"KPH(2E%@1]&@2<9B5)&)TL)XL%'Q'E6
M8 $*+)G4FD2=? S9,WJ?</?Z^4\6KE#!6;_J7#<_BC)'8^N992K7H\/=#3G+
M!0+O"X'3E9>8=UJQH!'FRB,>C4*&>X^\\C8)9Z66;&E5W2^N=E9=62!GRPO6
M_X<KV%3T_\'T?Y(".5C9UGF%G+$Y?$U*Y#RGB,A  G<AL5PFGZMY-.Y=B'(%
M-<OC?KAR!4\ZR&=U%'B[<@6IU;$=/X]R!7,L-%'K:[P W^N[7@O6Q*EM7Q3-
MATVWW>T<HD'LG<!VZ>Y6KZ X<9[*"[L3QZ+<3O^ (/= CNL@QD)59J$JWZ?[
M<@MBI%;.(\TE4)5 &;SR&B7!-<:>V.!S7VYQKXYWQ=]:7U6=N[^UJ.J<5'4J
MW0_LB,BY0(KEDQ&EP+Z@8%\DPJ2S07"7LW6)>F9EZ^O,-/[N]GK=KZU1Z^TY
M,(P2L5*#8+3-?O\,K(I8\.L>^#5=""DF1A3("#DF:6X>*!#L-!0EQ:-F5E!.
M\ U4HX2:/1?%?=!0LZ*X<U'<*7<F)TEY'5!R50I?,$A3S1&)E 1&09)T&&-6
M)\5]"7Z.']Z-5#&.1FNT_N&!^R5U;\%<'.]^6$T9M,90]CI+LB#8G;T<G^G6
MWH=/6,<$FXY$RC./N(U /3!5*$;+@\<4_JEZ^M4D)J4H:]U)Q\]TM22KS-G]
M,=1A(A37.GB4&$PI=PPC@Q-!7J?('8>7.:BB).@]@2JNM_J#7LN=5648&X-N
M V8>90WL==OM?#C7 F7LQ?Z@<=1MA]A[\@"SQ4.[NE"35@X>Z83^5JO3[;4&
MYYLCR19XFPG>IN/>DV N6 +PEAP#BH(],H819(5F7B2J@LHQ(]<96:5,]'/0
MVH<D*45KYZ2U4V<R2L@D@)08' GB0E*D392(<:6 0BB<0EI:9;+4AWXTG=N)
M/K9.!_W&;^-SR-\;O=C.[;4S->E^[0 !.6J=-@8]N,E0&/W&U];@Z&%H2S'2
M:G"D<U%>90R!NT>V%T=R+3 X$PQ.![Q3&G+-(XV$,Q[QI"0R 3M$07(TD"B3
M!_(BKHEW?3J[K.AO_0C,#:'K19,?3),G"0VEDA .QH>*$B/NE48ZB(@DB)4*
MDC1F(C<-KTGZ[0MPK@PK"5P7Z%R\*#7WHLP 9V^ZO4K0;\9R+NDX=\2TZ>[!
M)A$N%8Y(2R<0UUP!.]$*,6.#H2IJSOE],:UX5FIK6#QHR$G1W_GK[R0GB=Z;
MC,4H4F- ?R4'30X$&95RZ2,C54Q+J]=ETRY\^,G"EA68&U\I#=#K369N2"LN
M.'A?'/P\7:Y1)VL=HXAQZA WRH%M%C6R)M!@I2 BQNJ(Z#[.YL?J@E[T_WGX
M9HK^/YC^3_(@&Y103D44'8N(!YF0D1422,!PJQ4V"O2?S:-=WV.5%7A)=9=
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M _F?CHA/+AM850K\P>(J$,BLN-'OGL0<A).A_R@"USL:\KG^.;#,D^HRF2,
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MUK0H;%38*MY@U)W1R>62Q&O4IJX>9[Y6R^@6!1\?^,3JQL/?Z\^P;CI DZI
M5CW[(+I#O5F.7RO_6 JM)#&3D]S7Q_5AC,M6#*4B2:TYDW5;2JF6K%I3O6%9
M%RPIJL %E<2*S]]=E %:J+-6B165,F_K)/X_EM6Y2IV:+&%<J=2D8[^IUES5
MI[5L3*GM-AV7&BZ5X-LXBR)7BB^Y.=-Q=4P8NKU2)89[CX;#LU0?+RD??4P5
MO\H_5-7+6DG?[KP463[+\CZIMMOY>3_K>@ZFHW&ZQWAB8LR:*^5WL@;+O$_\
M$%J0=8FS#O.\C<MR<KF_Z_ZK)#ZK3IZ) .>Z<KEP7UTC+95PZRT*>IK)I.JV
M6<6.NK)>&@C;RQ*BO@<O/.EGA<]</&ZAO$>EPE,/<%;K61'QV6[]]_ "[&A4
MU@%)/U55[Z[4A%J4;%H<CK55WJZDI"[*4)5]EKLIFV+5OH^]<6\R7E$N_<=X
M?=FYNM3=@B[5P"^6S9MD<=:,Y.4PS#MFLZ[&CWO6?A-.5;7Q*C6P)-_X19&Q
MF;#7=NO/+WS-FEP;K)S. S,!/%B8T',A*)@[M>+3L@%=U2?+ E"M\V$O*\RV
M)M W<XVR)?&Q45*]&E7:8XLW/3%I>BXT=E'++$Y'>5JMI.PD6QTOW66AY&39
M V!%TTE]V1S_MK[8D7,)N+E6VA@H9<N;RTK5:0&]9\-3=:FOU":K1CY%@UV4
M[O(AB6(EN>'U2FAS>SO.I3T7X>>*S6VE<J:I\VI]3;\DO[4HKU]"QKB2"JVD
M.=<+H\W$ZF8JH[W)^(8WGK5^Z>O'HU#JJVWE6]5?ARE0U@_.-X%U?C(<92Q.
M,GFPGH*Q;;=>SG7&;ON6-1Z,%N3D*TE Z+.2(6RW?DR#NR6W6[^_NWV_O.Z6
MXD,/R3);ZSMHMH(O: 5G96 /4QCL=516::@OR^L\ #;\S==SK"SCNRP&/.>-
M63QR29J]5O/-]"^A?ZG+"YP.INE9F)P,8=HO-&=#(>,%S<LYF1M>I%H7,T7U
MK9+_S>^U5MUP#2?)C9M+>=9M[Y5/F=4*65B2G,EE^G+1"O KJV+,E:APKM6<
M^S]UU=55JWNR/  S.%D06:P>NBPR/W_^O([(NM=-+#HIS^<BP+F&1 D3:TAH
MJ2/?3V*?)=#!94D')-'25%)G1J&O&L)X^2T692>7B(9)\M:S=<*O"@:=+)AG
M@GX##9PY0-G=*4>I--1E2K1!%W5=GURA'V4'K%%F7%9B7*\1=JTHU+*(E*"!
M&%%@Y;A@-AJKN3'<895V/PUA3T4V*MM*EGS*)<U+E:90SOZYT.M56$JN5N59
MEL*NI5SY!G6IC;>I54WG#L@23JW#E5]\4HL:E;J?8!&)!?YZ4[DJ\L6A>2"U
MJAQL*R.OMY6K$L4V+>Y# 4JQFTDUW4I;:UN1K].5NDZMZNL$N[[45KZM5/&3
M]^M]M#7UJWQL(F"4K"HPS>'B1Q9A>HPJ87JUJY^&V-7]JX0]T8Z[E4I8(U?W
MY?[<R:+NC6#=5W3=3?(+?LJ.:6SJCFSJ21WB:!00FT8^I4;>9>ZOW);\L<S3
M]8DJ?Z[6V;F/Y+K;=-W:Q+C'UFO_YUL$OAYWYM+&E+_IV*_D^T7OI."%H5(P
M1AU5FELCO!.148&%N"8G&?%;%L7;KTL^[8S' ?[/=\VG61:@^*&3 (_9 ;2M
M3??)^^X^:7]^TSOL_M4[V-V'ZSY<'.Z^OWQ/#WN'I^\^74D"3$E_IWN?X?XG
M[5-XWJM_]SM_[[/V:;]WT/W7A\[IOT\/S_Y]!NU9)\XDJ?6T* 1RTA+$#/?(
M&*N1+T3!M>+",?GL15'P.SN>^XW)?(U Y?TD[YJ(.6?!.J8]B\YJK:/5!5;,
M&24U;LY_/N"L74W=#<(6E@N-;)'.U"L?D,4P,EQ:R@*+7D;S[ 4GV^1Q3-H'
MS\!MB$Q#9#83&:TM0)H-E#@-< >3*WK#I<=<4&:IO>;@0D-D'@ 2Z0HD,ET4
M)@H+D.@+Q*)52#LN4Z6H0A"@I$XJ(#(8;]/'@8D-D;D?(N.49M9+&;FGS.NH
MO&! <AE3@O.BT7I\T%G+5F8M3$MK<1!(T0"S5C",=# 616(P)\!IK H-D;G[
MT/$/$IUZE;+A!BD9K)'SN$?^(TQAL.>6F:B8QDP5J20!LXH;@;6/32#GL2'I
M545'*0LGM0H(%S:YA %<0N"RX!<ZRH7'F-KBV0NJY+9Z'"(?S4R^)V$>0[RD
MDFN1RC=[8@Q7.IK@ X4_,-<$<AYPUJX&<KS1$4>G@?\4#C&M)5*6 QWRP1NG
M%/$J/GO!BL<R:1^<_S2 <;=+?[",V4B"8#JRJ*667$C'N2/$4\-E$_IX?""R
M&OJ0C'K/98%4M  B0CADF&-(R$(K+!5Q&,/2S_2W"SDT2_\CF<EKEWX6?0PF
M>FHI3&O'8?F0)@CJ"LS!G[XNCMDL_?<Y:U=#'Y(H'A7AB&C+DC ?1JH(#HGH
MA(J%IU(+6/II(\KW4R;FO W]B,[-Y4.+73TAS+S*?@KNE!5!824QDX0KYK$
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M:9&402(FM$VEI# */!+%#!&NN#)QBIAV 8LHK(I,$ YFR8E1JC#8$6G5LU:
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M=_A!]]VG=O<].=C=89WC(V%H+*B6*!0.9JO@#ADNX"=OB)#>!J92R;B-@@O
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MEP1 _^K>DL+#5WMLXPO&^#4O*&\0QRB7')\DI[.)/,^0GKX%33*/I2DM@%1
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MT.3ZUUE^?<FIE?#MR*QB#!O%152*1DLCY=K1!Q1L7:_'^J5J$:6Z<RVG.HP
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MD-P(9+%R*&HGA+*!RV@WF-( X&X<SLTHQ8GGYSIO>3*UGTK+;#Z5^N43J2V
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M"$.Y"10F!U;>6$H;HO&]X>OM%:)A"XVUDA3%D&JU*ZQ3U0(#E-YS[H2VA7'
MYB7;6'BT"9K]^#.5%D$2BC%WW#/EG99*".UI*F[-N' -T?C^,_4*T<#.%\K#
M3%4!B(:U!BE!!8)!@5&2U.E4V9Y(LK%@]<\0-'N >?9[;Y /ZO=#TKL=6FC0
M_V/O2YO:2I9M_XJ"<]][[@@77?/@/D$$;; /'2W1MN7C@"]$C2"L@:O!&'[]
MR]J2&"1A! B08'>$&]#6GJHR5Z[,RLH<;D&^%[DH?:,YR44(R3,M:/2$"^JL
M]ESJ'((B'%Y_[D2[T>S]G2=OW"/DK,2JNV#5=!(=9YZGZ!7R5FK$L6#(<"(1
M8Y$(8A4<-VL;0K ;ZSV6X8O55U&O5?#!:,(8YE$9QS&1%FR8$58Z.O=27*FB
M"U#123IADS!$&8Z4$!1Q[S!RG!'DA0_<))F8$:"B6MS84*.,6SR*@N5&0>]
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M7LACB$='$7BN%CEE)?7:6DP(&+%BE[L?M5R\8L(6L"I>9CR^QHS'QTFU'CL
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M^"(X5PFU"NF@<Y==GIQS2C*6RB%?Z)##B'N>N$%24"!0-AJD:=2(>>X%\R*
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MN=S=^DKWZP'8R7YSM_Z=@\3^K+4^-.'?4?7X$,[9(_O'?WW?K7_(.SAQ]?!
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M>%(^Q$PJY (26,I(["J0BA+=YEU%3Q1[#?CE&(]!&\9YC(+1(# P=5&Z3,^
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M%4 IJ.+06\L7&]O6R;<IGKAI>[U&:@P_OAR"AZ,:H&@SWG1_$)&98CS]2+.
M=KWR/M\'/,_^>*8F7GG&^)T"O(_]U4*EYKK5+6]_^;[KE<5(X33E>3NR0V,B
M-HLWO7V >#SDC@\>P)O$YR6:NMU!=X8YJ]A#,/LC4Q%_7AWW&Q3W<K(/VP7"
M7)ON6P;\NLQ=:$)Q:J@,>OG>)]U& 0*M3HC-WM"V@-"< 36OC'2VXV ,?A0+
MSXWVR0"NU!L 4X$G/&O$)MQST 5UAEO:,9^:%I>_XX_8K-#Q!4XO]>?*VQPU
M0*: !)T-Q?C*D9&QGN'E#$-60X_@XJ7R=T</#T+7#K8;@$#TCSH!9O\PA[*
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MS*VG%BO)C4U8\B )CF5ZPC/ Z61Z G/:"<D2DBD7D;.)(IUB0$1@%;BT,06
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M<G4&H-BA]]N[RCT [-:A^ 6 F0F;/7,+[PK5H%!LG<JRK .G\Q7,>&B!@;(
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MW\4CQ%5CB7$Q+#X .(((X/5P@W"^J!L"#G49+(;A6@'M\: #F#8M*QC'@RG
M5:@9 M8.Z*@*PZD%DZ2C7D;'7D$8]]J+_AY%H"B,80MXH[ RFM'Y3!319#0-
MU>,3!F]1G9E&*4K33?RD2;< 4^G5!GS*ET %I\4Y7@!Z)#=\N48T&W:@/+O\
M/[LZO.U<?_-!=MJ>[\BJ[5LB^(BYH2N[#O?#,'1TP\ $1FV._Z.HIDJ(L,IA
MK\LGUASV"H?]\^SVFVMKMA4P)NN!&6)?#DWV#$^7'=?T%<T(X3\8::;,B30K
M#IN8SQ!X%G#7'K"9DY_X!S5M+ 1)PHFI4HO'<"-<X 14%F2U00T[BC4U"+(
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M47HU:C34 L+*R!;N17UT1L.\K:GWIN%<[("(!\Z.P\[92.R1>:.<8F!DE"P
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M-N5]:5WLH2U:NQQJE==K*.5N097IC>7X%G4-L"'2*(B8T*\38C$)BCYQ"3<
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M\3BX/AT(]0;6^L>X2#IZN6E&O\YNOX4*UP-=#63-4\&*,_50=FW?DG5F>D;
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MIJN.(=N.%8!QJH6RY^FNK )?!Y;N&I:E4L3I;#/&B<[DR[;[WA/VRH2N'T@
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M$DH=KH[T!S%U%U1/H')8,;!"#Y XC(CHD039#5A/:/^0JM#"[P#3 ,G?$J*
M'H1;P%@Y6E=^^*#E\!1$A:  .E).SP_(58_/ETLG'W& NHL $3 1X':$M'A
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M\KEX]?H:+TA JZ:PUL* *CG&*T-IVP7+:1%3PDL>?+;<'4Y KJ_Y(ZAM77I
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MYTN)/N)9FA=0\<8BT*BL297'$M4"CD0=K07AA***6R9B RG_=<Z=7AD7MDJ
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MF(B?AR"6KJ\3?BV88>6E*.D'CW8B).LUVB_HUB5)B;\ 2OQ&7',(S+[+,'X
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M#&6JV4QKHMW)5(/ O+O*DR3EFI1A>^]BYP2+X<6.K+?5.<$.R %%,-'KFO-
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MF@V B$X-3.8WC2_3.^U]X]>/KUY]^(>F_?%I/ "W5'>7B#B@RQ!TD &>L;,
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MHJ:R'*S[RU.BGDAF)@^L;*_OPOM2M/2,C?"@@O3D''RU%&08199GY#)](?)
MU!QYK]!?\SN][RY>":+9>M.%/IO#.,QA=% YT=M$ G27$T62G#+OM5%'>%6@
MD+R]44G4IH>^%3"MI7/%7N]1TCU2N"@!3B0U$^\*^;NC\N%L^VLSWN^M+]*(
M[]'X7YV2F(E/87R517_^7-D <,8C8J@[-PT36N+3&>(#.C>-[48$6Y:HO;EI
M\.A9?%Y#?%#KF@\#3(VI_ "&X7H!2W!O!BWQX:*;ALZ0@9T&L#D\#G9<T>@S
MH^[JIN&UQ#SL:0#O,QK>E24E'#BV[O,[@GOXO9V$+2.XOL,OR!#9Q.F"(?2
MEC/QF8W0+$]CSZK4YD4,S&7)YA-BUP9=0DQRV!++TDZ?:;8QZ>VK8,UGWFQ
M[6 ':TH'W,7G4N@$.8[7O$.,,9J+04/9NKN ?"G77ZZXI>E^N2?;RGJR#$Q&
M7#*_ZI^@\X>??Q0JVQERDU?!-R;\:2#>CGX'=3_ZRC8NO7T5K E*JX-ZZRF5
MU4X,B46#LWY SH(:??+$A^K2>XU6BF\79Z0VW_N"G/.#G3FHZ)(<'ZDC'M0R
M5'.1L<EM/;H"PZ'YR;4Q0;;8WI9DXEN(:3VT+]^#^XM_A4_%?'V3HV?"XR"/
ME.C)TRRRX'4]12_.)XOJWU)[HC"?(XX4)Y!2:NCW7K M%M,/D'WCJ_&B,T$*
M>14FA@DBF+(OQ$8Z7Z(:W%^Y*[JHW6R_55BI)JR"?6.D(_R$-BNJ(5$LOS((
MJF"/MP&$9%%$E]KIBY!DPSV6%0::'6\BEHO<8-6;* W@(=.?2'>F]($'($MW
M.32;[Q2NN0?#*D </!N2\\CPF2"1IO0KCS,>0H5X%'A"'^5Y,\$O7X@A/C4]
M)SL 4\Q#^8BK "P/G='0[,I5C0_(ND_X*H</T3[Y1!FCS_PIP>,D?M-9IX);
MF$]E PJ%FS[ /RF3QGFHEG7W))^?[?+!BB"F\#K;UU5457#R3>*1![C19Y!?
MP)<*H9*NJH\OJ:6L2QV:7_P*V?2AN[-Q^1#IJ):IUN_BM05WWFL+TE=3!5@<
M*?#A>@F):GN#^M6!",A0QS<HS;2TUC_;BLWY1V_@>$DE_KCP4DQD@!Q'3)4C
MQE?LNA#LIZ&D0BENNQ?/J@[<^ JYI4(\@^!G@^[M$G6VZO(]QY2OS5/'ZOD9
M5"1(EP$G7^0+5;C:$R\,'5!(% O&'(15>(ZFQ]?OR@;F[ZID7VQG0!F7I[>O
M@C7QK$&.?9Y,DBK8%-V(4L*3TK@*=G!UBBVS,PBJ8,](%F>*<F8NBC^/%,"D
MM*Z")=+E$R'[= $=[DZM![Y<7 SZGX;C9,JFU6SFR 'MR[H*?13W1'_CK%@.
M.D%5!<N^$(9T.B?X+V3(K?P[EQBV/RVFI[949!4-IG:_&"SZSH%.Y T'P\T9
M*?L>6<:G]6[R>VJ)U-=C1L1Y=+F532ZI8L\@97:+O'_O&%T*FN5*=LN0!:56
MD4XIO==53EAE^W;Z3(MND&>25&$^BHR)GJTS'MG[H=#:+\5.#Y[4E%7=!>^T
MFZUW7LC@1T+;>>5L3/-25P%>L4L@-@G$GD=XP,4_"9.>;%>157:(BGD(VHO(
M!$270395\<#(IJNLQ2-&=80,6\RMXKT2. 9:>+ N3#9'O@.;TA][<JUJ]BL1
M?JI*^3((JC"\)\@R^=+>+RA3I4AVM:V"%5W**(%/F+EV!QMC9&%D\O59CZ\H
MZ!+K<I+ETPYWL&YGW)OP?\-W9?KEL-XZ>(Q6?H56JF,?1595W7VKJE;EZBF-
MJ^ @,OF\65YD[S-%FE5U^1%?%O=)QJML.UFOLLW8NSB<B*IZ]U;%BS\L#Y _
M*<FQ"N,D##$ZRYE?93WQ#GATD5C:***5_/15L';GNT_7055$:$OJ(,G/X&=7
M3@05LUVZG(FE&.<ME)Y[7>R7W(O=.3&6'Y! 3/Y*-;T\PZK.!LDPFVL^6JQM
MK&-(1J(/"F<054RJ, J"0^^?D$G9QI7]SX&L&.**"Y'<CLY2G*_[*WO3NRR[
MRL9']PA:SD(\^:)O-MX^D)'M%$4X5,$C^N26K_$MNO+.93[2IW@.2I'@*,"@
M"O;*$S;Y=@AV-JV"#8I:OK(U@#__R:5*$4=3P[=8E'[,I +VE.XF\+/PI7/2
MY056]<D7+&-$7<>"S\DB7Z,NE5=05=58H9UW4CQ2LZ-*56<3535,[!!=:,9R
M[GZF-J_"_!:<#AT2;]=-;AL,S4T!5NS=XLI3IKGY5'9=$L[4P=Q]3^T5YG%W
M[B ME; *B,M=$CFI4$@>H..*HKYVLWV18W,EBZP*MFV?=DQ]!,L]9/%X04;'
M%GO*T%Z(0RC80"S;S0\GX*>?JXRF%>^HR_(G(:.MJX#ZEF[XJ4!M6+1UU2R9
MX)?\AD0:5\$./EFTVYLR#N7$LJ/M#[5"O@?$UA=\>?KQU?\ 4$L#!!0    (
M %1 HE;?4YN$Q!T  -X6 0 5    <V=R>2TR,#(S,#,S,5]C86PN>&ULY7U;
M<QM'LN;[_ JM]G73JOO%,3,G:)*>T89L*B1YYKPAZI(E(08$N  HB?OK-ZL!
M2"0%DB!133:]#@<O8*O[J\JO\U9967_]KZ^GDQ>?<;X8SZ9_>\E_8B]?X#3-
M\GCZ\6\O__CP*[B7__7WO_SEK_\#X+]_>??FQ=$LG9_B=/GB<(YAB?G%E_'R
MTXM_9US\YT69STY?_'LV_\_X<P#X>_>/#F=G%_/QQT_+%X()>?VO\Y\=ESYX
M-%!88J",D1"D]L!-5"J@1\_E__KX<^ H6(H1F)$"5 P:?/$!DF#9\.A=2KJ[
MZ60\_<_/]4L,"WQ!@YLNNE__]O+3<GGV\ZM77[Y\^>EKG$]^FLT_OA*,R5>;
MJU^N+__ZP_5?9'<U]]Z_ZO[Z[=+%>-N%=%O^ZK]_>_,^?<+3 ./I8AFFJ3Y@
M,?YYT7WX9I;"LIOS.W&]N/&*^AML+H/Z$7 !DO_T=9%?_OTO+UZLIF,^F^ [
M+"_J]S_>O;[RR,7Y_"/.+\["?#DE%OR49J>OZG6O#D]^/SK^_?WQ$?WP_N3-
MZZ.##\='OQR\.?C]\/C]/X^//[RGX72W7UZ<X=]>+L:G9Q/<?/9ICH4^^SB_
M@"IW)E>@_N<.=WWU'7@*DW0^Z>;I#?V^OG>%U\\8\.L2IQE7<[<!,9FE*Q=-
MJN1F\\V_G(2(D^[3T?D"/H9P-CI8+'"Y&!6IHL6,X'1QH(((X%$H",$4YS@O
M-L2K\U7'M*!!=5(N81$[4:]O2R(7XA5.EHO-)W5J13>M5Y^\FL)]\1^>S^?T
MHH^,"=9IB5 BO6,T# ->9 '1>^63] *Q]#*,-8"KH[E$B8-Y>C&;9YR3WGKY
MX@M6+;-682LT89Y^X,K5%VA]Q:O%^>EI=T\8+_%T\^^K/MM;LLM9J\E=B8\@
M[RO?M_/9&<Z7%V\G8;H\F.;C_W,^/JM*G7[^=3RMJNH-DD9Y5V?TI/RQP [T
M05GB_""1_J\"P'R$9W-,XY4LIOG@=#9?CO]O]^L(I7;>T@RQF.H,&0XN6 -"
MHM(Z.1U1-"9-_Z/:A8GB^3!Q8#1H1N_74[*V'\=QLL*[^!V7KZ=I<EY]FG_,
M9OG+>#(9:6F=#\E#TH$<BL #!*$YA*0\DUKY(F1C@NZ":Q>*R>=#L>:B:$B2
MS[A85K8O7D\/2AE/B,&X>'\>%^,\#O,Q+@CR+'6?$JW_]VP\7?Z++C^?XV(4
M RH3L@4E.0?E>02O+7FG)6=)G->DN9NS9P_ N]!*/2=:/9;PFO'MA%0MS<[T
MXS:5.DI!"I>-!Z=2!%68 I<UA4+*1<3L<TJF,9]N!;0+7_3SX4N[R6_&AR,L
M2"Y@)G4X.\4/X>LW!3FBJ-<@I_$Q9XBD+G*(T6;(F"CN=2A<](W)<#.:79A@
MG@\3&DU[.[6P_$3.U K#;)K644%AR),S!8P(-2HH&@)7#'+T-'*G>0JIM3K8
M!F07X=OG(_S])[N9W-^,0R2KM21+M0D%M66H74D@Z!NI(9F@QH; =(DF!B^=
MMHV%_B.*O5,'*<W.R2R_#1>!O+[-V#BW0:::X",(H*RBL14=(?$0B@^.F]R:
MT-N1#"F9L"<'?D@L[#_US>A]?'HVF5T@OL,N1-PR4FZE$E87\!8+*,P.?+$<
M4%CRP6(A>;;.*MT):DCQ?6-RM!5(6_.W!4Q &IWP D32"50J"-Z0BK84(MJ@
MBX\Q]V$ '\:)QPK(&W.BQ>2W,XBSZ<</.#\]PECS3X?A;+P,D\Y?/XF3\<=N
M?KY#3$(ZILE#\PPIA"/-%@OW()EQAK'(N&R=6K\7P"'%VXU9TY^@FG'I:HJ=
M$5U5T/3,3*Z=\DB#U9[&7C2Y?2(QR5OG:FY9O[C_: [#XE,WT8M/-4/[.4QJ
MWN-@>1CF\PN*:?\5)N<X\CQ%:RW%KR%E4#EXB$X8,#*GF#$ZKUN_$3L!&Y+#
M]7!>7'\)VLND'?G7;N [3$C R!.DX'8SYA)LP>P]Z"PY*)'(W(O ("AD,KN@
MHW<]^>';\ S)X6I'CF82:)KLGM(E%S7/$:,)5M(CK6.&HH*LP?E(OZ94)$=N
M(U,]Y*XWSQ^20]5.Y@^>X8:+NG@6QOGXZQE.%]^B/Z,M66"E0'I+4!SY]U&$
M L87:7BVTOO0?!UV"Y A.43MI+[_G/>12-S@L%:RQ&@H*G<T]!P\MP@1B83&
M2TXL[2^+> _!/^Y*0@O![SG;S:3^?CE+__DTF] T+JHCLKSXMKSZMB[#TS0O
ME_-Q/%]6,_1A5M.>L^F29HWN^/'U=(ES7"Q'$E4(N?KF&@F[YAP"&@U"6:ML
MCH:'UB:A#?+V\S<B2>5453:%1H)H4?-E40:*@Z-(CC2WQ?[G8DA>\Q-P[/KK
MMJ>8FKUNOXVGLWDW >M!N=2]\Q(HA)842).1]SJ3K^^<=(%'80)O3);K&(;D
M0P^ *GN)J$>]/,+BT=GBP I>!R7(*P@\ <LV%B4$&:'6GMA=>N5!3N9J_;2[
M]2K*+45AMMH 3;(#A260W+(%RRCJ]=XYE*T5YA88P]:8]Y+^%B]SKTEOQNK#
MV>GI;/H=Q<GYLA:VU]=[Q!U''[6$J+@"%6T!&B\",SG$Y*Q%H5OGGVZ&,VRE
MN!<;6@FA7<(IYW&=AC!Y2['0Z^DZ(SR2SKM"RAM\B1P4)XIZ&2I/K67)>L%<
M:T;< &5(*8?&;&@Q^2U3CYNBX"Y (JJ>S?$3Q<;CS[BJN'DS6]1BFY/R(7P=
MA5Q7'01991V)KD(5\";7:CS-L\'@T+>N>KLGQ"&E+5HSIT=A-6/4.UR&\13S
M<9A/2<$MKI2=EW$:DW\GA77!<N"RKC 1MR$:[T$IJ56,SI6 C4ET-ZHA93T:
M\Z:Q2/JHJ#J8YBV#EJCKN UDXV/=0L@@U$"@:/3<&R=\88V)<A>F'JK(#)G^
M4J2&A"0 Q;0&KT0")XK1B3-66.L5GH<533Q!E=7^O/AA,7P_ 3QR]<3(\E"\
MMG4-7A;R"EP 5Q('X[Q)=5,MIJ<IFQB2O]XO8=H+JJ<M"IMIN+A4*BL"FN04
M#14M*795*-+@Q4# *#*7A<+.UI7I=X(:DG/?*W7:BJ>W$KY+>!)CP9$S 2H7
MLOXF(FG!NKD5I<V%O(!L^J[BNQ]/GJ DJP>>M!%(0Q\^(YYV91!;T[VK(6\J
M9PY.:^W$2'(AL#@$J2U%&]Y2H!&2J-%&TD5'%[#UVN5#< [)S^^55+T+<6A+
MHB7(A-D9$%V"U6JRP$DS<)*SH.A'P5OO6.AC2?1I-VSU2LDG$/0UDO[UU?4Y
M?D._]]%WY?T'^OK;\>\?WI_\>O+V^-W!A]?TUZNP]FC <L/M^^[$LLNH&K5D
M^>8\'<X6RTK&=<W.8L12*)EB-A!:D9)*9!TCRQ90DT4TS(?V75IN!+-W&!CB
M;$[W6^_R6-]V)"0&E12#DIBFMXPL?I#1DYN8A9<B6&.:YP2V(AE27J -(WZ(
M[_:70#M+>'YV-B'5NP'A+-?9>@^<6])TKNZ:I.& 99P,=/21V];I]FL0AA3F
M]R/_?>:\97^?@HM%MRST*]*( H'PJ:X1"T-F%I.$D$J")*W-VLM,M&R^1'\5
MPY#"]'Y$O]>L[RW[:NF_#^Q:!Y\-&U$*;0Q!B"%WM3#DB_N0 4-2@15NH_%W
M.1"[/&A(L79;83>?YK9YF#K&[T/\AG.$M7LBN=/ DDV@@DODWP8!SJ3@K"@\
M-2\#OPW/D,+F?I1!,VFTS^Y^&Y_GEK&LD523J\MTGH&OM<N!8TR&(_+06].9
M5A[OS=(SLK86]675S$$EHR"JX &]<JJ8D)AO7OV^FU\_$+_W03RX,2F]U_PW
M(_D_D,+.,*EMZ/+I>#I>+"NZS]\T<PE")8D(GCORPQDW$*T/=9,[1YZ%8;QU
MO>X=D ;I$C>A1DM9-&R[]+U9(?T\P6U="X5CBKN4 (LF^\V*!]++#DP20GE-
M6MNUMI:[X!JD"]V$*LVETHPOOYPOQE/RZ@]GIY$\O0JD9@X_SKL?UU%^I_M&
M5MD8I;'@7:ZY3,+G4JV2*MKS$*3SI;4YW1W=(#WR)MSI24)M K)_S,-T^0X_
MX[1N!Z=X7R:1(9I0XT&*"$*(#(PMDJGDN"_7"N5OB+XNW_6>KC0\ \GN-W.-
M!!?&TUK^>#(]&B_.9HNNR/:DK+;\D68ZPC2;+F:3<5XI)XWDO'OK@6E9$5HD
M;UX&L#ZZVI),I>O%93?)]GX/ON=JS_,1?X_SWW!;_:9*]E>:B]4:U&^X_#3+
MEQJ4CACR(DPA[Z;;9TJ4!1^9A%2DTLJ8VB*BL5W8"=@]F_L]!^KT)YAV$<J:
MV&O#]&'VAJB]*OMZC\OE!"NV40Q*E!(=!)%L/14#Z]YD RQ$'C*16J76G-D)
MV"Z<<<^3,^T%TS:U]_ML2C[R^7S>+5Y7?F\"J>1]1)=HF*%N@,T^@HLF0C;,
M2&43JMRZ OYV1+NPQ#]+9[.A)-HG]KYKO9%!4X<C0<O:T]0&4^LJ!##!';FY
M%#'%UMT5M\#8OW*L<_^J#C^LE1LA+?\]7GXZ/%\LZ0GS;^4>U2N@_W/=IB)D
M%B('02^H2:!D">!8;1=K42:&2J70>M?9 V .,B'X0/[\6"K6K]1ZS(@7%D6H
MK0ZY88*T>ZKUD9H#S^A1.C2%]5;??)]<L7AT$]N(&_M->3/)KXZAV Q(TD.D
MM:S6??G:DLN HW"3&&B$5!*+%:WMYQ4 +9;[Q\MN*#GSE)@2H*VF,(C7'N8U
M9/9!"*Y$CCSU<.S.^NE#4FH/E_"V9?T'S&X_7-VIHI$CN1L:$9 I2<HT)HB"
M:TC2<9$DMUZV+O>Z-\A!:;EV9.E76$T+A-:<ME%;#(6,KG&91FMJLS)),;&.
M23%M,^.MST&Z26/LFX"IWL9X>DZSNS8SL^GB%RRS.7X[[0$71_3#8CE.Y')(
MEKG1H%E=GRSDL$<E.&21'!DR974/1_@\&.Z0=.L#V7-[DJ8_X35.]Q&0M?/R
M"TZ1)F*4O4DLU^J0K"GJ$]:!<X6#BLR96,O+FWN--T 9E%9M2I/]9KVGC._]
M.&M3$2H7!AHYS02-'#S6!F9>,R.]"Z%Y ZAF"J=-5H(K4TS0@H9<:L\V1OZ3
M%0Y,I/]<T!Y-:Y5[9U;B:57I8_'IQCCL@=)I>59CYP==R:.1JS3; .SZZ3*A
M%?,(I$<HXN3D?(>ZP]ZYR*1*5KO8_LVY&]>02G>>BDC-Y3>(+5:')[^]?7?\
M3[KF];^.7_].OQZ_.7G?SWZKFY[UF)NO=AIOHYU86_H,?>LQ5)2B\#H;L#K5
MOC09P6O48*3%S+,4R%N7T-P"IT&[O)MN_:"=BI84,#*M:OD*O:>*1PI1C02>
M<TZ\GI4J6R\*-A["D$QO*QYNZ<_W9%)OV>GQID'L!MK*J(NB&8NU$X5+%H)1
M" 4#LYE"-5U:U]GN"7E0H=,3<+.Y6!^#BP]ZH;+US&?NP2J#Z^9G/BBPR5 D
M62+OX:2</M7H7NF_VBK6T8@A2U^[UAM?SV<*(,C?UTX61E_^OU@P>$J6W;+D
M<!_YM-Y*MK4?9#WRZ-?)[,L_,7_$3<W,0:%1O\,T"8O%N(Q36-=O5WWEO;$B
M,@8QU^5"&;M.Q10+:,,<RF!9;,VPEOB'%.0-B:-/QI%A!(@'[__YZYN3?_<4
M$GZ[^Z,&@=O'U"KL(TY<.R[M'7%P/DZU/']UG-K5#RY=^1;GXUJ[F>9UF^T1
MKKY_X_SQU_0I3#_BN[#$XU(P+4<.T16.#DQ0 51)!0(Z SHJ+Z,3PC3?Z/6X
M(VRPK%PAD*GY/";I_G+QQZ*>BK[:SERK<])R_+GKW#.*C$Q-*:0FM*P[^4+=
MJ,6[@KF ]8UEO'4QV>[H!N5##)?C6Q:J^Q!_RZJ';?A6Y=M7\>408@J9@ZPG
M;2D?*506M=68"4%'R95DK9-&NZ,;E/OP[.FYK_C[IN?WQA#?\2E6.+?DMYOD
M)>%+$IRT!=!Z&XP44C?ONK,[NB%M*7W^]-Q7_$^A/1T:@UPI,+R>HQ5L79HO
MM1PS:&EC2AE[*!9[D/9\0*(C7'1;?3[,#A)Q98[T3)+1\N+M)$R[UASTZ=EJ
M8T=*2:&1!#>3E7.A'JV#!H0WT3-'(8EO[3#NCNZ>3D[OU7)]D.N')$@_LFM7
M0W<=WV8C,J[.S.@TUNHO><1"T=HZ1J:)6U#H+03& GW)2BMK8VQ?97</?(-*
M?C\5OUK)KV659D+,W8K^>S)S)X4^R>=U^+C:"#OB*0HI5(;(7>VPZSDXPR4@
MO0XENAQ<Z*&QVQVHAN14/!:9VHJJN9+Z=3:_#+%+WFUUIHOGHK@,,G<G_6@+
M+DD%$JW2TD<KFJ=-[@GQGHTL_E2JJ@\I]JBM;MIWG57.*M2.RZRV!8_"0"1#
M#3SJR)BV0?/V!T;N"&Y(G>F>3'>U$%Q_?M9-Z*)7A1D5070'<'..0%;;0N),
M>94%P^8U![MB&U27CJ?RKUK([2D2.+)$$YPHH'UVH%C(=8<.A?$LL%1D\<A:
MGV+RT 3.7J4 *>>0 \V^P'K '[((01L&V3*7BA8^L=;E9<,L!>B)&[>L\M]G
MZA^W%9YQ,3I,!5#[0!H@4LP363UFO=1# KD5HG6 T:H5WF.EU1^)+LW%U:91
M5BTMH-%OKP/'Y:C6JG'%R7K8VD17UA,^)!JH^V63<%%9O%9M=4-CK#L>=,^@
M\TE,;"M*-)_X=D<.? IS_"4L:L>]TPIE1<N$2MH@/2%(=0F1<0C667(<HT#G
M3.'-E^BV(QE2&\1'TAL-1/)$+?6B5$RE!,HQ"RI3/.M1.>"6,Y%]\,R7G31'
M#RWU'JVCXF-HDCX%T]!;*3B?U[%OWPX:<ZU2X!:D4[JV=E+@K<R00B3_R6F6
MFA]M>@>D(1W$]6@^2CLA/6Z7QB[E?S2NLS/-BY/Y46U770LHZ]:YD6,LA%IN
M+VU-?!#-P0NC@)&7E4LH/,K6RS?[HQY4?\='(N CR[JGHW<W[>04B_2\3'%@
M2C7]@@X"<Q&B#$9+9PM3K8.OK4#NV?7QST"D_0724G]=*VHY2*F>K[EXAPG'
MGVN)]TBRDJ41%IS)M?.@S82,3+3W-F6;ZGDCK9-4N^"Z9R?(/XL.:BNO-N[W
MC[!^PSQ.%!P0/)S4.<"\2=IV7M_*EO]C]AGGT_IIF'1-N1<C+!:#RP@\:(H=
M9.V5I%4$HZ(0VGM%QGPGS[P=IIWRA^S/H:.>4IP]:K5N.?/[>3+A;$P0N_8!
M7GHGD5 94]\5^A+I30*6E=*.)U]$Z_KSW='M1+RGKLWJ7\4U$5[?JSO;JMM9
M<98,MP),F4QZ\0I<2 %0.Z&%,T(U[Y3[T,T-]Y^'=WBVU@ GY<UL^O$#SD^/
M,"Y'TB!ZYTDJ2)9'.9_(A]&<ALX3*PH5+^V/5]^.Y3G4-NY+G!];Y#:02R^5
M&]]7;7\;3V=S"I^Z_.'ZF.U1H1>87F<!MFA7BY@*N.@S^)(9><"2\]*Z$\_N
MZ)[!HE!K(O4DNEZI]>MLWEF+;7/!C9 4=U/(;9.GX+MK%$<.LN"!<T$6JV"?
M]8P[0'P&Q8V/0;)60FQ>)G0IL[-Y#;[M=X[%%(V>@^[Z4$D;P$O+@5MFBU!<
M)]Z<77?#>@X5C<TIU5A:?="([/'KQ>*\GNZ[.CZ,91M*[8YF'=9EU4AVN<3:
M=)2;A)9GJ5KW";\%SG-8INJ1-GM)IQ?[MH%SW:6S5G+F21LRY*!$J6>7F016
M)JOH#Q)MZM&D;4?U#-:F^K1B#43U&&TH+H-[7V=S?C'K$"_7'Q[A,HPGBZN8
M=FM"L?.]&[:@>-AX&C6@N/SP@VE>IRBZ]/Y)G*Q/>EI\VS%Z>#Z?DZKY+2S/
MYVOR">UDUA9B5K7QEH_@N?<0A*V[CNL^^-;J?U_,^ZJWW9Z_?NPHB>*2=@A)
MN5H<H 2X3&%&Q)@]>7Y<V=;!X;T #JG&]%'9>%T5]B?69H9U-X@CEC125)NA
M=&?1U"KRH$NJ;>%]UAP+,ZVS=[LA&U(NXAEP[5Z"')+I'?$^C2_=_0G,[_4Q
M#<4 >X^90D$&1M4#P%$A1$9^H.>)7/Z0M&F^QOW4!K@+<Z:+Y?R\QCV'83Z_
MJ![Q:5U.'OGLF0]*0MT^"HKE#+59()0DT-L2DA2M6S?<AN=/95[OP[4?J^ :
M":V9-5W%4MB-_\TXQ/%DO+P8E1!X**1NZ_$<H!12N%."I[ Y>69DE#:W3H=M
M!?*GLI7[$&=_,34LM[W,X3^F8;7+!//1>-$5L[R=X^GX_+2K++B6BJG+OMXD
M%9 ,>&*20FF5-(1ZF(12.3JC:42J=<7_GI 'M8%D0/JK7]D_BB]7IVWQ/GW"
M?#[!6:G[(&;3FD><E7=5FK-ROEBW:0C3O'GS:!K79T$O9ZM;[)-N:8VAI5_8
MZ_PT\AZO%F1^UXY$\FR([6"TI\!!6PY., 6V.,9<XM*7WHYLO<V,-1OA)@P/
M,7B+)E#4A?0N293@5#$@!3=:""Y5\],?;D<T)'^O!3MN+P'>2QX]U8E_PU3W
M JYA=9UDA$#@3)'RK9ZFP]ITKI3@<BQ%8.LDW)V@AN3@/2)3'BB5-N6^UYU(
M%942].S@##F15@L(BM6C1(+1*I.3H.5=-FS+??L)3*S2,?""@,[74I6L:*+H
M)RT,<<\FAK9UIOW!@4G?&FY?8>X68]QGQOM69B,NK9"UZPB:;I<83_2R: J6
M0]U=*)%'WUK\.YGTIU%<K0G08M9[3DP$:RFVU0%,*O5H3U>[& 0#5DEC/<7#
M(;9N$+7#^]]H=!O_0:ODLI0.A"#)*<<]R3!@#95JQ)^]<*VSF;?A&8*N:\>*
MG;3>0R31+_,O>0P8#4H3?#W>UM K7NAE3\&!E-8K+QBI@-;)W3L@#4$9/C)#
M'BB/AAY<%W^?E#_6\?<H^F2=U1'09D]:.A?P/F=('CFR'(VY?IK.;7[<M;NW
M->C7H=/UD02!$*6K?;XBUKTF C++*1FKBW+]1B:WCO:IO;M]!'V[B=]'#KVH
MN^N > [T9 JBG:R>!XT,0J$O46 *5F9IFF\JN 7.$-1</[1H)8/'R]E>WGP=
MIGESKM3K:9G-3]>=L/9,R>[^B.89UP>.KM5R?'UZS=F/A(DF<TD.C]:U,W$V
MM;EUW;'GT:-T(>G6%:K?'M[6Y'3#*:$P$\B=4P95[5%3P/$HP*<L2I$V)].O
MG?EQ7$^\&/X@2=]N5.X]TVU\HLLJK(,0DTA%D[.>,,>Z.%HH)DX"$O>.R9(P
M73\Q^@9_Z/J=AV &V@AP_XEK([M_A?FX]CXXF.;WGV;S95W?_(Z'>U\K"2/D
MH)$,FR0:.:_!2U?3[)X7EW82Y*V/&=+NK092;3>E/;V> @7G/CK(B<:CHJBA
M-=>@@\_.)JN=VBU<N?WU;.J/7FFHZ;5SF@L&FG-)KTFTX)!9,+D>+Z5%$,W/
MOML1VA LS/Y"OX>/^F"Y]!+$;+:I;5H#>;36,$\O&S>U-WIUI5W@@$$J<ME-
M4,W/4;H%SA"L5[_DV&?^'R. .<+Y^'.HYW_4FHEZ$NZ5K4S?JRTV ZE'D[W_
M$L[JY9<_.Z2/3LZ7BR5]3K?8(^#I&U+# .E19Z]10/4=\^^S.O P69=\EB1"
MZ715X@54(5?+N=I4WQ8,-ALTH;4-N0G+_F6!F_MV*OG:0!-J;VW4X(0,] ZZ
MNCTO)C#(/3?H4XRM(Z]; 0W!1#9EQX^5>JW$T;!P= /I4A;]*BSCB^ ^ (VR
MGJ5E,L1B&!16D*%0RC0_I^-.4(,Z *UGJK20RV-8T-4)\ZOEETLUA^N=*WO8
MP=UNW-":/6 DK:HFZY,O/7*SY*GJ(:=><1#U.!_%DH8HZ]ZND#(I!I93:9WR
MNP'*_GWD5L;^;;BHD?!F@-S&XF7)%$V[6+NX$IFQ;B_3.G".3"K>NAWT=B1#
MLD$MV/!C*[B]YW__W,-\.5H_?_%A=GB^6,Y.:\LC9I/RG 7P/%<DG$%TH0 S
M2GHA$:78J8Z$[G^) /3;=^'?\.@AQ%]]2+W%3+=)-=5@\AV>S>;++4-+1289
MG(1@#!E*Y17X$@0@3\+J(C &>Y>5N/,I0\HE-I5QT^GMNUIP@ZE6T!9?C_\M
M=6$TA00T/@^9PG]C78ZB>?___<OC'^NHD3X4?T-YM.-('>=!2O-SS%N&ZT16
M+JH(3-5S,0M6#[=X"-8R\F^#=:%U&__;$0WIM,E>.-).'FVL1G<4X>J D^,%
MS<^7'WCKC.;"UBB9#!AA4JYJ.0V);)@,*7EG=CNOZLY'#:D'4W/[T7:B=PPW
MUY_7+Y%TTM__\O\ 4$L#!!0    ( %1 HE8*J=!C9D<  &D' P 5    <V=R
M>2TR,#(S,#,S,5]D968N>&UL[;U9<QS)L2[X?GY%3]_7"77LB^SH7./6$FW8
M!(>DI#M/L%@\R#HJ5%&UL!OGUX]'+0!8"Y!9%9D%%FC6HH "D/&%NZ>'[_&?
M__N/J^%/7V$R'8Q'?_F9_8G^_!.,XC@-1I_^\O/?/_Y*[,__^[_^XS_^\_\B
MY/\\?__FIY?C.+^"T>RG%Q/P,T@__3Z8??[IGPFF__HI3\97/_US//G7X*LG
MY+\6?_1B_.5Z,OCT>?83IUQL_G3R9\N$\PXTR312(K46Q OE"--!2@\.'!/_
M]Z<_>P:<QA (U8(3&;PB+CM/(J=)L^!LC&KQT.%@]*\_EW^"G\)/N+G1=/'M
M7W[^/)M]^?,OO_S^^^]_^B-,AG\:3S[]PBD5OZQ_^^?5K_^Q]?N_B\5O,^?<
M+XN?WOSJ=+#K%_&Q[)?_\]N;#_$S7'DR&$UG?A1O%\#ET^SF#^^B4;\L?XB_
M.AW\>;KX^S?CZ&<+]CRXA9_V_D;YCJQ_C92/".-$L#_],4T__]=__/33DG)^
M$B?C(;R'_-/JR[^_?[V-=#":_9(&5[^L?N<7/QPBXL439M=?X"\_3P=77X:P
M_NSS!/)>].LM%U"JP/E?Y6F_'(WI,P*9Q'D @I_"J AX18R[GGX\YIMGD039
MSX>SBHBWGUT5[_C*#VH2>.O1%= N'D2NX"K I";4;YY[!^<:Y";"\LCI?/()
M)M=?_&0V0O7[ISB^^F6!\L7%VY>OWGYX]1*_^'#QYO7+9Q]?O?SP$?_][=7;
MCQ\N?OWP\>+%__.WBS<O7[W_\.K__?OKC__?PWN9?II<DZ*!J5B^\__KD&7N
M; UE:# :%+7T!K]=K57P][1)^&,&HP3IYY\&Z2\_#RB'I"V#%%64E#N7>,S!
MI!PEYP#F\I %RV[7^QV.XS?K#XM2'M](T= '&"X^O9Q/R2?OOUQ^F.'Y6(Y*
M)!"\QB^GERQ&"\Q9$K/*1 KOB=4&""@I;6:>XOFW+8/3M4QG/PT+*5PM@=+(
M^2\PG$W7GQ06\P5[]Z-8<O'P?;T>13SZI_ 2EO__>O1A-H[_^CP>)F3QJW_/
M![/K]^/A\-?QY'<_29<F6:Y &1*<2$26@]HBGTC6*L?D@THJ5=YT2XC?4N16
MLI]-UK19:9 #54RQBZK*QFS<'TN68H'[^_FG\00?]Y>?Z;$2]&)\=35>0OSP
MV4]@>C&?%0NI&)V7+ACIH]"$+N@0;"3>1$>T2E2&&+VRN;*XW(>G?]GHE)GC
MCCBQ+27L6"G9WC529C@OT-Z-)PL>S&:309C/?!C"Q_';,?HMHQF2&I_XZ?5H
M!KB?V65B-!OT%8A))A#I#2=!)$V A8"'!H\R\^HZMP;R\Y:\$W!W6T;YL3+Z
M%F8(>WP%;\;3Z8,;F$ "].?PVSV[09)Q3C,G$)DE4E'<312,.,DM94JJ!*RR
MK-;=P7G+[ FYO2V[HHI^?3V=SB&]G$_*1F R&*?E.;#X]SG2,^$1\04=L44$
MXM)0:ZC3D@3MD7K9XU><!Y(Y_A^>%5;1VK;< 3#/6PJ[YMNVJ,F.1.T??CB'
M/8BUL4PJY4AQ[(AD&6DE$#%$&AFWREIN^I&T>U ^24&KQ;5M.5/'RMG%[#-,
M"J )?"[!HZ]PJZ]1>5_DC_Z/2R%]HE:@VG4@\%UPAC@;$N&"&V6,YS+5/F2;
MX#IO6:K.F6WIT8=*3XF-7>(9_6+[C'X6D0K3!1^FST;IY6#Z93SUP^E%7O_&
M]&\P3,^O=__YWY:DQ U>*NU9]AFI)1G@88\;]. B"<% =%I!SN*AD%T?0,]3
M#!\=B[?%UQRK_'X;C,:3A1^U1+:FYZ](<=S5TCHMN]SG3*VV<IF\-U:@MZ\A
M>R)=QGVP9(J%&@55#A2K??36PGZ>TGM2#F]+JNTT_N>=498'0RQZ0$0&I8EW
M,I&@;* @07MZNOC?R:)8S@$-' TKYP3ZBLD;XHOK:+C4#$DC<Q1=F,.5HUA'
M9%$^EE4NN8U:>DZ)T"H@'6@DUBI&K.0>2LK'Y]K2\2V"BAKF3M*\\PS!$63<
M%=K]:9D"_7,<CM$%^,O/L\D<;C]$*8 _9J^&BP71D(%/Y8MJDK 4QF),CD?X
M[?39'X/II0Z242TMX:H$ I41:#M&1[Q&K9% 6K"Q*\'8!:BBG-Q3R'"/W!S
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M(?3(RPN/..B/I&\',Q'V)M^;X'JJY86M>-:TK.P0@O=97A@E:KKH/,FB7/2
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M]UI*#Y8XYX#(6(*:3&G"K.66F80(ZP\W^)XJZHZ1B=H,Z$ O//=#/XKPX3/
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M_F^=3T>3NHM[ ^Z"NC1&!*L<)5F 1%6H K'<1^)BC)Y)'G6HG8+Z!D#__*[
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M]2!-@%Q]2NQC3]L>P_\ZA.X];<N41!-&9T*U*+K.X&Y%]H1ZRM# ,5:)Z@-
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M2,44(H$BR$A$H,P$Q2B1F7)(2'Y6S.1X<B&/%HLND?/G\;38Y_""TM#^XRF
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MZ:V2H-;2,>SM))!V='HU/ /3XB$R Z21ZH3 5Z#;21GC!KAUF7D4V-;YL'M
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MX.K)J^>_>7)D9M?%D^.'W4O:?*1/E,UE]:5XM:J6Q8,>5K,TY7H1%DOM4<D
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M3ZAZSC6+@%>KLM13[RP-*%6$"Y-'+(,H9F8?5X_1)"*!<=030IUV;T^+F=I
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MPUAH'XEG5*_)C(\4I#RF89)$J;IJ-WU'V-3(Z9/\)A<K:3*>5++\EG,)C!!
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M89(Q$H4D)3#D66 "H"*(,QY"SF1*!*8A39S2@Y\6,S5>6FL)7DN5\]R1ALY
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MJ[PL=&R\OGDPFB*4:FB\[R&C ]8"99*6,H<%0QCBHB@@0X6$'!,A;-26EFG
M *9HD \?E V%O.OA;-SO;L\OT UX[;3L1N-?J\+"C=+F7QV8!ARVNH,4[:C4
M0>3 !YWN(!P?4WI<&]Y)[L-T)=CLOQ5;?C _64U405@I,(,X4R7$*K?=ILP_
M[9 L67)""'(Z6^R0,39>W[1*J_4$5E%0:>K?2NX0SFY&B012SP02@$]0+[DS
M"%S52^[PGH/WDCMCU*E><N<^&N;6V;-#MOK^9;GX,35QYYN7/U9*?IQO"^W$
M>OJC\A\WW5%$EK$RU\:_RW)# (GQ/JA0&B:Y2"@OA!;<:RBUOPICHX:J4;R>
M+7ZNZM3Y;0,)MM'=LT5-P+JXN27]HMTSQ]AM]PKL5GW 7\ OU@)@=^%W:G$W
M5O32X28<Q$A.3( "@[HTX0 =.CA7W"FDM<+ZNUK>J^6/J5#MY'@BL10E%;"@
MG-BNN1KR!-O^N0I3G&F1%M2M1\LY$3Y/V# M62HEP:K6$BS5#S5_]MHV.P6D
MP\[CE>#T3#\U*JUZE[MJNL'BTQ[A.GB&:HG@"9-G%X3S&'1W/CAQW8#=#LYK
MO=_AH.-S5R9U?=J,L]=IFA=<((A0B2%F/(,,TQ*F4A<D%05#*BR3ZU/(F/N!
M._A_<IAK[PJDF\MU'3P]<YHG,N%)6D?&Q\[,V@IXG72L(P//YF =?S+LT=YM
M@?)E.9V+Z1.;-=/B5I,\Q4PG*H%$:N.W*%Y")J6&.)4YY^8/J;WROSNEC>V!
MKY6UH8"P\<+B>;T3G^FF2T_5WL^SIU\WYFZ$$ W)GKGAH)O11M5V(F&$G1TO
M2"(Q1K>L0<G#R>Q#'G&[*(Q2_K8P <;<WNFMK<XVX53CI3)1E G/"B@28;=^
ME()<2PZEHHA330J4>QWMG1,T-B+9ZNG'$V>!=*.(&/#TS Y;%4&K8P^#!BX!
M$8D3SHH9E XN&7O(!!<_'[ %LLD,^[1M>_M)F1^J@QF6ME=PRG$&%35_8"T+
MR,N4PXRG*2-9H4KEM _L)75L]+ [072GU,'\:Z^E<),8:3.!=PP$7U7=.&"]
MJ-^Q/CLLSNODL.W2!_H]L\].JNF.TC>@5MMG&.D5T'ILW?0!\4#[.?&@]MOI
M\86L<_O'^6;#[0GYVK>W4>1]\35-+FP"L>WA4Q</_:[6WQ?RX_R'6JTKG_.S
M6M_I=U.[03^7J[OE7JN?B2!::4$I%(*9]P12TGB.QH?,E<AD1A.M91*4J'2M
M9DZ/VO!I3$WAW'0.5-MEQKQ.GN?;/&WSQF!:FT4W?UU564[V$W*O85==^*QD
M2'N+JY;;S;\=:/4&'8#;E$546PS-(M8F@1V;J@0JNUP;N\SSN-]L+78OBQ@H
M1^U3<95"K]"#(@: I_M+1+ES#RU7OYI_?E@L?[*EG.28%072.4QS)"&F)86L
MY!K:740I94D02YW]? _!8W/UC<+P[8D&B"L P4Y[Q3^M":"QP<?K]%D3!Y^^
M)Z1[IM++?2J' 3AB%]% H$?3&-05\+A]/D^@=E7KSMW[C:<;YPDKO1ILGKH^
MU-%OWSIW/^=*WJX_L.GR[VSVK"98X1(+)"!"0AD'7A/(<LRAD*76929*7'H=
M))T7-3;*MXJ!'U8SZ[%-MR]F7Z_Z++:NWG(,Q'KW@ELE0:7E#6!K4"%8:1K3
MJ[V$1C1O]:R@@;W02P8?>Y<7KPCR&JN8\L/T+R7O?[*GN[EJ#C4P8ZG*[5!:
M5FB(>99"GDD!L2:4$98A+GQ\Q#-BQD8/C:)06TW!RJCJY8V< ]/)N8L 4>^N
MW"XZ5DM@U S)FCL/E9>;%@&RP9RRD]#5^D9SP"[@<<'=.G?UD,[5!0L.7*E+
MGPYSG-KZVZ]LK=XM'MET/LD(83HA#*9%EMDR"=MF')6PD EG*=<,(:_FXL<B
MQL:$F[)PJR+XLU;2,[_N!)!NWM%U\/3,@I[(>#M#YXV/Y 2=$#"H\W/>P$.G
MI^.3@?EUK=/TYF7SU]^F:FEN]/WED_IA[*X:(V(JB"8%1()1B'.&(>6IA$5!
M14$*Q#C%7HEV3F+'1@%;3Q]LE*T.O#_?_CVH6:(C^FX<$1_3GGGC&CC]L^^\
MT(F5AN<F=-A\/"\@CA+S_*X.B,#>+I:+.?LQ73ZO;J?RJYI-E;Z=R_?&O,7C
M5-PK\;RT@\/%^NWMU_?WYK_;%*&_+=E\W7A!YM*G-F>5%IKI/$E@J4L%<<&E
M\582#CG.%4D$2XO<J1J@+P7'1G1;S>RFT(-5VO>XM;>U= @=7WF%>J;-'>N
M,>\&U ;>5-39V@A:(VV=**C,M'^[ 3LIC96IH+75WN?I4M+S,$OL$?*^\E(/
M%"R_YI+[A=P]KD=GL-Z'W.'"_!Y1V]L@Z%-.6/RQ/T6^2BB]TW^L5)7[-9&%
M*DV<@2!2N888YP7D(L\@5;J@*-&9HL*M+ME)GL^3/TR1\EZ&[;;G0E75 UB5
M'^<7<73CG? T+3@A,)&VYPT1)LQ+:0IQEF")2I5JX;6K$PWM(9R>N][A=8OC
MHH'6LQ^RQ:LIGMI\6?]HT\'CA6].H$2*VKIE#1JL.9E]&*.Y710\CJ<=,5?5
M<=N"@*7ZKN8K\UJH$[[::BJ,,UP(!)E.<L,@F8:49A*6I2QTF>>D2'UG\[A)
M'ANO[(Y/K/L&[*G>YE36)GB/\'%<#3?JZ07CGFGH]N[M1W"[KI,&JVWH]0)\
M8<NJWCMZK98W0O$&^CC*'7JZCQ\<)T;]>-X@8$O)W*>:T=O.ZOTX_UW)J3#?
M$2->S2Q;*ME6EU8-P[5:+I7<.K]VWIG=!)D41%":$@ZS4MLL $DA8SF!LB@H
M(P721>&>!1!/K[%Q7FL'8%M#P&9/J9X64=L"'G:,:;::/+8?(BZMP\;2ZRQ8
MSP3:&@5^:<VR+R.P6<(=TS95\<W\@V8)=\VKMQA>:0D]-HY>9RD'VB\:=DG]
M=HCB ]^Y,111W'#[0?$QVML&ZN'VUW=W:8O\7II!?YM6,G>ZZ73"9E^:X1[O
M_UI;#\$X>Y^FJ[4]G29IJ11$PK;K%+R$)1?4O)Y%(LP;J-!NY1MQU1K;._F@
MU<G&L,VDRQNP[91D9QRTYH'6/O#GUD)@3?0][HZSW(['X8,O8M_'Y7'7[_W<
MO(GJ.;TQC]FCHMY#-YPKE'JUMCG7 ]G57R?"W6/L_3>-W2<)2P@K\P32 ML]
M?TXA9SJ'4I&"IIJP-//:-SHI96S<; OOJBY>]=9S,]WAFKWG%LZ0/>< D(;>
M:WY_ :$K-Y@/$.AE8[F5\8H;R@=F=F\D'WXX?-3"-^,[UGSR53TMENN)R(4F
MBA:0$<)M_V'S]&-!8)I0RG6*J%9.T]*ZA(SMD=\,$]@J"FI-_8<M' ':_=3'
M@JGGASX H:!Q"^<@N&K>PM%-!Q^X<,ZL4Q,7SG[6_R'_9#"???F^F*MZ0->D
MS E-"D)@D2("L18:<E4(2)0L9"($S35U?;@/;SZVA[K2#U0*-M/BW!_F(^ N
M/\37P-'SP^N!A-=#>\[DH(?UZ&:#/:3GS-A].,]^YDIW>]N78R)*2H5()$QQ
MF9@7K^:PE)S # DE.2)EGI')>K%F,T]G>RO#ZQ'=2!K"E9P&G+B> M'3Q0Z#
M9C '>Z_33P_^];'YL;WK'0FOXUL?FWC6LS[QT<"GNSX]7:UM/E_MJ6^$3 I*
MN,HQ@LHXVA#3A)E7<"IADB6*V?-++;TV2+N$C>V57*=<;'/GFMC:-[&K"UY'
M H@$6M],T*2HK-9U=G$[:'*C:T1.<$ D%CETB1J6)1R,/J(+EVO">..=XNN/
M\]5Z6<4!?YAOAG'_I_]4\MUT)1;/\_67I7J</C_:J:"<2<'R+(="<FR\A83"
M$B<%S&5AXO34N/?$JT&VA^RQL<J.LD!O6ZC(1G$_<O%9 S>NZ0G9O@-^HS78
MJGT#=E%N-0>_-+K_&GE0:P!FD<C)1_*@7!4 R2%UA=PBI*6W!=7<\FFQ8K-V
M[!05*16<&K?'Q#D0\R*%%"D&\S+)"RJ2-,/NR5JG)(R-E:R*8*.C3SOH4_!U
M4TT44'HFE'T\0OJRG 3&IR?VE0 -E##D^,7Q;&[=87MW(^M3%P[8M+I#[_T&
MU5T?#'/'_DO9='TE;W\8]^ZAV?BYT_??F5GNN^?U:FV<<N/UO9O.GM<UB<X6
MJ^=E/6QI,RBUI$61$,Z@(G:*+<,4<IQ)B J2LBQ5M'1K5A57K;'196L58+59
MP,3BCXLY6%5FV8E*K5U^_ERD171S]89?FIY)>[,JC47-]K%-::F- CM6V5I6
M\TA7C<*K#)<>1N'&13B2SQA)J4'=R;A 'GJ:D>\>QM]O*P:Y7R_$/XX$3R1&
M1!%>PDS(!&*9I]#NL4.6%RS'N2PE\AHKWB5L;%S[MJ%6J^S-"88%O]0_.[_E
M[(^WP$KD1 A(E<6;R!+2C!4P21*LD: (<3QY4LOI0MZOV7(]+.J'@OO#_@V;
M59F#; VX>IC.[<0%2Z>U!GT@+ZE0&2,(LD0PB&TK7:H(@7F1TR25-$\);Y!_
M/Y>O@7LK=A#4U5SVB[>;JQ +P9X=@(8J[FNJJ#6]V7WIQWNUNR 2Z87=*6K0
MU["+T8<O5Z=KKFW+O?HXO]T,?;E_YJNIG+*EG7N_6BU$]=/;N?R_%M/Y^N_F
MX^;5O9H4I6)8E2F4(A40HT)!+IB"98)E4602<R,JJ'-W@#9C>^GN&&.'[=CS
M'"9_6%9:V2K9[82=T&;?(2OFQE6#K4//9'9B"6[K); K<+LSXVC7M!NP-:[N
M\E/9!UH#^^@T?@7.T9N1A^CR2OW*KX#M?$OS:VX:.A5W(7].9[,)+XJ2H%(9
M+UGE$-M=(Y9R!J7QVI+4.&Y847^GN;W].!WD5KN;4_ZQ[U#<!D>"L2@*N_LF
M&;,C)01DF)L74Y'D6G.E--6^+G XBOV[NUL,][S=0/0XD2G1!8$\2R3$C*2P
MU 1#6HH"*:018EZA<@ARP\Q>KO4*A,GM71IB?,^OQ8MV!TQ1WC<RVM3DYK8#
M3TG>-^9X*O+![SV/3)?KR5?%9N]7MM;+O$EVVG"\4T]+)>KMU,]F!>_TEZ7-
MGEJ_-!W+&4U(2A"U3$8@5N8%P3GA4&.9&6K#*)%.^=S7*#&VQ]CJ:#FOU=*S
M/_Q5ZW'AF'8@E'OF"W^ W<\J(R#413;F_CM$8_ZU)9FK1 ]S(!H!G,V9:8Q[
M!>2&;$X"GI</4\%F'YAHI@E7DX/>[@R=G0A:(I27&AH70T%<ILSX';8$E2M4
MD"(UKK![RHB'X-$1VN;,;=4H#_1&>["HAU_MCNOUR*GP68\+Y-8CRGT36@WP
MG0:MWF"K>#M=[&W_ 'ODLO0$]$ I+CNGR%<"[I<%$X!:9W*,S_V&RYD)L'(O
ME2;D^FO&O7]C?S6)U&_47.GI>J)5(DN,)-2H1!#G!8.,:WMDE2C$5)+8WK>A
M,]R/Q#D](,,/9F^*?];L+\!K1<$O3<&$YW'5.9A==W_#41MT(+I1L2V1 +\T
M6D:LFKJ 0]21Y<=27F$.^5E33P\7/__QZQM2'33.]6A0Q(R?6&HIH2$-0R6E
M,DYD0DO(5(F+4@E4IG[3DF)H-38/\Z"=T7'SZ$';484OMANA#;Z$/=-?Y-7K
MOQG5U:#WT(LJ7*=7:T5U-8Q=G:BNOWD8ZW]9-@T.J_R&+VQYMZQDRVJ\U1>U
MK%(>)I*0E"HE8*YY!C&F&-*<I# I",4E,[_*A ^MNXD=&V]OM&YS^9Y86_WV
MRW0._KA_9T]^Z@P_3Y_1<1W<&#<^NCU3ZA;8)O/)Z&R^QC6/RF90GM&[SHB*
MQY)^0$6B04>A@_*<'Q"'1.9Y]37!ZX88-Z4"C&6E+G,*19X+>VB/(=>:0H4,
M2U&:VN-GORRHDW+&QD5-$+;U-!S2_[UP]8E6KT)KF&C5"ZC 8/4L#%&#U6,I
MKQ"LGC7U=+!Z_N.!LUBDK'PAXQ6QJ?PX?\N>IFLV:XH459&@)*4%3*F=>6G;
M(Y<93B"E).<"\41G7HF1G=+&1@Q;98'5%AK'I-'7<\!*)\1N[! -N)XYXCQF
M?<Q1<0$EUNR43EG#SDMQ,?MH1HK316$<TA0IW']7:FW[C5DY35X!%:G6+,]@
MIC/K4^#2<(?U+I J$4VH))G7,+CSHL;&'FWE1J4J:'7US.EP0-B-/^+@UC-Y
MA$+F31R7T8C$&AV"!J6,RP8?\H7#%>&]>S],5[8K897;^<'\;#7A.B%)D6I8
M")LP7%#C:%"F(+'5%UF2<%44OLU[CZ2,C2(VO6EK34&M*JAT]>_?>PQJ-S5$
M@ZIG5@A"*:B'[UD4KFKB>WS7P;OXGC7L5!O?\Q\.W1A="*7DZH-1[9[-U)U^
M_S_/T_7+[VK]?2%WRA4F)"]1F2D&$R0QQ-JX#1R7&N:,\#)!2F&_:,-9\MB(
MH54<V.4$*Z/ZRIY_J$I[,-TJ[KLUZKH2KKNC/>#;^P;I+K16:XMLK3>H%0<?
M'0 .V"'U!"O:)JFKW('W23WA.-XJ];U!U&8Z30.(XRIJ+@M)1<XA*A(-L;##
M'86@,+<G.[G*2IQY%9UXRA\;E35Z!M:K^X*?Y+G !4DAT6EJP$<"LEQ:\"43
M1:$09XG?K/<>X1]F^OM1?Z+CMAD0R$%7R>WMTB/R/;]CO)H/W8#&HMY[#5U"
MKM^F0F>ECZ%[T"5H'-L$7;Q-8#\@MER^F-O48S6,U$?;\_(#FRZK8\%M$Z)F
M2UD4@A1)CB#GM#3!=('-W_(4RIPR8ASI4DBOU#%/^6-[!;7J@UIOSXXIGMB[
M<5N/B/;,;:W&32K![XI9->OCP.@;_($PQ6JVXBE]V/XK8= <M60)O$V,/N&V
M1*O9Q"Z8QH26":0H3>SV7PIM_JOMPI)EI4"Y]$MV/2=H;-1TU*RZ*E$,.R,X
M"ZX;)<6 K.^=P#"TKFSB?0Q%+QV[=\2\8GON8V.[>W&?^'Q <>57)95Z9'RF
M/ANE%_.U,6!6#38Q#Z&)X[\L9E/Q\DW]M7YC5/_'1)1%SF@A;%"=0YRD!618
M<2AU5K*BY(DJG,9[A@@?&X78J9]OMUJ#5NW5O_Z+(5/TGUOS/(K_?!>DFV+Z
MAKEWEZ?5'.RKOL$:_%EK#ZSZH-+?IS^X+]H>Y98]HCY0R65D]/WJ+@/AZZR]
M]+WG</67@=;NU6"&WB,P\^1Y-9VKU>I6_,_SM$[JK_ZZ5*WSPZ3(,B%SB%*A
M(.;F54$U5S#%K%2)*'"*O29!7Y0XMO=#JS#8T?@&M#J'YJ-<Q-W-Z8R*9L^O
M@6N!],]2<04G5K+*17G#YJRXFG^4NN)\X76D\W;QR*?SZO5GV>VA+CW[JJI>
M)';0UFJB,YQAB17,,+(MC!6"998;'BJX0AFB)>)!['-9]-AHJ!H.S$25T&5;
M44ZW:@-A%0XC((<U\&.BN,@.14D[6M^ ';U!HW@UBB_B8;8_6I$YRD'PJY"5
M.R#G6,OC#F'T=:_FT\7R\V*M-B.NTK+ (L,P(8:@L"XUI%DJ(5%"(HR92DJO
MPI\C"6,CHUI!4&GHQSO'X+G1RU60],PBNVCTL(E_UO1(E'!\_T&?_+/F'3[@
MYS]XY2CN>_50);HT7\@4)RI-.8>(%M0\S8C DA$.$RX9RQ1)./<:L'E&SMB>
MZ>WPZ5;/P*'<!W"Z/=\10.KY*3_&IX=G_0(,L8=T'TAYG4'=ITT].ZS[S,=#
M,P-6WS_,%C]_4_)!_<V$-G8(^+?%&_55B1E;K:9ZJN1_3=??I_-O/]7LA_I]
M,5]_7TU(F<DT-:_X7.2&(U0N(4\9@9FD,L\+@B1+ _I4!:KC])0,W\>J/@L%
M:K6>/E9.]'H!N ++'5L 6P%F?B*?Z\C&?&+:[DHV+:_ XH=:@KG=FDP1>*P,
M]DU!"%MD-^;J<\T&&O5B+ #6!%#9 *P1X!=KQJ_-DNV: GY6MMC%^+U[,0+2
M%:Z",EK:0I@6 Z<O7 75<1K#=;<+.+-L1W;^;;EX?C)>736*>&X8_EG)ANP7
M\S8QK WNU*J^S#:)S8C*=<)A*A+;" 8Q2 E-(2UXR23CJ5).*0\QE!F;+[?-
MEVS9= 56BYE/^])KE\?A1'- T'MFT-824)ER8T-!L&L-V)AS [8]9[<F@=:F
M 1?(XQ!TP(4:Z%"T_P7S.R>-A'#GN>FU,H8[1XV$QMZY:JQ[QFAN5N<WWSZO
MOR^6TW^:9S%!B2*9G=28<@PQP1321'-8X(0PK4QHD3A-<W 3-[:WU5$SLZ;"
M@FTT#JRKN("ZFW\?#\N>7T)'K<N:6HFMLGVU*SL'2B]MRHZ$O6)[LG.&=[<E
M.WM5&+>\9TL[*VO5=C=[PU93\<GP5S52>5*692$I8Y 796FX14O(=&ZXI<@8
M*PN%*?<ZG.@6-S9N:;7=]NR[ 97&-X"_@&;(Z5L;XMAS/S%[KL8@?_NYJ'_8
M5K3^:0T$E86>F1X75L>-@^)AWC,'#0FW-VFYH1B)M"X(&Y2TW P_)"W'JX*;
M&M@]O[?6@/FZ.:.=KO[1'!I@K@G)20:%SHG-^[#-NU$)"X&Y%*7 K&2>G0PZ
MQ(V-M+ZJ'\KXI>"^NJ-WCX(N8%U]GEAP]>[S5(J"/4V!5;6'PQDW5.*U'>@2
M-G2O 0?#3S08<+DJC#_^SI93FR3;IL6^-Z'<^F7[7E4ZIRQ5)12\S"#F&$%*
M4 JQ1(F4G$A6>!5$79 W-@9IU=WF>-<*7^'(7$+<C5DBXM@SM5P'H3>Y. (3
MB5TN21N47AQ-/^07U\O"3X;M_VU3E!]L9D^<OQHARZFP:63F%[=SN?^#G4].
M:&9;,RH!)4]*V_=5PS(C#!*J=*:DT@DM_.<W7Z63SZ,UW-#GZNS1YK,*^Q>U
M51>P]?5SH*];1)SP,L_S J8BM8E 4D.:YG;D*E;V)2)8DOD.CQYX"?N?.-VY
M@%<,H;YNZ=R/[@=9C $.\&] M1(["MZ K>Z@_HA=IX,?[EX1]R3_:F0CGN>'
MZS+XJ?[5L)TZV[_^I@$G_+L=QKZIY:/-RK9#9I?FYNOI#[6M@MXD=]T*\XMJ
MXN D237'FE&HF!T"2TKS"I4$0XV))EPSE)+$^7S_*E7&YMQ7^3DV6:HQQ,15
M'N?&UZV*P['^8%CWO[>PT^EP:PG8FK+73&&;(+HU9[!U\3C-'VQ]!CK+[W6=
M_([QHT#;>8A_G83ACO"C(+%W@!_GCF'!X&>UKJ>'V+2XV[5Y5?+GM8T]ORU.
M5VE/N)9I28D) !.:0,SM]/)$8XB91E(BB9.$!20(>ROB]+P.GQK\2:U6_P&,
M-6!:#\5A.[;8I-/Y8@YW>Q5L\MC\H@C_A2M*05)="L@UT1 CH2"C2$*19YEB
MF4P*5+0+-YXUZWFYQKA0;B%>/^ /-)U>V6Y-%>I--O;M ?AG&GK$B^."X8L4
MN_G+'S1>"X;G,$8+OU'@[N;B\7%:MW<VT=_;*A'N0<W%M,IX:UK6;1OFE(5(
M4F5>7TE>FG>8)#FD4A10I&E"E6)<N_6+"A,_MOAK1_MJ1V5/?\]=+K]U<-S6
MZ@W=OO>QNH %6]W!GU$[%5V'6ZQ=*C_APVY+!0%SM \5=I<P@OLT97PZJWS_
MM\_+Y=Z8SC+G:4I2J!%'$)-$0\8XA[Q$.*,ZR1$I?<CLO*C1$5>M'IAM-?X/
M/[[J@-6-F^* U3,/[2AY UK0^AC6>1F-2.S2(6A0)KEL\"%K.%QQ_5B=CZO5
MLYW6=:<_+>8/=G?!=NF<Y%HH0KGM_JVI80IIT_*)@GE6$"Y*(4J_412718Z-
M,=XLELO%SRJC<Z'!S&@*[:XSD$;7\-DY9^!V8Y"X( ZZA]RJ:[&T"D.K,7C7
MA>558W*ZX>EA/LX9@:\V&*<;@*Z).!>N#(^Z%O.=&@ K1<D)U5PCD5<CNP3$
M24%,>$5+2$N>)GF6)5(Z#>^[(&=LY-*D@^\7_4PK50,+?LX![!XW70G;  &2
M06ROON<&U&K&C8,Z<(@8\)R2,GADTV'JJ1"FZ^,!A^2?%%NIKW8:RIW^8Z5N
M5RNUGNB$%XFB&10*V?0QFD"6H1RR5(J4T53E93Y9+]9LYG#V?4J"%Q5LY/3W
MQ?YF98"9U=3V!#$:^AR=GL30X:3Z6F3Z#D.L>C>@4A#>:6A4!)6.UT+C<5A\
M+40#G0'O0;5P@<KO8+<+AL[SVI,7#G<,VZ7WWNEJYP<#^ZNMOZNE8<RGI?JN
MYJOJB+;=XC[9;^16&Z]CVW"DGIG\C?TU*2D2:9XA*#.9FSC,$"-/2F38D6&"
M,#94Z=>1+99F8_.H=C(>6'WV_7(#UNPOSTYNT1;.S>]ZE>7HF;LKF\">4?MG
M>4V^YK;MTLUNWZ4;P*R-X-#(&_"M8S7]V\W%1CY6@[IH>@W;TBXVG$=-\*(+
M"*/V#].Y#8ZKE\:F_*)NUS;)=4YIKDN8$6*"652DD"L3VZ9,%83P@C&_L\(.
M66.CWTVED(G1*E]V=Z?=CX.[$'9CU4BX]<R3C9:@<>"VM5:UIO&HS@&.2.35
M)6E0.G(P^9!@7"Z)UO1_9[[ 7L/Y(D>:*6IX W%JHM^$& ;A B*2$$E+DE/D
M5;OI+GILA%)58,'GIT@=_L\![D8H_<#8,[^<[O"_H_> '?XOH-5?A_]S@E^[
MP_\%0!PZ_%^ZP_7N37O^^-*</DX28D)\I13$"280%V4*2RI*F*:\%)J+@I$\
MU+\Y%#8V/FK4"G=ECM#T]V6NP6A89V:CZ2:)H!]WYAPB/?@S1Z)>S:$Y9W27
M1W/VFH!]^WLUTU_82].JI>FN0C)5(B0-(PB4F]A'(4A5(2'!)58,:94DJ7/-
MVBD)8R,$JR-\8B\>.](G@7/8K+\6CIZ?_0H)HQ]HF_=<[#_C"(W'9OVU$ VT
M6>\/E=]F?1<,G9OU)R\<;K.^2^^]S?K.#P9P6;6M],6LNEG[>[7\,16JN7?=
M@:H=Y:$UT5@84DL%%A"GM(!,I0H2DJ=YR:D)TK@SO3D*'1OC56I[/-.NV#HP
M8 ^(#;(+WJ@,&IW!?GLSAS$JX:AZD&</Z [$IY%0]B-93[@Z>=?U7L-1L:=U
M>^SL>ZT?84LUG=R:+Y6T7ZP/,_8P*;)2"Y*44)8V6215-B U/BCF*4])KC!W
M:W5V=.>Q4>]&.6"U<V.+8[BZB?8J$'IF4T?[G9_CL[:>"!Q72OS[P^+'_VFN
MJ6-&\Y=MJ'A\IT$>U;,&M,_C^0\$UX';8[8OR\6/J53RS<L?*R4_SC_.?]@A
M1WL-&8I"Z%)F.918V)F0G$"6$ EQ0F6!-4Y%6KJD</F+]GIL!\CMLF6L57.H
M9YO<-9V;_S4ZMTD*WJ=C'NO@ML'4#[H]\X$%MDHB:-6V/99_^:-&^5>P43YJ
MGXMPQ.*5!+L*'KH6V!.0$T7 OG>X<O)EM2MF=\PG B=IPO,<YF6F#4FI!%*I
M<EBP+"ETEB:8>9VY'8L8FS>Q;0-3']4''+&=P-&-;JY#I^^@;0-,LX]M]>MA
MQ.61[;&G6VX%O,Y@RR,#S\ZT//YD<$V;5JN5B3;9[(,R;S^59"EA.84%M\,?
M5,Y@F944)EKG:8HHP:579<FA@+$]U+OZ527DCTI.A?F[5KX^QA&6;H_V-0CU
M_&#O@?.A"Y"0JK.35L>K,=N__= 592>-.U$_=OIS$4^A-^76J7F"*4(8ZH+:
M)!FB(<M%"66>\42F2B._"0F=TL;VF+<'K4=)=I[E[-T0NSWPT8#K^>D_=SC=
M2V&[$RA]GD^_3GF[D]E.)]17%KE7&Y'M-+O[Y^6#?0E^8*)Y3.Y^SI6<Y"5/
M<$DSJ&1)(-89A:5MN,H)3U!:"D+=*,1%V-@89#LA==4H#/1&8["P*GL<1UQ"
MVN%P)R)^?6\[;*!K=05;9<%=9.@\3G B0CC0R<TU4/H=USABTWE,<^D>PQW/
M.%JS=RSC>DW\8K?/:GVG;3D40E)(D1:P9$)#3'5JHC&10H:YI@E)"IGX;;(X
M"!T;\9XJC&I:2_XRLZ5/\6K5-K@[;LI$1K/O;9K+%69V@]APRV E8X<H#5 -
MMA$YFD*O0Q!\:KB.KHU6:W&_5D\[R=*VP__ZI:WP^%CG42^5^L"FR[^SV;-*
M)SDIB4I* 8V;:+Q#J3ED6E-8I+K 2$@BF-=,XAA*C8W,/I]I?GMCG,GI$ORP
M2E]=M>&_=&Y\-_2"],R'IRL]K$6[Y1XWH#9J6VDVG8/6KAM@+0-_[URV&)4@
MP3CW5R/BK])K5X\$@^A05Q)^[^#.4(?O@XWWH@N4IYQK*'6F(%:I- XC2Z%6
M*F$)PI*6F4\F08>LL:4.['LWM7]XKA&Y]>O5\@5\8<OUW'!_-6#XW[W[1YU=
M!C=2C01NSUSIZ#7>'#4<-^!&+6-Q@"M>NZFSDH9N.77)Y!-MIRY>$L8[?ULL
MY,_I;-80FGSWO#1^S)=J7MN$L")/D:"0$HKL$4,"2Z$DY#G'12YUJG.O(X8N
M86/S[';(WS#)=#.J_&EA7 :V4S[*Y/]^7M5=C?VXIA-Z-[*)!6C/;-.J>=,Z
M6A+4FH(OW8,!O>G$!9!(?-(I:E!"<3'ZD%&<K@FCE-^5?0^O=A^@V[E\-UV9
M1Z?^Y[;;]VK;VCY7+,.Y(C!1I?%R4F9X!DL%&1*LR 32$GEUY0Y38\PT5.4S
MU :PF2?9!"Z*&PWU#W7/!-48L-<78!?NY@<[5O0T@> Z)",Q6Z 2@W+>=4 =
MLN&5=POCR7OQ7<GGF;K3]^K!^@]?U=-BN:YFO.C%\K&*0]^\-+_</I,9-92H
M$8&"<9O2Q3BD$F'(!5)8YX4HJ%=_I4 ]QL:4K1DV=*E/U*=L!G9,L,G1M6E5
M,-/8XT>CH6OFQJ,#K$3/1+J["(V:8&/$[F+<V-5H/_'GMVI%>F'4*S&-1*FA
M6@S*J5="=4BJU]XND%4/9%6G+??3AWG5_<[^PJ(QM;OU']?J\:WA]L5L*FWG
MF$W>ER0"248HU)09ALU2#GDF",S3HL!:I0(1Y<6PU^LT-K;=J%Q3JWG<;ZLX
MV(1V[]]\_/;NUC,1+\:R.9+LL(O1-^$>DNP-J,^%=RP".R8!:Y/-Z-]:U4O^
M7T248U%P!(V&I>-X$!Y1<\1;^U<OOY^OMRUX-CK<K]GZ>3517!8)Y1KFB&J(
MF:%=*HK,_%/H(DL(2G+G8N8N06,CU%K7S;"IK=-4J^M>[-R);C=%QL2L9]X+
MA<NK-MH%BZ!2Z<X;#U8Y[6+>;B&UT^>OC87?L^7<CIOZ8@C)3MAXPU93\>:E
M'KSQUK8QKH*%29*6)"&XA)PA"7&I%:1:<&@B85IPA AF3JUH@C48&X'LAEZM
M"79_O9X2<P,J,ZJPJQDB4YE2'9(V1QO??B[J'X+?U?K[0C9QF6-;EO"E] V.
M>UB@ </B@=;FBD#9$]_H(;*K_%<*CCWA.1\6^][HBL3DXR&*$Y;+3*8D@5F>
M6P(U/E:99!AF&1)<9W;BL_#.13Z6,S::K*,C<3P(-2#M^ 2J6:E9D6($$ZPX
MQ$610HIE#G/CUJ8"I[D@V"=7)P:J0XUOBH.@V]L@ BX]<W[]13LU239R+O9Y
M%&*F7Y^0,GS&]7E33R99=WS\"BZM1B.M/ANUFV^L*GA)2:)@@3DV3&J"5Y85
M"FJ4<"U+C*CR<D5/2ADGCVX'POK,;.N&TX, K@%ID,>_5O &;%6,_/"?0R#F
MHW\D8_@'_YR9)Q_[LQ\.Z?*\7RSVTO3S:]M+)@)3E-F\.((UQ&F20X[*%!(3
ME2JJ,>+8Z:3 0=;8"."P8/&E;3SI,[CQ KS=5! 9M+YCP+-X!76*[@;.IV=T
M- "'ZAY]!9">?:2=H.GN*-U]BP%[2SO9LM]EVNV2,%?JG7I:*E$?'YJ_SU0U
MS6,N;Q_MMN(_ZR\N+=.\2 L&*3/A*=:9AI2:?R*2:Y9H3%3N-??11>C8>'97
MYRHEC>THZ^=O.6%NXG^%"J6AI"F#F"H3P1:*0$I$@M*,"&0BV!]JR1>OA?JN
M\/__X.[F]L;&LN>7WJZZ-V"C<(7GK0N>WEZQ#T"1G&0GD8/ZS#X@'+K07M<&
M<O]TQ1X>ENJANMF=;KICUZ<!BO%"EJF$.4E2B 5/(1.20Y'D*:*ZQ$)ZY8%W
M"1L=U^_I:D\+-A,R0HYB.G%VY)M(Z/7-,\' ^1., R*QB*5+U+"$XF#T$9&X
M7!,0DK=5N%_96KUE3]]^+MKA2ZDL$H)S*%*"("XR 9G.)$S*E">Z%)G(G!H6
M=$H9&V5LRMB71E$@V)-'$'D628>X.P8^/9/"!AJK(S!*5J>H <'V69P\PNP8
M> T48)_$+5)(?0F&SF#Z[,7#A=&7]-\+H"]^.&CLW'RZ6/XQ7RGQO%3R\V*M
M5N^>E0$K;[Z4W- =3A,%<T%-T)PB;()F6<"":IX@FAAVE&X!G)O \85NY-^+
M//E?8%5I#IY;U<'<Z@ZD\0JL]EYSV2Z![K)3&1/(OC<K:^@VRH)*6_"N@2YL
MMMTE#+T&W47$<K"I=YV81IM]YXC,A4%XE^XRY%0\1XL.1N2Y7A6Z?\G7'^>K
M];+ZZOPQ;W:'E*T:%(OG^?K+4CU.GQ]M':']Z&KU;)N\5M.)/ZOUA$N6BE1Q
MF&=408P5A1R;OQET6*)%R7/$)W/K/"OYS6>'\RJUG!Z;LGYLCI3K[]'YI%:K
M_S!$OK$&2*,\F#;:UZ,;JDTEV9CI>1)][6JZ;M[UOSA#[>L9^+>FW( =8T!K
M#?BEL>?7NI2ZNJ9=LLJHJM=,S+V_*/A&VQ:\3IN!=PRC0'>\F1CGMF$<_54)
MFT59%;54>Q#/ZSM]*\S;_KD:%7^N$V.384Y+BEB10E+JU#!TDE@_.H49U5+F
MA FNO Z?KM)F;-L.A\: Q7/5-&K''M#1H#1H._.ZY72CZ,$6J6>"[GE]O*DY
M"JZ1B/DZ70:EY2BP'9)RG)L&[%W<VIK"&5L>9JNH-"T3I N(5%I"G)<EY#)'
MD&@B:9KC0JK$>>/VC)"Q$>A&S9"TJ7- .NQ"1("G9^HZ1B9DN^$<1!Z;#!&@
M&FAK(00ROVV%"UAT;B:<NW:X+80+VN]M'%SZ;)@K^M%\!^8/4T.@37:J6F^*
MN]I>;(8'69+KI(2BS"C$"2H@+SB"7(A2%IPQ1+V&M;D('1LOMGI5(>.B\E"F
M&S.:+/,;,.\(&\/Q=W,18Z/:_RE8B]XF&UV9V'Q;6]@J?7[R@K>[YX-1)*_.
M2>2@SIL/"(<^FM>UH2T8K%NW?%HLFX[7]I3*QN3+E[<+J2:2JA0AQJ 6B818
MY 26B2UE2PN>II3B1#N5M3C*&QL1-1T&]G2^J=H+* ,S:#0'5G7?Y@S=N'>S
M4 ]H]DQ ,8 ,:-O@!,\5W1NZ[S]P$P<G8X][.;A==FU+A]UC\'=J.?UAQ/U0
M=7'S3EO#G(BTH#E$1!40LX)"FDL*F2P5)0AC7CH%@8'RQT8_>RT#M%:BVK[9
M3\VX_\F>/ \Z?%?%S27J$>N^#[IW8-X'=T?[@1H4>F$7O>N"F_17ZKG@!<WY
MC@M^MPGCO9VBXTUGNDPCG@@I8(XUM@T%"63&@X*JQ"05::)DZ37W[82,L?'7
MI^"9O*< =*.A*V'IF6IVM.NEY5Z']9'(XI2$00FAP\3#A[[KHX%#U=AJNJHV
MRJV/9+OE+V93\5+_N7UCTC23N1(I+(A-OS./N'%A-(.,8U[0C&5%Z=57Q4WL
MV![_2FO[4OUB[MIN@'I.0G/#VXT:XJ/8,UML -RJ? -J=<&?S7][\4?\D(HU
MC\Q-Z+ 3Q[R .)HIYG=U8#^2)V5CM_E#-3O\"WNIQM!,-"ZXXDI!)6D"L28(
M\EP7,"$LP67&L:)^8V9/BAD;Y6RT!(*MOML#;SU;_%P!N[)@L?GES-K@VZCD
M-,YNU',]>CU3S1:X2D-#,XV.$7N5=&(0JUG):2'#=BOI-/2H74GWIP,#$,87
MR]NY_*JJT_SW?SVI^4I-."D40MCX)1E2$%-20(X(AD@P(FA2)HAYU56>%C,V
M4KAG,[:T'K<]3N)JKO34-S?T#)Z.(<G5*/4=E5@%*W0:%4&C8\3 I!.#6+')
M:2'#AB>=AAY%*-V?#DUY?&I8Y$Y_6LP?OJGEH\VLG)28E#@U/D&>%P7$1!20
M*2IA6M*\$#3EFHF ?/-S\IR^X<,GDG]93N=B^L1FH%4;+.8[7<QL6KEO4N(9
MP-WXX2K\ADHEW&*E@5426BVK?.Z8"8+=0$3+_3LC9N"TOFYCCS/V+GP^C"S>
M/S[-%B]*W:]-*'+W9$/T-B./D[(@,H4Z%=)$$"R%C&4"4I1P5""1:R1]G(6S
MDD;G+U@%3;10#?WR8X+S:+I1012,^CXNL7V*H8EMC9_0N*O@=KDT'U%U'4BM
M=\3L,V=T(A'$>3F#,L1%<P\IXO(%P;U:JGF3?ULNGI\^+]95X8;=T'A6L@E?
M%O._L>G<#H^^F[<?G_!$&<;(%<Q*VQ0USW/(B6:P%(QG&:*2)M2SC528)CY/
MSS#ER5_,([1F?X$'HVL[T]P\,[*=[%D7LMD1+,W4%7\N"ETU-Z8:8"5ZYK%6
M)5"98/NSKL&N%6!CQ@WX6[5,G]IE:B^-VE'F&CCC-9L)TF+H/C370'6B1<U5
MMPNCU'HZI:KV?-ICJI=MN]HJ#\>^3>_T9H[EEV8.Z?N_UK8B@\_,A:OU1&DI
MF4@3J)/2!'490L9-(Q3F*<EHD66\3%(?-RV:9F-SZQK#V@W.C6V[G9F;G+3*
MI]F;(=J:"/[<&@FLE9[U:_'6W8VF7V4U>R;N^ OY?O[\V#SI$=W5Z-A'8OEX
M>@W*^]'A/'P3Q!<0N'F_MV>G5)$5.8*RH 1BG&M8,B1@HGF29ZD2"#.O+?O
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MC?%WF]_7K67%7N TK2SP<_Q\E\3-+>P1Z)[? HX#!NI\^KH5K0E@C0WQ?,M
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MIMRWJ1I 4UE5C]%H[ +K!=BUS+=E=N#ZN5'7$*O2,Z<%+4*O4PJO!35:^^Y
M-09N[WT=6,?MOZ^\7QC/_CZ=+Y;5E-BZU.Z=$DO;'\T*?C==K9=3_EQMA'Y;
MV**\Q7QM0)I56T7U!;\M9D::\>N(0@@5"&:\$!!GG$)*$(/&UZ/<<+*)U63
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MHE_XKZ!5U[V@[0B];MZX%I.>^<$7#J]BMG-V!U6R'=ULL#*V<V;LUK"=_4Q
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M<J[M//TW-IW;).V[^?9GG]5ZPH5.>&F\U[2P8[]$FD&>%ASF*6>R2(Q+*[*
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M6RZ>GU8;[>UGC*+3^;.235?3Q7Q514631.%<I:F""=488ET4D.8X@PA)BI7
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M?Q4<-EM'M, ]O_ML4M^.KCL),KO6 F/NYD6WLIMV&XN!-1F\>0'G[@0:NV_
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MV4B9/WQ9+O1T;=,/;/>%IA^9\7BW1U9V_Z =>%@@(HU?2: 6A8 8T]+$UHF
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M_#F'<8(EE^N%1I-X[X=&1<:3F]\<^0"CQ5<'"8:#Q:>>A=E\ZN-\(&UT5+!
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M>#(/E/TL+("Q6G2YVV TGZV_<KOM]J'K4$NR7N-L-H/Y[(;+I$PV(@5TIJW
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MK(,2C%-/."\-/91+)."N6#2*RLJPY'RH[3SM0V"_2>V.D-:=BII(1CZRAVP
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MF'AMI-VGH-^F;OUCZPA]-("F#X >[A64'C@E55>D\?MP_N7\:C:?7,)T<Z^
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M\6@S14+KJ;++EJF8=CN(=ERPGT3\R7#3A=B;@-+F'6?))E@?B/!E_ "-@@3
M39&$E#SY&!B3N\.F_3O"@]W:8X77Q!WA4V][O(PR)^4(B[0TJU*9.)$829$I
M13,7PI_@?<%>#_&Z&S18.]526P$->+U//>M!<3"ME2=*2S2["D444G8$DBA-
M@:31K',L?0_OZ?92^1[OZ?:1?PM06MU$;GO*I4SR626%3%"._II@Q 8O2;)
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MG'?^<KV='#C@.@B42$*Q:"%+29,C3(4<<DK1;EXG5(;/+2T]=Q\\4L=/0N9
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M\C;=+=TGL$9YBGZ]Y0;P^%'HW ,S1&3%?#:)"5';2.](VH_PC&D?]#VH]^U
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M1Z^)=-F70EA-N#,^2U!.FMI%='>6[[<<O4MD'"KCQC.LB^EPR\&_BTZ=BSG
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MZ0=N5D[\N- F8JGU>%KPNB\J"< 8.7EGL3!E,I>Q]4O 3D)Z\G7:8.=T>7<
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M0_$R[IR@\:*M+K#1P1EY>U5/]KN?1H3?XNL_\V6ZL P%J_L/ZC/0.G/K?$J
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M0<;EH=$SAONBBDF0O6>@@A400JX;N"B6\B87Q-9=,<]GUL]!.MYSUL\A N\
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M4$L! A0#%     @ 5$"B5AG0-"\)"   52,  !4              ( !)0@
M &$R,#(S<3%E>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( %1 HE8]WYXS"P4
M /47   5              "  6$0  !A,C R,W$Q97AH:6)I=#,R,2YH=&U0
M2P$"% ,4    " !40*)6F>L9G/V: 0"Q.Q( $0              @ &?%0
M<V=R>2TR,#(S,#,S,2YH=&U02P$"% ,4    " !40*)6UBCRFJ,0  !LL
M$0              @ '+L $ <V=R>2TR,#(S,#,S,2YX<V102P$"% ,4
M" !40*)6WU.;A,0=  #>%@$ %0              @ &=P0$ <V=R>2TR,#(S
M,#,S,5]C86PN>&UL4$L! A0#%     @ 5$"B5@JIT&-F1P  :0<# !4
M         ( !E-\! '-G<GDM,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    (
M %1 HE;(7M^L!,\  #9P"  5              "  2TG @!S9W)Y+3(P,C,P
M,S,Q7VQA8BYX;6Q02P$"% ,4    " !40*)68.;0*YU_  "\IP4 %0
M        @ %D]@( <V=R>2TR,#(S,#,S,5]P<F4N>&UL4$L%!@     )  D
*4P(  #1V P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
